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Liver transplantation has become a well-established therapy for end-stage liver diseases over 
the last decades. Despite the huge progress in perioperative care of liver recipients, which led 
to an exponential increase on early graft and recipient survival rates, patients are doomed to 
stay under long-term immunosuppression treatment, being exposed to the consequences of 
its late side effects. Recently, supported by experimental animal studies and clinical 
observations, which have endorsed the hepatic tolerogenic trend, attempts to completely wean 
the patient off immunosuppressive drugs have been made. In a recent published study, 41 
(42%) of the 98 enrolled liver recipients could be completely weaned off from 
immunosuppressive drugs, achieving the operational tolerance status, defined by normal 
maintenance of clinical graft function without immunological damage in the absence of 
immunosuppression treatment. On the other hand, eventual rejection episodes were mainly 
mild and easily treated mostly with reintroduction of the baseline immunosuppression regimen 
with complete normalization of liver function tests and no graft loss as a consequence of the 
rejection episode (1). Furthermore, functional analyses performed on baseline liver biopsies 
suggested that operational tolerance was associated with a differential expression of genes 
related to iron metabolism (2). In the current study, we checked the influence of iron levels on 
the immune response using a murine model of ConcanavalinA induced T cell mediate acute 
liver hepatitis. Iron deficiency significantly blunted the inflammatory liver damage, which was 
associated with less T cell and NKT cell activation. Aiming to decipher the iron effect on liver 
tolerance establishment, we set up a fully vascularized rat liver transplant model in the context 
of iron restriction. Furthermore, taking advantage of the opportunity provided by the sequential 
liver biopsies and blood samples collected from rejecting recipients in the aforementioned 
clinical trial, we conducted an extensive molecular analysis trying to identify biomarkers of 
acute cellular rejection during the immunosuppression withdrawal. Rejection episodes 
produced distinct blood and liver tissue transcriptional changes independent of HCV status 
and pharmacological immunosuppression. Gene expression profiles were used to build a 
blood predictive rejection model in HCV-negative patients. The model identified molecular 
changes associated with rejection, which were detected 1-2 months before its clinical 
diagnostic during the clinical trial. Altogether, our results provided insights on the effect that 
iron has on the tolerance process and in the understanding of molecular rejection biomarkers; 
6 
which could improve the patient selection and the safety of the future immunosuppression 
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Chapter 1 Introduction 
 
1.1 Liver Transplantation Background 
Since the pioneering work conducted by Prof Thomas Starzl’s group in the 1960s (3), liver 
transplantation has had a fantastic evolution over the last five decades. Initially considered a 
procedure only performed in high-level academic centres due to its challenging surgical and 
clinical characteristics, it has become a “popularized” treatment performed in over 80 countries 
worldwide (4). Currently, many centres around the world can achieve reasonable results 
reflected by the one-year and five-year patient survival rates around 90% and 70% 
respectively as observed by the two most important liver transplant registers: the United 
Network for Organ Sharing (UNOS) register in the United States of America (USA) and the 
European Liver Transplant Registry (ELTR) (5, 6). 
The consolidation of liver transplantation as a therapy for end-stage liver diseases can be 
accredited to: a huge improvement in surgical techniques, in anaesthetic protocols, in better 
patient selection and better perioperative management, establishment of better organ 
allocation systems, the creation of transplant intensive care units, the extensive use of 
radiological imaging for monitoring vascular and biliary status, and in the radiological and 
endoscopic interventional procedures to treat vascular and biliary post-transplant 
complications (4, 7). 
The previous “multidisciplinary approach”, which fundamentally contributed to the evolution 
and success of liver transplantation as therapy, was markedly influenced by the constant 
development and introduction, throughout the years, of new immunosuppressive drugs and 
protocols in the clinical practice. The poor initial armamentarium of immunosuppressive drugs 
constituted by corticosteroids (CS) and azathioprine (AZA) was expanded with the addition of 
the calcineurin inhibitors (CNI) cyclosporin A (CSA) and tacrolimus (TAC) in the 1980s. Later 
the introduction of mycophenolate mofetil (MMF) replaced AZA as purine inhibitor of choice, 
and then the mammalian target of rapamycin (mTor) inhibitor sirolimus (Rapamycin®) and 
posteriorly everolimus (Certican®) were introduced and used as liver immunosuppressive 
drugs in cases of nephrotoxicity due to CNIs and due to its protective oncological properties. 
Mono- or polyclonal antibodies have also been developed and used as induction 
immunosuppression (IS) strategy or in the treatment of CS-resistant rejection episodes (8). 
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This constant progress resulted in the observation of very defined eras on the patient 
immunological outcomes over time. After the introduction of CNIs, acute cellular rejection 
(ACR) rates decreased to 10% to 40% from approximately 80% before them and the chronic 
rejection to less than 5% (8-11). The remarkable reduction in the ACR rate in the era of new 
refined immunosuppression protocols contributed to the decrease of the incidence of 
opportunistic infections in the early time post liver transplantation, given that less CS pulse-
therapy, the commonest treatment for ACR, was administered to the patients (8). As a result 
of the highlighted progress and advances, one-year patient and graft survival rates improved 
considerably. Once the major problems affecting outcomes in the initial post-transplant period 
were overcome, the transplant medical community shifted its attention to improving the long-
term patient and graft survival rates, which have been impacted in most cases by three main 
issues: recurrence of liver diseases, consequences of long-life IS treatment, and failure of the 
liver allograft caused by chronic rejection. It is worth noting that long-life immunosuppression 
treatment can be implicated in at least in some degree in all of these issues. Autoimmune liver 
diseases can easily recur in under-immunosuppressed patients; allograft livers can develop 
chronic rejection under sub-optimized IS schemes (12-15). In contrast, over-
immunosuppression and long-term immunosuppressive therapy are strongly associated with 
increased morbidity and mortality of liver transplant recipients, mainly due to their 
consequences on recipients renal function, cardiovascular events, metabolic syndromes, 
infections and recurrent or de-novo malignancies (16-19). 
Aiming to reduce the negative effects of long-life IS treatment, many approaches to optimize 
and/or minimize IS regimens and in addition, to completely withdraw immunosuppressive 
drugs in well selected patients under strictly controlled clinical conditions have been conducted 
in recent years. Some IS withdrawal clinical trials reported that around 20% to 40% of selected 
liver recipients can be completely weaned off IS achieving the Spontaneous Operational 
Tolerance status (SOT) defined by persistent stable graft function without clinical and 
immunological damage in absence of immunosuppressive drugs treatment (20, 21). To better 
evaluate the patient baseline immune status, predict the success of the IS treatment 
withdrawal and eventually to early diagnose the failure of withdrawal attempt before the 
rejection episode has been set, liver transplant immunologists have combined a number of 
strategies to identify and develop predictive biomarkers of tolerance (22). In a recent 
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prospective multicentre clinical trial of IS withdrawal, the hepatic expression of iron 
homeostasis genes and serum-iron parameters were associated with the success of 
immunosuppressive drug withdrawal, pointing for the first time to the role of iron metabolism in 
the establishment of operational tolerance in liver transplant recipients (1, 2). Further clinical 
and/or experimental studies are needed to confirm the influence of iron on possible molecular 
and functional pathways involved in T-lymphocytes mediated immune response and its 
contribution to the establishment of operational tolerance. 
 
1.2 Long-term Immunosuppression consequences 
Nephrotoxicity, cardiovascular (CV) events, diabetes, hyperlipidaemia, obesity, infections and 
malignancies are associated with long-term IS treatment. These conditions have a huge 
impact on morbidity and mortality after liver transplantation, being responsible for 50 to 60% of 
deaths in the late period of liver transplantation (23-26). Although new immunosuppressive 
agents have been introduced, until now, CNIs remain as the keystone for the early and long-
term IS regimens in liver transplantation, therefore they are strongly implicated in the 
development of such immunosuppression comorbidities and consequences aforementioned 
(8, 27). 
 
1.2.1 Immunosuppression nephrotoxicity 
Twenty per cent of liver transplant recipients developed chronic renal failure at 5 years post 
transplant and among those surviving more than 13 years, 18% required dialysis or kidney 
transplantation (16, 28). Pre-transplant renal status, diabetes, hepatitis C virus (HCV) 
infection, nephrotoxic antimicrobial agents, and per-operatory hemodynamic and volume 
oscillations are risk factors for renal dysfunction; nevertheless the CNIs have a preponderant 
role (28-31). CNI-related nephrotoxicity is a continuum process initially reversible 
characterized by glomerular afferent arterioles vasoconstriction with tubular vacuolization and 
thrombotic microangiopathy, which reduces the glomerular filtration rate. Over time the lesions 
become irreversible and are marked by arteriolar hyalinosis, glomerular and tubular ischemia 
resulting in glomerular sclerosis and interstitial fibrosis. CNIs directly or indirectly activate and 
trigger many mediators and factors associated with these processes (32, 33). 
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1.2.2 Metabolic consequences of Immunosuppression 
A recent meta-analysis study was not able to identify IS treatment as a major risk factor for the 
metabolic syndrome due to data scarcity, contradictory results and lack of control groups. 
However in numerous previously published series, IS drugs have been considered a risk 
factor for various conditions of metabolic syndrome criteria (34). CS-free protocols in liver 
transplantation showed lower rate of weight gain, osteoporosis, hypertension, dyslipidaemia 
and diabetes on patients without CS or on those with early CS withdrawal. (35-37). Among 
recipients under CNIs therapy, TAC prompts to more diabetes occurrence, whereas CSA to 
more weight gain, hyperlipidaemia and also arterial hypertension (38, 39). The mTor inhibitors 
(sirolimus and everolimus) are strongly associated with hyperlipidaemia and 
hypertriglyceridemia requiring specific therapy in most of the cases (40). 
 
1.2.3 Cardiovascular events in Immunosuppressed liver recipients 
CV events are more prevalent in liver transplant recipients than in the general population 
being responsible for up to 20% of post transplant deaths. (23). CV causes of death include 
cardiac disease, myocardium infarction, cerebro-vascular accident and sudden death (41). 
Early post-transplant CV complications are more related with pre-transplant CV conditions 
whereas late complications are associated with long-life IS treatment. Apart from the CNIs 
direct effect on the arterial endothelium causing a hypertensive effect, immunosuppressive 
drugs, as previously cited, are associated with diabetes, nephrotoxicity, hyperlipidaemia and 
obesity, being in turn risk factors for CV events (15). Patients with elevated high-risk scores for 
CV events can be benefited by CNIs-free immunosuppression protocols introduction (17, 42, 
43). 
 
1.2.4 Malignancies and infections in liver transplant recipients 
The incidence rate of de novo malignancies in long-term liver transplant recipients is two to 
three times higher than in general population (5, 26). Furthermore, in a study with 4483 liver 
recipients surviving more than 1 year, malignancies were responsible for 30% of deaths (25). 
Besides the multiple factors associated with malignancies such as viral infections, exposure to 
sun, alcohol and tobacco consumption, and transplant indication; immunosuppressive drugs 
play an important role. Mainly the CNIs and AZA are particularly implicated due to their 
25 
molecular carcinogenic effects (19, 44, 45). For example, the recurrence rate of hepatocellular 
carcinoma is around 20%, and strongly associated with CNIs levels in spite of very strict pre-
transplant selection criteria (46). Chronic immunosuppressed liver recipients are more 
vulnerable to opportunistic infection, mainly viral, and some of them are strongly linked to 
development of specific type of malignancies (Kaposi sarcoma, nasopharyngeal carcinoma, 
cervical and vulvar cancer) as well immune-related malignancies as post-transplant 
lymphoproliferative disorders (PTLD), and tumours localized in sun-exposed areas (skin 
cancers) (19).  
All together, the described consequences of long-term IS exposure; raised the attention of 
medical transplant community to develop new strategies to minimize IS treatment, and with 
special interest on protocols aiming to completely wean the IS treatment (31, 47, 48). 
 
1.3 Liver allograft rejection 
Despite the immunosuppression protocols currently in use in liver transplantation, ACR rates 
are still around 40-50% (8, 10). If left untreated, ACR can cause graft destruction, which in the 
end may require a new transplant to save the patient’s life. ACR is the result of an 
uncontrolled immune response orchestrated by T cells against donor allograft cells (49). This 
phenomenon can be divided into three phases, beginning with the presentation of donor 
antigens; mainly MHC molecules expressed on the surface of donor cells, by specific APCs to 
the recipient T cells. This alloantigen recognition leads to the activation of recipient alloreactive 
T cells with their subsequent clonal expansion. Later, alloreactive T cells infiltrate the allograft 
and orchestrate an inflammatory reaction through direct cytotoxicity or via pro-inflammatory 
mediators, mainly against cholangiocytes and hepatic endothelial cells (49, 50). 
 
1.3.1 Alloantigen recognition 
Three different pathways of donor alloantigen recognition by recipient T cells have been 
described (51, 52). In the direct pathway, intact donor MHC molecules are recognised by 
recipient CD4+ and CD8+ T cells on the surface of donor-specific APCs, which are eventually 
transferred to the recipient within the liver graft. This pathway is predominant in the early 
stages after liver transplantation and it is the main allorecognition pathway involved in 
episodes of ACR that occur in the first weeks after liver transplantation. In the indirect 
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pathway, recipient APCs traffic through hepatic graft phagocyte soluble extracellular protein 
complexes that have been eliminated by donor cells by necrosis and/or apoptosis. These 
donor proteins are processed and presented on recipient MHC class II molecules to 
allospecific CD4+ T cells. Because of that, the indirect pathway takes longer to occur 
compared to the direct pathway, however, it becomes the dominant pathway in the long-term 
as the graft is a continuous source of alloantigens. On the other hand, the direct pathway 
tends to disappear as the donor APCs population decreases over time. The semi-direct 
pathway involves both donor and recipient APCs as intact cell surface molecules, including 
MHC molecules, which are transferred from donor to recipient APCs by direct contact between 
them or by engulfment of donor APC-derived exosomes (49-51). 
 
1.3.2 T cell activation 
As a consequence of alloantigen recognition, recipient T cells receive antigen-specific signals 
through the T cell receptor CD3. These signals alone are not able to induce a full T cell 
activation. For that, a second signal provided by the interaction of co-stimulatory molecules 
and their ligands is required. Co-stimulatory molecules are essentially divided in two main 
families: the B7 family containing the T cell co-stimulatory molecules CD28, CD152 (CTLA-4) 
and PD1, among others, which bind to the CD80/CD86 ligands on the APCs; and the 
TNF/TNFR receptor family, represented by the prototype CD40 and CD154 (CD40L). 
Following T cell activation, large amounts of IL-2 and other pro-proliferative cytokines are 
produced and act in autocrine and paracrine fashion providing the third signal necessary for 
the clonal expansion and differentiation of activated T cells (50, 51, 53). 
 
1.3.3 T cell differentiation, graft cell infiltration, and tissue destruction 
The fate of T cell differentiation depends on the microenvironment and the additional signals 
they receive upon activation. In the presence of TGF-β and in absence of proinflammatory 
cytokines, CD4+ T cells acquire tissue protective phonotype, which is involved in the 
regulation of the immune response, the so-called regulatory T cells (Tregs). On the other 
hand, in the presence of proinflammatory cytokines, CD4+ T cells acquire tissue destructive 
phenotype such as the Th1 and Th2 cells. These CD4+ and also CD8+ cytotoxic T cells 
infiltrate the graft causing tissue damage through direct cytotoxicity (49). Graft destruction is 
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also caused by the classic delayed-type hypersensitivity (DTH) reaction, which is stimulated 
by alloantigen-specific CD4+ (mainly Th1) and CD8+ T cells that have been activated by the 
direct and indirect pathway. There is a huge production of many soluble mediators as pro-
inflammatory cytokines and chemokines contribute to the graft infiltration by the other cells 
such as activated leukocytes, mainly monocytes and eosinophils, natural killer cells and 
macrophages among other cells. A third mechanism of graft injury is mediated by the 
complement activation or antibody-dependent cytotoxicity; this mechanism is responsible for 
the antibody mediated acute rejection. ACR is mainly due to CD4+ and CD8+ T cell infiltration 
and tissue destruction and by the DTH reaction (51, 54). Due to the necessity of specific T cell 
priming, activation and proliferation, ACR usually does not occur in the first week after liver 
implantation. The incidence is higher in the first three months post-transplant, but it can also 
occur months or years after transplantation. The clinical symptoms are nonspecific, usually 
with late onset in the course of an ACR episode and are characterized by fatigue, fever, 
abdominal pain and jaundice. Elevated levels of bilirubin, transaminases and alkaline 
phosphatase reflect liver damage caused by ACR. The diagnosis is confirmed by a liver 
biopsy that shows characteristic histological findings of portal tract inflammation, bile duct 
injury and venous inflammation, which is often associated with centrilobular necroinflammation 
of hepatic venules and surrounding hepatocytes (55-58). 
 
1.4 Liver transplant tolerance 
Due to its anatomical, cellular population and functional characteristics, the liver presents a 
unique immunological capacity. It is able to move from an orchestrated immune response 
against invasive pathogenic microorganisms towards a still incompletely understood immune 
hyporesponsiveness and immune tolerance observed in specific conditions such as HCV 
infection, and in a more intriguing way after liver transplantation (59-61). Indeed, in the solid 
organ transplantation setting, the liver has been considered more tolerogenic than other 
transplanted organs. This concept was initially supported by experimental studies showing a 
liver recipient exhibiting a spontaneous tolerance against donor liver graft in a full 
donor/recipient major histocompatibility complex (MHC) mismatch pairs in pigs, mice and in 
some rat strain combinations (62, 63). In addition, some strategies to induce tolerance 
revealed to be successful in rodents (64). In humans, clinical findings endorse the 
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aforementioned hepatic trend toward tolerance. Liver transplant recipients need less potent IS 
regimens, with lower blood through levels of IS drugs than those practiced for other solid 
transplanted organs and/or preconized by pharmaceutical industry (65). Hyper acute rejection 
is a rare condition in liver recipients, and episodes of ACR do not impact liver recipient long-
term outcome. Chronic rejection is less frequent than in all other solid transplanted organs. 
Furthermore, there is not a significant benefit from human leucocytes antigens (HLA) 
matching, and even that positive cross match could be associated with more acute cellular 
rejection episodes; their correlation with worse outcome is not clearly demonstrated (66-70). 
Besides that, it has been demonstrated that a small group of liver recipients (non-compliant 
patients, patients with severe infections or malignancies), who had completely discontinued 
the IS treatment, were able to keep the liver allograft with normal function and without 
immunological graft injury for a long period of time, a stated posteriorly so-called spontaneous 
operational tolerance as described previously (20, 71). 
 
1.4.1 Distinctive immunological hepatic properties 
The aforementioned distinctive hepatic immunological properties have been attributed to its 
anatomical position, cellular population and physiology. Anatomically situated between the 
gastrointestinal tract and the systemic circulation, the liver has a peculiar dual vascularisation. 
Approximately 80% of its blood volume is supplied by the portal vein (PV); and while only 20% 
of the total blood volume reaches the organ via hepatic artery (HA) almost all-hepatic 
oxygenation is artery dependent. Intestinal, pancreatic and splenic low oxygenated blood 
outflow is drained to the liver through the portal system bringing all necessary food nutrients 
but also constantly exposing the hepatic parenchyma to all food-derived antigens, 
environmental toxins, pathogenic (mainly bacterial) and blood degradation products (59, 60). 
Inside the liver, venous and arterial blood flows are mixed passing through a unique 
honeycomb shaped system of sinusoids formed by a specific cellular type named liver 
sinusoidal endothelial cells (LSECs), arranged in such a way that makes it the only interface 
between blood flow and hepatocytes due to the lack of a basal membrane supporting the 
LSECs. At the same time blood pressure drops drastically from the PV and from the HA to the 
sinusoids resulting in a very slow blood flow into the sinusoids. These two conditions facilitate 
the contact and interaction between all blood contents with the multiple subsets of 
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parenchymal and non-parenchymal liver cells, which include LSECs, the professional antigen-
presenting cells (APC) dendritic cells (DC), Kuppfer cells (the liver resident macrophages), 
hepatic stellate cells (HSC), intrahepatic lymphocyte T cells (T cells) and hepatocytes. Also, 
interactions between those cells are common and sometimes they present overlapping 
functions. The hepatic chronic exposition to lipopolysaccharide (LPS) and other bacterial-
derived products from the gut and the recognition of these molecules by Toll-like receptors 
results in an anti-inflammatory cytokines production such as interleukin-10 (IL-10) instead of a 
pro-inflammatory response (72, 73). An additional key aspect of liver immunobiology is the fact 
that antigens can be presented in the liver microenvironment not only by professional APCs 
such as DCs, but also by cells such as LSECs, HSC and hepatocytes. Of note, presentation of 
antigens by these cells may usually result in sub-optimal T cell activation, as a result of the 
lack of adequate co-stimulation and the abundance of immunosuppressive cytokines. The 
result of this tends to be the apoptotic deletion of the antigen-specific T cells. In the clinical 
setting, the use of co-stimulation inhibitors in combination with reduced doses of CNI has been 
proposed to reduce the side effects associated with CNI. The use of CTLA4-Ig, which inhibits 
the CD80/CD86 co-stimulation signalling, has been addressed by many studies in kidney 
transplantation with interesting results (74). In contrast, in the context of liver transplantation, 
patients treated with CTLA4-Ig had a higher rate of rejection and mortality compared to 
patients who received CNI-based immunosuppression (75, 76). In addition to the potential bias 
due to the study design, one of the mechanistic reasons for these discouraging results could 
be that, in the hepatic environment, different co-stimulation pathways are involved in the 
activation of T cells. As animal studies show, PD-1 / PDL-1 co-stimulatory signalling is strongly 
involved in the activation of T cells in liver transplantation (77). 
 
1.5 Achievement of Tolerance in Liver Transplant Recipients  
Initial anecdotal clinical observations that some liver recipients can remain completely off IS 
treatment without immune allograft damage prompted the conduction of many clinical trials 
aiming to minimise or completely discontinue IS treatment as a strategy to avoid the 
deleterious effects of long-term IS. Such minimization strategies included conversion to non-
CNI IS schemes, early steroid withdrawal or avoidance, and minimizations of CNI protocols 
usually made on a trial-and-error basis. Another approach tested to decrease specific IS side 
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effects, such as diabetes and nephrotoxicity, was the combination of IS drugs at reduced 
doses. Due the wide variety of IS minimisation study designs with variable sample size, non-
homogenous patient inclusion criteria and different IS weaning protocols, results have not 
been consistent. This in turn has hampered the elaboration of evidence-based IS guidelines in 
order to decrease patients IS associated comorbidities. Therefore, long-term IS minimisation is 
still considered an empirical clinical practice (78, 79). Attempts to induce tolerance in early 
time post liver transplantation have been tried by employing T cell depleting therapies, 
associated or not with simultaneous infusion of donor hematopoietic cells, followed by rapid 
minimisation of the maintenance IS, generally based on monotherapy immunosuppression. 
Unfortunately, due to toxic effects of induction therapies, issues due to availability of donor 
cells, small series and patient selection bias; it has been difficult to interpret the overall results 
from these studies (80-83). Supported by experimental animal studies, the infusion in the post-
transplant period of ex-vivo expanded liver recipient regulatory T cells (Treg) collected at any 
time before or after the transplant procedure has been advocated as a promising therapy to 
induce tolerance. Several groups are currently exploring this strategy. Many of the on-going 
trials are still in the initial phases and various issues have been raised concerning the doses 
and infusion time of cells (84, 85). In a recent seminal Japanese study, the infusion of Tregs in 
the earlier time post living donor liver transplantation (day 13 post-transplantation) was 
employed to induce tolerance. This strategy was associated with a per-operative splenectomy, 
T cell depleting therapy at day five post-transplantation and an initial triple IS therapy 
(Steroids, Calcineurin inhibitors and Mycophenolate Mofetil). Steroids and Micophenolate 
mofeil were withdrawn by the end of the first month and calcineurin inhibitors supposed to be 
completely withdrawn at the end of the 18th months post transplantation. Using this protocol, 
the authors were able to induce tolerance in 7 of the 10 enrolled liver recipients. All ACR 
episodes occurred in patients presenting autoimmune liver diseases. Although the clinical trial 
was designed to enrol 40 patients, it was suspended early because 3 episodes of ACR 
occurred during the IS weaning period. It is interesting to highlight that splenectomy, a 
procedure not often performed in Western countries during the liver transplantation, was a part 
of their robust induction protocol. Furthermore, the Treg-enriched cell pool was generated from 
leukapheresis performed few weeks before the transplant and from splenocytes harvested 
from the spleen specimen resected at the time of the transplant procedure. Cells were not 
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cultured in good manufacturing practice (GMP) conditions and at the end, a mixture of immune 
cells with a wide variation of cell subsets between patients were infused, making the 
reproducibility of their protocol difficult. Also, in western countries, most transplants are 
performed using cadaveric liver transplants, which makes it more difficult to prepare and 
infuse the Treg-enriched cell pool at predefined times. For these reasons, the use of such a 
protocol in western countries would not be appropriate. However, these remarkable results 
have already been considered as a milestone in liver transplant tolerance research, prompting 
new studies to search for more accurate protocols using Treg cell infusion (86, 87). 
 
1.6 Immunosuppression withdrawal trials 
The complete discontinuation of IS treatment in stable liver recipients is a feasible approach to 
identify liver transplant recipients who spontaneously became tolerant in the later times post 
transplantation when realised under controlled conditions. This concept came about after 
Starzl et al. reported a small series of 6 liver transplant recipients who maintained normal liver 
function tests (LFTs) after total discontinuation of IS drugs due either to non-compliance or 
lymphoproliferative disorders. This initial report inspired posterior prospective studies in order 
to better characterise this phenomenon (20, 71, 88). Prompted by the capacity of those 6 
previously mentioned liver recipients to maintain normal LFTs and no histological damage in 
the absence of IS therapy, Mazariegos et al., from the same group of Prof. Starzl, planned and 
conducted the first prospective clinical trial of intentional IS withdrawal in patients presenting 
clinical adverse effects of long-term IS therapy. Out of 95 liver recipients enrolled, 18 were 
successfully completely weaned off IS therapy (71, 89). From this clinical trial onward, many 
studies aiming to completely wean the IS treatment have been reported often in small series of 
liver transplant recipients. These studies employed different criteria for patient selection and 
for the IS weaning strategies, which could had contributed to a wide range of success going 
from the lowest 5% successful rate in one study up to a 60% in recent well controlled study 
with a overall average prevalence of 20% (Table 1) (20, 21). However, from the review of their 
patient selection criteria and IS weaning protocols, some favourable inclusion clinical criteria 
for successful IS withdrawal were visible. They were composed of: liver recipients with at least 
3 years after transplantation, preference for more than 6 years after transplantation, 
predilection for non-autoimmune liver disease as an indication of transplantation (due to the 
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increased risk of recurrence of primary autoimmune liver disease and risk of developing a 
rejection episode during the weaning protocol), there are no recent ACR episodes and there 
are no significant histological or LFT abnormalities before the start of the IS weaning protocol. 
Furthermore, withdrawal protocols are generally performed over a 6 to 9 months period with a 
progressive IS drugs weaning with usually no more than 25% dose reduction at each 3- to 4-
week interval. 
Table 1: Immunosuppression withdrawal clinical trials on liver transplant recipients 













Mazariegos et al(89) 1997 Pittsburgh – USA 95 19 (18) 26/0 0 
Devlin et al(90) 1998 KCL London – UK 18 16.7 (3) 28/5.6 5.6 (1) 
Takatsuki et al(91) 2001 Kyoto – Japan 26 23.8 (6) 12/0 0 
Pons et al(92) 2003 Murcia – Spain 9 33 (3) 6/0 0 
Eason et al(93) 2005 New Orleans – USA 18 5.6 (1) 61/0 0 
Tryphnopoulos et al(94) 2005 Miami – USA 104 19 (20) 67/1.9 0.96 (1) 
Tisone et al(95) 2006 Rome – Italy 34 23.4 (8) 76.4/0 0 
Assy et al(96) 2007 Ontario – Canada 26 8 (2) 58/0 0 
Pons et al(97) 2008 Murcia – Spain 12 41.6 (5) 58.3/0 0 
Feng et al(98) 2012 American multicentre 20 60 (12) 35/0 0 
Benítez et al(1) 2013 European multicentre 102 42 (41) 58/0 0 
de la Garza et al(99) 2013 Pamplona – Spain 24 62.5 (15) 33/4.1 0 
Bohne et al(100) 2014 Barcelona/Valencia – Spain 34 50 (17) 44/0 0 
 
Due to the importance of this strategy, substantial research grants have been recently 
allocated to support studies of IS discontinuation in liver transplantation, notably by the 
Immune Tolerance Network (ITN) in the USA and the Reprogramming the Immune System for 
the Establishment of Tolerance Consortium (RISET) by the European Union. These programs 
supported the first two very well controlled multicentre clinical trials; whose results suggested 
that tolerance could be achieved in higher rates at late time points after transplantation. In the 
American paediatric study, 60% of the 20 living donor liver recipients enrolled were able to 
completely discontinue IS drugs, while in the European adult trial, 41 out of 102 enrolled liver 
recipients achieved the status of spontaneous operational tolerance (1, 98). A second IS 
withdrawal clinical trial that was conducted by the same European group, was designed to 
investigate whether the presence of on-going liver infection process could impair the SOT 
achievement once all enrolled liver recipients were HCV-RNA positive. Employing the same 
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previously described IS withdrawal protocol, 50% of the 34 enrolled liver recipients were able 
to achieve the study primary end-point and became SOT (100). In all three clinical trials, 
rejection episodes in patients who failed the withdrawal were mild and almost all patients were 
treated by re-introduction of initial IS doses with a short course of CS in a low dosage. No liver 
recipients lost the allograft due to the IS discontinuation attempt. The clinical characteristics 
associated with successful IS weaning were older liver recipients, longer time passed from the 
transplant procedure, and minimal IS treatment before starting the weaning protocol. Being 
statistically significant in the first European and in the American multicentre clinical trials, the 
most robust clinical marker associated with SOT development was when more time had 
elapsed after the liver transplant (1, 98). Unfortunately, none of these clinical parameters could 
be used as predictor marker of operational tolerance achievement. In that context, the 
identification of biological markers of tolerance could be very helpful, in order to circumvent the 
exposition of less tolerogenic liver recipients to unjustifiable risk of rejection episodes (88, 
101). 
 
1.7 Biomarkers of spontaneous operational tolerance and of acute 
cellular rejection occurring during IS withdrawal from liver transplant 
recipients  
Even taking into account the inclusion and/or exclusion clinical criteria already identified in 
association with successful IS weaning, there is still a considerable risk for rejection 
occurrence during IS withdrawal protocols. In this scenario, the identification of liver recipients 
likely to become tolerant or liver recipients bearing tolerance characteristics before the 
initiation of IS weaning protocols should be a key step in the liver selection process (101, 102). 
Unfortunately, the two most robust “clinical markers” of successful IS weaning (age and time 
elapsed from liver transplant procedure) are not able to precisely forecast the result of IS 
withdrawal protocols; which raises the necessity for identification of more accurate biological 
predictors of liver spontaneous operational tolerance (88). Biomarkers were defined as “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” 
by Biomarkers Definitions Working Group (103). Tolerance biomarkers can be used to identify 
those liver recipients prone to become tolerant, thus circumventing the exposition of unlikely 
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tolerant liver recipients to the ACR development and graft failure risks. Likewise, they are also 
useful for the immune monitoring of established tolerant liver recipients over time when 
tolerance status could in theory fails at later time point after its establishment. Furthermore, 
the identification of biomarkers able to predict ACR episodes before their clinical or histologic 
manifestation could be used as immune monitoring safety tool in IS withdrawal protocols. As 
different types of cells, and different subsets of T cells, are involved on the liver allograft 
tolerance development and on the occurrence of ACR episodes, tolerance and rejection 
biomarkers will be, by analogy, characterized by allograft cell phenotype and their behaviour. 
In fact, the already described biomarkers and assays used in this setting aim to 1) 
characterize the allograft cell populations and subsets, 2) identify and quantify cytokines or 
other cellular product from defined immune cell population, and/or 3) investigate the immune 
cell functional status quantifying the degree of activation, proliferation, gene transcription 
profile, and the production of immune related molecules as pro-inflammatory cytokines by 
activated T cells (102). 
 
1.7.1 Biomarkers of spontaneous operational tolerance in liver transplantation 
Biomarkers of SOT have been researched since the description of the original 6 tolerant liver 
recipients. Indeed, in the same report, the authors reported an exhaustive series of tissue and 
blood analyses performed in a series of liver recipients, which included those off IS treatment, 
aiming to clarify the allograft acceptance phenomenon (61). Subsequent reports, from the 
same group and others, attempted to differentiate tolerant from non-tolerant liver recipients 
using flow cytometry cellular immunophenotyping. So, the Pittsburgh group described a higher 
plasmacytoid DCs/monocytoid DCs cell ratio in SOT or liver recipients undergoing IS 
withdrawal in comparison to liver recipients under IS therapy or those who had failed IS 
withdrawal attempt (104, 105). Later on, other cross sectional studies comparing long term 
SOT liver recipients with age-matched volunteers and/or stable immunosuppressed liver 
recipients disclosed a higher frequency of regulatory CD4+CD25+ T cells among SOT 
recipients in peripheral blood mononuclear cells (PBMC) by flow cytometry in paediatric and 
adult SOT liver recipients (106, 107). The presence of FoxP3+ T cells was detected in liver 
biopsies from SOT paediatric living-donor liver recipients, whereas FoxP3+ T cells were absent 
in liver recipients with clinical characteristics of chronic rejection (108). In a prospective IS 
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withdrawal clinical trial, CD4+CD25+ and CD4+CD25high+ T cell populations and FoxP3 
transcripts progressively increased in blood samples sequentially collected throughout the IS 
weaning protocol and stayed elevated in liver recipients who were able to completely 
discontinue IS drugs, a phenomenon that was not observed in recipients who failed the 
protocol, in whom these cell populations remained stable during the entire protocol (97). In a 
first study employing microarray gene expression profiling, Martinez-Llordella et al. sought to 
identify gene footprints present in peripheral blood samples capable to differentiate long-term 
SOT liver recipients from those under IS treatment. Those signatures contained genes 
encoding for γδ T cells, CD8+ and natural killer (NK) receptors, and many proteins associated 
with cell proliferation arrest (107). In the following work, with an enlarged cohort of SOT liver 
recipients, the same authors, using the training and validation set protocol design, reported a 
group of gene signatures containing up to seven genes capable to accurately discriminate 
tolerant from non-tolerant liver recipients suggesting that transcriptional gene profile of 
peripheral blood could be useful in identifying candidates to IS discontinuation (109).  
Focusing on the identification of possible mechanisms involved in the tolerance development 
process and on tolerance biomarkers which could predict the success of the weaning protocol 
before changes in the IS treatment, Bohne et al. conducted a molecular study analysing 
sequential biological samples taken at the enrolment time, during the weaning protocol, and in 
the follow-up after total IS discontinuation or after the rejection episode from patients enrolled 
in the initially mentioned European multicentre IS withdrawal clinical trial. The molecular 
analysis of liver biopsies taken before the initiation of IS drug diminution accurately 
discriminated tolerant from non-tolerant liver recipients. The two groups of patients had 
differentiated expression of genes involved in iron homeostasis, notably the transferrin 
receptor (TFRC) and the hepcidin antimicrobial peptide (HAMP). Differences were also 
observed in the serum levels of hepcidin (the only iron absorption regulator currently known), 
ferritin, and in levels of hepatocyte iron deposition. Five genetic classifiers with up to 9 genes 
transcripts were reported to be able to forecast the result of IS weaning protocol with much 
sensitivity, specificity, and negative and positive predictive value; with less than 17.5% overall 
error rate. All of those genetic footprints contained at least two genes involved in iron 
homeostasis. Altogether, these results highlighted for the first time the influence of iron in the 
regulation of intra-graft allo-immune responses in liver transplantation pointing to the necessity 
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of further clinical and experimental studies in order to better understand how iron metabolism 
could interact with liver allograft acceptance by the recipients (2). 
 
1.7.2 Biomarkers of acute cellular rejection during intentional IS withdrawal 
protocols 
In the context of IS withdrawal monitoring, the identification of molecular biomarkers able to 
detect ACR in its early phases during the weaning period could be as useful as the finding of 
predictive tolerance biomarkers prior to starting the withdrawal protocol. Such ACR-associated 
biomarkers could be used as a fundamental monitoring immunologic tool throughout the IS 
weaning period. Theoretically, the detection of molecular biomarkers of rejection by non-
invasive tests before serum liver tests deterioration alteration and/or liver graft histological 
alteration in a given patient under IS weaning protocol could trigger some clinical strategies in 
order to halt the rejection evolution. Some of these measures could be: 1) holding up the 
weaning protocol, 2) reverting the doses of IS drugs to the previous IS doses, 3) spacing the 
time between drug reductions and 4) excluding the liver recipient from the weaning protocol.  
Blocking the ACR progression in its beginning when only rejection biomarkers are detected 
and no intense lymphocyte allograft infiltration has yet occurred could in theory, spare future 
non-tolerant liver recipients from the complete immune system reactivation manifested by 
clinical, laboratorial and histological ACR image. This strategy could avoid the “rejection 
priming effect”; which can prevent later attempts of IS withdrawal when those patients will be 
older and more time will have elapsed from the transplant procedure, these two being the 
most robust clinical factors associated with successful complete IS withdrawal. It is worth 
highlighting that normally, candidates for IS withdrawal clinical trials present stable LFTs, no 
important histological liver allograft damage at enrolment time and no occurrence of ACR 
episode in the previous 12 months before trial inclusion (1). Furthermore, in liver transplant 
settings, few studies have addressed the molecular profile and cellular pathways associated 
with ACR, hampering its own characterization and making difficult the comparison with cellular 
rejection occurring in other solid organs transplantation, such as in kidney and heart 
transplantation difficult. This could be related to the fact that the molecular assessment of ACR 
at the early time post-liver transplantation is strongly influenced by possible confounding 
factors such as ischemic-reperfusion injury, surgical complications inherent to the procedure 
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and/or systemic consequences of underlying liver end-stage disease, as well as the high 
incidence of opportunistic infections. Historically, liver recipient patients with more than 3 years 
post transplant have higher probability of becoming SOT when compared to liver recipients 
with less than 3 years after transplantation. Therefore the minimum period of 3 years after liver 
transplantation is currently accepted as an inclusion criterion in most clinical trials of IS 
withdrawal. In addition, at this stage, the aforementioned confounding factors that may 
influence the molecular characterization of ACR are absent and sequential biological 
specimens (liver tissue, blood samples, urine and stools) can be obtained at precise time 
points for monitoring purposes. So, it is expected that detected molecular changes will 
probably be more related to the ACR episode than to another possible event. As such, the 
clinical setting of IS withdrawal trials appears to provide the appropriate scenario for 
characterizing ACR biomarkers. In these studies, liver recipients recruited less than 6 years 
after transplantation were the most at-risk population to fail the IS weaning protocol and to 
develop an episode of ACR, compared to liver recipients whose transplants were performed 
more than 6 years before (87% vs. 62%) (1). Thus, the majority of patients included in a 
prospective study to characterize ACR biomarkers in the context of IS withdrawal should have 
less than six years of follow-up after liver transplantation. 
 
1.8 High-throughput gene expression experiments  
Microarray essays have the property to determine transcription expression levels of thousands 
of genes at the same time. The study of the all cellular or tissue sets of ribonucleic acid (RNA) 
transcripts, the transcriptome, can provide a comprehensive dynamic understanding of physio- 
or pathophysiological processes in a given moment. This so-called gene fingerprint 
determination is particularly interesting for studies related to the dynamic allograft acceptance 
or rejection processes in the organ transplant field (110, 111). However, some specific 
measures should be observed for the correct use of the microarray technology, otherwise data 
acquisition and analysis can be problematic and lead to spurious conclusions. Such measures 
include experiment design, array probe selection, samples choice, control of probe 
hybridization, expression levels image acquisition and transformation, data normalisation and 
filtering, correct statistic analysis and interpretation (112).  
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1.8.1 Microarray technique 
Basically, the microarray method requires messenger RNA (mRNA) extraction from biological 
samples, which is reverse-transcribed into complimentary deoxyribonucleic acid (cDNA). The 
cDNA is labelled with a fluorescent dye and then applied into a slide support, usually a quartz 
surface sealed inside a plastic cartridge, the microarray gene chip, where dozens of 
thousands of cDNA probes, each of them characterizing a particular gene, are robotically 
printed in a defined address in the array support. After a “hybridization” phase, the gene-chip 
is washed to eliminate probe-unbound cDNA. Finally the gene-chip is laser-scanned for data 
acquisition by capturing the image of all fluorescent intensities of the dyes labelled to the 
hybridized cDNAs with posterior transformation into intensity values. When the signal captured 
at a determined spot is more intense; then the expression profile is more abundant for that 
gene specifically identified by the probe placed at the exact position in the gene chip (113, 
114). Initial gene-chips made with cDNA probes currently have been replaced by gene-chips 
printed with oligonucleotide probes due to their higher DNA specificity and lower cross-
hybridization effects that were frequently detected in first cDNA gene-chip versions (115). 
 
1.8.2 Microarray experiments 
Gene profiling experiments using microarray technology have been widely used in 
transplantation (116). In transplant research, as well in other clinical fields, microarray 
experiments are usually divided into unsupervised and supervised methods. In the 
unsupervised methodology, clinical samples are clustered based on gene expression profiling 
with no previous knowledge of biological and clinical information. The objective here is to 
identify subgroups presenting specific patterns with possible clinical interest based on gene 
similarities (117). Applying the hierarchical clustering methodology, Mueller et al. were able to 
disclose a subgroup of kidney transplant recipients at increased risk for developing delayed 
graft function based on the analyses of the transcriptome of post-reperfusion kidney biopsies 
(118). Conversely, the supervised method’s objective is to determine differentially expressed 
genes that fit a predefined clinical pattern. These strategies are subdivided in class 
comparison and class prediction studies. The former approach aims to differentiate distinct 
groups based on differentially expressed genes, while the latter strategy’s objective is to 
generate a mathematical algorithm containing differentially expressed genes that could 
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accurately predict the response to a treatment or to a specific clinical strategy adopted (119). 
As aforementioned, Martinez-Llordella et al. used a class comparison strategy to analyse 
PBMC gene expression profile in order to discriminate tolerant liver recipients from 
immunosuppression-dependent patients. In the following study, the same group applied the 
class prediction approach to define a gene signature to predict which liver transplant recipients 
were prone to develop spontaneous operational tolerance (107, 109). 
 
1.8.3  Microarray experiment design challenges 
In a representative microarray experiment, expression levels of thousands of genes are 
produced per sample in the same experiment, which represents an enormous quantity of data 
to process and analyse. This condition, the “curse of dimensionality” is tightly linked to the 
restricted number of samples normally available per study group, the “curse of dataset 
scarcity”. The challenge concerning this common situation in transplant studies is to extract 
the correct clinical interpretation from too much data originated from few tested samples (120). 
The risk here is to find a highly superior number of gene candidates to constitute a gene 
classifier from a reduced number of available cases. Such classifier could accurately 
discriminate a specific data set but with no veritable correlation between the gene profiling and 
the clinical pattern studied. Experiment designs including internal validation mechanisms try to 
circumvent the reduced sample’s limitation (121). The “split sample validation” strategy has 
been largely used in studies aiming to determine tolerance gene signatures, particularly in 
kidney transplantation due to the low availability of tolerant kidney recipients to include, as well 
in other transplant organs. This methodology uses a “training set” of samples to create the 
gene classifier, which is posteriorly confirmed in a distinct “validation set” of samples (109, 
122-124). The leave-one-out cross validation (LOOCV) method is mainly employed when the 
creation of two distinct groups is very limited by the scarce number of samples. Here the 
classifier is repeatedly developed as many times as the number of samples, testing at each 
time one different sample against the group of remaining samples used in this case as the 
training set (125). Microarray analysis of cardiac biopsies from heart recipients using the 
LOOCV method was able to identify two different gene sets to differentially predict ACR from T 
cruzi infection at least 2 weeks before histological diagnostic (126). A similar approach, the 
leave-one-organ-out analysis, was applied in meta-analysis examining data sets from four 
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different transplanted organs (kidney, heart, lung and liver) to determine a common rejection 
gene signature. Due to the unbalanced number of datasets from each organ and in order to 
determine a gene-set overexpressed independently from the organ origin, Katri et al. removed 
datasets from each organ one at a time. A common signature containing 11 genes significantly 
overexpressed was identified across all four transplanted organs during the acute cellular 
rejection process (127). 
 
1.8.4 Microarray data analysis 
The analysis and interpretation of the huge amount of data generated by microarray 
experiments constitutes an unquestionable challenge for biological researchers. Currently, it is 
impossible to tackle those tasks without the help provided by Bioinformatics, the umbrella term 
used to define an interdisciplinary science field that combines biological fundaments, 
mathematic tools, statistical methods and computational software to analyse and interpret 
biological data (128). 
 
1.8.4.1 Data normalization 
Raw microarray results are inappropriate for a straight statistical analysis and interpretation. 
Actually there are many causes of systematic variation in a microarray experiment that are not 
truly related to the biological phenomenon. Sources of variation such as differences in dye 
labelling efficiency, unequal RNA quantities, background noise, spot overall intensity and 
probe gene chip position (print-tip variation) are inherent to the microarray method, which can 
influence the gene expression levels measurement (129). Those systematic variations need to 
be removed by the data normalization process before any definitive analysis. Data 
normalization aims to minimize the influence of those variations. As consequence, the true 
biological differences become more evident, which makes the analysis of gene expression 
levels within a single gene chip or between more than two gene chips comparable (130, 131). 
The transformation of raw data in a logarithmic scale is a recommended pre-normalization 
step due to the fact that fluorescent dye intensity values are highly asymmetric and it is 
assumed that log scales provide normal distribution data (132-134). Different normalization 
techniques are available, such as: quantile normalization, variance stabilizing normalization 
and background subtraction. The choice of the normalization technique will depend on the 
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type of microarray experiment. As an example, quantile normalization can be used in 
experiments employing two fluorescent dyes, as it renders the dyes’ intensity distribution 
identically for all arrays and colours. Also, depending on the experiment’s configuration there 
are three possible obtainable situations: i) normalization inside one gene chip, ii) paired gene 
chips normalization and iii) multiple gene chip normalization. For each situation, a set of genes 
has to be defined for the normalization. Global normalization uses all the genes in the array for 
the normalization when it is expected that only a small proportion of genes will be differentially 
expressed or there is symmetry in the expression levels of down- and up-regulated genes. 
Another option is the local normalization, when only a small group of genes that presents a 
constant expression level across different conditions, the so-called housekeeping genes, is 
used as reference in the normalization process (132, 134). 
 
1.8.4.2 Data Filtering 
Usually, a small number of samples generate thousands of gene expression levels in a 
microarray experiment, which is responsible for a dimensionality issue. Statistically, it is 
expected that the number of false positive results, the type I error, increases when thousands 
of gene expressions levels are tested at the same time. However, the strict control of the false 
positive rate can decrease the sensitivity of the experiment to disclose the real differentially 
expressed genes (135, 136). Furthermore, many probe sets in a gene chip are associated with 
non-expressed genes or genes with small expression profile and with no relevant association 
with the biological condition in question and their expression levels. Removing those genes’ 
expression levels, considered experiment background noise, through a filtering process 
reduces the dimensionality problem (fewer results to analyse) and increases the experiment’s 
power to discovery the real differentially expressed genes (137). However, as filter strategies 
and threshold levels are arbitrarily defined, caution should be taken to avoid an over filtering 
issue, which can exclude the true differentially expressed genes with real interest for the 
investigated biological condition from the final microarray analysis (134, 138). 
 
1.8.4.3 Controlling multiple hypothesis testing  
The greatest advantage of a microarray experiment for determining the expression level of 
thousands of genes at the same time can also be a risk factor for the data analysis, due to the 
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fact that there are too many data being analysed simultaneously. This situation characterizes 
the multiple hypothesis testing, wherein each gene expression level from all the genes from 
that specific microarray experiment are tested at the same time against the null hypothesis, 
which on occasion can be defined by not been differentially expressed and no association 
between the expression level and the studied condition (129, 139, 140). Therefore, traditional 
t-statistic tests and parameters are not adequate for such analyses. For instance if the 
historical p-value of 0.05 is used as significance threshold to identify differentially expressed 
genes in a microarray experiment where the expression levels of 25.000 genes were 
determined, it is expected that approximately 1250 genes would attain this value merely by 
chance, even when they are not truly differentially expressed. More appropriate statistical 
methods to analyse the multiplicity testing effect of microarray data, have been described 
(129). Probably the simplest and initially extensively used is the Bonferroni correction method. 
A new significance threshold value (α) value is calculated when the p-value (0,05) is divided 
by the number of n separate tests performed. In other words, the α value expresses the 
probability that at least one gene is considered significantly expressed when it is not. This is 
known as the family wise error rate (FWER). As FWER is considered too strict for the 
microarray analysis, a better option is to define the percentage of genes identified by chance 
in a given microarray experiment, the so-called false discovery rate (FDR). The proportion of 
truly differentially expressed genes, the true difference distribution, measures of variability, 
and samples characteristic, influence the FDR calculation (141). FDR is frequently calculated 
using the significance analysis of microarrays method (SAM) in most of the studies focusing 
on tolerance or rejection allograft signatures (100, 142-145). SAM employs adapted t-test 
methods for each gene in a dataset. A score for each gene is calculated based on its 
expression level changes in proportion to the standard deviation of repeated quantifications for 
that gene. Normally, in a SAM procedure, up to a thousand permutations tests are performed 
per each gene in order to identify whether the expression level is significantly associated with 
the condition studied by the experiment. Genes with values above a pre-determined threshold 
are considered as being significantly differentiated. A smaller or a larger set of identified 
significant genes depends on adjustments to the threshold level. Normally, most of studies 
assume a FDR threshold to 5% (146).  
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The prediction analysis of microarrays (PAM) is another t-statistic test modified by the 
incorporation of a fudge factor in its formula; which is commonly employed in class prediction 
transplant studies (109, 147). PAM aims to identify significant genes to be included in a 
prediction gene classifier by the measurement of the difference between the mean expression 
level of a given gene in a set of genes with the overall mean of expression level of such gene 
(148). In the transplant field, the PAM methodology has been used to identify gene signatures 
able to predict tolerance in long-term stable transplanted patients as well as constructing gene 
classifiers able to predict acute cellular rejection (109, 147). 
Furthermore, a possible microarray interpretation pitfall is only to consider the expression level 
changes from individual genes, which can produce misleading results. A given list of 
statistically significant genes may have no correlation with the biological condition 
investigated. Single-gene analysis does not consider the global effect of gene sets in a 
specific biological pathway. Sometimes a small expression increase of all genes involved in a 
particular metabolic pathway is more effective to regulate a cell process than an exponential 
increase in the expression level of a single-gene (149). The gene set enrichment analysis 
(GSEA) assesses microarray data considering gene-sets, which are defined based on the 
understanding of previous biological pathways. Liver biopsy GSEA analysis identified IFN I 
(IFN α/β) as the most transcriptional pathway associated with tolerance in HCV positive liver 
recipients when compared to publically available transcript gene sets databases, whereas in 
HCV negative liver recipients, tolerance was more associated with iron ion homeostasis 
pathway (2, 100). Employing a stepwise mathematical algorithm, GSEA estimates the 
tendency for members of a gene set to appear on the top or on the bottom of a ranked list of 
gene expression levels in order to determine the correlation between the gene-set with a 
specific biological phenotype. GSEA interprets gene expression profiles paying attention to 
their genic chromosomal location similarities, to their biological function and regulation 
analogies with the objective of obtaining a thorough understanding of specific biological 
mechanisms and discovering data clinical implication (149, 150). Further, GSEA allows the 
possibility of comparing gene datasets originating from independent laboratories, as well as 
comparing experiments performed using distinct microarray platforms (151). 
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1.8.5 Bioinformatics software and microarray public databases 
All of the aforementioned described complex statistical methods to analyse the huge amount 
of microarray data required the development of sophisticated software customized to explore 
thousands of components of biological information and hypotheses at the same time. 
Bioinformatics package systems, notably the R package, were developed by consortia of 
renowned universities and kept online for free use (152). Package systems process raw 
microarray data into normalised expression levels; calculate differential expressions and 
control false positivity; select significant expression cut-offs levels; and create clusters based 
on identified gene regulation similarity along with many other functions (153). Additionally, in 
order to facilitate microarray data sharing, research groups are encouraged to store their data 
in online public repositories sponsored by referent universities, where free online consultation 
is allowed for comparison purposes. The result comparison strategy seeks to check data 
reproducibility and to certify clinical validity of data from different experiments and laboratories 
increasing the data robustness, sensitivity and biological relevance (154). 
 
1.8.6 Technical validation 
Microarray technology is a powerful and widely employed assay to determine gene 
transcription changes in organ transplantation immunological studies (111). Results are 
interpreted more correctly due to the development of adjusted statistic tools and sophisticated 
software. Modern gene expression microarrays are commercially available making microarray 
experiments easier and more simplified. Meta-analysis studies allow the possibility to disclose 
gene expression similarities, which can characterise immunological process throughout 
different transplanted organs (127). However, microarray results can be contaminated by the 
presence of experimental noise due to inappropriate probe annotation, cross-hybridization due 
to lower probe specificity, different platform designs, and laboratory and researchers’ 
dependent factors. Also, microarray expression profiling is usually employed to investigate 
thousands of genes aiming to identify a small set of them with biological and clinical 
implications (155). Then, in order to exclude the presence of all these experimental noises, it 
is strongly advised to validate the microarray results for the given genes of interest by 
employing a different method such as the quantitative polymerase chain reaction (qPCR). This 
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strategy, not only excludes factors of interference, but also contributes to confirm the future 
gene classifier for clinical application using a reduced number of genes (156, 157). 
 
1.8.7 Transcriptome analysis using next-generation sequencing  
Since its discovery in the 1990s, microarrays have been widely used in many areas of 
biological science. More specifically in the transplant field, this technique has proven very 
useful for determining transcriptomes associated with specific immunological phenotypes after 
organ transplantation (2, 107, 122-124, 158, 159). Accordingly, microarray technique is used 
in the present study to determine gene signatures associated with acute cellular rejection in 
the context of immunosuppression withdrawal post liver transplantation (160). However it 
should be noted that microarray limits, such as probe cross hybridization, background noise, 
and inaccurate measurements could compromise experiment results and analyses In addition, 
only genes for which a specific gene-probe is present in the microchip can be detected by a 
microarray experiment, excluding unknown genes that could be eventually differentiated (112, 
113, 129, 134, 137, 161). Conversely, the new platform RNA-seq uses high-throughput 
sequencing techniques, the so-called next-generation sequencing (NGS) to direct sequence 
all transcriptome of a specific sample. Briefly, RNA-seq comprises sample RNA extraction and 
fragmentation with posterior reverse transcription into stable double strand complimentary 
DNA (ds-cDNA). The ds-cDNA is sequenced by employing high-throughput short read 
sequence methods. Then, sequences are aligned to a reference genome sequence to 
determine which genome regions have been transcribed. The acquired data are used to 
determine gene annotation and relative levels of gene expression. (162, 163) This promising 
platform could replace microarrays for genome-wide transcriptome profiling studies (164). In 
the meantime, there are still some challenges ahead. RNA-seq exponentially generates more 
data than microarrays, which requires special data storage platforms as cloud technology and 
complex bioinformatics algorithms, for accurate analysis and interpretation. In addition, the 
RNA-seq popularisation as a technique of choice for large-scale studies of gene expression is 
still limited by its high cost (162-165). 
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1.9 Iron homeostasis 
Due to its capacities to accept or donate electrons, iron is a vital cellular element, which is an 
essential component of many molecules implicated in metabolic and synthetic processes, 
oxygen transport, mitochondrial metabolism and DNA cycling. However, unbalanced iron 
redox activity can generate toxic and harmful free radicals as reactive oxygen species (ROS) 
via Fenton/Haber Weiss reactions (166, 167). Elaborate pathways are responsible for 
maintaining iron homeostasis, avoiding free iron accumulation and delivering the required 
amount of iron to organs and tissues avoiding the deleterious effects either of iron overload, 
the pathogenesis of many iron disorders, or iron deficiency which leads to anaemia and its 
consequences (168). Iron has been also implicated in immune defence mechanisms, once its 
serum restriction could be considered a protective mechanism against pathogenic 
microorganisms. Besides its contribution to innate immunity, iron is also important for the 
immune cell development and physiology participating in this way with the immune system 
modulation (169). 
 
1.9.1 Iron Uptake and trafficking 
The mean concentration of iron in an adult human is around 3-4g. Iron is presented in all 
tissues, but approximately 60% of all body iron is found in erythrocytes (≈ 2-3g) as component 
of heme in haemoglobin. Transferrin (TF), the main plasma iron transporter to tissues, is 
usually 20-40% saturated (≈ 3-7mg) in normal conditions. About 1g of iron is stored within 
intracellular proteins as ferritin and hemosiderin (167). Daily body iron requests are supplied 
by recycling iron from aged erythrocytes and by dietary absorption. On the other hand, 
radiotracer studies estimated quotidian iron losses at 1-2mg per day via cell desquamation or 
exfoliation, and minimal blood losses in gastrointestinal and urinary systems (170). Even 
though these losses could be considered a kind of iron excretion mechanism, currently there is 
no mechanism of iron excretion described; which makes the iron dietary absorption of the sole 
evolutionary instrument to regulate body iron content (171). 
 
1.9.1.1 Dietary Iron Uptake 
Diet contains two principal forms of iron: inorganic or non-heme iron is present in a vast 
assortment of aliments and is poorly absorbed, and heme iron mainly originates from animal-
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protein. Ferric iron (Fe3+), the most abundant form of inorganic iron is taken up in the proximal 
duodenal portion (172). The presence of acid gastric secretions enhances Fe3+ solubility 
promoting its reduction into Fe2+ by the apical membrane reductase duodenal cytochrome b 
(DCYTB). Fe2+ crosses the enterocyte membrane coupled to the divalent metal transporter 1 
(DMT1), initially known as natural-resistance-associated macrophage protein-2 (NARMP2), 
through a proton gradient generated by the Na+/H+ exchanger-3 protein (NHE3) (Figure 1) 
(173). Heme dietary iron, originating from animal proteins, is more effectively absorbed than 
inorganic iron, however its absorption mechanism is not fully understood. The heme carrier 
protein 1 (HCP1) and the proton-coupled folate transporter (PCFT) have been proposed as 
candidates to transport heme from duodenal lumen into enterocytes, where iron is released as 
Fe2+ upon heme haemooxygenase-1 (HO-1) degradation (174-176). 
 
1.9.1.2 Heme iron recycling and heme-oxygenase-1 
Senescent erythrocytes are mainly phagocytised by macrophages situated in liver sinusoids 
and in the splenic red pulp. Whereas the haemoglobin proteolysis occurs inside the 
phagolysosome, heme compound is exported into the cytosol coupled to the heme-responsive 
gene-1 (HRG-1) protein to be degraded by the HO-1 with subsequent release of Fe2+ for 
posterior reutilisation (177-179). The degradation of heme is necessary to avoid the 
consequences of its pro-oxidant effects and to recycle iron for later reuse. Indeed, heme is 
involved in the production of oxidative radicals that can lead to tissue damage such as lesions 
on endothelial cells (180, 181). Specific enzymes called heme oxygenases (HO) degrade the 
heme molecule. Three isoforms of HO have been described: HO-1, HO-2 and HO-3, with OH-
1 being the most studied and characterized. HO-1 is mainly expressed in hepatic, endothelial, 
myeloid, and respiratory epithelial cells (182). In the presence of oxygen and nicotinamide 
adenine dinucleotide phosphate (NADP), HO-1 cleaves the heme compound giving the 
antioxidant molecules, biliverdin and carbon monoxide, as well as the pro-oxidant Fe2 + (183). 
The sequestration of Fe2+ by ferritin neutralizes its pro-oxidant effects (181). Finally, CO acts 
as a co-signal of biliverdin reductase in the reduction of biliverdin to bilirubin. In addition, 
beyond its enzymatic actions and anti-oxidant cytoprotective effects, other important roles 
have been attributed to the inactive form of HO-1 as cellular signalling, which includes 
transcription factor activation, protein binding, phosphorylation, among others (181). New 
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evidence suggests that HO-1 suppression may be associated to the increased inflammatory 
status in patients with lupus erythematous and multiple sclerosis (184, 185). HO-1 plays a dual 
role in the evolution of cancer; the nuclear expression of HO-1 is associated with cancer 
progression and metastasis in prostate cancer and in malignant head and neck tumors (186, 
187), while it seems to play a protective role in breast cancer (188). More specifically, in organ 
transplantation, the expression of HO-1 has been associated with the modulation of ischemia 
reperfusion injury and the innate and adaptive immune response (189, 190). 
 
1.9.1.3 Iron export and trafficking 
Intracellular Fe2+ originating from diet uptake can be sequestered and stored within Ferritin, 
the main iron-storage protein; or be exported to plasma coupled at Ferroportin (FPN) at the 
level of duodenocyte basolateral membrane (191-193). Currently, FPN is the unique 
mammalian iron transmembrane protein exporter described. Then, it also mediates the 
transfer of iron originated from erythrophagocytosis from macrophages and hepatocytes to the 
plasma (194, 195). Iron export from macrophages needs the multicopper oxidase 
ceruloplasmin protein to convert Fe2+ into Fe3+ before being loaded into the main plasma iron 
carrier TF, while Fe2+ exported from duodenocytes requires a ceruloplasmin homologue, the 
hephaestin to be oxidised to Fe3+ (191). TF deliveries ferric iron to all tissues, however about 
two thirds of all body iron is required by bone marrow for the erythropoiesis. At the cell 
surface, TF binds to the Transferrin receptor 1 (TFR-1) being internalised via endocytosis. 
Endosome pH changes favour iron releasing and reduction into Fe2+ by the six-
transmembrane epithelial antigen of prostate (STEAP3) reductase (196). The apotransferrin-
TFR1 is recycled at the cell membrane with posterior release of apotransferrin into the plasma. 
Fe2+ is transported from the endosome to the cytosol coupled to the DMT1, where it is 
sequestered and stabilised within Ferritin in its ferrous nonreactive reduced status, precluding 
the production of noxious free ROS via Fenton/Haber Weiss reactions (197). 
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Figure 1: Iron uptake and trafficking: (A) Duodenal cytochrome b (DCYTB) reduces dietary inorganic Fe3+ to Fe2+ at 
the cellular apical membrane, then Fe2+ crosses the cellular membrane coupled to the divalent metal transporter 1 
(DMT1). Ferritin stabilizes and stores Fe2+ avoiding its intracellular oxidation.  Ferroportin, situated at the basolateral 
membrane, exports Fe2+ that is prompted oxidized by Hephaestin to Fe3+ facilitating the Transferrin (TF) uptake. (B) At 
the macrophage membrane, iron-load-TF binds to transferrin receptor 1 (TFR1). Fe3+TF-TRF1 complex enters the cell 
by endocytosis. Fe3+ is reduced inside the endosome to Fe2+ and transported into the cytosol coupled to DMT1 to be 
stored by Ferritin; the apotransferrin is recycled and liberated into the plasma. Heme oxigenase 1 (HO-1) catalyses the 
degradation of heme compounds originated from phagocytized senescent erythrocytes recycling Fe2+ for posterior use. 
High iron levels induce hepcidin transcription at the hepatocyte level. Hepcidin binds to Ferroportin at the macrophage 
membrane inducing its internalization and degradation, resulting in intracellular iron accumulation. The author based on 




























































1.9.2 Iron homeostasis and hepcidin 
Iron overload and/or deficiency, inflammation status, erythropoiesis, and hypoxia are identified 
stimuli that modulate the iron homeostatic machinery. It happens at different levels as uptake, 
trafficking, utilization and storage (198). Hepcidin, a small protein constituted by 25 amino 
acids on its active conformation and mainly produced by hepatocytes has a central role on iron 
regulation (199-201). In physiological conditions, when iron levels are sufficient, hepcidin binds 
to FPN at the cell membrane of duodenocytes, macrophages and hepatocytes. This 
interaction triggers FPN endocytosis with subsequent proteolysis at lysosomal level. Reduced 
availability of FPN at the cell membrane level inhibits iron efflux from duodenocytes. The same 
occurs with macrophages and hepatocytes, where cellular iron efflux inhibition due to FPN 
cellular internalisation leads to intracellular iron overload with consequent reduced serum iron 
levels (202). Hepcidin expression modulation takes place in hepatocytes at transcriptional 
level in a negative feedback way. Hepcidin synthesis is enhanced by iron overload and its 
production is down regulated in the presence of iron deficiency. The bone morphogenic 
proteins and signal mothers against decapentaplegic homologs proteins (BMP/SMAD) 
pathway is the main regulator of hepcidin expression on physiological conditions. BMPs react 
to high iron levels and bind to type I and type II BMP receptors at the hepatocyte membrane. 
Hemojuvelin protein (HJV) acts as a co-receptor of BMP ligands, mainly BMP2 and BMP6, 
and binds to BMP-BMPR. The complex HJV/BMPR/BMP triggers the phosphorylation of 
receptor-activated SMAD proteins forming at the end activate transcriptional complexes 
including the common mediator SMAD4. The SMAD4 complex translocates to the nucleus, 
where the hepcidin antimicrobial peptide gene HAMP, the main hepcidin-coding gene is up 
regulated (203). Additionally, at high levels of TF-Fe2+, HJV protein enhances the interaction 
between TF-Fe2+ to TFR-2 instead to TFR-1 via modulation of the hemochromatosis protein 
HFE (a major complex class 1-like protein). Then the complex TF-Fe2+/HFE/TFR-2 probably 
induces hepcidin expression via SMAD signalling pathway (168, 204, 205). Hepatocytes can 
sense plasma iron levels through multiple interactions between TRF1, TFR2, HJV, and HFE. 
High levels of TF-Fe2+ promote the interaction between HFE and TFR2 instead of TFR1. Then, 
the HFE-TFR2 complex activates the ERK/MAPK and BMP/SMAD signalling pathways 
leading to hepcidin expression (Figure 2: Iron sensing). In the same way, BMP-HJV complex 
combines with its receptors BMPR1 and BMPR2 at hepatocyte membrane inducing receptor-
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activated SAMD phosphorylation (R.SAMD-p). SMAD proteins (1, 2, 3, 5 and 8) undergo a 
sequential phosphorylation with a final formation of activated hepcidin transcriptional 
complexes. Finally an activated hepcidin transcriptional factor is formed involving the co-
SMAD factor SMAD4. The SMAD4 complex translocate to the nucleus, where the hepcidin 
antimicrobial peptide gene HAMP is up regulated (Figure 2: BMPR complex) (203-205). 
 
1.9.2.1 Iron homeostasis under hypoxia and erythropoiesis 
Besides iron levels alterations, hepcidin expression is also modulated by hypoxia, 
erythropoiesis and infection/inflammation. Stress conditions as hypoxia or bleeding stimulate 
erythropoiesis in order to enhance oxygen transport to tissues. Erythropoiesis stimulus 
enlarges the population of erythropoietic precursors increasing iron consumption destined to 
haemoglobin synthesis. Hypoxia-inducible factors (HIF) are key actors in cellular adaptation to 
oxygen imbalance. Hypoxemic conditions inhibit the activity of oxygen-dependent prolyl-4-
hydroxylases, decreasing the hydroxylation of HIF. Then, stabilized HIF-1 and HIF-2 are 
translocated to the nucleus to bind to the HIF-1β subunit, resulting in the up-regulation of a 
variety of genes involved in different pathways, including cell proliferation, energy metabolism, 
angiogenesis, among many others (206, 207). In mice exposed to hypoxia, HIF is involved in 
the up-regulation of HO-1 (208), which is involved in heme degradation and iron recycling, as 
discussed in section 1.8.1.2. Furthermore, hypoxic conditions per se inhibit hepcidin 
expression; volunteers maintained in hypoxic chambers during 6 hours and under physiologic 
and exercise conditions presented low levels of hepcidin associated to an elevation of the 
platelet-derived growth factor BB (PDGF-BB) (Figure 2 Iron sensing) (209). In addition HIFs 
modulate erythropoietin (EPO) hepatic and renal production (210). EPO-induced 
erythropoiesis supresses Hamp1 expression in mice leading to the suppression of hepcidin 




Figure 2: Regulation of Hamp transcription at the hepatocyte level: Inflammation: Pro-inflammatory cytokine, IL6 
binds to its receptor (IL-6R) at the cell membrane provoking the phosphorylation of the Janus kinase 1 (JAK1). IL-6-IL-
6R-JAK1-p complex induces the phosphorylation of the signal transducer and activation of transcription 3 (STAT3) 
factor. STAT3 forms homodimers that translocate to the nucleus where they bind to STAT3-R the interferon γ-activation 
sequences which drives the hepcidin transcription. Suppressors of cytokine signalling (SOCS) factors can inhibit the 
JAK1-STAT3 pathway of hepcidin transcription. BMPR complex: BMP/SMAD pathway is the main described regulator 
signalling of hepcidin transcription responding to iron-related and inflammatory signals. BMP6 interacts with its receptor 
BMPR1 and BMPR2 inducing the phosphorylation of receptor-activated SMADs. Phosphorylated R-SMADs make 
activated transcriptional complexes with phosphorylated SMAD4. P-SMAD4/R-SMAD-P complex enters to the nucleus 
and stimulated hepcidin transcription. Hemojuvelin (HJV) can inhibit this downstream signalling; TMPRSS6 interacts 
with HJV provoking its fragmentation. Iron sensing: The HFE-TFR2 complex can also trigger hepcidin transcription via 
the extracellular signal-regulated kinase (ERK1/2) and the mitogen-activated protein kinase. Iron sensing factors as 
upstream stimulatory factors (USF) compete with hypoxia inducible factor-1 for the binding to hepcidin transcription 























































































1.9.3 Iron immune system modulation  
Iron levels interfere not only on the host immune response modulation, but also on the 
invading microorganisms growth and survival. Besides their influence on the innate immune 
response, the iron/hepcidin axis participates in T cell activation and proliferation influencing in 
this way the adaptive immune response (169) (212).  
 
1.9.3.1 Infection/Inflammation and iron modulation 
In response to noxious stimuli as infection and inflammation, a coordinated response is 
initiated by activation of many cell types as monocytes, macrophages, and T cells amongst 
many others (213). Pro-inflammatory cytokines enhance immune cell recruitment and promote 
the synthesis and secretion of a high number of other proteins involved in the inflammatory 
response. In a murine model, Pseudomonas aeruginosa intraperitonal challenge enhances 
hepcidin production via TLR4-dependent pathway and increases iron deposition in splenic 
macrophages. In the same work, subcutaneous infection of group A Streptococcus in mice 
induced local neutrophil infiltration with increasing hepcidin expression on infected skin 
biopsies, suggesting a mechanism of local hepcidin production (214). Moreover, Nemeth et al 
showed in an elegant work that in vitro hepcidin production by human and mice cell cultures 
requires IL-6 after microbial stimuli (215). Additionally, iron excess contributes to the formation 
of ROS, which can cause tissue injury via oxidative stress and inflammation. So, iron 
restriction decreases the oxidative stress and inflammatory tissue injury in models of acute 
hepatitis, renal interstitial fibrosis, experimental autoimmune encephalomyelitis (EAE), and 
type II diabetes in rodents (216-220). Specific pro-inflammatory cytokines as IL-1 and IL-6, IL-
22 and type I interferon strongly induce hepcidin expression via the Janus kinase 2 and signal 
transducer and activators of transcription (JAK/STAT) pathway. IL-6, the main inflammatory 
hepcidin stimulus, binds to its receptor alpha and gp130 on the hepatocyte cell surface. The 
formed complex activates JAKs with subsequent phosphorylation of STATs, mainly STAT3. 
Phosphorylated STAT3 translocates to the nucleus leading to the HAMP up-regulation with 
consequent hepcidin expression (Figure 2: Inflammation) (221, 222). 
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1.9.3.2 Iron levels modulate innate immune response 
Infectious and pro-inflammatory stimuli induce hepcidin expression mainly via IL-6 pathway; 
leading to cellular iron export inhibition with macrophage and hepatocyte intracellular iron 
overload. This results in plasma iron restriction. In the inflammation/infection scenario, such 
iron restriction inhibits microbial growth and has been considered an important mechanism of 
defence in mammals against microbial damage (215, 223). Hepcidin-deficient mice infected 
with Vibrio vulnificus presented increased bacteremia and higher mortality when compared 
with wild-type mice. Administration of hepcidin agonists leads to hypoferremia, with 
subsequent diminution in bacterial counting and animal survival improvement (224). 
Hereditary hemochromatosis (HH) patients, characterized by iron overload and a variable 
degree of hepcidin deficiency, present an elevated risk for atypical infections including Vibrio 
vulnificus, Yersinia enterocolitica, and Listeria monocytogenes (167, 225). An experimental 
model of malaria infection suggests that Plasmodium beghei infection induces hepdicin 
production with iron redistribution from hepatocytes to macrophages, which could impair future 
iron hepatocyte uptake by Plasmodium reinfections (226). Additionally, clinical data shows that 
iron supplementation in an endemic malaria African country increased children hospitalization 
rates and mortality suggesting that anaemia is a defence mechanisms against Plasmodium 
infection (227). Conversely, macrophages, a key player in the innate immunity, present 
deficient phagocytic functions and impaired cytokine production under iron surcharge, which 
undermine their ability to clear intra-cellular infecting microorganisms. In addition, some 
microorganisms acquire the capacity to utilize intracellular accumulated iron, escaping from 
innate defence mechanisms (228, 229). 
 
1.9.3.3 Iron and adaptive immune response  
Besides iron effect on the innate immune response, the axis iron/hepcidin can influence the 
adaptive immune response required for immune cell function, activation and proliferation. Iron 
deficient patients presented impaired lymphocyte activity as reviewed by Dallman in the late 
80s (230). A potential reason could be the influence of iron level changes on the activity of 
ribonuleotide reductase, an iron-dependent enzyme, involved in DNA synthesis and cell 
division (231). However, other mechanisms could be involved in the influence of the iron 
homeostasis on the adaptive immune response. In the EAE model, an experimental model of 
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CD4+ T cell-mediated demyelination, designed to study multiple sclerosis-related human 
disease, iron-deficient mice did not develop EAE up to 42 days post myelin basic protein 
(MBP) administration. The authors claimed that activation of CD4+ T cells was hampered by 
iron restriction. In this way, inactive CD4 + T cells cannot infiltrate the central nervous system 
and cause the symptomatology of EAE. In addition, the authors hypothesized that iron-
deficient mice may have a higher frequency of regulatory T cells, since iron-deficient mouse 
lymphocytes produced more IL-2 than the control group when they were incubated in the 
presence of MBP (219). Furthermore, in a model of type 2 diabetes using Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats, iron restriction improved lipid and glucose levels, and also 
diminished hepatic and pancreatic iron deposition, with less oxidative stress and lower IL-6 
levels. These results could be explained by the reduced production of ROS with consequent 
less tissue damage (220). In vitro stimulated splenic lymphocytes originating from iron 
deficient mice presented lower protein kinase C (PKC) activity and inhibited hydrolysis of 
phosphatidyl inositol-4,5-biphosphate (PIP2) when compared with control or pair fed animals. 
These results correlated with decreased lymphocyte proliferation rates suggesting that both 
impaired PKC translocation or activation, and reduced PIP2 hydrolysis are implicated in the 
reduced lymphocyte proliferation rate in the presence of iron scarcity (232, 233). Conversely, it 
has been suggested that hepcidin is an important factor for the inflammatory response 
following LPS challenge, rather than iron deficient per se. Administration of hepcidin one hour 
before LPS challenge in iron deficient mice abrogated the subsequent inflammatory response 
(234, 235). In fact, basal hepcidin messenger RNA expression reported in human PBMCs was 
up regulated after lymphocyte activation (236). However, the hepcidin influence on LPS-
induced inflammatory response was not confirmed by Wang et al. studies, which suggested 
that iron levels modulated cytokine expression after LPS challenge in mice (237). 
 
1.9.3.4 Iron and immune response in organ transplantation 
In the context of solid organ transplantation, T cell activation is a fundamental condition on the 
orchestration of the allo-immune response. Iron levels changes or iron transporter and storage 
proteins availability can modulate all of the signals of the proposed three-signal model for the 
allo-immune-mediated T cell activation process (238, 239). Allo-antigens presented to T cells 
by MHC class II molecules express on APC cell surfaces characterises the signal I. The 
56 
transferrin receptor CD71 is co-expressed with the T cell receptor CD3. Upon T-lymphocyte 
activation induced by CD3 antibody, CD71 expression increases on the T cell surface, making 
the CD71 a marker for T-lymphocyte activation (240). Furthermore, anti-CD71 antibody 
inhibits foetal T-lymphocytes proliferation in vitro (241). In addition, blockage of CD71 inhibited 
T cell function, altered cytokines production including IL-2, IL-10 and IFN-y resulting in a 
prolonged allograft survival in an experimental model of murine heterotopic cardiac 
transplantation. Based on those studies the use of anti-CD71 monoclonal antibody was 
proposed as a new potential immunosuppressant (242, 243). On the signal II, CD80 and CD86 
expressed on the surface of APCs co-stimulate T cells through their engagement with T cell 
CD28. This engagement is preceded by an interaction between the CD40 ligand on the APC 
surface to the CD154 expressed on T cell surface. Even that iron deficiency can alter CD80 
and CD86 concentration and function, the reduced T cell proliferation observed in iron 
deprivation can not be explained by such marker alterations in vitro and in vivo studies (244). 
Conversely, CD28 expression is reduced under iron deficiency and might contribute to lower T 
cell proliferation in vitro murine studies (245). The outcome of combined signals I and II is the 
activation of (i) the calcineurin, (ii) the RAS-mitogen-activated protein kinases (MAPK), and (iii) 
the nuclear factor kappa B (NF-kB) pathways. Calcineurin, the main target protein of 
tacrolimus and cyclosporin, is an iron dependent phosphatase, which requires iron to 
dephosphorylate the nuclear factor of activated T cells (NFAT) (246). Activation of MAPK and 
NF-kB pathways is iron dependent on cell cultures of hepatic macrophages (247). In fact, iron 
chelation treatment inhibits the NF-kB pathway and induces cell apoptosis in a lymphoma 
experimental model (248). Furthermore, iron changes are associated with cell survival in 
ovarian cancer cells in mitogen-activated protein kinase (MAKP) dependent manner (249). 
Signal I and II induced the expression of many molecules including IL-2, CD25 and CD154. IL-
2 interacts with CD25 on the T cell surface in a paracrine way leading to the activation of the 
mTOR protein, which constitutes signal III for the initiation of the cell cycle (239). Iron chelation 
with deferasirox inhibits mTOr signalling in myeloid leukaemia cells through up-regulation of 
Regulated in development DNA damage responses 1 (REDD1) gene, a hypoxia inducible 
factor-1 target gene, which is crucial for the inhibition of mTOR (250). 
Finally, as previously mentioned, the possible role of the iron/hepcidin axis in the adaptive 
immune response was surprisingly highlighted in an immunosuppression withdrawal 
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prospective clinical trial in liver transplant recipients. Patients who failed the IS weaning 
protocol presented lower storage iron parameters as serum ferritin, and serum and 
intrahepatic hepcidin levels in comparison with patients who were able to completely 
discontinue immunosuppression treatment (2). Taking in account that the achievement of 
spontaneous tolerance in rodent models of liver transplantation is marked by a transitory 
recipient alloreactive T cell activation followed by deletion of intra-hepatic lymphocyte 
population (60, 251, 252); and the iron changes effect on lymphocyte function and 
differentiation aforementioned, we could speculate about the potential involvement of the 
iron/hepcidin axis effect on the establishment of spontaneous tolerance in liver transplantation. 
 
1.9.4 Iron and liver transplantation 
The impact of iron levels changes has been also investigated in other phases of the liver 
transplantation process. In the context of liver cirrhosis, the reduced hepatocyte population 
presents an abnormal hepcidin expression with increased overload of iron in the remaining 
hepatocytes (253, 254). In fact, around 30% of patients listed for liver transplantation present 
hepatic iron overload, regardless the chronic liver disease aetiology (255). Liver recipients with 
marked iron deposition in the explanted livers present higher risk for infections and heart 
failure in the post-transplant period (256-258). Ischemia reperfusion injury, the inherent 
consequence of the cold organ preservation interval is influenced by cellular iron homeostasis 
as well. In fact the released iron from hepatocytes and Kupffer cells, during the liver cold static 
storage period enhances the free oxygen species formation intensifying the ischemia-
reperfusion tissue damage. Therefore, the use of iron chelators in preservation solutions in 
rodent experimental models reduced this oxidative process improving graft primary function 
and viability (259, 260).  
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2.1.1 Operational tolerance in liver transplant recipients is influenced by the 
axis iron/hepcidn. 
2.1.1.1 The axis iron/hepcidin plays an important role in the T cell immune mediated response 
influencing the achievement of spontaneous tolerance in liver transplant recipients. 
2.1.1.2  Iron changes modify intra-hepatic T cell immune mediated response in a murine 
model of acute liver failure induced by Concanavalin A (ConA), which is driven by 
macrophages, natural killer T cells, and T cells. 
2.1.1.3  Iron changes influences the anti-donor T cell response modulating the development of 
spontaneous liver transplant tolerance in experimental models of rat liver 
transplantation. 
 
2.1.2 Molecular biomarkers identified during immunosuppression withdrawal 
clinical trials forecast ACR episodes before their clinical, biochemistry and 
histological manifestation.  
2.1.2.1 Transcriptional changes in blood samples sequentially collected alongside the weaning 
process precede the clinical, biochemistry and histological manifestations of ACR in 




To decipher the influence of the axis iron/hepcidin in the tolerance process in liver transplant 
recipients and to determine ACR-associated molecular biomarkers we aimed to perform the 
following specific experiments:  
 
2.2.1 Effect of iron in the intra-hepatic lymphocyte response 
a) To manipulate iron dietary content in order to induce mild iron deficiency in mice 
b) To characterize the phenotype of immune cells in mice in the setting of iron level 
modulation  
c) To set up a murine model of immune mediated liver damage 
d) To assess the impact of iron levels manipulation on the lymphocyte population 
and their functional status 
e) To validate the impact of dietary iron levels manipulation on the liver immune- 
mediated damage by changing other factors that can change iron homeostasis as 
gut microbiota or metabolic changes  
 
2.2.2 Effect of iron deficiency in the establishment of tolerance in liver 
transplantation 
a) To set up a full vascularized model of rat liver transplantation 
b)  To check the feasibility of the model in different rat strain combinations as 1) the 
syngeneic, 2) spontaneous tolerance, and 3) the Tacrolimus-induced tolerance 
combinations  
c) To study the effect of iron dietary modulation at the pre-, per-, and post-transplant 
outcome in all rat strains combinations described above  
d) To study the effect of iron dietary manipulation at the post-transplant outcome of 
the same strain combinations under inflammatory challenge 
  
60 
2.2.3 Molecular characterization of acute cellular rejection biomarkers during 
intentional immunosuppression withdrawal in human liver transplantation 
a) To define the patient population and to identify the available biological 
samples for future analysis 
b) To define possible control groups for comparison purposes with the rejecting 
patients from the withdrawal clinical trials 
c) To identify liver tissue gene expression markers associated with ACR in liver 
biopsies collected at the baseline before start IS weaning and at the time of 
rejection 
d) To identify liver gene expression markers associated with ACR in sequential 
blood samples collected at the baseline before start IS weaning and at the 
time of rejection 
e) To identify ACR-associated transcriptional patterns in tissue and blood 
samples and to check possible functional pathways associated with ACR 
employing the Gene Set Enrichment Analysis 
f) To correlate the ACR-associated gene expression patterns with liver 
histopathology analysis  
g) To check the influence of immunosuppression regimens on gene expression 
patterns at the time of rejection 
h) To validate microarray results using real-time polymerase chain reaction (q-
PCR) on sequential blood samples collected during the weaning IS period 








Sub-clinical changes in iron and hepcidin levels have been associated with unsuccessful 
development of SOT in stable liver transplant recipients in a recent IS withdrawal clinical trial 
(2). In experimental animal models, SOT required an intra-hepatic lymphocyte infiltration and 
activation before their subsequent deletion. Besides that, lymphocyte activation is impaired by 
iron deficiency in-vitro studies. On account of these findings, we hypothesized that light 
alterations in iron levels could be responsible for intra-hepatic lymphocyte activation in vivo 
which could modulate the intra-hepatic immune responses. To check this hypothesis we first 
chose a well-proven murine model of sub-lethal immune-mediated hepatitis induced by ConA 
administration. ConA-induced liver damage is triggered by T cells, Kupffer cells and, NKT cells 
interaction and activation with the involvement of many pro-inflammatory cytokines (261, 262). 
To reproduce the small iron level variation observed in the liver recipients enrolled in the IS 
withdrawal clinical trial, we used an iron-modified diet regimen or a treatment with iron-specific 
chelators prior mice ConA challenge. We assessed how these induced iron homeostasis 
alterations influenced immune cell populations, the intra-hepatic lymphocyte activation and 
viability and its consequences on pro-inflammatory mediators production. 
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3.2 Material and Methods  
 
3.2.1 Reproduction of the mild iron deficiency status in mice employing iron-
modified diets: 
Four-week old males C57Bl/6 were purchased from Charles River, France, and bred under 
specific pathogen-free conditions. A special regimen of an iron deficient diet (<6mg/Kg) or iron 
replete (iron deficient diet supplemented with 200mg/Kg iron carbonyl) diet (SAFE, Augy - FR), 
introduced after an acclimatization period of five days, was given for a total of three weeks in 
order to induce a mild iron deficiency prior to the realization of any experiments. Experiments 
were realized under isoflurane inhalation anaesthesia and euthanasia performed by 
exsanguination under anaesthesia or in CO2 chamber. All procedures were in accordance with 
the national and institutional guidelines for animal care and use, and had been approved by 
the Animal Welfare and Ethical Review Body – King’s College London (AWERB-KCL) at the 
Denmark Hill Campus and the Home Office – United Kingdom (UK).  
 
3.2.2 ConA immune-mediated acute liver failure model in mice under iron-
modified regimens 
To investigate the potential iron-related functional effects in the immune system, we used an 
immune modulated model of acute hepatitis using a sub-lethal intravenous injection of 
15mg/Kg of type IV ConA (Sigma-Aldrich, Saint Louis, MO - USA). In this model, acute liver 
hepatitis is mediated by the interaction of sinusoid endothelial cells, T cells, macrophages and 
NKT cells, which mimics the physiopathology of autoimmune hepatitis (261, 262). Following 
ConA injection mice were anaesthetized with isoflurane (Abbott – UK) and sacrificed at 
various time points to collect blood, spleen, lymph nodes, and liver tissues. An initial 
experiment was performed to test the model efficacy using mice fed with normal diet. 
Otherwise, when not mentioned, the following experiments were performed using the modified 
iron diets.  
 
3.2.3 Hepcidin and iron chelators administration 
Systemic iron levels regulate the hepcidin expression, which controls the subsequent iron 
absorption in the duodenal mucosa. To verify whether the effects of iron-modified diets on the 
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immune-meditated hepatitis induced by ConA were dependent of hepcidin levels rather than 
iron levels, we first performed additional experiments where a single dose of 100μg of 
exogenous mouse hepcidin (PLP-3773, Peptides International, Louisville, KY, USA) or 
phosphate-buffered saline (PBS) (control group) was injected via intra-peritoneal two hours 
before the ConA challenge. In the same way, we realized experiments where a 3 day-course 
of a hydroxypyridinone iron based chelator administration (HPO CP28, 20nmoles, intra-
peritoneal, ip.), which does not modify the hepcidin level (263, 264), was performed before 
ConA challenge in vivo experiments. For in vitro experiments using iron chelators, cells were 
incubated with low doses of either HPO CP182 (5µM) or deferoxamine (DFO) 10µM (Sigma-
Aldrich, Saint Louis, MO - USA). At these doses iron chelators had no apparent effects on 
lymphocytes cell death (Figure S1 - Appendix B). 
 
3.2.4 Modulation of mice gut microbiota 
To determine whether the effects of iron deficiency on the liver environment is influenced by 
the bacterial growth and microbial composition, mice under the 3-weeks IrDef and IrRepl diet 
regimens received simultaneously a broad spectrum cocktail of 4 antibiotics in order to reduce 
the faecal microbial populations by around 90%: Ampicillin, 1g/L; vancomycin, 0.5g/L 
(Laboratorios Normon S.A. Tres Cantos - Spain); metronidazole, 1g/L (BBraun Medical S.A, 
Barcelona - Spain); and neomycin, 1g/L (Laboratorios Salvat, Barcelona, Spain) were 
dissolved in drinking water, which was changed every 3 days, and given throughout the entire 
period of three weeks as previously described (265). Afterwards, mice were challenged with 
ConA as stated in the section 3.2.2.  
 
3.2.5 Biological samples collection 
For biological specimen collection, mice underwent a midline laparotomy under inhaled 
anaesthesia. Then, a cardiac puncture was performed through the diaphragm to collect blood 
samples. Immediately after blood harvesting and completion of the euthanasia, the PV was 
cannulated and the liver perfused with 10ml of PBS to wash all remaining blood volume from 
the liver. Then liver samples were collected as described. A small slice of liver tissue was 
immediately conditioned in formalin solution for posterior histological analyses, samples for 
gene expression studies were conditioned in RNAlater® solution (Ambion, Carlsbad, CA - 
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USA) kept at 4ºc for 24 hours, and then stored at -80ºc for later analyses. A fresh liver slice 
was immediately sent for iron measurement when necessary. The remaining liver tissue, 
reserved for cell isolation, was conditioned in sterile PBS at 4ºC and rapidly processed within 
next two hours. 
 
3.2.6 Samples manipulation, serum biochemistry and hematologic 
measurements, cytokine analysis and intra-hepatic iron measurement 
Serum was obtained after 10 minutes centrifugation at 8.000g at room temperature (RT) from 
recent harvested clotted blood samples, and then stored at -20ºC for posterior analyses. The 
alanine aminotransferase (ALT) plasma activities, which reflect the liver injury intensity, and 
the serum iron level, were quantified by automated measurements using the ADVIA 2400 
Systems kits (Siemens, Erlangen - DE). Hematologic parameters were assessed in fresh 
blood samples conditioned in appropriate tubes by automated measurements using the ADVIA 
2120 System kits (Siemens, Erlangen – DE). Serum cytokine levels were measured with 
multiplex fluorescent bead-based Luminex Flexmap3D technology according to 
manufacturer’s recommendation (Thermo Scientific, Waltham, MA –USA). A small biopsy of at 
least a 10 mm slice of fresh liver tissue was used for intra-hepatic iron measurement using the 
ICP – MS method (Inductively Coupled Plasma – Mass Spectrometry) (NexION 350D – 
PerkinElmer, Waltham, MA, USA) according to the manufacture’s recommendations. 
  
3.2.7 Liver Histology  
Formalin-fixed and paraffin embedded liver tissue sections were stained with haematoxylin 
and eosin (H&E). Then, a senior liver histopathologist Dr Miquel Brugrera (MB), Hospital  
Clinic, University of Barcelona, Barcelona Spain, who was blinded to the identity of the 
experimental groups assessed the slices for the presence of hepatocytes ballooning, cellular 
infiltration, hepatocyte cohesion and necrosis. Liver tissues from mice that were not exposed 
to ConA were used as controls 
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3.2.8 Isolation of non-parenchymal liver cells, splenic and lymph node 
leukocytes 
After liver collection following the description in section 3.2.5, samples were digested at 37ºC 
in the presence of collagenase II 5% (PAA Laboratories, Exton - UK), and 100µg/mL DNase I 
(Roche, Mannheim -DE) for 30 minutes, as described by Ramachandran (266). Liver tissue 
was then passed through a 70µm nylon mesh. Hepatocytes were removed following low-
speed centrifugation (60xg, 2 minutes, RT), and liver mononuclear cells were isolated using 
Ficoll-Paque (GE Healthcare, Uppsala – Sweden) separation (800xg, 20 minutes) (RT). 
Spleens were smashed and passed through a 70µm nylon mesh to obtain single cells 
suspensions, then red blood cells were removed using 5mL ammonium chloride potassium 
(ACK) lysing buffer (Life Technologies, Carlsbad CA – USA) for 5 minutes (RT) followed by a 
second washing in PBS. The same procedure was used to isolate lymphocytes from lymph 
nodes. 
 
3.2.9 In vitro naïve CD4+ T cell stimulation 
Lymphocyte proliferation was investigated using the carboxyfluorescein succinimidyl ester 
(CFSE) assay. CFSE has the ability to bind covalently to long-live intracellular molecules and 
to be retained intracellularly for a long time. At each cell division, the fluorescent 
carboxyfluorescein dye is divided equally into each daughter cell, which has half the 
fluorescence of the parent cell. CD4+ naïve T cells were isolated from spleen and lymph nodes 
after preparation described in the previous section using EasySep Mouse Naïve CD4+ T cell 
stimulation kit (STEMCELL Technologies, Vancouver - CA). Enriched cells were labelled with 
2.5 µM CFSE (Carboxylfluorescein succinimidyl ester) (BioLegend, San Diego CA - USA) for 
10 minutes. A total of 250x103 cells were incubated for 5 days in 96 well-plate coated with anti 
CD3 and CD28 antibodies (BioLegend – San Diego, CA – USA) (2µg each, clone 145-2C11 
and 37.51, respectively) in RPMI-1640 (Life technologies, Carlsbad, CA - USA) supplemented 
with 5% Foetal Calf Serum (Sigma-Aldrich, Saint Louis, MO - USA), 1% penicillin-streptomicyn 
and 2mM L-glutamine AND 50µM β-mercaptoetanol (Life technologies, Carlsbad, CA - USA). 
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3.2.10 Cell phenotyping - Flow cytometry 
Cells aliquots up to 1x106 cells were labelled in staining solution (PBS, Foetal Calf Serum 2%, 
2mM EDTA) (Sigma-Aldrich, Saint Louis, MO - USA) using the following antibodies: APC/Cy7 
antiCD3e, PE/Cy7 anti CD4, APC anti-CD25, PE anti-CD4, FITC anti-CD62L which were all 
purchased from BioLegend. In order to quantify cell viability, dead cells were stained either 
with 7-AAD (BioLegend – San Diego, CA - USA) or Livedead cell viability assay (Life 
Technologies, Carlsbad, CA - USA). Before cytometer acquisition cells were fixed for 20 
minutes using fixation buffer (BioLegend – San Diego, CA - USA) in the dark (RT). To label 
regulatory T cells, cells aliquots were initially incubated in a FOXP3 Perm/Fix solution for 20 
minutes with PE anti-FOXP3 antibody (BioLegend, San Diego, CA - USA) according to 
manufacturer’s instructions. Intracellular IFNγ staining was performed using permeabilization 
buffer following manufacturer’s instructions and FITC and anti-IFNγ antibody and APC anti-IL4 
antibody (BioLegend, San Diego, CA - USA). Experiment results were acquired on a BD 
FACSCanto II flow cytometer (BD Becton, Dickinson and Company, Franklin Lakes, NJ - 
USA). Analyses were made employing FlowJo software (FLOWJO LLC, Ashland, OR - USA). 
 
3.2.11 RNA extraction and gene expression experiments 
Liver or spleen tissue samples were harvested, processed and stored at -80ºC as described in 
the section 3.2.4. For RNA extraction, samples were initially thawed and homogenised using 
an RNAse-free pestle in TRizol ® reagent (Invitrogen, Carlsbad, CA - USA), total RNA was 
extracted according the TRizol manufacturer’s protocol. DNA was removed from total RNA 
preparations using Turbo DNA-free DNAse ® treatment (Ambion – Carlsbad, CA - USA). RNA 
quality and quantity were assessed with the Agilent 2100 Bioanalizer® (Agilent Technologies, 
Santa Clara, CA - USA) and Nanodrop ND-1000 (Thermo Scientific, Waltham, MA - USA), 
respectively. Total RNA was then reverse transcribed into cDNA using the High-Capacity 
cDNA Reverse Transcription Kit® (Applied Biosystems, Foster City, CA - USA). A pre-
amplification of cDNA was performed using pooled TaqMan assays® (final concentration of 
0.2x each) and the TaqMan PreAmp Master Mix® (Applied Biosystems, Foster City, CA - 
USA) using 10 cycles of amplification. qPCR was performed using the 48.48 Dynamic Array® 
following manufacturer’s protocol using a BioMark Instrument (Fluidigm Corporation, South 
San Francisco, CA - USA). To quantify transcript levels, target gene Ct values were 
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normalized using Ct values of HPRT1 as reference gene to generate -∆Ct values. Real-time 
PCR gene expression experiments were performed using liver samples collected at 12 hours 
post ConA injection.  
 
3.2.12 Statistical analyses 
Statistical analyses were performed with GraphPrism software version 5.0. Student T-test was 
used for comparison between two groups and ANOVA analysis with Tukey’s post-hoc 
correction for pairwise comparisons was used to compare more than 2 groups. Fisher test was 
used for categorical variables. P-values inferior to 0.05 (two tailed) were considered 
statistically significant in all analyses. 
  
68 
3.3  Results 
 
3.3.1 Induction of mild iron deficiency employing iron-modified diets 
When compared to mice fed with an iron-replete diet (IrRepl), mice fed with an iron-deficient 
diet (IrDef) presented decreased serum iron and serum transferrin saturation (73.22 ± 56.49 
versus 156 ± 36.99 µg/dL; p<0.0001 and 18.80 ± 6.32 versus 56.20 ± 4.53%; p=0.0013 
respectively). Additionally, liver tissue analysis exhibited reduced iron stores and hepcidin 
(Hamp) gene expression (p 0.017 and p<0.0001, respectively). When IrRepl samples were 
compared with samples from mice fed with the regular diet, there were no differences in those 
iron parameters. IrDef mice also developed mild anaemia (haemoglobin 107.6 ± 46.10 versus 
147.9 ± 6.50 g/L; p=0.028) and increased platelet count (145 ± 469.2 versus 769.4 ± 174x109 
/L; p=0.0004), which is in accordance with the previous description in the literature (234, 267). 
Animals from both groups presented the same clinical evolution without behavioural changes 
and with both groups gaining presenting comparable gain weight at the end of 3-weeks under 
iron-modified diets (Figure 3). 
 
Figure 3: Iron and haematological parameters in mice fed with iron-manipulated diets. Mice were fed for 3 weeks 
with an iron-deficient diet (IrDef) or iron-replete diet (IrRepl). Bars plots display mean and SEM. Abbreviations: RBC: red 
blood cells, Hb: haemoglobin, Plts: platelets, WBC: white blood cells. Hamp:  Hepcidin antimicrobial peptide, gene 
responsible for Hepdicin codification. Number of animals IrRepl/IrDef: Serum Iron: 34/33, Transferrin Sat: 5/5, Liver Iron: 


































































































































3.3.2 Mild iron deficiency does not modify the steady state immune cell 
repertoire and systemic cytokine levels 
To check the influence of mild iron deficiency caused by the iron modified diets on immune 
parameters; we initially compared liver and spleen immune cell subsets in IrDef and IrRepl 
mice. Both groups of mice exhibited similar frequencies of intrahepatic NK1.1+CD3+NKT, CD4+ 
and CD8+ T cells, FOXP3+ T cells, and resident CD45+CD11+F4.80+ Kupffer cells (Figure 4A). 
Likewise, no differences between IrDef and IrRepl splenic T cell subsets were noted (Figure 
4B), which can suggest that in the steady state the mild iron deficiency induced by IrDef 
regimen did not induce major immunological effects. 
 
Figure 4: Influence of iron levels on the immune-phenotype of intra-hepatic leukocytes (A) and spleen (B) 
leukocytes. Mice were fed for 3 weeks with an iron-deficient diet (IrDef) or iron-replete diet (IrRepl). Bar plots show the 
frequency (mean and SEM) of specific leukocytes subsets in the liver (A) and in the spleen (B), as assessed by flow 
cytometry after excluding dead cells. Number of animals IrRepl/IrDef: Liver: CD3+CD4+: 8/8, CD3+FOXP3+: 8/8, 
























































































































In the next experiment, we explored the effects of iron deficiency on pro-inflammatory and 
immunoregulatory genes by measuring the expressions of interleukins Il2, Il4, Il6, Il10, Il15, 
tumor necrosis factor α (Tnf), transforming growth factor β (Tgfb1), interferon γ (Ifng), Cd86, 
forkhead box P3 (Foxp3), and Cd274 in whole livers, spleens and mesenteric lymph nodes 
from IrDef and IrRepl mice. Only small decreases were observed on the Tnf expression (Fold 
change [FC] =-0.36, p=0.032) and IFNG (FC=-0.72, p=0.044) in the liver and spleen of IrDef 
mice, respectively (Table 2). Again, no significant changes were observed on the production of 
serum cytokine between IrDef and IrRepl mice measured by the Luminex technique following 
the manufacturer instructions (Table 3). 
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Table 2: Gene expression in liver, spleen and mesenteric lymph nodes (mesLN) of immune-related molecules 
from IrDef and IrRepl mice 
Symbol Name 
Liver Spleen mesLN 
FC p.value FC p.value FC p.value 
Il2 Interleukin 2 0.75 0.090 -0.49 0.20 -0.26 0.28 
Il4 Interleukin 4 0.32 0.14 -0.038 0.90 0.24 0.50 
Il6 Interleukin 6 -0.20 0.39 -0.094 0.70 -0.48 0.15 
Il10 Interleukin 10 -0.15 0.48 -0.11 0.74 0.060 0.83 
Il15 Interleukin 15 0.098 0.68 -0.38 0.18 0.36 0.13 
Ifng  Interferon gamma 0.31 0.26 -0.72 0.044 0.40 0.54 
Tnf Tumor necrosis factor -0.36 0.032 -0.29 0.38 0.024 0.94 
Tgfb1 Transforming growth factor, beta 1 0.17 0.14 -0.26 0.14 -0.12 0.53 
Foxp3 Forkhead box P3 -0.046 0.88 -0.32 0.34 0.052 0.85 
Cd86 CD86 antigen 0.003 0.97 -0.41 0.083 -0.24 0.26 
Cd274 CD274 antigen 0.10 0.38 -0.40 0.10 0.020 0.95 
Fold change is exhibited as Log2 of IrDef/IrRepl values. Genes with significant differential expression are highlighted in 
bold. 
 
Table 3: Serum level of cytokines measured by Luminex technology from IrDef and IrRepl mice 
Symbol Name FC p.value 
IFNy Interferon gamma 0.85 0.59 
IL-1α Interleukin 1alpha -0.73 0.57 
IL-2 Interleukin 2 -3.35 0.20 
IL-4 Interleukin 4 0.90 0.48 
IL-6 Interleukin 6 -0.48 0.68 
IL-10 Interleukin 10 -1.11 0.26 
IL-15 Interleukin 15 1.47 0.10 
IL-17 Interleukin 17 -1.69 0.15 
CXCL10 chemokine (C-X-C motif) ligand 10 (IP-10) 0.008 0.96 
CXCL9 chemokine (C-X-C motif) ligand 9 (MIG) 0.41 0.61 
TNF α Tumor necrosis factor alpha -0.27 0.51 
Fold change is exhibited as Log2 of IrDef/IrRepl values. 
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3.3.3 Mild iron deficiency significantly reduces inflammatory liver damage 
following ConA administration 
As described in section 3.2.2, we used the ConA-induced immune mediated hepatitis model to 
check the functional effect of mild iron deficiency on intra-hepatic lymphocyte responses. IrDef 
mice presented a significantly lower increase of alanine aminotransferases (ALT) than the 
IrRepl mice (p=0.0028 and 0.0035 at 6 and 12 hours after ConA administration, respectively) 
(Figure 5A). Likewise, IrDef mice showed reduced serum levels of the pro-inflammatory 
cytokines IFNy, IL-6 and TNFα, which reached statistical significance at 6 hours after ConA 
challenge (p=0.0037, 0.0013 and 0.0021, respectively) (Figure 5C). Similar changes were 
observed in the intra-hepatic expression of Il4 and Tnfa, whose transcript levels significantly 
decreased in IrDef mice 12 hours after ConA injection (p=0.0053 and p=0.021 respectively) 
(Figure 5D). These results were in agreement with the liver histopathology analysis, which 
demonstrated decreased hepatocyte necrosis and inflammatory infiltration in IrDef as 




Figure 5: Iron deficiency results in attenuated immune-mediated hepatitis following ConA administration: (A) 
Serum levels of alanine alanine aminotransferase (ALT; IU/ml) before 6 hours and 12 hours after administration of ConA 
in mice fed for 3 weeks with IrDef or IrRepl diets. (B) Representative liver histology (H&E, 200x) at 12 hours after the 
administration of ConA in a IrRepl mouse (upper picture) and in an IrDef mouse (lower picture) and histologic evaluation 
of necrosis and infiltration (lateral graphic). (C) Cytokine levels in serum samples collected before, 6 hours and 12 hours 
after the administration of ConA. (D) Transcript levels of Il4, Il6, and Tnf in liver tissue samples collected before and 12 
hours after the administration of ConA. Number of animals (IrRepl/IrDef) (A) 0h: 32/31, 6h: 23/20, 12h: 28/19; (B) 0h: 























































































































on p = 0.021
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3.3.4 Decreased iron availability blunts lymphocyte proliferation and activation 
ConA administration initiates an inflammatory cascade, which requires activation of T and NKT 
lymphocytes and macrophages; at the end these events lead to liver tissue damage (261, 
262). Being activated by ConA administration, lymphocytes produce IFNy, which is directly 
implicated in the pathogenesis of ConA-induced hepatitis (262, 268, 269). Additionally, NKT 
cells down-regulate NK1.1 and CD3 surface markers, whose expression is inversely 
correlated to the degree of NKT activation (270). To investigate that the iron deficiency effects 
were mediated by inadequate lymphocyte activation, we assessed the phenotypic and 
functional properties of splenic and intra-hepatic lymphocytes isolated at different time points 
after ConA administration. IrDef mice presented significantly less accumulation of liver-
infiltrating CD3+ lymphocytes when compared to IrRepl mice (p=0.048 at 6 hours) (Figure 6A). 
This was associated with a less prominent decrease in the expression of NK1.1 in CD3 cells 
(a NKT cell activation marker) both at 3 and 6 hours after ConA injection (p=0.0056 and 0.029 
respectively) (Figure 6A). Additionally, intra-hepatic NKT and T lymphocytes from IrDef mice 
exhibited lower intra-cellular IFNy levels at 3 hours after ConA injection when compared to 
IrRepl mice (p=0.034 and 0.081 respectively) (Figure 6B). It is worth noting that contrary to the 
significant differences detected in the liver compartment, IFNy-producing splenic lymphocytes 
presented comparable frequencies in IrDef and IrRepl mice (Figure 6C). 
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Figure 6: ConA-Induced T and NKT lymphocyte activation is reduced in iron deficiency. (A) Intra-hepatic 
frequency of CD3+ expressing NK1.1 and CD3+ NK1.1- at baseline, 3 hours and 6 hours after ConA injection. (B) Intra-
hepatic frequency of IFNy production by NKT cells and T cells, defined as CD3+ NK1.1+ and CD3+ NK1.1-, 
respectively, (left panel) and representative staining of IFNy production by NKT cells (right panel). (C) Frequency of 
splenic CD3+ NK1.1- T cells and the percentage of these ones producing IFNy. Number of animals (IrRepl/IrDef) (A) 
































































































































































To corroborate the influence of iron deficiency on T cells activation and proliferation, we 
incubated splenocytes in vitro in presence of ConA (0.1mg/ml) and low doses of a specific 
hydroxypyridinone iron chelator (HPO CP182; 5 μM) or desferoxamine (DFO; 10μM) (263, 
264). Iron chelation provoked an impaired CD3+ CD4+ T cell proliferation (p<0.0001). 
Additionally, the presence of iron chelator also hampered the activation of isolated CD4+ naïve 
T cells, which after stimulation within anti CD3/CD28 plate-bound, showed decrease CD25 
expression and cell proliferation (Figure 7). 
 
Figure 7: Iron chelation impairs CD4+ T cell activation and proliferation in vitro: (A) The graphic on the top 
represents the percentage of CD4+CD3+cells from splenocytes undergoing at least one division, which is detected by 
the CFSE assay as shown in the representative fluorescent histogram on the lower part of the panel. Splenocytes were 
incubated 96 hours in presence of: ConA (0.1mg/mL), CFSE, and in presence of low doses of iron chelator (HPO 
CP182, 5µM or DFO, 10µM). Data were acquired on a BD FACSCanto II flow cytometer (B) Graphic showing the 
percentages of CD4+CD3+cells from isolated naïve CD4+ cells undergoing at least once division as represented on the 
histogram at the bottom of the panel, and (C) Graphic at the top of panel represents the CD25 MFI detected on the 
fluorescent histogram in the lower part. Isolated CD4+ naïve T cells incubated 5 days in presence of anti-CD3/CD28 
plate-bound antibody (2µg each). Un means un-stimulated cells. Number of animals: (UnSt/Ctrl/DFO/HPO) (A) 2/6/6/5; 
(B) 3/4/4/4; (C) 3/4/4/4. 
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3.3.5 Iron deficiency influences intra-hepatic inflammatory responses 
independently from gut microbiota modulation 
Taking in account the impact of gut microbiota on the liver environment (271) and the well-
described modulator effect of iron changes on bacterial growth and intestinal microbial 
composition (272), we checked if the blunted immune-mediated hepatitis observed in IrDef 
mice could be influenced by changes in gut bacteria population. Mice under the 3-week IrDef 
and IrRepl diet protocol received simultaneously and for the same period a broad spectrum 
cocktail containing 4 antibiotics in order to decrease more than 90% of gastrointestinal 
microbiota before ConA administration at the end of 3-week period (265). IrDef mice receiving 
antibiotics presented comparable results to experiments realized in IrDef mice without 
antibiotic treatment, with significantly reduced levels of ALT in IrDef mice in comparison with 
IrRepl mice (Figure 8A). 
 
3.3.6 Intra-hepatic inflammatory responses are influenced by iron but not by 
baseline hepcidin level. 
Low iron availability leads to a reduced hepcidin expression, which can have a direct impact 
on the regulation of immune responses as demonstrated in some experimental models (234). 
We sought to determine whether the influence of an iron deficient diet on an immune-mediated 
hepatitis model might be related to differences in hepcidin levels rather than to alterations in 
iron levels. To do this, we performed a first experiment employing mice fed with standard diet 
(normal iron concentration) and receiving a 3-day course treatment of HPO CP28 iron chelator 
(263, 264). Before the ConA challenge, we checked whether the iron chelation treatment had 
an influence on the expression of intrahepatic hepcidin. The iron chelator-treated group had 
similar levels of intra-hepatic HAMP (the hepcidin gene coding) expression compared to a 
control group (p=0.48) (Figure 8B). Subsequently, following ConA challenge, mice treated with 
HPO CP28 exhibited a significantly blunted hepatitis compared to controls, similar to that 
observed with an iron deficient diet (p=0.041) (Figure 8C). In a second experiment aimed at 
determining whether hepcidin levels could restore the IrRepl ConA-induced hepatitis 
phenotype to IrDef mice, IrDef received a single dose of exogenous hepcidin two hours prior 
to ConA challenge (234). Hepcidin-treated IrDef mice had ALT levels similar to those of 
placebo-treated IrDef mice, suggesting that exogenous hepcidin treatment failure to restore 
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the IrRepl phenotype of ConA-induced hepatitis to IrDef mice (p=0.84) (Figure 8D). Altogether, 
these results suggested that iron restriction inhibits lymphocyte activation and ConA-induced 
hepatitis independent from its effects on hepcidin secretion. 
 
Figure 8: The inhibitory effects of iron deficiency in ConA-induced hepatitis are independent from changes in 
gut microbiome and hepcidin levels. (A) ALT serum levels (IU/ml) before, and 12 hours after the administration of 
ConA to mice fed for 3 weeks with iron deficient (IrDef) or iron-replete (IrRepl) diet, in the presence or absence of a 4-
antibiotic (Atb) cocktail. (B) Relative expression of Hamp in liver tissue samples from mice fed with standard diet 
(normal iron concentration) receiving a 3-day course of HPO CP28 (20nmoles, daily) compared to control mice receiving 
PBS (p=0.48). (C) ALT serum levels 12 hours after ConA challenge in mice fed with standard diet (normal iron 
concentration) treated with HPO CP28 or with PBS (p=0.041). (D) ALT serum levels 12 hours after ConA challenge in 
mice fed with IrDef diet pre-treated with a single intraperitoneal injection of 100µg of mouse hepcidin or sterile PBS two 
hours before ConA challenge (p=0.84). Bar plots display mean and SEM. Number of animals: (A) (IrRepl/IrDef): 0h: 8/8, 
































































































































Chapter 4 : Impact of iron changes on the spontaneous 
tolerance development in a rat liver transplant model 
 
4.1 Introduction:  
Based on clinical observations that alterations on iron and hepcidin levels were associated 
with the outcome of IS withdrawal in stable liver transplant recipients (2), we hypothesized that 
iron stores and/or hepcidin levels influence the intensity of the intra-hepatic non-specific 
inflammatory reactions and the anti-donor T cell mediated responses. Using a well-known 
immune-mediated hepatitis model induced by ConA, we previously tested the influence of iron 
and/or hepcidin levels on the magnitude of the intra-hepatic non-specific T cell response. 
Here, our aim was to set-up a rodent liver transplant model to check our hypothesis that iron 
and/or hepcidin changes impact the anti-donor T cell mediated response, which can influence 
the establishment of spontaneous tolerance across different rat strain combinations. In the rat 
liver transplant model, allograft liver tolerance spontaneously develops in some donor/recipient 
rat strain combinations in spite of the presence a full MHC mismatch. This phenomenon may 
prevent complete replication of the clinical setting in which long-term liver recipients can be 
weaned off immunosuppression therapy. However, spontaneous tolerance in the rat liver 
transplant model is associated with a transient immune response. In this model an allograft T 
cell infiltration was observed in the early phase post-liver transplantation. This was followed by 
subsequent T cell deletion some weeks later resulting in a clinical long-term allograft 
acceptance. The same pattern was observed in transaminase levels after transplantation, with 
an increase at the beginning of the post-transplant period, followed by normalization over time 
(273). At the same time, a percentage of SOT liver recipients present a transient worsening in 
the LFTs during the IS weaning protocol. Furthermore, in tolerant liver recipients, portal 
lymphocyte infiltration increases at 1 year post IS withdrawal and decreases at the 3 years 
follow-up biopsy (1, 274). Given the immunological similarities described above, the rodent 
liver transplant model provides the best conditions for closely replicating the human clinical 
context of spontaneous operational tolerance. To do that, we aimed to establish a fully-
vascularised rat liver transplant model including the HA anastomosis, which is considered a 
challenging step in rodent liver transplant models. The rationale to arterialize the liver allograft 
was based on the fact that hypoxia can modulate the iron/hepcidin axis (209). Furthermore, it 
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has been shown that arterialisation of the liver allograft decreases the rejection rate in a 
rejecting donor/recipient strain combinations (275). As soon as we achieved more than an 
80% long-term survival rate, we started our experiments by transplanting animals that were 
kept on iron-modified regimens in the same way as in our murine model of immune-mediated 
acute hepatitis. Conversely to the clinical setting, the rodent model of liver spontaneous 
tolerance does not require long term IS treatment, so we administered high doses of 
recombinant human IL-2 (rhIL-2) in order to challenge the immune system during the early 
phase post-transplant aiming to check the influence of the iron-deficiency on the spontaneous 
tolerance establishment (276, 277). To quantify the impact of the iron deficiency and the rhIL-2 
inflammatory challenge, we assessed the post-transplant survival rate under such conditions 




4.2 Material and methods: 
 
4.2.1 Rat liver transplantation model 
All procedures were in accordance with the national and institutional guidelines for animal care 
and use and were approved by the Animal Welfare and Ethical Review Body – King’s College 
London (AWERB-KCL) at the Denmark Hill Campus and the Home Office – UK. Lewis and 
Dark Agouti male rats were purchased from Harlam (UK), whereas Brown Norway male rats 
were purchased from Charles River (UK). The purchases were planned so that the animals 
presented a weight of approximately 180 to 220g at the time of the transplant procedure. The 
rat liver transplant technique described by Kamada et al. was employed in our first 
experiments (278). This technique, considered somewhat easier to perform, employs small 
plastic cuffs on realization of the termino-terminal PV anastomosis and on the termino-terminal 
infra hepatic vena cava anastomosis (IHVC). However, this technique does not contemplate 
the arterialisation of the liver graft (279). We were trying to completely replicate the clinical 
scenario of human liver transplantation, and take into account that axis iron/hepcidin is 
influenced by hypoxia; the non-arterialisation of the liver graft which could influence our 
results. Furthermore, circulatory and hemodynamic changes such as portal hypertension and 
increased cardiac index observed in the post-transplant follow-up have been attributed to the 
fixation of the PV and IVHC diameters caused by the plastic cuffs (280, 281). Based on that, 
we moved to the fully-vascularized technique of rat liver transplantation initially described by 
Lee et al. in 1973 and modified by Ariyakhagorn et al. in 2009 wherein venous anastomoses 
were performed by running suture and re-arterialization of the liver allograft was achieved by 
the HA anastomosis employing small plastic stent (282, 283). The donor and recipient 
procedures are described in the following sections. All procedures were performed in sterile 
conditions. 
 
4.2.1.1 Rat liver transplantation – Donor procedure 
Initially the animal was put in the induction chamber, where induction was achieved by 
employing isoflurane at 5% (Forane®. Abbott, IL - USA). After induction the animal was placed 
and attached using plastic adhesives on a wood pad previously and continuously warmed 
using an appropriate warming device placed under the wood pad. General anaesthesia was 
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maintained with vaporization of isoflurane at 2% with oxygen flow at 2l/min. Antiseptic 
measures were taken: the abdominal region was shaved; a povidone-iodine base antiseptic 
solution (Iso-Betadine ®, Meda – UK) was applied and sterile surgical drapes were positioned. 
Painkillers were used following the AWERB-KCL recommendations. Then a cruciform 
laparotomy was made, the liver was dissected from its attachments, the supra coeliac aorta, 
the infra renal aorta, the supra hepatic vena cava (SHVC), the IHVC, the PV, the common bile 
duct (CBD) and the HA were identified and dissected. The infra-renal aorta was catheterized 
in order to perfuse the liver with 20ml of Celsior ® (Institute Georges Lopez - Lion, France) 
preservation solution. The supra coeliac aorta was cross-clamped and the perfusion was 
started. The SHVC was sectioned for exsanguination. After finishing the liver perfusion, the 
total hepatectomy was completed. Two corner stiches of a 7/0 polypropylene (Prolene® - 
Ethicon - OH – USA) were placed on the SHVC stump and one corner stich of 8/0 
polypropylene was place on the left corner of the PV stump. Afterwards, the graft was kept in a 
small bowl, immersed in cold preservation solution at 4ºC until the time of implantation in the 
recipient. 
 
4.2.1.2  Rat liver transplantation – Recipient procedure 
The animal was anesthetized following the same protocol as described for the donor in the 
previous section, once appropriately installed and with sterile surgical drapes in place, a 
median laparotomy was made; the native liver was mobilised from its attachments, the SHVC, 
the IHVC, the PV, the CBD and HA were identified, dissected and freed. The PV, the IHVC, 
the SHVC, and the HA were clamped and divided. Then the native liver was taken out 
finishing the recipient hepatectomy. At this time isoflurane concentration was decreased to 
0.5% and the oxygen flow rate increased to 4l/min. The donor liver implantation was started by 
the SHVC anastomosis performed by a running suture using the corner stiches placed during 
the donor hepatectomy, followed by the PV anastomosis performed by a running suture using 
the 8-0 Prolene® stich previously placed. The PV and the SHVC clamps were released with 
the consequent reperfusion of the liver allograft. Then, anaesthetic parameters returned to 
initial concentrations and flows. The next step was the IHVC anastomosis, which was 
performed by a running suture using the 8-0 Prolene ®, at the end the IHVC clamps were 
released re-establishing the normal circulation. Finally the HA and the CBD anastomoses 
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were performed using an internal plastic stent secured with two 7/0 silk ligatures. The 
haemostasis was secured and the abdominal wall was closed, the anaesthetics were stopped 
and the animal was awakened (Figure 9). 
 
Figure 9: Panels displaying the sequential anastomoses of the liver allograft implantation. (A) Supra hepatic 
vena cava (SHVC anastomosis). (B) Portal vein (PV) anastomosis. (C) Few seconds after liver reperfusion, note the 
partial recoloration of the liver graft. (D) Infra hepatic vena cava (IHVC) anastomosis construction. (E) Hepatic artery 
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4.2.2 Different strain combination 
Two different agglutinins (a and m) and their respective agglutinogens can be detected in the 
blood of the Rattus norvergicus species, which allows the identification of four different blood 
types. However, agglutination is a very rare event that occurs only in very few combinations of 
strains. Normally, there is no agglutination between most of the rat strains currently used in 
laboratory experiments. For this reason, the blood group is not taken into account in the rat 
liver transplant model (284). Conversely, the antigens of the major histocompatibility complex, 
which in rats is named the RT1 barrier, are more relevant in transplantation research. 
Laboratory rats present a limited number of standard and derivative RT1 haplotypes, with a, 
av1, l, n and u being present in the most common strains used for transplantation research 
(285). Skin grafts performed against the RT1 barrier are rapidly rejected, with the same 
happening in the rat kidney transplantation. However, indefinite tolerance can be 
spontaneously achieved in the rat liver transplant model between animals with complete MHC 
mismatch depending on which strain combination is used; for example, livers from Brown 
Norway (RT1n) donors are accepted by Lewis (RT1l) recipients, whereas, livers from Dark 
Agouti (RT1av1) donors are rejected up to two weeks post-transplant by Lewis (RT1l) 
recipients. This tolerance phenomenon is not a passive event since there is a clear rejection 
type process evidenced by the allograft lymphocytic infiltration associated with abnormal LFTs 
in the first two weeks post-transplant. Some weeks later, the LFTs progressively and 
spontaneously normalise and the lymphocytic infiltrate similarly disappears (273). For our 
experiments, we decided to only work with one rat strain as recipient and change the donor 
strains to have the following different phenotypes: 1) syngeneic, 2) spontaneous tolerance, 3) 
rejection (no treatment), and 4) Tolerance induced by tacrolimus strain combinations (286). In 
the spontaneous or induced tolerance combinations, transplanted rats surviving more than 
100 days are considered tolerant (287). The strain combinations used in our experiments are 
shown in Table 4. 
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Table 4: Rat strain combinations 
 Donor Recipient Phenotype 
1 Lewis (RT1I) Lewis (RT1I) Syngeneic combination 
2 Brown Norway (RT1n) Lewis (RT1I) Spontaneous tolerant combination 
3 Dark Agouti (RT1av1) Lewis (RT1I) Rejection combination (no treatment) 
4 Dark Agouti (RT1av1) Lewis (RT1I) Tacrolimus-induced tolerant combination* 
*Tacrolimus (1mg/Kg) IM during 10 days post transplant. RT1: rat related MHC locus. 
 
4.2.3 Induction of Iron Deficiency employing iron-modified diets 
Inbred rats weighting around 120 to 140g were used as donors, they were fed with either iron-
deficient (<6mg/Kg iron) or iron-replete (iron deficient diet supplemented with 200mg/Kg iron 
carbonyl) diets (SAFE, France) for a total of 3 weeks; rats weighting around 160 to 180g were 
used as recipients and fed for 1 week prior to the liver transplant procedure. After three weeks 
of iron-modified diets the donor rats weighed around 180 to 220g, and the recipients after one 
week of the iron-modified diets achieved the same weight ranges, which were considered the 
ideal weights to perform the liver transplant procedure. Rats with less than 180g have very 
delicate vascular structures and rats weighting more than 300g present increased abdominal 
fat tissues making the procedure both more difficult and longer. 
 
4.2.4 Recombinant human Interleukin 2 administration 
The establishment of tolerance in similar experimental rat models of spontaneous tolerance 
strain combinations was abrogated by a course of high doses of rhIL-2 (276, 277). We 
replicated this strategy in our model of spontaneous tolerance in order to question if iron level 
changes can interfere with the rhIL-2 effect in the tolerance establishment. An injection of 
200.000IU of rhIL-2 was performed every day by intra-peritoneal via during 21 days. Blood 
samples were collected at day 0, 3, 7, 10, 14, 17 and at day 21 by tail puncture for 
biochemistry analyses. Animals were sacrificed at day 21 and blood and tissue samples were 
collected for further analysis. Two additional experiments were realized on long-term 
transplant survivors following the same protocol, with only an adjustment on the rhIL-2 doses 
to 400.000IU per day proportional to the animal weight gain overtime. 
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4.2.5 Statistical analyses 
Statistical analyses were performed with GraphPrism software version 5.0. The Mann-Whitney 
U test was used for comparison between two groups, whereas the two-way ANOVA analysis 
with Tukey’s post-hoc correction for pairwise was used to compare more than 2 groups. The 
Fisher test was used for categorical variables. Survival rates were calculated using Kaplan-
Meier estimation. P-values inferior to 0.05 (two tailed) were considered statistically significant 




4.3.1 Survival curves between the different rat strain combinations 
Our first results using the Kamada technique were discouraging with no long-term survival 
after 76 transplant essays using Wistar rats as donors and recipients. At this point I had only 
15 animals had survived few hours after the procedure, two animals had survived more than 
24 hours and only one more than 48 hours. So we decided to move to the fully vascularized 
method due to the aforementioned reasons, and in order to be fully trained on this technique I 
attended a one-week training course at the Charité University Hospital in Berlin. From that 
week onward and after changed the rat strain used from Wistar to the Lewis as donor and 
recipient, which is more appropriate for the liver transplant procedure, our survival rate 
improved up to 80% in the syngeneic strain combination and in the spontaneous tolerant strain 
combination where the Brown Norway strain was used as donor. The tacrolimus induced-
tolerance strain combination presented the worst survival rate, around 50% (Figure 10A). All 
long-term survival strain combinations presented similar clinical and biochemistry post-
operative outcomes - gaining weight in the same proportion and with prompt normalization of 
the liver transaminases (Figure 10B and C). These results allowed us to start the experiments 
to check the influence of induced iron-deficiency on the anti-donor T cell mediated response. 
 
Figure 10: Post-liver transplantation outcome between the different strain combinations. (A) Overall survival rate 
post-liver transplantation including all transplants performed with animals under normal diet. (B) Rats weight evolution 
on the post-transplant period reflecting the clinical evolution between the three different strain combinations. (C) Alanine 
aminotransferase (ALT) kinetics on the post-transplant period: Number of animals: Lew-Lew: 12, BN-Lew: 11, DA-Lew: 
11, DA-Lew (TAC): 8. 
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4.3.2 Induction of mild iron deficiency in rats 
Once we had set up our rat liver transplant model with an overall survival rate of 80 to 90%, 
we tried to induce mild iron deficiency by modifying the iron levels in the animal diets as we 
had done in our work with mice. Rats were fed for three weeks with an iron deficient diet 
(IrDef) and the control group with an iron-replete diet (IrRepl). When compared with IrRepl, 
IrDef rats presented a decreased serum iron from the first week under the special regimen, 
which achieved statistical differences at three weeks (mean 16.87±2.77 versus 
36.63±0.73µg/dL; p<0.0001). Additionally, intra-hepatic iron measurement revealed reduced 
iron stores at day 21 (131.0±7.04 versus 321.0±12.5µg/g of dried tissue, p=0.0002). IrDef rats 
presented no significant decrease in the haemoglobin serum levels in comparison to IrRepl 
rats (mean 130.7±4.33 versus 141.7±1.g/L; p=0.07), a slightly significant difference in RBC 
(8.41±0.09 versus 8.80±0.9x1012/L, p=0.048), and in WBC (5.77±0.94 versus 
6.72±0.52x109/L, p=0.42) and increased platelets (624.7±43.77 versus 462.7±115.0x109/L, 
p=0.25). Otherwise, IrDef rats remained clinically healthy and gained weight at the same rate 
as IrRepl rats with no differences in evolution of ALT levels over the post-transplant time 
(Figure 11). 
 
Figure 11: Clinical, biochemistry, iron and haematological parameters in Lewis rats fed with iron-deficient 
(IrDef) and iron-replete (IrRepl) diets over three weeks. (A) Rats weight evolution over the three weeks of iron-
modified diets regimen. (B) Serum alanine aminotransferase (ALT) kinetics at the same period. (C) Serum iron evolution 
at the same period. (D) Haematological parameters and liver iron concentration evolution at the day 21 under iron-
modified diets regimen. Bar plots display mean and SEM. Abbreviations: ALT: alanine aminotransferase, Hb: 































































































































































4.3.3 Survival curve between the different rat strain combinations under iron-
modified diets 
For these experiments, donor and recipient rats were fed with iron deficient or iron-replete 
diets for a 3-week period. In a preliminary experiment, IrDef recipient rats presented a 50% 
per-operatory mortality rate, and all rats died within 3 days post-transplant. IrDef recipients 
presented an important colonic dilatation with liquid accumulation. They exhibited a high 
sensibility to anaesthesia and some of them became very unstable, even with a small amount 
of blood loss (Table 5).  
Table 5: Post-liver transplant survival rate in a preliminary experiment using the iron-modified diets  
 IrDef (n) IrRepl (n) 
Per-operative deaths 2 0 
Deaths < 3days 2 2 
Survivals > 100 days 0 2 
Survival rate at 100 days 0% 50% 




Therefore, we decided to feed the donors during three weeks and the recipients for only one 
week before the transplant procedure. Using this protocol the survival rate for the three strain 
combinations used under iron-modified was similar to the transplanted rats for the same strain 
combinations under normal commercial diets. In the iron-modified diet experiment, all of the 
three strain combinations performed, the IrDef recipients presented similar clinical and 
biochemistry outcomes when compared with IrRepl recipients (Fig12 A and B).  
 
Figure 12: Post-liver transplant outcome between different strain combinations treated with iron-modified diets 
before (3 weeks for the donors and 1 week for the recipients) and after the procedure. (A) Animals weight 
evolution on the post-transplant period reflecting the clinical evolution between the three different strain combinations 
under iron-deficient diet (IrDef) and iron-replete diet (IrRepl). (B) ALT kinetics on the post transplant period reflecting 
similar liver function in both groups IrDef and IrRepl in all of the three strain combinations. Number of animals 
(IrRepl/IrDef): Lew-Lew: 2/2, BN-Lew: 2/2, DA-Lew: 2/2.  
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4.3.4 RhIL-2 administration induces clinical deterioration and liver function 
impairment associated with more cytokine production in Iron deficient animals 
In the previous experiment, we had demonstrated that the induction of a slight iron deficiency 
could not hinder spontaneous tolerance. We then administered a potent immune-stimulatory 
treatment, such as high doses of rhIL-2 for three weeks, to amplify a possible subtle effect of 
iron deficiency on the establishment of tolerance. For these experiments, four groups of 
grafted liver rats were used: 1) spontaneous tolerance IrDef, 2) spontaneous tolerance IrRepl, 
3) IrDef Syngeneic and 4) Syngeneic IrRepl, where the last two groups were considered as 
control groups. IrDef transplant rats presented a clinical deterioration reflected by the 
significant decrease in body weight in comparison with IrRepl animals (177.0±10.39 vs. 
217.8±13.36g at day 21, p<0.0001). Furthermore, IrDef were apathetic and presenting 
piloerection, which are signs of animal illness (288). The LFTs presented an earlier worsening 
and a more accentuated deterioration in the IrDef group. Serum level of bilirubin was 
increased in IrDef animals at day 21 (94.60±21.15 vs. 63.40±18.98umol/L p=0.02) and ALT 
remained increased in IrDef animals in comparison with the IrRepl group during the 21 days of 
rhIL-2 administration. Upon euthanasia, IrDef transplant rats presented more intra-hepatic 
CD4+ T cells and less CD8+ T cells and more cytokine production. Interestingly, both 
syngeneic groups did not present the clinical deterioration or the LFTs impairment observed 
on the Spontaneous Tolerance IrDef group. Furthermore, the Syngeneic IrRepl did not present 
the late deterioration of the LFTs presented by the Spontaneous Tolerance IrRepl group. 
Altogether, these results suggest that the use of a potent immune inflammatory stimulus has 
been able to detect differences in post-transplant immune outcomes between groups with 
different levels of iron stores. These differences appear to occur only in the case of allograft 
lymphocyte infiltration in combinations of strains exhibiting complete MHC mismatch. This was 
the case with the Spontaneous Tolerance strain combination of Brown Norway / Lewis rats 
employed in such experiments (Figure 13). 
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Figure 13: Post-liver transplantation outcome after rhIL-2 challenge. (A) Animals weight evolution on the post-
transplant period reflecting the clinical evolution between the syngeneic and spontaneous tolerant IrDef and IrRepl 
groups. (B and C) Graphics showing the post-transplant ALT and bilirubin evolution. (D) Frequency of intra-hepatic 
CD4+ and CD8+ T cells in the two groups of spontaneous tolerant IrDef and IrRepl at day 21 post transplant and post 
RhIL-2 administration. (E) Intra-hepatic frequency of Interferon Gamma production by CD4+ and CD8+ T cells in a 
second identical experiment in where the animals were euthanized at day 14 post-transplant and post rhIL-2 
administration. (F) Pictures showing one IrDef transplant rat (upper panel) and one IrRepl animal (lower panel) aspect 
after 21 days under rhIL-2 challenge (Spontaneous tolerant strain combination). The IrDef transplanted rat present 
piloerection, peripheral vasoconstriction and signs of losing weight. Number of animals: Syngeneic (IrRepl/IrDef): 3/3, 












































































































































































































4.3.5 RhIL-2 challenge does not seem to affect IrDef spontaneous tolerant long-
term survivors  
In order to check the influence of the transitory lymphocyte liver allograft infiltration in early 
time post liver transplantation, we replicate the rhIL-2 protocol in some spare spontaneous 
tolerant long-term survivors that had been kept under the same iron-modified diet protocol 
over all post-transplant period. For this experiment two IrDef spontaneous tolerant and only 
one IrRepl spontaneous tolerant animals were available. Mean serum iron level on the IrDef 
animals was 13,2 ug/dl while the IrRepl animal presented 41ug/dl of serum iron levels. 
Animals were challenged with 400.000IU of rhIL-2 (adjusted for their body weights) for 21 days 
in the same way as in the previous experiments. There were no modifications in animal 
weights or behaviours. Also no differences and/or alterations were observed in the ALT and 
bilirubin levels throughout the entire experiment (figure 14).  
 
Figure 14: Outcome of long-term spontaneous tolerance transplanted survivors (BN – Lew) challenge with rhIL-
2. (A) Animal weight evolution on rhIL-2 challenge period showing the similar clinical evolution between the 
spontaneous tolerance IrDef and IrRepl groups. (B and C) ALT and bilirubin kinetics during rhIL-2 challenge in the same 
groups. Number of animals (IrRepl/IrDef): 1/2. 
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4.3.6 RhIL-2 challenge seems to affect IrDef long-term induced tolerance 
survivors 
RhIL-2 challenge caused a clinical and laboratorial effect in early spontaneous tolerant 
transplant rats, but not in early syngeneic transplant rats. Also this initial effect was abolished 
on long-term spontaneous tolerant transplant survivor rats. Then, we questioned what could 
be the effect of the rhIL-2 challenge on the induced tolerant strain combination. We aimed to 
replicate the same experiment on the aforementioned strain combination (DA-Lew). 
Unfortunately again, only two IrDef induced tolerant transplant and one IrRepl induced tolerant 
transplant rats were available for the experiment. In spite of that, one IrDef induced tolerant rat 
showed clear LFTs deterioration during the rhIL-2 challenge while one IrDef transplant rat did 
not present alterations. Likewise, the IrRepl animal did not show alterations in its weight and 
LFTs (Figure 15). 
 
Figure 15: Outcome of long-term Tac-induced tolerance transplanted survivors (DA – Lew) challenge with rhIL-
2. (A) Animal weight evolution on the post-transplant period showing no apparent clinical changes between the Tac-
induced tolerance (DA-Lew) IrRepl and the two IrDef transplant rats during the rhIL-2 challenge. (B and C) ALT and 
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4.3.7 Post-transplant long-term complications suggests a systemic effect of 
iron-modified diets  
We initially checked the iron-modified diets’ impact on the growth rate and on the hematologic 
and biochemical parameters before starting our transplants in rats previously fed with those 
diets. Three weeks of the special diet protocol did not alter the weight gain between the two 
groups. Likewise, we did not detect important differences in hematologic parameters or in 
LFTs. Those observations allowed us to proceed with the transplant on animals under the 
special diet protocol. However, we aimed to interrogate whether the use of the special iron-
modified diets for a long period was detrimental for the clinical evolution after transplantation. 
For that, we checked our clinical evolution records for long-term transplant survivor rats kept 
for more than 4 months under the iron-deficient and/or iron-replete regimens and we 
compared them with a large group of spontaneous tolerant transplant rats kept under normal 
chow diet. Transplant rats under special iron diets (iron deficient and iron-replete) showed a 
higher rate of complications (p=0.0001). They developed more abdominal wall abscesses, 
incisional hernias and biliary obstructions with hepatic abscesses and cirrhosis than the group 
fed with normal chow diet (Table 6 and Figure 16). 













Total  Total % 
Normal 36 168.78 0 0 3 3* 8.3 
Iron-modified 27 137.14 5 4 10 19* 70.4 
Iron deficient 14 135.28 4 2 5 11 78.5 
Iron replete 13 139 1 2 5 8 61.5 
* p=0.0001 
 
Figure 16: Clinical complications on long-term survivors transplant rats: (A) Picture showing an incisional 
abdominal wall hernia on an IrDef transplant rat. (B) Picture showing abdominal wall abscesses alongside the surgical 
incision on an Ir Repl transplant rat. (C) Picture showing an intra-hepatic abscess with a cirrhotic liver in an Ir Def 
transplanted rat. 
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Chapter 5 : Molecular characterization of acute cellular 
rejection occurring during intentional immunosuppression 
withdrawal in human liver transplantation 
 
5.1 Introduction:  
Spontaneous operational tolerance was initially observed in non compliant or in liver transplant 
recipients that interrupted IS treatment due to uncontrolled infectious episodes or by the 
presence of malignancies such as PTLD. These observations instigated the realisation of 
intentional IS withdrawal on stable liver recipients. On average, around 20 to 40% of the 
enrolled liver recipients could be completely weaned from the IS treatment in such studies. On 
the other hand, eventual ACR episodes are mild and mainly treated by reintroduction of initial 
IS treatment. Since recruited liver recipients have been transplanted for more than three 
years, we can expect that such ACR episodes are not influenced by the ischaemic-reperfusion 
injury, surgical complications and/or by the consequences of the underlying liver disease that 
are very intense in the first weeks post liver transplantation. In agreement with that, we 
hypothesized that molecular profiling analysis of sequential biological samples collected from 
rejecting liver recipients during the IS weaning protocol could be used to decipher ACR 
pathways and to discovery rejection biomarkers without the interference of such mentioned 
confounders. In the present study, we analysed liver tissue and blood samples collected 
before starting the weaning protocol and at the ACR time, in addition to sequential blood 
samples taken across the weaning process. We conducted a gene expression profiling 
employing whole-genome microarrays and real-time PCR technologies. Results were 
correlated with the type of immunosuppression and with the histological damage intensity. 
Furthermore, we compared our gene molecular dataset with public gene set databases. 
Finally, we analysed the gene transcriptional profile from the sequential blood samples 
collected during the weaning process, trying to define a gene signature that could diagnose 
ACR before its clinical or histological manifestation in that specific set of IS withdrawal.  
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5.2 Material and Methods 
 
5.2.1 Immunosuppression withdrawal clinical trials in liver transplantation  
From April 2006 to December 2009, one hundred and thirty-six stable liver transplant 
recipients were enrolled in two prospective multicentre clinical trials of IS withdrawal. The first 
trial (ClinicalTrials.gov NCT00647283) was designed to study the development of operational 
tolerance in a very selected liver transplant recipient population that met the following inclusion 
criteria: more than 3 years of follow-up since the liver transplantation; no history of 
autoimmune liver disease; absence of graft rejection in the last 12 months, aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) levels less than 2-fold and 
alkaline phosphatase (AP) less than 1.5-fold the local laboratory superior normal limit; 
presence of comorbidities associated to immunosuppressive regimens (arterial hypertension, 
diabetes, renal dysfunction), and risk of malignancy occurrence (previous history of extra 
hepatic cancer, history of smoking or alcohol consumption, older than 60years-old). From 341 
patients initially screened with more than 3 years since the liver transplantation, 102 patients 
were enrolled in the trial, 24 of whom were transplanted for HCV related cirrhosis and 12 
presented RNA-HCV positive at the time of enrolment (1). The second trial (ClinicalTrials.gov 
NTC00668369), focused on the investigation of the influence of the inflammatory responses 
induced by the hepatitis C virus (HCV) on the development of operational tolerance, screened 
130 patients and enrolled 34 patients who matched the following inclusion criteria: liver 
transplantation for HCV-associated liver disease with more than 3 years of follow-up after the 
transplant, positive HCV RNA at study enrolment, no indication for anti-HCV treatment, no 
history of autoimmune disease, absence of graft rejection in the last 12 months before 
enrolment, stability of LFTs, and positive biomarker screening (high blood Vδ1/Vδ2 T cell ratio 
measured by flow cytometry on whole blood samples and/or elevated SLAMF7/KLRF1 
transcript level expression detected by real-time PCR platform (100). Exclusion criteria were 
similar in both studies: age inferior to 18 years; pregnancy; alcohol or illicit drug abuse; 
psychiatric or medical illnesses interpreted as incompatible with safe participation in the study 
(e.g., cardiac failure; chronic obstructive pulmonary disease; on going malignancy, major 
depression); altered baseline LFTs; altered baseline liver biopsy with: (1) signs of acute or 
chronic rejection as stated by Banff criteria (55); (2) portal inflammation more than 50% of 
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portal tracts unrelated to chronic HCV infection; (3) central perivenulitis in more than 50% of 
central veins; (4) or fibrosis stage III-IV as stated by Metavir criteria; HIV co-infection or 
combined liver-kidney transplantation. In both studies, an identical drug withdrawal protocol 
was employed and has been previously described (Figure 19) (1, 100). Initially, 
immunosuppressive drug doses were gradually tapered, by reducing 25% to 50% of the 
dosage at each 3-week interval. Once the minimum possible daily dose was attained, the next 
step was to space the doses over the weekdays, always respecting the 3 week period for each 
dose reduction until one dose per week was achieved and then the immunosuppressive 
treatment was completely discontinued. The weaning process was realized over a 6-9 month 
period and patients who completely stopped the IS treatment were followed for a minimal 
period of 12 months. Patients who did not develop rejection were classified as operationally 
tolerant as long as immunosuppressive drug cessation was maintained for at least 12 months 
with no laboratorial and no histologic evidence of acute and/or chronic rejection were 
observed. 
 
5.2.1.1 Liver biopsies protocol 
Protocol liver biopsy samples were obtained in all patients at baseline, at 12 months after 
successful drug withdrawal in patients who did not reject or at the time of rejection in those 
patients that presented it. Blood samples were taken at enrolment, at every three weeks 
during the withdrawal period, at the rejection episode and monthly during the 12 months after 
drug cessation or after the rejection episode resolution. During the weaning process or after 
complete IS treatment withdrawal; allograft dysfunction was determined by any increase of 
AST, ALT, or simultaneous increase on gamma-glutamyl transpeptidase (GGT) and AP above 
the superior normal limits. In patients with initial abnormal LFTs, allograft dysfunction was 
considered when they presented an increase superior to 2-fold the baseline levels and/or an 
increase on GGT an AP at the same time superior to 1.5-fold the baseline levels. When LFTs 
were increased more than 2-fold the baseline levels of AST or ALT, and/or more than 1.5-fold 
increase of GGT and AP baseline levels, liver biopsy was promptly realised. In case of 
alterations of LFTs inferior to the previous cut-off described, drug minimization was temporarily 
interrupted and LFTs were repeated in two weeks time. If the deterioration persisted, a liver 
biopsy was carried out, and in case of amelioration of blood tests, the weaning protocol was 
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reassumed. Rejection was diagnosed by the combination of allograft dysfunction and 
characteristic liver biopsy findings according to BANFF criteria (55).  
 
5.2.1.2 Rejection treatment 
Rejection episodes were predominantly mild to moderate and promptly resolved following 
reinstitution of baseline immunosuppression regimen (29 patients, 21 from the first trial and 8 
from the second trial) associated or not with low dose steroids (20mg/day over a period of 4-6 
weeks) (35 patients, 30 patients from the first trial and 5 from the second trial) or moderate-
dose steroids doses (7 patients, 4 patients from the first and 3 from the second trial), only one 
patient required steroid boluses to treat the rejection episode. No grafts were lost due to the 
rejection episodes. At the end of both studies, drug withdrawal was successfully achieved in 
41 patients while 57 rejected in the first clinical trial; whereas, in the second clinical, complete 
IS weaning was successful in 17 patients and rejection occurred in 15. In total, from the initial 
136 liver transplant recipients enrolled, 58 patients were considered tolerant, 72 patients 
presented a rejection episode and 6 patients were excluded (Figure 19).  
 
Figure 17: Flow chart showing immunosuppression withdrawal trial design. Data was included from two trials with 
identical withdrawal protocols (ClinicalTrials.gov NTC00647283 and NTC00668369). A subset of these patients was 
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5.2.2 Rejecting patients population and control groups 
Even though the previous described clinical trials had been designed to study the 
development of operational tolerance in liver transplant recipients, with all derived recent 
publications reported mainly focusing on the clinical outcomes of operational tolerant 
recipients and possible mechanistic pathways involved on the development of operational 
tolerance (1, 2, 100, 274), these studies also provide an exceptional opportunity to investigate 
the molecular mechanisms of acute cellular rejection, which still represents an important 
concern for the  liver transplant follow-up. This present worked focused on the rejecting patient 
population in those trials aiming to identify possible biomarkers associated with acute cellular 
rejection occurring during intentional immunosuppression withdrawal in liver transplantation. 
 
5.2.2.1 Rejecting patients and samples selection 
Out of the total population of 72 liver recipients who developed an episode of ACR during the 
two previous described clinical trials, 55 patients were included in the current study. Forty-
seven patients were enrolled in the first clinical trial, one of them was RNA-HCV positive at the 
enrolment time (1), and the remaining 8 patients were initially included in the second clinical 
trial destined to enrolled only RNA-HCV positive liver recipients (100) (Table 7). Patient 
selection for the present study was based on availability of liver samples for molecular and 
histologic analyses and blood samples for molecular analyses. Thirty-three patients were 
identified having 61 liver tissue samples available for analysis, (34 biopsies at baseline and 27 
biopsies at rejection time). Sequential blood samples were initially available from 77 patients. 
Due to the variation in the days of blood sample collection in relation to the day of rejection 
episode, we defined time intervals in order to uniformly group the samples according to the 
time before and after the rejection episode for rejecting patients and/or the time before and 
after complete immunosuppression withdrawal for tolerant recipients used as control groups 
(Table 8). After processing and control tests, one hundred and ninety-three sequential blood 
samples from 45 rejecting patients were used in our study.  
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Table 7: Demographic and clinical characteristics of enrolled rejecting patients 
Characteristic Total cohort (55) 
Age at transplant (years) 48.23 ± 11.73 
Age at weaning start (years) 55.53 ± 11.83 
Gender (% male) 54.5 
Caucasian (%) 100 
Transplant Indication  
          HCV cirrhosis 21 
                    VHC-RNA positive at enrolment (9) 
          HBV cirrhosis 9 
          Alcoholic cirrhosis 9 
          Amyloidotic polyneuropathy 5 
          Fulminant hepatitis 3 
          Other causes 8 
Time from transplant to weaning start (years) 6.83 ± 3.55 
Time from weaning start to rejection (months) 7.82 ± 4.49 
Immunosuppressive therapy at weaning start  
          Tacrolimus 25 
          Cyclosporin A 22 
          Mycophenolate 11 
          Rapamicine 2 
          Cyclosporin A + Mycophenolate 5 
CNI-based immunosuppression at weaning start (%) 85 
Immunosuppressive drug trough levels  
at weaning start (ng/mL) 
 
          Tacrolimus 5.2 ± 2.3 
          Cyclosporin A 57.4 ± 36 
Liver function tests at weaning start  
          Aspartate aminotransferase (U/L) 33 ± 22 
          Alanine aminotransferase (U/L) 38 ± 35 
          Gama-glutamyl transpeptidase (U/L) 40 ± 70 
          Alkaline phosphatase (U/L) 172 ± 64 
          Total Bilirubin (mg/dL) 0.75 ± 0.3 
Rejection severity  
          Indeterminate 19 
          Mild 23 
          Moderate 7 
          Severe 6 
Banff Score* 4 (2-9) 
Liver function tests at rejection time  
          Aspartate aminotransferase (U/L) 150 ± 137 
          Alanine aminotransferase (U/L) 207 ± 196 
          Gama-glutamyl transpeptidase (U/L) 188 ± 208 
          Alkaline phosphatase (U/L)  287 ± 173 
          Total Bilirubin (mg/dL) 1.55 ± 4.51 
Rejection treatment  
          Baseline IS 23 
          Baseline IS + Prednisone 20 mg/day (4-6 weeks) 26 
          Baseline IS + Prednisone 40-60mg/day (4-6 weeks) 4 




Table 8: Time distribution of sequential blood samples selection 
Sample 
 Code 
Time interval for  
samples collection 
Blood samples 
from 45 rejecting 
patients 
Bloods samples 
from 7 tolerant 
patients 
- 6 > 9 Mo bef.  45 7 
- 5 < 9 Mo and > 6 Mo bef. 4 4 
- 4 < 6 Mo and > 3 bef. 8 5 
- 3 < 3 Mo and > 1 Mo bef. 9 6 
- 2 < 1 Mo and > 15 days bef. 6 6 
- 1 < 15 days and > 7 days bef. 8 4 
0 Rejection episode/ Complete IS stop 45 5 
+ 1 < 15 days after 6 4 
+ 2 > 15 and < 1 Mo after 11 7 
+ 3 > 1 Mo and < 3 Mo after 12 7 
+ 4 > 3 Mo and < 6 Mo after 13 7 
+5 > 6 Mo and < 12 Mo after 14 7 
+6 > 12 Mo after 12 7 
Total Total 193 69 
 
5.2.2.2 Patient control groups 
A cohort of 86 stable immunosuppressed liver recipients, from Hospital Clinic in Barcelona – 
Spain, with no biological evidence of rejection; no previous attempts of drug withdrawal, from 
whom at least one cryopreserved blood sample was available, was used as control group for 
the molecular blood samples experiments. All patients in this group were initially enrolled in a 
previous clinical study designed to investigate the immunologic characteristics of stable liver 
transplant patients under immunosuppression treatment at determined time. The 86 patients 
selected as control group for this present study were matched for age, sex and time from 
transplantation with the group of 22 rejecting patients from whom, sequential blood samples 
were used to construct predictive models of rejection (Table 9). At least one cryopreserved 
blood sample in conformity for molecular analyses was available per patient. An additional 
experiment was performed to check if ACR-associated gene expression was differentially 
expressed between tolerant and rejecting patients before starting the weaning process. For 
that, we reanalysed a previously generated gene expression data originated from baseline 
blood samples of a group of 25 tolerant patients and compared with results of 43 rejecting 
patients, all of them enrolled in the first clinical trial (ClinicalTrials.gov NCT00647283) (1) 
(Table 10). Finally, in order to create a positive control group of rejection happening in the 
early time post-transplant and outside of drug-withdrawal setting, nine early post-transplant 
rejection biopsies collected originated from clinically stable and without major surgical 
complications (vascular and biliary events) HCV negative patients within the first 4 weeks 
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following transplantation were included as a control cohort and used in the tissue molecular 
experiment. 
Table 9 : Demographic and clinical characteristics of patients used in the rejection prediction model test 




(86) p- value 
Age at transplant (years) 53 ± 9.59 50.49 ± 9.34 51.97 ± 10.16 0.88 
Age at weaning start or sample 
collection (years) 
59.71 ± 8.84 60.43 ± 8.69  58.33 ± 9.95 0.80 
Gender (% male) 68.2 85,7 69.4 0.45 
Transplant Indication     
          HCV cirrhosis 8 0 36  
          HBV cirrhosis 5 3 8  
          Alcoholic cirrhosis 4 4 25  
          PAF 2 0 5  
          Fulminant hepatitis - 0 1  
          Other causes 3 0 11  
Time from transplant to wean 
start or sample collection  




Table 10: Demographic and clinical characteristics of Non-tolerant and Tolerant patients from whom previous 
qPCR data at the baseline were reassessed 




(25) p- value 
Age at transplant (years) 47.75 ± 10.34 46.15 ± 11.53 50.45± 7.40 0.068 
Age at weaning start (years) 56.11 ± 10.85 52.62 ± 11.40 61.96 ± 6.70 0.000 
Gender (% male) 68.5 60.5 72.0 0.34 
Caucasian (%) 100 100 100  
Transplant Indication  
          HCV cirrhosis 21 12 9  
          HBV cirrhosis 18 11 7  
          Alcoholic cirrhosis 12 6 6  
          Amyloidotic polyneuropathy 4 4 0  
          Fulminant hepatitis 3 3 0  
          Other causes 9 6 3  
Time from transplant to weaning start (years) 8.20 ± 3.81 6.50 ± 3.29 11.06 ± 2.80 0.000 
Immunosuppressive therapy at weaning start  
          Tacrolimus 29 21 8  
          Cyclosporin A 25 16 9  
          Mycophenolate 17 6 11  
          Tacrolimus + Mycophenolate 2 1 1  
          Cyclosporin A + Mycophenolate 2 1 1  
Liver function tests at weaning start   
          Aspartate aminotransferase (U/L) 23.03 ± 5.3 24 ± 5.67  21.5 ± 4.54 0.18 
          Alanine aminotransferase (U/L) 21.29 ± 6.84 22.9 ± 6.52 18.75 ± 6.82 0.10 
          Gama-glutamyl transpeptidase (U/L) 28 ± 33.6 20.89 ± 16.53 39.9 ± 49 0.23 
          Total Bilirubin  0.73 ± 0.23 0.7 ± 0.33 0.71 ± 0.2 0.41 




5.2.3  Biological specimens 
As previously mentioned, liver biopsy samples were obtained in all patients before the 
initiation of the immunosuppressive drug weaning protocol (baseline), at the time of rejection if 
it occurred, and at 12 months after successful drug withdrawal in patients who did not reject.  
Blood samples were taken at enrolment, at every three weeks during the withdrawal period, at 
the rejection episode and monthly during the 12 months after drug cessation or after the 
rejection episode resolution. 
 
5.2.3.1 Liver samples collection and conditioning: 
Liver specimens were collected through a percutaneous or a trans-jugular liver puncture under 
aseptic conditions and local anaesthesia. A 10- to 15mm portion of the biopsy cylinder was 
immediately formalin-fixed and sent to pathology laboratory to be posteriorly embedded in 
paraffin, sectioned and stained in haematoxylin-eosin and Masson’s trichrome preparations. 
The remaining liver tissue, usually a minimum of 2- to 3mm portion of the biopsy cylinder, was 
immediately preserved in RNAlater® reagent (Ambion – Carlsbad, CA - USA), kept at 4ºC for 
24 hours, and then snap frozen in liquid nitrogen after removal of RNAlater®. 
 
5.2.3.2 Blood samples collection and conditioning: 
After venepuncture under aseptic conditions, blood samples were collected, conditioned in 
specific laboratory tubes and sent for haematological and biochemistry tests. An additional 
blood volume (2,5ml) were directly collected for immediate stabilisation in Paxgene® tubes  
(Qiagen – DE), specially designed for RNA preservation, then filled tubes were stabilized for at 
least two hours in RT and then stored at -80ºC until thawing for posterior analyses.  
 
5.2.3.3 Total RNA extraction from liver tissue and blood samples 
For total RNA extraction, frozen liver tissue samples were thawed and homogenized in Trizol® 
reagent (Invitrogen – Carlsbad, CA - USA) using a pestle and nuclease-free 1.5ml reaction 
tubes (Ambion – Carlsbad, CA - USA) and then total RNA was extracted following the 
manufacturer’s instructions, posteriorly, RNA extracted quality was checked using Agilent2100 
Bioanalizer® (Agilent Thecnologies – Santa Clara, CA - USA).  
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For total RNA extraction from the frozen whole blood samples, blood samples were thawed in 
RT for a minimal period of two hours, then samples were processed using the Paxgene Blood 
RNA kit ®  (Quiagen – DE) following the manufacturers instructions, after extraction the RNA 
quality was assessed using Nanodrop1000 Spectrophotometer (Thermo Scientific – USA).  
 
5.2.4 Histological examinations  
The liver biopsy slides stained with H&E and Masson’s trichrome stain were systematically 
analysed by a senior hepatic pathologist (R.M.) who was blind to all clinical and biological 
data. For histological analysis purposes following criteria were quantitatively measured: 1) 
lobular inflammation, 2) central vein perivenulitis, 3) central vein endothelitis, 4) portal 
inflammation, 5) interface hepatitis, 6) bile duct lesions, 7) ductular reaction, 8) ductopenia, 9) 
portal vein endothelitis, 10) perisinusoidal fibrosis, and 11) portal fibrosis.  
 
5.2.5 Liver tissue and blood microarray gene expression 
Several thousands of genes could be differently expressed during biological processes and it 
is particularly evident during an inflammatory and immunological event as the acute allograft 
cellular rejection. Depending on which kind of stimulus they receive, genes can be 
overexpressed, down regulated or not be influenced by the on going stimulus. To 
simultaneously access the expression profile of several thousands of genes probably 
associated with the acute cellular rejection phenomenon we employed the microarray 
technology. This technology, which involves many steps and requires sophisticated software 
and algorithms to analyse the huge amount of generated data, has its core principle in the 
hybridization of two complementary strands of nucleic acids using a biochip consisting of a 
small solid substrate covered in a high density way by thousands of oligonucleotide probes 
specific for the target genes. Biological samples were processed and analysed employing two 
microarray platforms in the present study: Illumina® (San Diego, CA – USA) microarray 
platform for liver tissue experiments and Agilent® (Santa Clara, CA – USA) microarray 
platform for blood samples analysis as described below: 
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5.2.5.1 Liver tissue data extraction and normalization 
Transcriptional profiling of liver tissue samples was conducted employing Illumina® 
microarrays. Fifty-eight liver tissue RNA samples (pre-weaning and rejection time points) from 
28 patients (21 HCV-negative and 7 HCV positive patients) were processed into cRNA and 
hybridized onto IlluminaHT 12 Expression BeadChips containing up to 48,771 probes which 
correspond to 25,000 annotated genes and analysed using BeadArray Reader (Illumina®). 
Then, microarray expression data was computed using BeadStudio data analysis software 
(Illumina®) and subsequently processed employing quantiles normalisation using the Lumi 
bioconductor package (Bioconductor® project – www.bioconductor.org). Next, a conservative 
probe-filtering step was conducted excluding those probes with a coefficient of variation <4%, 
which resulted in a list of 20,965 evaluable from the original set of 48,771 probes. 
 
5.2.5.2 Blood sample data acquisition and normalization 
RNA extracted from blood samples was analysed on a custom Agilent® complementary DNA 
(cDNA) microarray containing probes for 5069 preselected immunology-related transcripts 
(123). Seventy-four paired blood samples (37 pre-weaning and 37 rejecting blood samples) 
from 37 non-tolerant HCV-negative patients were hybridized on the custom Agilent cDNA 
microarrays according to the manufacturer’s instructions. Array images were acquired with 
Agilent’s microarray scanner G2505C and signal data was collected with dedicated Agilent 
Feature Extraction software (v9.5.1). Probes with gIsPosAndSignif (Boolean value 
representing whether the spot's Cy3 signal exceeds significantly background) value of zero in 
at least 10 samples were disregarded and labeled as "null". Background adjustment and 
normalization were done using normexp and quantile normalization. Median values were 
calculated for multiple probes with the same Agilent Probe ID. 
 
5.2.5.3 Statistical microarray analysis 
Analysis for differential expression on a probe basis was done by limma Bioconductor® 
software package, which included the correction for multiple testing using the FDR method. 
We defined statistically significant differences in gene expression as those that showed a FC > 
1.2 and a FDR <0.05. When we compared expression data between different microarray 
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platforms (blood [Agilent] versus liver tissue [Illumina]), a lower threshold of significance was 
used (FC >1.2 and p-value <0.01). 
 
5.2.6 Gene Set Enrichment Analysis 
The huge amount of gene profile data generated by microarray experiments makes the 
analysis and interpretation a real challenge due to many factors as the massive volume of 
results by itself, the large number of tested genes, reduced number of samples and the high 
variability between tested individuals. In complexes biological processes, it is unlikely that a 
given specific gene, differentially expressed with statistical significance in a microarray 
experiment, could be determinant for that process where thousands of genes are involved. 
Furthermore, the same given gene can present different expression profiles across individuals 
with the same phenotype. Considering these factors, it is more logical to analyse the results 
for pre-defined sets of genes known to be involved in the functional pathways associated with 
the biological process in question. To assess the functional pathways associated with ACR in 
the present study, we used the GSEA application (149, 150). This tool, which compares 
differently expressed genes with previously identified gene sets, presents three fundamental 
steps: 1) An Enrichment Score (ES) for each gene set from the complete list of expressed 
genes is calculated taking in account the position (top or bottom) of each gene from the list of 
genes to study in a pre-defined gene set and its correlation with the biological phenotype. The 
score is calculated by a normalized Kolmogorov-Smirnov statistic like sum walking across the 
list of genes, its value increases when a gene from the list is encountered in the gene set and 
decreases when the gene is not present in the gene set. The ES corresponds to the maximum 
deviation from zero in the random walk across the gene set. 2) The statistical significance of 
each ES (nominal P value) is estimated though an empirical class label permutation (1,000 
times), which at each time recorded the maximum ES over all gene sets. In this way the 
alternative hypothesis of association between gene sets and the class phenotype is tested. 3) 
Once a complete database is evaluated, the ES of each gene set is normalized in regard to 
the size of the set, which generates a normalized enrichment score (NES), then a FDR 
correspondent to each NES is calculated in order to estimate the probability that a gene set 
with a given NES is a false positive result. In the present GSEA analysis, three different gene 
set databases were employed: 1) Hallmark gene sets from the molecular signature data base 
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(MSigDB) at the Massachusetts Institute of Technology (MIT) Broad Institute (Cambridge, MA 
– USA) (149), which include 50 gene sets mapped to known biological processes; 2) 
HaemAtlas gene set database (289), which contains gene sets preferentially expressed by 
specific peripheral blood subsets (CD4, CD8, CD19, CD14, CD56, CD66B, EB, MK); and 3) 
Pathogenesis-based transcript gene sets, which have been associated with different sub-types 
of rejection in both experimental animal models and in human kidney and heart allografts 
(http://atagc.med.ualberta.ca/Research/GeneLists/Pages/default.aspx) (158, 290). The full list 
of gene sets used is shown later on the results section (Table 12 and 13). All analyses were 
performed using the GSEA Pre-ranked tool, based on t-statistic and a weighted scoring 
scheme with 1,000 permutations. 
 
5.2.7 Correlation between gene expression profiling and liver histopathology  
To check which histological compartment on liver biopsies contributed to the transcriptional 
changes at the moment of rejection, we correlated histopathology data with complete liver 
tissue microarray data. A total set of 80 biopsy samples with full quantitative histological data 
for the each of 11 parameters mentioned on the section 5.2.4 could be uniquely mapped to 
tissue microarray data. Using this criteria, 21 samples taken at the rejection time, 57 biopsies 
taken before the drug withdrawal and two follow-up biopsies taken 1 year after complete 
withdrawal of immunosuppressive drugs. A graduation scale from 0 to 3 (0: absent, 1: mild, 2: 
moderate, 3: severe) was used to quantify all parameters in each sample. For each 
parameter, differentially expressed genes were identified using the limma Biocondutor 
package. Gene expression was correlated with severity of each parameter using a linear 
regression model constructed for that purpose.  
 
5.2.8 Influence of type immunosuppression on gene expression pattern 
To check whether maintenance immunosuppression regimens (TAC, CSA, MMF, and mTor 
inhibitors) could influence gene expression profiles in samples collected before starting the 
weaning protocol, we employed linear regression models constructed employing the limma 
Biocondutor® package to analyse our microarray data originated from 74 blood samples and 
33 liver tissue samples at baseline.  
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5.2.9 Validation real-time polymerase chain reaction experiments in peripheral 
blood samples  
Quantitative real-time polymerase chain reaction (qPCR) gene expression experiments were 
performed using a Fluidigm Biomark HD® system (Fluidigm, South San Francisco, CA - USA) 
and following the manufacturer’s instructions as described below to validate a set of gene 
expression profiles generated by microarray experiments performed in blood samples and 
liver tissue samples at the baseline and at the time of rejection. 
 
5.2.9.1 Genes and samples selections for Fluidigm Biomark HD system qPCR 
experiments 
We selected forty genes from the results of liver tissue and blood microarray gene expression 
profiles based on their FC and FDR classification and, on their overlapping expression 
between the two compartments. A small group of 5 genes were intentionally added taking in 
account their involvement in immunological processes (GZMB, PRF1, FOXP3, TGFB1 and 
IL15). HPRT1 and GAPDH were added as housekeeping genes for the Fluidigm experiments 
(160)(Table S1 Appendix C). Sequential blood RNA samples from 22 rejecting recipients (14 
HCV-negative and 8 HCV-positive) and 7 tolerant recipients were used in these experiments; 
which includes samples at baseline, during the weaning process, at the rejection time for the 
rejecting patients, at the time of complete IS stopping for the tolerant recipients, and samples 
from the follow-up period after rejection episode or after complete IS stopping following the 
selection criteria described in the section 5.2.2.1 (Table 7). Cryopreserved blood samples, 
from a cohort of 86 stable immunosuppressed liver recipients (one sample per patient) with no 
biochemical evidence of rejection, were included for comparative purposes (Table 8).  
 
5.2.9.2 qPCR experiments using Fluidigm Biomark HD system 
Total RNA extracted from blood samples following description protocol in section 5.2.3.2 was 
initially treated with Turbo DNA-free DNAse (Ambion, Carlsbad, CA – USA) in order to remove 
DNA contamination. RNA purified samples were then reverse transcribed into cDNA using 
HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA - USA). A 
pre-amplification step was performed as stated by Fluidigm Biomark HD protocol. Then, qPCR 
transcriptions were run using the Fludigm 96.96 Dynamic Array™ IFC plates following 
111 
manufacturer’s instructions. To quantify transcript levels target gene Ct values were 
normalized to the housekeeping genes HPRT1 and GAPDH to generate ΔCt values. The 
results were then computed as relative expression between cDNA of the target samples and a 
calibrated sample according to the ΔΔCt method. 
 
5.2.9.3 Additional real-time PCR experiment 
At the same time of the Fluidigm analysis, we conducted additional real-time PCR experiments 
as part of the biomarker portfolio studies determined by the Reprogramming the Immune 
System for the Establishment of Tolerance (RISET) European consortium. For these 
experiments, the gene expressions of CD3, FOXP3, MAN1A1, PRF1, and TOAG-1 were 
quantified in blood samples collected before the initiation of weaning from 43 non-tolerant and 
25 tolerant patients (Table 9) using an Applied Biosystem real-time PCR platform. 
 
5.2.10  Determination of predictive gene expression signature of rejection 
To determine a gene expression signature predictive of rejection before its clinical and 
laboratory detection, we performed a multivariate logistic regression analysis to identify gene 
signatures predictive of rejection among the 45 genes analysed by Fluidigm real-time PCR. 
Initially, we analysed all gene expression data from 44 paired blood samples (collected at 
baseline and at time of rejection) from 14 HCV-negative and 8 HCV-positive patients plus the 
86 comparative samples from stable immunosuppressed liver recipients. The 28-paired 
collected at baseline and at the time of rejection from the 14 HCV-negative patients were used 
as training set. The regression algorithm used to build a gene model to predict rejection was 
defined in the varSelect method of the MMIX Bioconductor package. Following variable 
selection, a generalized linear model was generated employing the glm method in the R 
statistical pachage (R Foundation for Statistical Computing, Vienna - AT), using the 28-paired 
samples to classify a given sample into a rejection or non-rejection sample (baseline) group. 
Internal cross-validation was performed using the boot R package. Given the small number of 
samples available the analysis was confined to signatures containing up two genes. The best 
gene model was used to compute the risk probability of rejection in the blood samples 
collected from the same HCV-negative patients, but at different intervals of time as described 
in section 5.2.2.1 and in all available blood samples from the remaining patients (HCV-positive 
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rejecting recipients and Tolerant recipients). When applied to samples from patients not 
exhibiting clinically apparent rejection, we defined the model as giving “correct” result if the 






5.3.1 Acute cellular rejection presented a very well characterized transcriptional 
pattern when compared with baseline analysis.  
To determine the gene expression profile associated with ACR in the context of 
immunosuppression withdrawal clinical trial, we initially conducted an unpaired microarray 
analysis employing all liver samples available from rejecting patients at the baseline and at the 
rejection time. For this experiment, (28) pre-weaning liver samples were analysed, while only 
(20) samples at the time of rejection were available for analysis. Nevertheless, for each 
rejection sample employed, a baseline liver sample from the same patient was 
available.  Using Illumina microarrays platform, we identified 158 differentially expressed 
genes with a FDR <5% and a FC >1.32. The Heat map plotting the 50 genes with the highest 
FC showed a clear differentiation pattern between the baseline and the rejection time. Mainly 
of these genes were associated with pathways related to inflammatory response, interferon 
signalling, IL-6/JAK/STAT3 signalling and apoptosis (Figure 18 and Table 11). Some of the 
differentiated genes such as CXCL9, CXCL10, UBD, STAT1, CCL19, GBP1, GBP2 and CCL8 
are related to the interferon pathway, which is one of the most important pathways associated 
with acute cell rejection. The secretion of chemokine (C-X-C motif) ligands 9 and 10 (CXCL9 
and CXCL10) by different cell types such as monocytes, endothelial cells, and fibroblasts 
increases with IFNy stimulation. Through their interaction with the CXCR3 receptor found on 
the on the surface of monocytes, T cells, NK cells, and dendritic cells, both ligands can act as 
chemokine promoting immune cells attraction, migration, differentiation and activation (291). 
Both of them have been associated with ACR (147, 292). Other significant expressed genes 
are IL32, CD2, CD83, TAP1 and HLA-F. Their corresponding encoded proteins are associated 
with the innate and adaptive immune response. In the presence of a mitogenic stimulus such 
as IL-2, expression of the IL-32 gene in human lymphocytes and NK cells is stimulated. 
Cytokine IL-32 can induce immune cells such as monocytes and macrophages to secrete 
other inflammatory cytokines, such as TNFa, IL-6 and IL-8. (293, 294). Cluster of 
differentiation 2 (CD2) is a specific cell marker found on the surface of T cells and NK cells, 
which is involved on the T cell co-stimulation. The engagement of CD2 with its CD28 and 
CD58 ligands induces the proliferation and differentiation of various T cell subsets such as 
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Tregs and CD28-CD8+ T cells (295-297). CD83 is an immunoglobulin that can be expressed 
in its soluble form (sCD83) and in its membrane form (mCD83). sCD83 expression is 
increased during autoimmune diseases and hematological malignancies. mCD83 is cell 
surface activator marker that is found in many immune cells, but primarily in the activated 
dendritic cells. Its inhibition seems to be related with clinical improvement of graft versus host 
diseases (GVHD)(298). The transporter-associated protein-1 (TAP1) is involved in the antigen 
presentation by acting in the translocation of antigenic peptides into the endoplasmic reticulum 
where they are loaded onto major histocompatibility complex I (MHC I) (299). HLA-F, a non-
classical MHC molecule, has recently been associated with antigen presentation. It is 




Figure 18: Differentially expressed genes in liver tissue: Heatmap displaying the top 50 genes differentially 
expressed in liver tissue based on t-statistic comparing unpaired baseline samples (28 samples) with rejection samples 













CXCL10 3,32 HLA-F 1,57 
CXCL9 3,26 ABCB4 1,57 
UBD 2,68 CD3D 1,56 
TOP2A 1,97 UBE2C 1,56 
STAT1 1,95 MELK 1,56 
GPNMB 1,93 GBP1 1,55 
STAT1 1,92 CD2 1,55 
CCL19 1,80 CXCR4 1,54 
GBP1 1,74 HLA-H 1,54 
DHRS9 1,72 BIRC3 1,54 
STAT1 1,70 NUSAP1 1,54 
TAP1 1,67 PTTG1 1,54 
LYZ 1,66 CD83 1,53 
CD8A 1,66 CCL8 1,53 
IL32 1,65 HCP5 1,51 
IL18BP 1,63 IL32 1,51 
IRF1 1,63 PLA2G7 1,50 
CD52 1,61 PSMB9 1,50 
CD8A 1,61 CECR1 1,50 
GPNMB 1,61 IGSF6 1,49 
HMMR 1,60 LOC613037 1,49 
APOL3 1,60 CD3D 1,49 
PLEK 1,60 CCNB2 1,49 
GBP2 1,59 CDC20 1,48 
MMP9 1,58 FCN1 1,48 
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5.3.2 Acute cellular rejection was associated with a common transcriptional 
signature in spite of the presence of underlying liver inflammation  
To more accurately identify the transcriptional patterns highly associated with ACR we re-
analysed the liver tissue microarray gene expression results employing only the liver tissue 
paired-samples available for the baseline (pre-weaning) and for the time of rejection. In animal 
models, concomitant pathogenic infections, particularly viral infections, are associated with the 
production of pro-inflammatory mediators and / or the direct activation of specific T cell 
populations (301, 302). In the clinical context, it is difficult to histologically distinguish an 
episode of ACR from a recurrence of hepatitis C in the post liver transplant period (303). Then, 
to verify whether a concomitant inflammatory process, hepatitis C in this case, influences the 
transcriptional rejection profile, liver recipients were grouped according to their HCV RNA 
status at the time of enrolment in the clinical trials. In this way, 40-paired samples were 
available from 13 liver recipients RNA HCV-negative and 7 recipients RNA-HCV positive. The 
influence of rejection was more considerable in HCV-positive recipients, in whom it 
significantly modified the gene expression profile of 408 genes. In HCV-negative recipients, 
rejection was associated with statistically significant changes in 34 transcripts. A small set of 
19 genes presented an overlapping expression profile being significantly expressed in both 
groups. (Figure 19 A and B) (Table 12). Most of such genes were already identified as 
significantly differentiated in the first microarray experiment (Figure 18 and table 11) as 
CXCL9, CXCL10, UBD, CD83, CD2, IL32, and TAP1. In addition, four overlapping genes 
encode proteins of the major histocompatibility complex: HLA-DMA, HLA-DRA, HLA-F, and 
HLA-DQB1. More recently, the presence of donor specific antibodies (DSA) was associated 
with the risk of ACR in liver transplantation (11). Unfortunately, we were unable to investigate 
the possible association between its presence and the rejection episodes observed in the 
current study, since the measurement of the pre-transplant DSA was not a clinical routine at 
the time when the patients included in our study were transplanted. 
We used the GSEA methodology to explore which functional pathways were more highly 
associated with ACR episodes. For that, we first compared our liver tissue gene expression 
profile with the Hallmark gene sets from MSigDB to identify high-level functional pathways. 
Hallmark pathways are a collection of 50 sets of annotated gene sets, which represent specific 
biological states or well-defined processes. Differentially expressed genes were involved in a 
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variety of functional pathways related to, among others, allograft rejection, inflammatory 
response, interferon signaling, IL-6/JAK/STAT3 signaling, IL2/STAT5 signaling, TNFα 
signaling, complement and apoptosis. These gene sets had elevated normalized enrichment 
scores (NSE) and significantly differentiated FDRs according to the GSEA analyses. Hallmark 
pathways were more over represented in liver tissue transcripts. The GSEA analysis showed 
that transcripts from liver samples of HCV-pos patients presented a significantly differentiated 
FDR with 40 of the 50 Hallmark gene sets, while transcripts from liver samples of HCV-neg 
patients were significantly over represented with 31 Hallmark gene sets. The weakest 
association was found with the gene expression profile of blood samples, which showed a 
significant over representation with only 7 gene sets of Hallmark gene sets (Table 13).	Next 
we explored the overrepresentation of our results with pathogenesis-based transcript gene 
sets, which were previously validated in kidney and heart human allografts (290, 304, 305). 
Gene expression profiles from liver samples collected at the rejection time showed significant 
overlap with gene sets associated with T cell-mediated rejection in kidney and heart allografts, 
with infiltrating macrophages and effector T lymphocytes being the principal cell subsets 
involved. Although with a weaker signal when compared with T cell-associated transcript gene 
sets, hepatic ACR also presented enrichment in transcript gene sets related to B cells and 
donor-specific antibodies (Table 14).  
We aimed to confirm the specificity of our rejection gene expression profile results, taking in 
account the particular characteristics of the ACR episodes analysed in the present study: 
notable rejection episodes which occurred during intentional immunosuppression withdrawal 
clinical trials at least three years after the liver transplant, with low Banff scores in the majority 
of cases, and easily treated with the reintroduction of baseline IS regimens associated or not 
with a short course of low-moderate doses of corticosteroids. For that, we compared the 
results from the 13-HCV negative recipients with 9 early post-transplant rejection biopsies all 
taken from HCV-negative patients within the first 4 weeks after transplantation. The two cohort 
of recipients differed in the expression of 213 genes, however no differences were noted in the 
expression of the overlap group of 19 genes, which were associated with rejection over all 
conditions (Figure 19 C). Furthermore, we applied the GSEA methodology, both groups 
showed enrichment in similar functional pathways (Table S3 – Appendix C). 
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Figure 19: Transcriptional changes associated with rejection in HCV-neg and HCV-pos recipients. (A) Venn 
diagram displaying the number of up-regulated (red) or down-regulated (green) genes at FDR˂5% and FC ˃1.2 
following LIMMA analysis comparing liver tissue samples obtained from HCV (-) and HCV (+) patients at baseline 
(before IS weaning) and at the time of rejection. (B) Heatmap displaying the common set of 19 significantly expressed 
genes when comparing baseline (pre-weaning) liver tissue samples with those collected at the rejection time in HCV (-) 
and HCV (+) patients. (C) Heatmap showing the 18 genes set in 13 HCV-neg recipients undergoing weaning (at 
baseline and at rejection time) and in HCV-negative recipients developing rejection shortly after transplantation. HLA-
DRA is excluded due to poor data quality in the control group. FC, fold change; FDR, false discovery rate; HCV, 
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Table 12: Liver tissue gene expression markers associated with acute cellular rejection 













CXCL9 Chemokine (C-X-C motif) ligand 9 3.214 0.002 3.241 1.42e-6 
GPNMB Glycoprotein (transmembrane) nmb 1.779 0.006 1.832 0.001 
HLA-DMA Major histocompatibility complex, class II, DM alpha 1.573 0.027 1.764 0.001 
SLC1A3 Solute carrier family 1 (glial high affinity glutamate transporter), member 3 1.572 0.027 1.854 0.001 
HLA-DRA Major histocompatibility complex, class II, DR alpha 1.529 0.027 1.734 0.001 
ITM2A Integral membrane protein 2A 1.554 0.027 1.615 0.003 
HLA-F Major histocompatibility complex, class I, F 1.520 0.041 1.605 0.004 
HLA-DQB1 Major histocompatibility complex, class II, DQ beta 1 1.615 0.008 1.607 0.005 
ANXA2 Annexin A2 1.556 0.032 1.743 0.006 
UBD Ubiquitin D 3.370 0.002 1.678 0.009 
CD83 CD83 molecule  1.615 0.008 1.667 0.009 
FABP5 Fatty acid binding protein 5 (psoriasis-associated) 2.105 0.002 1.625 0.011 
CD2 CD2 molecule 1.480 0.034 1.503 0.013 
PLA2G7 Phospholipase A2, group VII  1.631 0.013 1.454 0.022 
RFX5 Regulatory factor X, 5 (influences HLA class II expression)  1.419 0.029 1.403 0.026 
IL8 Interleukin 8  1.549 0.021 2.194 0.029 
IL32 Interleukin 32  1.848 0.006 1.537 0.031 
CXCL10 Chemokine (C-X-C motif) ligand 10 3.738 0.002 1.485 0.039 
TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 1.651 0.027 1.363 0.047 
Table 11 shows the 19 common differentially expressed genes in HCV-negative and –positive liver recipients when compared liver samples at rejection time with liver samples 




Table 13: Functional pathways significantly over represented in liver allograft rejection-associated transcriptional 
patterns (Hallmark pathways, MSigDB GSEA analysis)  













ALLOGRAFT_REJECTION 2.93 0.00* 2.97 0.00* 1.84 0.02* 
INTERFERON_GAMMA_RESPONSE 3.00 0.00* 2.38 0.00* 2.11 0.00* 
E2F_TARGETS 2.51 0.00* 2.56 0.00* 1.79 0.02* 
INTERFERON_ALPHA_RESPONSE 2.77 0.00* 1.78 0.00* 2.14 0.00* 
G2M_CHECKPOINT 2.31 0.00* 2.55 0.00* 1.69 0.03* 
IL6_JAK_STAT3_SIGNALING 2.25 0.00* 2.22 0.00* 1.86 0.02* 
INFLAMMATORY_RESPONSE 2.49 0.00* 2.24 0.00* 1.56 0.07 
TNFA_SIGNALING_VIA_NFKB 2.66 0.00* 2.25 0.00* 1.13 0.39 
APOPTOSIS 2.28 0.00* 2.33 0.00* 1.37 0.17 
IL2_STAT5_SIGNALING 2.19 0.00* 2.25 0.00* 1.31 0.22 
COMPLEMENT 2.08 0.00* 2.09 0.00* 1.26 0.23 
EPITHELIAL_MESENCHYMAL_TRANSITION 1.79 0.00* 2.60 0.00* 0.97 0.66 
P53_PATHWAY 1.91 0.00* 2.07 0.00* 1.29 0.20 
MYC_TARGETS_V1 1.36 0.07 1.62 0.01* 1.75 0.02* 
ESTROGEN_RESPONSE_LATE 1.75 0.00* 1.91 0.00* 1.05 0.48 
UV_RESPONSE_UP 1.66 0.00* 1.48 0.03* 1.52 0.08 
PI3K_AKT_MTOR_SIGNALING 1.60 0.01* 1.66 0.01* 1.30 0.21 
APICAL_JUNCTION 1.64 0.01* 1.86 0.00* 0.89 0.73 
MTORC1_SIGNALING 1.72 0.00* 1.65 0.01* 0.96 0.66 
KRAS_SIGNALING_UP 2.28 0.00* 2.48 0.00* -0.80 1.00 
ADIPOGENESIS 1.21 0.21 1.16 0.23 1.38 0.17 
PEROXISOME 1.30 0.11 1.27 0.13 1.08 0.46 
DNA_REPAIR 1.12 0.34 1.54 0.02* 0.73 0.91 
SPERMATOGENESIS 0.91 0.66 1.31 0.10 1.07 0.48 
NOTCH_SIGNALING 0.95 0.62 1.46 0.03* 0.81 0.84 
MITOTIC_SPINDLE 1.87 0.00* 2.00 0.00* -0.83 1.00 
TGF_BETA_SIGNALING 0.92 0.66 1.18 0.21 0.93 0.67 
MYC_TARGETS_V2 0.88 0.71 1.19 0.21 0.94 0.67 
ANGIOGENESIS 1.83 0.00* 2.23 0.00* -1.26 1.00 
HYPOXIA 1.56 0.01* 1.71 0.00* -0.73 1.00 
GLYCOLYSIS 1.60 0.01* 1.80 0.00* -0.86 1.00 
MYOGENESIS 1.69 0.00* 1.41 0.04* -0.60 0.98 
ESTROGEN_RESPONSE_EARLY 1.55 0.01* 1.80 0.00* -0.88 1.00 
HEDGEHOG_SIGNALING 1.50 0.02* 1.45 0.04* -0.73 1.00 
PROTEIN_SECRETION 1.39 0.06 1.64 0.01* -0.88 1.00 
UNFOLDED_PROTEIN_RESPONSE 1.42 0.04* 1.49 0.03* -0.78 1.00 
COAGULATION 1.45 0.03* 1.59 0.01* -0.98 1.00 
ANDROGEN_RESPONSE 1.10 0.36 1.50 0.03* -0.64 1.00 
UV_RESPONSE_DN 1.47 0.03* 1.60 0.01* -1.12 1.00 
REACTIVE_OXIGEN_SPECIES_PATHWAY 1.64 0.01* 0.99 0.50 -0.84 1.00 
HEME_METABOLISM 1.48 0.03* 1.19 0.21 -1.19 0.95 
WNT_BETA_CATENIN_SIGNALING 1.09 0.37 1.42 0.04* -1.05 1.00 
APICAL_SURFACE 0.97 0.59 1.61 0.01* -1.23 1.00 
PANCREAS_BETA_CELLS -1.13 0.43 0.83 0.77 1.36 0.17 
KRAS_SIGNALING_DN 1.10 0.35 0.90 0.66 -1.33 1.00 
CHOLESTEROL_HOMEOSTASIS 1.30 0.11 -1.61 0.04* 0.82 0.84 
XENOBIOTIC_METABOLISM 0.81 0.82 -1.55 0.03* 1.22 0.26 
OXIDATIVE_PHOSPHORYLATION -1.04 0.50 -1.25 0.10 1.50 0.08 
FATTY_ACID_METABOLISM -0.83 0.84 -1.41 0.04* 1.25 0.22 
BILE_ACID_METABOLISM -1.31 0.25 -1.50 0.03* -0.92 1.00 
1 Normalised Enrichment Score, as generated by GSEA software 
2 False Discovery Rate 
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Table 14: Pathogenesis-based transcript sets significantly enriched in liver allograft rejection associated transcriptional patterns (GSEA)  










Human orthologs of IFN-gamma dependent, rejection associated transcripts defined in mice. Expressed 
in TCMR, especially in association with AMAT1. 
(306) 19 2.64 0.00* 2.42 0.00* 
QCMAT 
Macrophage associated transcripts defined in purified cell lines, associated with TCMR in kidney 
patients.: 
(307) 45 2.54 0.00* 2.34 0.00* 
QCAT 
Transcripts associated with cytotoxic T lymphocytes, defined in purified cell lines. Associated with TCMR 
in renal transplants, with expression levels correlating with T cell infiltration. 
(304) 21 2.48 0.00* 2.44 0.00* 
IRITD3 
Injury and rejection induced transcripts up regulated day 3 post isograft transplant (humanised results 
from mouse model). 
(308) 173 2.30 0.00* 2.60 0.00* 
IRITD5 As for IRITD3, measured on day 5. (308) 133 2.25 0.00* 2.68 0.00* 
CIRIT 
Cardiac injury and repair induced transcripts, expressed following heart isograft transplant. Mouse data 
extrapolated to humans. 
(309) 174 2.20 0.00* 2.22 0.00* 
IRRAT 
Injury-repair response associated transcripts, defined in early renal transplants with no rejection, and 
derived as a model for AKI. 
(308) 22 2.05 0.00* 1.67 0.00* 
BAT B-cell associated transcripts, derived from purified B cells. Up regulated in both ABMR and TCMR. (310) 55 1.97 0.00* 2.15 0.00* 
DSAST 
DSA Positive specific transcripts derived from comparative analysis of DSA + and – renal biopsies. 
Observed in both ABMR and TCMR with much higher levels in ABMR. 
(311) 15 1.64 0.01* 1.18 0.29 
HTS Heart selective transcripts derived from control mice without inflammation present. (309) 385 1.54 0.03* 1.59 0.01* 
TCB T cell specific transcripts based on purified cell lines. (312) 4 1.47 0.04* 1.66 0.00* 
ENDAT 
Endothelial cell associated transcripts derived from purified cell lines. Increased in ABMR and TCMR 
with higher levels in ABMR. 
(313, 
314) 
81 1.46 0.04* 2.23 0.00* 
NKB 
NK cell specific transcripts derived from purified cell lines. Identified in early TCMR and late ABMR in 
renal patients. 
(312) 3 1.43 0.05 1.04 0.43 
IGT Immunoglobulin associated transcripts, observed in both ABMR and TCMR. (310) 4 1.36 0.08 1.57 0.01* 
AMAT1 
Alternative Macrophage Associated Transcripts 1. Human orthologs of mouse data. High GRIT1+AMAT1 
scores correlate with TCMR. 
(307) 6 1.31 0.12 1.73 0.00* 
MCAT Mast cell associated transcripts, associated with scarring and poor survival in renal transplants. (305) 3 -0.80 0.78 1.13 0.32 
ABMR, antibody-mediated rejection; AKI, acute lidney injury; DSA, donor-specific antibody; FDR, false discovery rate; GSEA, gene set enrichment analysis; IFNγ, interferon gamma; NES, normalized 
enrichment score; TCMR, T cell-mediated rejection. *Significance threshold based on FDR < 0.05 n gamma;  
1 Size is the number of transcripts in gene set.  
2 NES – Normalized Enrichment Score as calculated by GSEA software (http://www.broadinstitute.org/gsea/doc/GSEAUserGuideTEXT.htm#_interpreting_GSEA_results) 
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5.3.3 Histological features of acute cellular rejection correlate with specific gene 
expression changes 
Liver ACR is characterized by portal and, sometimes, lobular inflammation, portal tract 
nonsuppurative cholangiolitis and portal and/or central vein sub-endothelial inflammation. To 
identify the main histological drivers of transcriptional patterns associated with ACR, we 
correlated liver tissue gene expression profiles with quantified histological data. In the cohort of 
samples studied, the distribution of histological damage and the number of genes for which 
expression was significantly differentiated correlated with severity of damage (FC > 1.2, FDR < 
0.05) (Table 15). There was a correlation between the magnitude of histological damage in 
each histological compartment and expression of a set of 423 genes mostly associated with 
inflammation and rejection. The genes expressed were relatively homogenous across 
histological compartments; however, the signal was much stronger in acute inflammatory 
processes such as lobular inflammation, portal inflammation and interface hepatitis (Figure 20) 
(Table S4 - Appendix C).  
We applied the GSEA methodology to check which functional pathways could drive these 
pathological processes, and, once more, results disclosed homogeneity over histological 
compartments with inflammatory and rejection-associated pathways being up-regulated across 
all compartments (with exception of ductopenia, which was a very rare event and thus could not 
be appropriately accessed) (Table 5S - Appendix C). The overall severity of rejection as defined 
by the Banff Rejection Activity Index (55) was not associated with significant differential gene 




Table 15: Differential gene expression by histological compartment  
Histological compartment 
Number of patients by severity level 
Gene count 
0 1 2 3 
Lobular inflammation 29 34 15 0 354 
Portal inflammation 17 33 21 2 223 
Interface hepatitis 44 23 10 0 284 
Portal fibrosis 29 24 21 2 31 
Bile duct lesions 51 19 3 1 16 
Central vein perivenulitis 53 12 4 0 10 
Endothelitis portal veins 54 16 3 1 4 
Ductopenia 76 3 0 0 4 
Endothelitis central vein 70 3 0 0 1 
Ductular reaction 50 20 0 0 0 
Perisinusoildal fibrosis 52 8 5 0 0 
 
 
Figure 20: Differentially expressed genes across histological compartments. (A) Clustered heat map demonstrating 
all genes significantly differentially expressed across histological compartments (fold change > 1.2 and false discovery 
rate <0.05 in at least one compartment). Analysis performed in limma comparing gene expression against quantified 
severity score for each histological parameter (Red indicates up-regulation and green indicates down regulation). (B) 
Venn diagram representing the number of genes differentially expressed in each histological compartment and 






































I   − Lobular inflammation
II  − Portal inflammation
III − Interface hepatitis
IV − Bile duct lesions























5.3.4 Acute cellular rejection also presented distinct transcription changes in 
blood samples, although with only partial overlapping with those observed in 
liver allograft  
To determine ACR-associated transcriptional patterns in whole blood compartment, we 
employed the same exploratory strategy described for liver tissue experiments. However in this 
case, analyses were conducted using a custom Agilent microarray to analyse 74 paired 
baseline/rejection samples from 37 HCV-negative patients. We identified 293 differentiated 
genes using the same statistical thresholds (FC > 1.2 and FDR < 0.05) employed in the liver 
tissue experiment (Figure 21). 
In functional analysis employing GSEA methodology with the MSigDB Hallmark gene sets 
displayed comparable up-regulated pathways in blood and liver tissue, however with weaker 
signals for the blood than liver tissue results (Table 13). Further analyses employing HaemAtlas 
gene sets (289) unveiled the significant association of ACR with transcripts preferentially 
expressed by CD14-positive cells (monocytes). In contrast, transcripts associated with CD8 
(cytotoxic cells) and CD66B (granulocytes) cells were significantly down regulated at the time of 
rejection. Within the analysed samples, no other blood cell types showed significant contribution 
to the rejection-associated transcriptional pattern.  When we compared transcriptional patterns 
across the two compartments, a reduced group of 22 genes, mainly associated to immune 
response and cell cycle control (e.g. CXCL9, CXCL10, CNPM, CDC20, CCNB2, and CD74), 
were significantly associated with ACR in blood and liver tissue samples This small group of 
overlapping genes within the two compartments could also be attributed to the fact that there 
are proportionately less inflammatory cells in a liver biopsy sample than in the blood, which is 
essentially composed of inflammatory cells, while hepatocytes are the main population cell 




Figure 21: Differentially expressed genes in whole blood. Heat map of top 50. Genes differentially expressed in whole 
blood based in t-statistic comparing paired baseline (pre-weaning) and rejection samples. All liver samples in this 




























































Figure 22: Significantly expressed genes in liver tissues and in PBMC of HCV-negative liver recipients. Heat maps 
displaying the common set of 22 significantly expressed genes when comparing baseline (pre-weaning) liver tissues 
samples (A) with those collected at the time of rejection in HCV-negative liver recipients, and in PBMC samples (B) in the 
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5.3.5 The blood transcriptional patterns of ACR-associated genes at baseline did 
not predict the success of immunosuppression weaning 
To interrogate whether ACR-specific genes were differentially expressed between tolerant and 
rejecting liver recipients before the initiation of IS weaning protocol, we revisited a previously 
reported Affymetrix® microarray gene expression database generated with blood samples 
collected at the baseline from 43 rejecting and 25 tolerant liver recipients. Before starting the IS 
discontinuation, none of the ACR-associated gene expression markers showed significant 
differentiated transcription patterns between recipients who would eventually reject and those 
who would successfully discontinue IS drugs (data not shown). In addition to this reanalysis, we 
quantified the expression of CD3, FOXP3, MAN1A, PRF1, and TOAG-1, which made part of the 
RISET consortium biomarker portfolio and had been previously evaluated in the setting of 
kidney transplantation (123, 315). From all genes tested, FOXP3 expression, which was up 
regulated in tolerant recipients, was the only marker differentially expressed between tolerant 
and rejecting liver recipients at baseline blood samples (Figure 23). 
 
Figure 23: Baseline acute cellular rejection-associated gene expression in rejecting and tolerant liver recipients. 
Graphics showing the quantitative gene expression in blood samples of five genes included in the Reprogramming the 
Immune System for the Establishment of Tolerance (RISET) consortium biomarker portfolio performed at baseline (pre-
weaning) in 43 tolerant and 25 rejecting liver recipients. Tol, tolerant; Rej, rejecting liver recipients. *p <0.05. Due to the 






































































5.3.6 Immunosuppressive drug regimens presented a minimal effect on ACR-
associated gene expression profiles in both blood and liver tissue samples 
We interrogated at which level the type of immunosuppression at the time of enrolment could 
impact the gene expression profiles on liver tissue and blood samples from our rejecting liver 
recipients. A linear regression model was applied to analyse the gene expression patterns on 
three microarrays datasets available (microarray liver tissue, microarray blood samples and 
Fluidigm blood qPCR results). Our results show that the type of immunosuppressive regimen 
did not impact liver tissue gene expression profiles at baseline. Furthermore, analyses of blood 
transcriptional profiles disclose no differences between patients on CSA monotherapy against 
TAC monotherapy. Conversely, a set of 17 genes was differentially expressed between patients 
on CNI inhibitor monotherapy and patients on MMF (Table 15), but only 8 out from the 17 genes 
were included in the set 293 genes associated with ACR (LOC652494, ENST00000359488, 
LOC100132941, ENST00000377226, C13ORF33, A_24_P110487, ENST00000322032, and 
SPTA1).  
 
















0 CSA 14 23 11 





N/A MMF monotherapy 6 12 0 





3 CNI + MMF 6 8 6 





3 Other therapies 44 72 29 
CNI, calcineurin inhibitor; CSA, Cyclosporin A; MMF, mycophenolate mofetil; mTOR, mammalian target of rapamycin, 




5.3.7 Sequential gene expression profiling in blood samples collected over the 
immunosuppression withdrawal period predicts the occurrence of rejection 
Aiming to identify specific changes in rejection-associated transcriptional markers occurring 
over the IS weaning period and preceding the clinical and histological diagnosis of the eventual 
episodes of ACR, which could be used as predictive gene signature of rejection, we quantified 
the expression of the target set of 45 genes described in section 5.2.9.1 in sequential blood 
samples collected from 14 HCV-negative and 8 HCV-positive rejecting liver recipients. In 
average, six sequential blood samples collected before the diagnosis of rejection were available 
per liver recipient. Initially, univariate analysis of gene expression profiles from samples 
collected at baseline and at time of rejection unveiled that eight and two genes were 
significantly up regulated at the time of rejection in HCV-negative and –positive liver recipients 
(Table 17). Next, a stepwise multivariate logistic regression analysis identified CXCL10 and 
FOXP3 as the best combination of markers, which discriminated rejection and baseline samples 
in the cohort of HCV-negative liver recipients (cross validated area under de curve [AUC] 0.82). 
Applying this gene signature in all sequentially collected blood samples showed that the 
probability of ACR continuously increased over time, with a peak that coincided with the time of 
the diagnosis of biopsy-proven ACR and showed a rapid decline after reintroduction of 
immunosuppression treatment (Figure 24A). We used the cohort of 86 liver recipients with 
stable graft function 3-10 years after transplantation under immunosuppression as a negative 
control group; CXCL10 plus FOXP3 expression correctly predicted the absence of rejection in 
81% of the liver recipients. Surprisingly, this model failed to accurately classify 70% of 57 blood 
samples sequentially collected from 7 tolerant liver recipients who successfully discontinued the 
immunosuppression in the clinical trials. Taking in account the well-described influence of CNIs 
on FOPX3 expression, we excluded the FOXP3 in second analysis made only with CXL10 as 
gene signature (316) (Figure 24B). This strategy proved that CXCL10 was the most powerful 
gene signature to predict rejection and non-rejection samples in HCV-negative liver recipients. 
CXCL10 alone precisely categorized rejecting samples with a cross-validated AUC of 0.76 and 
accurately predicted absence of rejection in 79% of stable liver recipients and 67% of samples 
from tolerant recipients (Figure 24C). The probability of rejection as predicted by 
expression of CXCL10 increased 1-2 months before the rejection episode was clinically 
suspected and a liver biopsy was considered indicated according to the protocol 
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criteria. However, a detailed analysis of the evolution of the hepatic function tests 
measured in the same blood samples used for the molecular analyses showed that 
changes in CXCL10 expression began to increase approximately two weeks before the start 
of the increase in serum LFT levels in liver receptors that presented an ACR episode 
approximately two months later (Figure 24D). Opposite to these described findings for HCV-
negative liver recipients, an ACR predictive molecular signature with accurate diagnostic 
interpretation could not be created from the same 45-gene Fluigdim data set in the in the cohort 
of eight HCV-positive liver recipients (data not shown). 
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Table 17: Significantly differentially expressed genes at baseline versus rejection 
based on univariate analysis of Fluidigm data  
Gene p-value (HCV-negative) p-value (HCV-positive) 
ABCB1 0.441 0.048* 
APOL3 0.383 0.942 
CCL19 0.570 0.369 
CCN2B 0.053 0.799 
CD52 0.083 0.144 
CD74 0.567 0.742 
CD8A 0.587 0.011* 
CDC20 0.777 0.559 
CECR1 0.141 0.911 
CENPM 0.634 0.505 
CXCL10 0.019* 0.794 
CXCL9 0.010* 0.809 
DHRS9 0.046* 0.933 
DOCK11 0.412 0.511 
EMILIN2 0.096 0.604 
EZH2 0.329 0.263 
FOXP3 0.002* 0.321 
GBP1 0.689 0.078 
GBP2 0.680 0.610 
GPNMB 0.856 0.233 
GZMB 0.149 0.234 
GZMK 0.518 0.053 
HLA.DMA 0.718 0.927 
HLA.DMB 0.935 0.624 
HMMR 0.935 0.254 
IL15 0.335 0.436 
IL18BP 0.592 0.761 
IL32 0.586 0.136 
IRF1 0.084 0.532 
LYZ 0.062 0.952 
ME2 0.327 0.554 
MMP9 0.836 0.366 
PARVG 0.353 0.354 
PLEKHG1 0.788 0.873 
PRF1 0.670 0.068 
RFX5 0.604 0.731 
STAT1 0.024* 0.839 
TAP1 0.154 0.937 
TGFb1 0.166 0.098 
TK1 0.019* 0.608 
TLR8 0.978 0.748 
TOP2A 0.203 0.572 
TYMS 0.013* 0.720 
UBD 0.002* 0.209 
ZWINT 0.144 0.368 
HCV, Hepatitis C virus.  




Figure 24: Prediction of rejection by sequential gene expression in blood samples: (A and B) Time evolution of risk 
probabilities for rejection based on gene signatures for CXCL10 plus FOXP3 and CXCL10 alone, respectively. Both 
models show a peak coinciding with acute cellular rejection biopsy-proven diagnosis (time 0), with a rapid reduction 
following reinstitution of reinforcement of IS. (C) Evolution of risk probabilities in operationally tolerant recipients up to and 
after complete withdrawal of IS (time 0), showing that CXCL10 plus FOXP3, but not CXCL10 alone, misclassifies as 
rejecting 70%of blood samples. (D) Sequential risk probabilities based on gene signature models alongside conventional 
LFTs. Risk increases gradually ≈1-2 months before rejection, correlating with a rise in LFTs. IS, immunosuppression; LFT, 
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Chapter 6  Discussion 
This research work was triggered by the results of a recently published European multi-centre 
clinical trial of immunosuppression withdrawal in long-term post-liver transplantation recipients. 
This study demonstrated that liver recipients who developed a rejection episode during the 
withdrawal protocol displayed lower iron storage markers (e.g. serum ferritin and serum and 
intra-hepatic hepcidin) than liver recipients who successfully finished the IS withdrawal 
becoming operationally tolerant recipients, the primary end-point of the study. These alterations 
were reproducible and statistically significant even though they were not clinically evident. 
Furthermore, those rejection episodes occurred at least three years after the transplant 
procedure; when clinical and biochemistry changes attributed to the baseline liver disease, 
inflammatory response to the ischemic/reperfusion injury and to the surgical procedure and/or 
early complications were not present. Rejection episodes were well controlled and unable to 
provoke a graft loss in any rejecting patient (1, 100). We postulated that this clinical scenario 
could be an adequate opportunity for the molecular characterisation of the acute cellular 
rejection process. 
Using a very well known immune-mediated experimental model of acute liver failure we 
checked the influence of small iron changes on the intra-hepatic T cell activation and function. 
Afterwards, we aimed to check the impact of iron changes on the specific anti-donor T cell 
response employing a full-vascularized rat experimental liver transplant model. Furthermore, 
taking advantage of the availability of the sequential blood and liver tissue samples collected 
during the weaning protocol from rejecting patients, we investigated if progressive 
transcriptional changes could forecast over time the ACR before clinical, biochemistry, and 
histological manifestations of the rejection episodes. 
 
6.1 Effects of Iron deficiency in the Intra-hepatic lymphocyte responses 
As spontaneous liver tolerance requires an initial activation of recipient alloreactive T cells 
before lymphocyte deletion (60, 251, 252), we hypothesized that the iron-hepcidin axis could 
exert an unrecognized place in the regulation of intra-hepatic lymphocyte activation and 
function. To investigate this concept, we replicated the mild iron homeostasis changes detected 
in the liver recipients included in the clinical trial by administering iron-modified diets to mice for 
a short period of three weeks or by the administration of low-dose iron specific chelators. While 
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it is challenging to define the ideal level of iron deficiency due to the many factors to be 
controlled, the iron deficiency induced by our iron-modified diet protocol was comparable with 
other studies addressing the influence of iron levels on the acute inflammatory responses (234). 
Furthermore, our three-week iron-modified regimens did not significantly affect the animal 
outcomes, their liver function tests, and the hepatic steady-state immune cell population. In 
order to challenge the liver immune homeostasis, we employed a well-known experimental 
model of immune-mediated acute sub lethal hepatitis induced by ConA. A close interaction 
between Kupffer cells, lymphocytes and cytokine production regulates the ConA model, where 
the intra-hepatic T/NKT cell activation is necessary to trigger the inflammatory liver injury (261, 
262, 269). Then, in our experiments, the intensity of the liver injury provoked by the ConA 
challenge was significantly reduced in iron deficient fed mice, which was determined by 
decreased serum ALT levels, hepatic necrosis and intra-hepatic cellular infiltration on histologic 
evaluation. These findings were associated with reduced serum levels of IL-6, TNFα and IFNγ 
(pro-inflammatory cytokines) and with an increase in intra-hepatic transcript levels of Il4 and 
Tnfα, all of which are implicated in ConA immune-mediated acute liver failure (262). Other 
studies, using different models of acute hepatitis as the thioacetamide-induced toxic hepatitis 
and Fas-induced fulminant hepatitis also reported a favourable effect of iron restriction induced 
by diet or iron chelation on liver inflammation (216, 217). The possible beneficial anti-
inflammatory effects caused by iron restriction in those studies were credited to a reduced 
oxidative stress and less Kupffer and hepatic cell activation. Oxidative stress and macrophage 
activation are manifestly implicated in the amplification of the ConA induced liver injury in our 
experiments. However, our observations of less T/NKT lymphocyte infiltration in intra-hepatic 
histologic analyses from iron deficient mice suggest that reduced lymphocyte activation and 
effector function in this animal group could also influence the outcome of the immune-mediated 
hepatitis by a direct inhibition of intra-hepatic lymphocyte function. We confirmed this hypothesis 
performing an in vitro experiment in which isolated T cells were challenged with either ConA or 
anti-CD3/anti-cd28 associated with iron chelation, which resulted in impaired T cell activation 
and proliferation. 
Again, our findings suggesting that lymphocyte activation and proliferation due to iron 
homeostasis modification can modulate the inflammatory hepatic injury are in agreement with 
the results observed in an experimental CD4+-driven model of autoimmune encephalomyelitis, 
where iron deficiency inhibits the neurological damage evolution (219). The possible 
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mechanisms responsible for this T cell inhibition are not yet completely revealed. Intracellular 
iron deficiency can decrease the activity of various enzymes implicated in the cell-cycle control 
such as ribonuclease reductase involved in DNA synthesis during the phase S of cell cycle, 
cyclin A, and Cdc2 (317, 318). Other proteins essentials for the intracellular signalling cascade 
triggered by T cell activation can also be inhibited by iron restriction as the hydrolysis of 
phosphatidyl inositol-4,5-biphosphate and the activity of protein kinase C (232, 233). 
Furthermore, at least in the central nervous system, CXCL10 release following the engagement 
of the Toll-like receptor 3 (TLR3) is inhibited by desferrioxamine, which can decrease the tissue 
infiltration by CXCR3+ T cells (319).  
Using a systemic inflammatory model induced by LPS which also induces liver damage, Pagani 
et al. and Di Domenico et al. were able to demonstrate that hepcidin directly inhibited 
inflammatory responses after LPS challenge independent from iron levels (234, 235). In this 
way, we investigated whether low hepcidin levels impact the influence of iron levels on the 
ConA-mediated immune hepatitis. In agreement with the previous reports, iron limitation led to a 
decrease in hepatocyte hepcidin expression, and this figure persists after ConA challenge (data 
not shown). Trying to dissect the role of hepcidin on the ConA immune mediated hepatitis, mice 
fed with normal iron diet were treated with an iron-specific chelator that does not influence 
hepatocyte hepcidin expression before the ConA challenge. Iron chelation pre-treatment 
reproduced the results observed when an iron deficient diet was employed. In the next 
experiment mice fed with iron-modified diets received one injection of exogenous hepcidin prior 
to ConA challenge. On the contrary with what was previously reported in the LPS model, 
exogenous hepcidin did not influence the effect of iron deficiency in our model of immune-
mediated hepatitis induced by ConA. Altogether, those series of experiments allow us to 
conclude that in our model, low iron levels are the main determinant factor for the reduced liver 
inflammatory injury in iron deficient mice after ConA administration. Taking in account the 
effector role executed by macrophages in ConA immune mediated hepatitis and the 
hepatotrophic characteristics of ConA action, our findings seem to be in contrast with 
observations reported in the two previous mentioned studies, where LPS challenge exacerbated 
the pro-inflammatory mediators release by iron-deprived macrophages (234, 235). Although 
those observations need further investigation, as Wang et al found contradictory results using 
the LPS model (237); they point to a complex immunological regulation elicited by iron 
deficiency with different outcomes depending on which cell is targeted and which organ is 
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involved in the inflammatory response. Consequently, we theorized that effective T cell 
activation is required in the ConA model to induce immune mediated liver damage, different 
from that which is observed in the systemic inflammation model caused by LPS administration, 
which could influence the different outcomes demonstrated by the two models in the presence 
of iron deficiency.  
Changes in dietary iron concentrations influence the gut microbiota constitution, which in turn 
may influence liver metabolism and immunogenicity (271). In order to check the impact of gut 
microbiota modifications in our model we administered an antibiotic cocktail well known for the 
reduction of more than 90% of the faecal microbial populations (265). Iron deficient mice treated 
with the cocktail still presented a significantly reduced immune mediated liver injury after ConA 
challenge. Furthermore, worth highlighting is the fact that those antibiotic treated mice 
presented lower transaminase levels following ConA injection when compared to non-treated 
mice. This result was especially evident in iron deficient mice, in which transaminases elevation 
was almost completely abolished. These findings are in accordance with a study reported by 
Chen et al., which showed that depletion of gram-negative gut derived bacteria induced by 
gentamycin treatment decreased the ConA-induced liver damage. This effect was mediated by 
intestinal dendritic cell function impairment and by changes in intra-hepatic NKT cells activation 
(320). While our preliminary results do not allow us to draw deeper conclusions about the 
influence of the intestinal microbiome on the allograft immune response, it is worth noting that 
several recent studies have addressed how the intestinal microbiome can influence the efficacy 
of immunotherapy against malignant tumours (321, 322). In fact, the intestinal microbiome 
composition can influence the efficacy of the immune checkpoint inhibitors targeting the co-
signalling PD1/PDL1 axis to treat cancers (323, 324). Patients having an abnormal gut 
microbiome composition, as e.g. after having an antibiotic treatment during their cancer 
immunotherapy, were resistant against PD1/PDL1 inhibitors (325). As for the continuation of our 
preliminary experiments, additional studies are being carried out in the laboratory of Prof. 
Sanchez-Fueyo with the aim of verifying the influence of the intestinal microbiome on the liver 
steady state immune cell repertoire. 
Iron deficient mice showed decreased serum IL-6 levels after ConA challenge; on the other 
hand Il6 intra-hepatic expression was increased. These findings are consistent with the different 
kinetic profiles of the expression of IL-6 (cytokine) and the expression of Il6 (gene) after an 
acute liver injury previously described by Sass el al. Indeed, serum levels of IL-6 reach a 
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maximum at 3-4 after the ConA challenge with the subsequent decrease to their lowest levels at 
12 and 24 hours. Although the increase in the expression of the Il6 gene is not as intense, it 
reaches a maximum at 1 or 2 hours after ConA and shows a plateau effect during the next 10 
hours, when it has a second peak approximately 12 hours after the challenge ConA (269). The 
literature usually reported the IL-6 as a pro-inflammatory cytokine, however our clear outcome 
of transaminases in the ConA model rules out an exacerbation of liver inflammation. Those 
findings are in agreement with some studies that reported a protective effect made by rIL-6 
injection before ConA challenge and a possible IL-6-gp130-STAT3 pathway mechanism 
involved in the liver protection on the ConA T cell mediated liver injury (326-329). Indeed, the 
most studied IL-6 hepatic protective mechanism involved the IL-6 induction of MAPK pathway 
and the induction of STAT3, a key-signalling molecule in intracellular pathways, which blocks 
apoptosis and induces liver regeneration. Briefly, IL-6 binds to its sIL-6R soluble receptor, then 
the complex IL-6/sIL-6r binds to the gp130 cell surface receptor that leads to the 
phosphorylation and activation of JAK into the cytosol. p-JAK can activate MAPK, a 
transduction signal, which induces nuclear transcription of genes associated with liver 
regeneration. p-JAK, also induces STAT3 phosphorylation with subsequent activation and 
translocation to the nucleus, where transcription of anti-apoptotic and anti-necrosis genes is 
induced, which favours liver regeneration (330, 331). The increase Il6 expression in the iron 
deficient group is coherent with a hepatic protection effect demonstrated in our model, however 
from those findings we are not able to infer that iron deficiency per se contributes to Il6 
increased expression or that its expression is hindered by the increased liver necrosis observed 
in the IrRepl group. The contrast between serum levels of IL-6 and the hepatic expression of Il6 
may display the different immunological outcomes in the liver prompted by the iron deficiency 
when compared with other compartments. More specifically it could be due to a divergent effect 
exerted by changes in iron levels on different cell types, as what is observed in hepatocytes and 
in macrophages. In fact, the decreased hepcidin expression caused by an iron deficient 
environment could be involved in the increased IL-6 production by intra-hepatic macrophages 
as previously reported (235). 
In conclusion, in this first part of our work, we report that iron restriction dampens intra-hepatic 
lymphocyte activation and proliferation leading to a favourable effect on the acute T cell and 
NKT mediated hepatitis induced by ConA. Taking in account the pivotal place of the liver in the 
iron homeostasis tuning, even as an important iron reservoir or as the main place of hepcidin 
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synthesis, these findings could be implicated in many inflammatory liver conditions. Future 
studies are needed to establish the iron restriction effect on different lymphocyte subsets. 
Additional studies could focus on the iron effect in the lymphocyte function in the situations of 
chronic antigenic stimulation as observed in the clinical trial of immunosuppression withdrawal 
of long-term liver transplant recipients. For that, the use of rodent models of liver transplantation 
appears to be a more indicated model. 
 
6.2 Impact of iron changes on the spontaneous tolerance development in 
a rat liver transplant model  
As previously mentioned, successful IS weaning has been associated with iron and hepcidin 
levels in a recent IS withdrawal clinical trial in stable long-term liver transplant recipients. Based 
on that, we hypothesized that iron and/or hepcidin changes impact the anti-donor T cell 
mediated response influencing the establishment of spontaneous tolerance. To investigate the 
possible responsible mechanisms involved in such association we set up an experimental 
model of liver transplantation in which we reproduced the mild iron deficiency in rats. We chose 
the rat liver transplantation model because of the possibility of having different post-transplant 
immunological phenotypes depending on the donor/recipient rat strain combination employed 
(syngeneic, spontaneous tolerant, rejection and IS induced tolerance) (273, 287). 
The rat liver transplant model, however, is a challenging surgical model with a high rate of 
failing procedures. Hori et al described that a minimum of 30 procedures are typically required 
before completing a successful transplant and recommended performing at least 50 transplants 
in order to be technically competent to perform the transplants in a standardized way (332). In 
my case the training phase was even more challenging, as I did not achieve long-term survival 
in my first 76 transplants. This had to do with the use of Wister rats, which are cheaper than 
other strains but do not tolerate complex surgery well, and with problems in executing the cuff 
technique described by Kamada et al. (278). My results gradually improved after switching to 
Lewis rats and following a stay at Charité Hospital in Berlin, where I was trained in the fully 
vascularized hand sewn rat liver transplantation technique (283). To reproduce the subclinical 
iron deficiency conditions observed in the non-tolerant liver recipients in the recent IS 
withdrawal clinical trial; we employed the same protocol on iron-modified diets set up in our 
previous murine work. As demonstrated in mice, three weeks on iron deficient diet were 
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sufficient to induce mild but statistically significant iron deficiency as compared with control 
group. IrDef rats showed only mild differences in some hematologic parameters such as 
haemoglobin, white blood cells and platelets levels but no differences were noted on growth of 
LFTs. This is in contrast to the effects on weight, growth, LFTs and other biological parameters 
that have been described by other studies (333, 334). These divergent results can be attributed 
to the fact that in previous studies iron deficient diets were compared to normal commercial 
animal chow. In our case, both the IrDef diet and IrRepl diets were prepared with the same iron-
free ingredients and the only difference was the supplementation with iron carbonyl to reach 
normal iron ranges in the IrRepl diet (notice from the diet manufacturer SAFE®, Augy - France). 
Despite the apparently mild effects induced by the iron-deficient diets and described above, rats 
fed for three weeks with IrDef diet did not tolerate the liver transplant procedure. First, they were 
shown to be much more sensitive to inhalation anaesthesia and even small blood losses that 
IrRepl rats. Second, despite appearing healthy, they developed severe colic dilatation with liquid 
sequestration. Due to these complications, we modified the protocol to induce iron deficiency by 
feeding the rats with the iron-modified diets for only one week prior to the transplant procedure. 
This led to acceptable survival rates in both animal groups. Of note, when we compared the 
long-term results observed with either the IrDef of the IrRepl diets with those observed in rats 
fed with normal commercial chow, we observed that the use of both IrDef and IrRepl diets was 
associated with more frequent long-term complications such as abdominal hernias, abscesses 
and bile duct obstructions with secondary cirrhosis. Prasnicka et al. demonstrated an increase 
on the bile flow with augmentation of bile acids, glutathione, cholesterol and phospholipids 
excretion in rats under iron-deficient regimens for long-time (333). Based on the similarly 
increased morbidity rate induced by both iron-modified diets in comparison with liver recipients 
kept under normal commercial chow, we hypothesized that the iron carbonyl supplementation 
does not prevent the occurrence of complications initially attributed to iron deficiency per se, 
including in our case the biliary complications. Consequently, the use of iron-modified regimens 
could be considered a confounding factor for studies where animals should be kept under such 
regimens for long time.  
As aforementioned, the rat liver transplant model affords the possibility to have different 
immunological phenotypes depending on which donor/recipient rat strain pair is employed (273, 
287). However, what cannot be accurately replicated is the clinical setting in which long-term 
surviving liver recipients on maintenance IS are gradually wean from IS. In rats, when the 
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rejecting strain combination is employed, tacrolimus is capable of inducing tolerance after just a 
10-day course (286). Furthermore, as described above, the long-term use of iron-modified 
regimens results in multiple complications. For these reasons, we chose to concentrate for our 
experiments in the immediate post-transplant period. We first investigated if the induction of 
mild iron deficiency was capable of breaking spontaneous tolerance, but this what not the case. 
We then explored whether tolerance was still established in the presence of iron deficiency and 
a potent immune-stimulant such as high dose of rhIL-2 (276, 277). In comparison with IrRepl 
liver recipients, IrDef rats developed a clear clinical deterioration during rhIL-2 administration; 
reflected by piloerection, weight loss, raised LFTs and behaviour changes. At the end of two 
weeks, IrDef liver recipients showed higher frequency of intra-hepatic CD4+ T cells and less 
CD8+ T cells. Furthermore, IrDef showed more inflammatory cytokine production by the intra-
hepatic CD4+ and CD8+ T cells. No differences were observed in the frequency of 
macrophages and on regulatory T cells, which are normally involved on the tolerance and 
rejection phenomena (335, 336). Furthermore, at the end of rhIL-2 treatment, no marked 
histological differences were observed between two iron-modified groups (data no shown). 
Differently to the previous two reports that described 100% mortality rate when the one-week 
rhIL-2 is administered, none of our iron-modified liver recipients died during our three weeks 
rhIL-2 treatment protocol. The main technical difference between our surgical protocol and the 
two models referenced is the fact that our protocol, unlike the other two included arterialization 
of the liver allograft (276, 277). As previously mentioned, we opted for the arterialization 
technique due to the well-established impact that hypoxia exerts on the iron/hepcidin 
homeostasis (209). The use of arterial anastomosis in the rat liver transplant model, however, is 
known to improve the micro vascular liver circulation, prevent biliary damage, improve graft 
function and reduce the rate of rejection (275, 337-339). We believe that this technical 
difference contributed to our better survival rates and the weaker effects observed with rhIL-2. 
Of note, RhIL-2 administration did not have any significant harmful effects on rats fed with the 
two iron-modified diets and transplanted with syngeneic livers. These results suggest that the 
association of the mild iron deficiency and the lymphocytic allograft infiltration in the early time 
post-transplant contribute to the effects of the rhIL-2 treatment evidenced on the IrDef 
spontaneous tolerance transplanted rats. We replicated the same experimental conditions in 
spontaneously tolerant animals surviving more than two months post-transplant, when no intra-
hepatic lymphocytic infiltration can be observed anymore. Differently to the early post-transplant 
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period, in this setting, IrDef animals were not affected by the rhIL-2 treatment. We had planned 
to replicate these experiments in a transplant setting (i.e. induction of tolerance by tacrolimus) 
more immunogenic than the BN to Lewis model. Unfortunately, due to time and funding reasons 
we were not able to replicate the rhIL-2 protocol on such strain combination at early times post-
liver transplantation. We could however perform a limited number of experiments using Lewis 
rats that had been tolerized to DA livers for several months after having received the short 
course of tacrolimus. While at this late time the Lewis rats bearing a DA liver are considered 
fully tolerant (286), we observed that in one of the two animals to which we administered 3 
weeks of rhIL-2 and under IrDef diet, the ALT/AST levels significantly increased. We have to 
acknowledge the very limited number of animals employed (2 IrDef versus 1 IrRepl), but one 
could hypothesize on the basis of these results that a tacrolimus-induced tolerance model could 
be a better setting to explore the effects of iron deficiency on liver tolerance than the 
spontaneous tolerance model.  
In conclusion, we were able to set up a fully vascularized rat liver transplant model and to 
replicate the mild iron condition. Such iron-deficiency was not able to abrogate the spontaneous 
tolerance establishment. Further, caution should be taken when the diet model is used because 
the high rate of complication at long term. The tacrolimus-induced tolerance rat strain 
combination seems to be a more appropriate strain combination to check the impact of iron 
levels on the tolerance establishment at early time points post liver transplantation 
 
6.3 Molecular characterization of acute cellular rejection in liver transplant 
recipients occurring during intentional immunosuppression withdrawal  
Until now, histologic examination is the backbone on the diagnosis of ACR in the organ 
transplant setting. Allograft biopsy is an invasive procedure and samples interpretation can be 
challenging and lead to misdiagnosis (340, 341). Because that, the determination of 
reproducible non-invasive and/or more accurate surrogate biomarkers of graft rejection is an 
important research field of in the organ transplantation. Post-transplant molecular profiles have 
been already exhaustively studied in the kidney transplantation leading to the characterization 
of subtypes of rejection and other different types of graft injury (159). Data from single- and 
multicentre studies, mostly using mRNAs as specific biomarkers, can be helpful diagnostic tools 
(342). Conversely, in liver transplantation; few studies approached the molecular 
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characterisation of ACR. Most of those studies were addressed in small series of liver transplant 
recipients, which limits results extrapolation for the general population of liver transplant 
recipients. By consequence, our comprehension of the predictive accuracy and specificity of 
molecular biomarkers in different clinical conditions and different biological samples in the liver 
transplantation setting remains incomplete. 
Our microarray experiments performed on liver samples showed a clear transcriptional 
difference between rejecting and non-rejecting liver allografts, in similitude with what has 
already been demonstrated in other organ transplanted organs as e.g. kidney and heart 
transplants. A clear transcriptional read-out was more evident in HCV-positive than in HCV-
negative, once that ten times more genes were differentially expressed in the former group 
when compared with the later group. In spite of that, an overlapping group of 19 genes were 
significantly expressed in both groups. A control experiment using liver samples taken from 
rejecting HCV-negative patients who rejected their liver in the first month post transplantation 
confirmed the rejection specificity of these 19 common expressed genes. 
Functional analyses comparing our findings with available public gene expression data sets 
revealed that many of our identified genes were already clearly associated with rejection 
occurring in other transplant settings, with many of then corresponding to functional pathways 
involved with allograft rejection, as nuclear factor-κB, STAT1/interferon-γ, tumour necrosis 
factor-α, chemokine receptor networks and immune effector networks. More specifically, from 
the previous mentioned group of 19 genes, 12 genes were already reported (CXCL9, HLA-
DMA, HLA-DRA, ITM2A, HLA-F, HLA-DQB1, UBD, CD2, IL8, IL32, CXCL10, TAP1), in a meta-
analysis published by Spivey et al., which include rejecting samples from liver, kidney, heart and 
lung transplant recipients (342). Then, 10 genes (CD2, CXCL10, CXCL9, HLA-DMA, HLA-
DQB1, HLA-DRA, HLA-F, IL32, TAP1 and UBD) were already demonstrated in rejecting kidney 
recipients (142, 143, 147, 343, 344); 3 genes (CXCL10, CXCL9 and HLA-F) in rejecting cardiac 
recipients as described by Karason et al., 3 genes (IL32, IL8, and ITM2A) in common with lung 
rejecting recipients demonstrated by Patil et al. (345, 346). None of the four liver rejection 
transcriptional studies included in the Spivey et al. meta-analysis disclosed overlapping gene 
with our list of 19 rejection-associated genes (342). Only seven genes were exclusively 
recognised by our study (GPNMB, SLC1A3, ANXA2, CD38, FABP5, PLA2G7, RFX5). Two liver 
transcriptional studies addressed the difficulties of rejection diagnostic in the context of HCV-
positivity. In Sreekumar et al. report, a rejection gene signature was described in protocol liver 
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biopsies performed at day 21 post-transplant from a small series of 4 rejecting HCV-positive 
patients compared with 4 non-rejecting HCV-positive recipients (347). In a larger cohort of HCV-
positive patients, Asaoka et al. used the Ingenuity Pathway Analysis methodology to analyse 
transcriptional profiles from liver biopsies taken in the second month post-transplant. They were 
also able to describe a differential gene signature in rejecting HCV-recurrent patients from those 
only with HCV recurrence (348). While there was a similitude between their rejection associated 
functional networks with those identified by our study, there was no overlapping with our list 19 
genes differentially expressed at the rejection time. In the following study from the same group, 
which included liver recipients also transplanted by other indications than HCV-related cirrhosis, 
two of their rejection-associated genes (CD2 and CXCL9) were also present in our list of 
differentially expressed genes (349). This reduced overlapping of individual genes among the 
transcriptional liver studies can be accredited to the issues concerning small series, different 
population characteristics, differences on biopsies collection time points, the employ of different 
transcriptional platforms and variation on the genes tested selection. Concerning to the 
interference of HCV-positivity on the ACR characterization, the higher number of differentially 
expressed genes in our HCV-positive recipients in comparison with HCV-negative patients, is in 
agreement with previous findings already reported by Bohne et al. who showed a significant 
interaction between HCV infection and alloimmune responses at the molecular transcriptional 
level. Nevertheless, the identification of ACR-specific rejection genes in the context of 
underlining HCV infection could be an important tool to discriminate ACR from HCV recurrence 
as previously stated by the previous mentioned studies (347, 348). 
Changes on the regulation of specific genes have been associated with acute cellular rejection. 
The detection of some specific gene polymorphisms genotypes as NFKBIA and TNFA-308 A/A 
in peripheral blood samples of liver transplant recipients has been associated repeat ACR 
episodes (350, 351). However biological conditions used to be a resultant of many factors, 
including the regulation of complexes genes pathways. Then, analyses of transcriptional 
changes of individual genes can lead to major misinterpretation of biological processes. We 
used available bioinformatics tools to explore which functional pathways were more highly 
associated with ACR, by comparing our data with pathogenesis-based transcripts gene sets 
already described in kidney and heart human allografts. This analysis disclosed a 
predominance of T cell associated transcripts differentially expressed at the time of rejection in 
our samples. The same picture was observed in other transplant organs, mainly kidneys, 
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suggesting a similar response by the liver allograft to T cell mediated rejection (TCMR) 
episodes. Furthermore, it is worth to note the presence of a significant association with 
transcripts containing genes reputed by an overexpression in the occurrence of antibody-
mediated rejection (ABMR) in kidney allografts, notably B-cells and NK cells related genes. 
Here again there is a similitude with what occurs in kidney transplant setting, where ABMR-
associated transcripts were also present with a weaker signal in the context of TCMR. These 
findings are in accord with the concept that transcriptional differences between TCMR and 
ABMR are more quantitative than qualitative. It is known that ABMR is less frequent in the liver 
recipients than in the kidney counterparts; however the fact that ABMR-associated transcripts 
could be differentiated expressed on the TCMR episode should be taken in consideration when 
liver allograft biopsies exhibit mixed or unclear histological patterns. In those cases, 
transcriptional analyses would be used to supply complementary diagnostic information.  
In addition to the functional liver biopsy analyses, we applied the same functional research 
algorithm to analyse sequential blood samples in HCV-negative rejecting liver recipients. Even 
though we found similar pathways associated with ACR, the blood compartment presented a 
weaker signal in comparison to the tissue compartment. Also, in contrast with the tissue 
observations, T cell associated transcripts were down regulated in blood at the time of ACR 
suggesting an allograft “tropism effect” evidenced by the T cells, mainly CD8+ T cells, migration 
to the transplant organ at the time of allograft rejection (352). In fact in the liver transplant 
setting, Taubert et al. found an enrichment on regulatory T cells in liver biopsies at the time of 
rejection and HE et al found a decreased frequency of CD4+CD25high FoxP3+ on peripheral 
blood of rejecting liver recipients (353, 354). 
We checked if our ACR-related group of genes were already differentially expressed at the 
baseline blood samples, which could be used as predictor of the IS withdrawal. In contrast with 
the association of iron-related genes transcriptional patterns in liver biopsies at baseline and the 
IS withdrawal outcome; none of our genes tested was differentially expressed at the baseline 
blood samples suggesting that at the moment allograft transcriptional changes are more 
accurate to predict the outcome of IS withdrawal than the transcript patterns on the peripheral 
blood compartment. 
We attempted to establish a correlation between molecular changes occurring in the liver 
allograft and in the periphery by comparing our ACR transcriptional data sets found in liver 
biopsies and in the blood samples, both taken at the time of the rejection episode. However 
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before doing that, we needed to acknowledge the fact that different microarray platforms were 
employed in each experiment, which can impair the outlining of definitive conclusions. Taking in 
consideration this condition and employing a slightly lower significance threshold to compare 
the two data sets, 22 genes were identified as differentially expressed in both compartments, 
with most of them known to be associated to the immune response and cell cycle pathways. 
These findings, in addition with the similar networks identified by functional analyses in both 
groups of specimens, support the concept of overlapping transcriptional profiles between the 
two biological compartments at the rejection time.  
As previously mentioned, diagnosis of allograft rejection episodes requires histological 
evaluation. Rejection histologic diagnostic criteria are usually built based on retrospective 
analyses of historical sets of histologic allograft specimens with correlation to clinical outcome. 
Worldwide renowned expert panel constantly review and updated the histological Banff rejection 
score system is in specific periodic meetings (355, 356). In spite of that, histological rejection 
approach presents some limitations, which can interferer on the final result and series 
comparisons as arbitrary lesions grading, subjectivity on biopsies readings, variability on site 
sampling, and the disagreement between pathologists on lesions scoring (340, 357). Studies 
comparing gene expression profiles on allografts specimens with histological Banff scores have 
showed a correlation of inflammatory expressed genes with histological rejection classification 
in the kidney transplant setting(147, 358) (358). Using a very detailed inflammatory 
classification, which included 11 histological parameters, we were able to demonstrate a clear 
correlation between the expression of inflammatory and rejection associated genes in liver 
tissues with the degree of inflammatory lesions disclosed by the histological scoring. Such 
correlation was relatively uniform over all different histological compartments analysed, however 
the number of expressed genes were remarkable in lobular and portal inflammation and in 
interface hepatitis. However, we need to acknowledge that few patients presented severe 
central vein endothelitis of ductopenia, limiting the detection of transcriptional signatures for 
more severe forms of ACR in our series. This is probably due the fact that patients achieved 
biochemical criteria for per indication liver biopsy in the early stages of the rejection process 
when no clinical symptoms were observed and only mild or moderate biological allograft 
dysfunction was detected by the strict biological monitoring protocol recommended by the 
clinical trials guidelines and, probably, as a consequence no serious histological damage has 
been installed yet.  
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The presence of CNI-based IS regimens at the time of enrolment was associated with the 
failure of IS weaning protocol in a univariate analysis but not in a multivariate analysis in the 
original cohort of patients from the IS withdrawal clinical trial reported by Benitez el al. (1). 
Therefore, we aimed to investigate if the type of IS at the baseline could influence the gene 
transcripts profile among rejecting liver recipients. In our sub analysis, baseline 
immunosuppression did not influence gene expression profiles on liver tissue. The same 
algorithm was employed on blood samples, which disclosed no differences between gene 
expression patterns between patients taking TAC monotherapy and patients taking CSA 
monotherapy. There was only a small group of 17 genes deferentially expressed between 
patients on CNI monotherapy and patients initially on MMF; however only 8 out of the 17 genes 
were included on the original set of ACR-associated genes. Altogether, these findings suggest 
that baseline immunosuppression regimens have no influence on the gene expression patterns 
at the time of enrolment, and it was not a confounding factor for our further analyses. Previous 
studies aiming to disclose gene signatures of tolerance in the transplant setting, mainly kidney 
but also in the liver transplant setting, did not pay much attention to the patient initial IS 
regimens (109, 122-124). Basically they compared patients completely off IS with patients under 
IS therapy without take in account the tolerant patients previous IS regimens. However, in a 
recently study, Rebollo-Mesa et al. re-analysed three independent cohorts of patients initially 
studied in some of such previous reports in addition with a new prospective group of kidney 
recipients under a corticosteroids weaning protocol. Employing complex bioinformatics 
statistical models in training, validation and proof of concept stepwise algorithm, they 
demonstrated that IS had a bias effect on their original tolerance gene signatures, with 
azathioprine exerting the major negative influence. In addition, they were able to disclose a new 
tolerance gene signature that remained stable before and after the corticosteroids withdrawal 
(359). Even that our analysis showed no interference of immunosuppression on the gene 
expression patterns from samples of our rejecting liver recipients, this mentioned study 
highlights the need for deeper analyses or re-analyses of rejection and/or tolerance gene 
signatures on the IS withdrawal in the liver transplant setting. 
We investigated if sequential transcriptional changes over the IS weaning period could be used 
as a gene signature able to forecast ACR episode before its biological, histological and clinical 
appearance. For that, we studied the kinetics changes on the transcriptional patterns in a well-
selected group of 45 ACR-associated genes, most of them identified by our own microarrays 
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experiments. From that group, using a univariate analysis, we were able to determine a target 
group of 10 genes differentially expressed in blood samples at the time of rejection in 
comparison with samples collected at the time of enrolment. Using a stepwise multivariate 
logistic analysis to construct a predictive model of rejection in the context of IS withdrawal, we 
identified that the combination of CXCL10 and FOXP3 were the most accurate gene 
combination able to determine rejection in blood samples when compare with baseline samples. 
The use of this gene signature on blood sequential samples collected across the weaning 
protocol showed a peak on the gene expression coinciding with the rejection episode and with 
the peak of serum transaminases. Gene expression levels decrease after that rejection 
treatment had been started, which was in agreement with transaminases serum levels 
normalisation. Since that most of rejecting liver recipients were under CNI-based IS regimens, 
and taking in account the effect of CNI on the FOXP3 expression, this gene was excluded in a 
second analysis (316). Then, a second gene signature containing only CXCL10 is more robust 
marker to determine the ACR episode evolution. We need to acknowledge that increases on the 
CXCL10 expression paralleled with increases on LFTs in the same time. Furthermore the 
CXCL10 gene signature misplaced as rejecting 33% of blood samples of tolerant liver recipients 
with normal LFTs and no clinical signs of rejection. One possible hypothesis to explain this 
finding could be the presence of a subclinical inflammatory phenomenon during the IS weaning 
protocol that is not strong enough to progress to a rejection episode. This subclinical 
inflammation was already described in animal models, where an intermediary lymphocyte 
allograft infiltration period is noted before the T cell deletion during the tolerance establishment 
process (273). It is also worth to note that unfortunately our rejection gene signature was not 
sufficiently sensitive to diagnose rejection episodes in patients with chronic HCV infection. The 
clear impact of HCV on the gene expression profiles at the rejection time was confirmed by the 
increased number of differentially expressed genes at the rejection time in HCV-positive 
samples in comparison with HCV-negative samples. Moreover, we need to acknowledge the 
small group of HCV-positive liver recipients in addition to the limited number of samples 
available from those patients; which could be confounding factors for the employment of our 
rejection gene signature. Furthermore, the limitations due to the small number of patients and 
available samples prevented us from being able to stratify our patient population into any 
subgroups other than HCV-positive and HCV-negative. We were unable to stratify for the 
presence of hepatocellular carcinoma, age, gender or other indications of transplantation. 
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Future prospective studies are necessary to address the influence of HCV infection on the 
rejection episode in liver transplant recipients, which should also take into account the advent of 
the new direct-acting antiviral-based treatment for HCV infection after liver transplantation as 
well as other patient subgroups as mentioned above (360, 361). 
The clinical utility of a rejection gene signature needs to be checked in larger IS withdrawal 
clinical trials, which combine gene expression kinetics in blood samples with LFTs evolution 
across the weaning period. We believe that gene expression profiles can improve the rejection 
diagnosis based exclusively on LFTs, which are neither sensitive nor specific for rejection. 
However, the measurement of LFT remains one of the most important parameters in decision 
making to indicate a liver biopsy to confirm or rule out a possible episode of rejection (362). The 
discovery of a more accurate ACR gene signature in the milieu of IS withdrawal could be an 
important tool for the immune monitoring of enrolled patients. As stated previously, such a 
monitoring tool could help to identify patients likely to develop a rejection episode across the 
weaning protocol before its biological, histological and clinical manifestations. In that case, once 
a future-rejecting patient has been identified, special clinical measures can be taken in order to 
hold the rejection episode evolution avoiding a complete reactivation of the immune system due 
to the IS withdrawal. This strategy could favour future attempts of IS withdrawal in patients not 
yet likely to be tolerant when such patients will be older and more time will have passed from 
the transplant procedure which are the two strongest clinical factors associated with successful 
complete IS withdrawal (1). The identification of molecular biomarkers associated with the ACR 
occurring in the early phase post liver transplantation could be an important immune monitoring 
tool as well. In this case, the ACR-associated gene signature could be used to tailor the IS 
treatment. Then in case of up regulation of ACR-associated genes this could be an indicator of 
insufficient IS treatment. On the contrary, down-regulation of such genes could be a signal of 
over immunosuppression. Unfortunately few studies have addressed this question in the early 
period post-liver transplantation. 
Our current study discloses a comprehensive understanding for the processes driving ACR in 
liver transplant recipients. We demonstrated a significant overlap with the rejection episode in 
kidney transplant recipients regarding the T cell-mediated processes. We addressed the 
potential clinical use of transcriptional markers detected in peripheral blood samples as a 
predictor tool of ACR in liver transplant recipients. Those markers could lead to more accurate 
ACR diagnoses reducing the need of invasive procedures in the rejection diagnosis, however 
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further studies are necessary either in the context of IS withdrawal or in the early period post 
liver transplantation. These studies could take advantage of the use of the new RNA sequence 
platforms, which use high-performance RNA sequence techniques, such as New Sequence 
Generation, for the identification of more specific and sensitive molecular rejection signatures. 
 
6.4 Final Conclusions and Future Work 
In the current work, we analysed human biological samples employing transcriptional 
technologies and set up two experimental animal models to investigate tolerance and rejection 
biomarkers in the context of immunosuppression withdrawal post liver transplantation, which 
resulted in two peer reviewed publications (160, 363).  
The analysis of biological samples collected from patients who developed a rejection episode 
during the weaning period allowed us to identify a distinct rejection transcriptional profile. Some 
of these genes were also differentially expressed in biopsies collected in cases of rejection 
taking place early post liver transplantation in patients treated with standard-of-care regimens. 
Furthermore, similarities were also encountered with rejection-associated gene-sets originating 
from other transplanted organs. When sequential blood samples were collected across the 
weaning protocol, at the time and after the rejection episode, a predictive rejection model 
employing up to two genes could be identified. While this gene signature could theoretically 
identify future rejecting liver recipients enrolled in similar IS withdrawal clinical trials, the 
rejection-associated gene set can be used as a biomarker for immunological monitoring 
purposes for long-term liver recipients not necessarily enrolled in such clinical trials. Indeed, the 
clinical utility of this biomarker was recently demonstrated in 2 clinical studies involving protocol 
liver biopsies collected from paediatric and adult liver transplantation, respectively, in which the 
statistical enrichment of our previously identified gene sets in the transcriptome of liver biopsies 
showing subclinical idiopathic inflammation suggested rejection as a plausible pathogenic 
explanation (364, 365). The implications of these recent studies in those patients bearing 
subclinical inflammatory histological abnormalities show that they might be in need of 
strengthened immunosuppression, which is something that will now need to be tested in 
randomised controlled studies. Efforts are needed to address the current limitations of 
biomarkers of molecular rejection, such as the low specificity and sensitivity to identify a 
rejection episode before its clinical, biological and histological manifestations and the time 
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required for sample processing and obtainment of results. Cost is another problem that must be 
addressed. If these points are attained, the molecular rejection profile can become an important 
clinical tool in the future for the diagnosis and monitoring of acute cell rejection in the field of 
transplantation. Our animal studies have provided information supporting a potential role of iron 
metabolism in the regulation of intra-hepatic inflammatory responses and tolerance. Given the 
significant influence of iron on bacterial growth, the participation of the gut microbiome in the 
effects reported in our murine model of immune-mediated liver damage, which we could only 
superficially explore in our studies, will need to be investigated further. Additional experimental 
work will also be required to better clarify the role of iron in the spontaneous development of 
tolerance, as originally hypothesized, the robustness of the model chosen might have 
overshadowed the effects of iron. To address this, our future work will include the use of more 
immunogenic donor-recipient strain combination. In this regard, experiments are in preparation 
using the Tacrolimus-induced tolerance rat strain combination, which might be more prone to be 
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Abstract
Hepatic expression of iron homeostasis genes and serum iron parameters predict the suc-
cess of immunosuppression withdrawal following clinical liver transplantation, a phenome-
non known as spontaneous operational tolerance. In experimental animal models,
spontaneous liver allograft tolerance is established through a process that requires intra-
hepatic lymphocyte activation and deletion. Our aim was to determine if changes in sys-
temic iron status regulate intra-hepatic lymphocyte responses. We used a murine model of
lymphocyte-mediated acute liver inflammation induced by Concanavalin A (ConA) injection
employing mice fed with an iron-deficient (IrDef) or an iron-balanced diet (IrRepl). While the
mild iron deficiency induced by the IrDef diet did not significantly modify the steady state
immune cell repertoire and systemic cytokine levels, it significantly dampened inflammatory
liver damage after ConA challenge. These findings were associated with a marked
decrease in T cell and NKT cell activation following ConA injection in IrDef mice. The
decreased liver injury observed in IrDef mice was independent from changes in the gut
microflora, and was replicated employing an iron specific chelator that did not modify intra-
hepatic hepcidin secretion. Furthermore, low-dose iron chelation markedly impaired the
activation of isolated T cells in vitro. All together, these results suggest that small changes
in iron homeostasis can have a major effect in the regulation of intra-hepatic lymphocyte
mediated responses.
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Introduction
Iron homeostasis and the immune system are closely interconnected. Inflammatory cytokines
induce a rapid increase of hepcidin [1], the central mediator of iron homeostasis, which
reduces iron export from enterocytes, hepatocytes and, most importantly, macrophages [2].
This results in iron accumulation within macrophages and decreased circulating iron levels,
which appears to be an effective defence strategy against extracellular microorganisms that
need access to iron to exert pathogenic effects [2]. On the other hand, iron loaded macrophages
exhibit reduced effector functions, which can compromise their capacity to clear intra-cellular
infections [3, 4]. Iron also contributes to the formation of potent reactive radicals, which pro-
mote oxidative stress and induce inflammation and tissue injury. Thus, iron restriction has
been shown to ameliorate oxidative stress and inflammatory organ damage in models of
murine acute hepatitis [5, 6], experimental autoimmune encephalomyelitis (EAE) [7], renal
interstitial fibrosis [8] and type 2 diabetes in rats [9]. In addition to its effects on innate
immune responses and inflammation, iron is also required for the function and differentiation
of adaptive immune cells such as T lymphocytes. Thus, iron deficiency impairs T cell prolifera-
tion in vitro [10]. The impact of iron homeostasis manipulations on lymphocyte function in
vivo, however, has not been investigated in detail.
A role for iron homeostasis in the regulation of intra-hepatic lymphocyte responses and in
the development of transplantation tolerance has been recently suggested on the basis of the
results of a clinical trial in which immunosuppressive drugs were intentionally withdrawn
from a cohort of 98 long-term surviving liver transplant recipients [11]. As compared to toler-
ant liver recipients who successfully discontinued immunosuppression and age-matched
healthy individuals, non-tolerant patients who rejected during the weaning process exhibited
lower serum hepcidin and ferritin levels, as well as lower intra-hepatic iron content and hepci-
din gene expression. An intra-hepatic iron-related gene expression signature was indeed the
most accurate marker to predict the outcome of the drug withdrawal protocol. The phenome-
non of spontaneous liver allograft tolerance has been extensively studied in experimental ani-
mal models, particularly in rodents, in which an essential step in the induction of tolerance is
the activation and subsequent deletion of liver infiltrating lymphocytes [12, 13]. On account of
these data, we hypothesized that small changes in iron homeostasis could influence intra-
hepatic immune responses by interfering with intra-hepatic lymphocyte activation. To test this
hypothesis, in the current study we induced mild iron deficiency in mice by administering
either an iron-free diet or low-dose iron chelators, and assessed how iron deficiency influenced
intra-hepatic lymphocyte activation and its downstream effects. Reduction of iron availability
significantly interfered with lymphocyte activation, proliferation and cytokine production and
resulted in dampened immune-mediated hepatitis. These findings highlight a previously not
well-recognized phenomenon through which small changes in iron homeostasis can influence
outcomes in inflammatory liver disorders.
Material and Methods
Mice
Male C57Bl/6 mice (purchased from Charles River) were bred under specific pathogen-free
conditions. All procedures were conducted in accordance with national and institutional guide-
lines for animal care and use and have been approved by the Denmark Hill Animal Welfare
and Ethical Review Body (AWERB–KCL) and the Home Office. Anesthesia was performed by
isoflurane inhalation whereas euthanasia was performed in CO2 chamber.
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Four-week old mice were fed with either iron deficient (<6mg/kg iron) or iron replete (iron
deficient diet supplemented with 200 mg/kg iron carbonyl) diets (SAFE, France) for a total of 3
weeks prior to the performance of experiments. In some experiments, mice also received an
antibiotic cocktail consisting of ampicillin 1 g/L, vancomycin 0.5 g/L, (Laboratoiros Normon S.
A., Spain), metronidazole 1 g/L (BBraun Medical S.A., Spain) and neomycin 1 g/L (Laborator-
ios Salvat, Spain), which was added to drinking water and changed every 3 days for the entire
duration of the 3-week period as described [14].
Concanavalin A (ConA) induced hepatitis
In order to investigate a potential iron-related functional effect in immune system, we used
an immune-modulated model of acute hepatitis using a sublethal injection of Concanavalin
A (ConA) [15]. Immune-mediated acute hepatitis was induced by intravenous injection of
15mg/kg of type IV ConA (Sigma-Aldrich, St. Louis, MO). Following ConA injection mice
were anesthetized and sacrificed at various time points to collect blood, spleen and liver tissue.
Additional experiments were performed with a single previous IP injection of 100μg of mouse
hepcidin (PLP-3773, Peptides International, KY, USA) or sterile PBS two hours before the
ConA challenge.
Iron chelators
For some in vivo experiments, a 3 day-course of a hydroxypyridinone iron based chelator
(HPO CP28; 20 nmoles, i.p.) [16, 17] was performed before ConA challenge. In vitro, cells were
incubated with low doses of either HPO CP182 (5μM) or desferoxamine (DFO, 10μM, Sigma-
Aldrich). At these doses iron chelators had no discernible effects on lymphocyte cell death (S1
Fig).
Serum biochemistry and cytokine analyses
Serum was obtained after 10 minutes centrifugation at 8,000g and stored at -80C. The alanine
aminotransferase (ALT) plasma activities, which reflect the liver injury intensity, and the
serum iron level were quantified by automated measurements using the ADVIA 2400 System
kits (Siemens). Hematologic parameters were assessed by automated measurements using the
ADVIA 2120 System kits (Siemens). Serum cytokine levels were measured with multiplex fluo-
rescent bead-based Luminex technology according to manufacturer’s recommendation.
Liver histology
Formalin-fixed and paraffin embedded liver tissue sections were stained with haematoxylin
and eosin stained and the presence of hepatocyte necrosis, cellular infiltration and hepatocyte
cohesion were assessed by a senior liver histopathologist who was blinded to the identity of the
experimental groups (MB).
Isolation of non-parenchymal liver cells
After harvesting, the liver was perfused with sterile PBS through the portal vein, and digested
at 37°C in the presence of collagenase II 5%,(PAA Laboratories) and 100μg/mL DNase I
(Roche) for 30 minutes, as described [18]. The liver tissue was then passed through a 70μm
nylon mesh. Hepatocytes were then removed following low-speed centrifugation (60 xg, 2min-
utes) and liver mononuclear cells were isolated using Ficoll separation (800 xg, 20 minutes).
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Isolation of splenic and lymph node leukocytes
Spleens were passed through a 70um nylon mesh, and blood cells were removed using ammo-
nium chloride potassium lysing buffer (Life Technologies) for 5 minutes.
In vitro naïve CD4+ T cell stimulation
CD4+ naïve T cells were isolated from spleen and lymph nodes using EasySep Mouse Naïve
CD4+ T Cell Isolation Kit (Stem Cell). Enriched cells were labelled with 2.5 μMCFSE (Biole-
gend) during 10 minutes. A total of 250.103 cells were incubated during 5 days in 96 well-plate
coated with anti-CD3 anti-CD28 antibodies (2ug each, clone 145-2C11 and 37.51, respectively)
in RPMI-1640 (Life technologies) supplemented with 5% Foetal Calf Serum (Sigma-Aldrich),
1% penicillin-streptomycin and 2 mM L-glutamine and 50μM β-mercaptoethanol (Life
technologies).
Flow cytometry
Up to 1.106 cells were labelled in staining solution (PBS, Foetal Calf Serum 2%, 2mM EDTA).
Antibodies used were: APC/Cy7 anti-CD3e, PE/Cy7 anti-CD4, APC anti-CD25, PE anti-
CD44, FITC anti-CD62L (all from Biolegend). Dead cells were stained either with 7-AAD (Bio-
legend) or Livedead cell viability assay (Life Technologies). Cells were fixed using fixation solu-
tion 20 minutes at room temperature (Biolegend). For regulatory T cells labelling, FOXP3
Perm/Fix solution was use with PE anti-FOXP3 antibody (Biolegend) according to manufac-
turer’s instructions. Intracellular IFNγ staining was performed using permeabilisation buffer
following manufacturer’s instructions and FITC anti-IFNγ antibody and APC anti-IL4 anti-
body (Biolegend). Data were acquired on a BD FACSCanto II flow cytometer (BD) and ana-
lyzed employing FlowJo software (Tree Star).
RNA extraction and gene expression experiments
Liver or spleen tissue samples were cryopreserved at -80C in RNAlater reagent (Ambion). For
RNA extraction, samples were first homogeneized using a RNAse-free pestle in Trizol reagent
(Invitrogen), and total RNA was extracted according to TRIzol manufacturer’s protocol. DNA
was removed from total RNA preparations using Turbo DNA-free DNAse treatment
(Ambion). Quality and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent
Technologies) and Nanodrop ND-1000, respectively. Total RNA was then reverse transcribed
into cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). A
pre-amplification of cDNA was performed using pooled TaqMan Assays (final concentration
of 0.2X each) and the TaqMan PreAmp Master Mix using 10 cycles of amplification. qPCR was
performed using the 48.48 Dynamic Array (Fluidigm Corporation, CA, USA) following manu-
facturer's protocol using a BioMark Instrument (Fluidigm Corporation). To quantify transcript
levels, target gene Ct values were normalized using Ct values of HPRT1 as a reference gene to
generate -ΔCt values. Real-time PCR gene expression experiments were performed at 12 hours
post injection. This time point was selected to coincide with the peak of transaminases and
after determining that it required more than 3 hours to detect significant gene expression dif-
ferences (in a pilot experiment, Illumina microarrays performed at 3 hours showed minimal
differential gene expression (data not shown)).
Statistical analyses
Statistical analyses were performed with GraphPrism software. Student T-test was used for
comparison between two groups and ANOVA analysis with Tukey’s post-hoc correction for
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pairwise comparisons was used to compare more than 2 groups. Fisher test was used for cate-
gorical variables. P-values<0.05 (two-tailed) were considered statistically significant in all
analyses.
Results
Induction of mild iron deficiency by dietary manipulation
As compared to mice fed with an iron replete diet (IrRepl), mice fed with an iron deficient
diet (IrDef) displayed decreased serum iron (mean 73.22 ±56.49 versus 156.38 ±36.99 μg/dL;
p<0.0001) and serum transferrin saturation (18.80 ±6.32 vs 56.20 ±4.53%; p = 0.0013) (Fig 1).
In addition, liver tissue analysis revealed reduced liver iron stores and hepcidin (Hamp) gene
expression (p = 0.017 and p<0.0001, respectively) (Fig 1). None of these iron parameters were
found different between IrRepl diet and regular diet. As previously reported [19, 20], IrDef
mice also developed mild anemia (hemoglogin 107.6 ±46.10 versus 147.9 ±6.50 g/L; p = 0.028),
and increased platelet count (1405 ±469.2 versus 769.4 ±174.4 x109/L; p = 0.0004) (Fig 1).
IrDef mice remained otherwise healthy and gained weight at the same rate as IrRepl mice.
Mild iron deficiency does not modify the steady state immune cell
repertoire and systemic cytokine levels
To assess the impact of mild iron deficiency induced by an iron deficient diet on immune
parameters, we first compared liver and spleen immune cell subsets in IrDef and IrRepl mice.
Fig 1. Iron and haematological parameters in mice fed with an iron-deficient diet.Mice were fed for 3 weeks with an iron deficient (IrDef) or iron replete
(IrRepl) diet. Bar plots display mean and SEM. Abbreviations: RBC (red blood cells), Hb (Hemoglobin), Plts (platelets), WBC (white blood cells).
doi:10.1371/journal.pone.0136106.g001
Iron Deficiency Impairs Intra-Hepatic Lymphocyte Response
PLOS ONE | DOI:10.1371/journal.pone.0136106 August 19, 2015 5 / 16
The 2 groups of mice displayed similar frequencies of intra-hepatic NK1.1+CD3+ NKT, CD4+
and CD8+ T cells, FOXP3+ T cells, cells and resident CD45+CD11b+F4.80+ Kupffer cells (Fig
2A). Similarly, no differences between IrDef and IrRepl splenic T cell subsets were noted, sug-
gesting that in the steady state IrDef does not induce major immunological effects (Fig 2B). We
next explored the effects of the iron deficient diet on pro-inflammatory and immunoregulatory
genes by measuring the expression of interleukins Il2, Il4, Il6, Il10, Il15, tumor necrosis factor α
(Tnf), transforming growth factor β (Tgfb1), interferon γ (Ifng), Cd86, forkhead box P3
(Foxp3), and Cd274 in whole livers, spleens and mesenteric lymph nodes from IrDef and IrRepl
mice. No significant changes were observed except for small decreases of TNFα (fold change
(FC) = -0.36, p = 0.032) and IFNγ (FC = -0.72, p = 0.044) transcript levels in the liver and
spleen of IrDef mice, respectively (Table 1). Serum cytokine levels were also measured using
Luminex technology, and again no significant changes between IrDef and IrRepl mice were
observed (Table 2).
Mild iron deficiency significantly dampens inflammatory liver damage
following ConA injection
To determine the functional effect of mild iron deficiency on intra-hepatic lymphocyte
responses we employed the ConA-induced immune-mediated hepatitis model. Following
ConA injection, the rise of alanine aminotransferases (ALT) was significantly lower in IrDef
Fig 2. Influence of iron levels on the immunophenotype of intra-hepatic (A) and spleen (B) leukocytes.
Mice were fed for 3 weeks with an iron deficient (IrDef) or iron replete (IrRepl) diet. Bar plots show the
frequency (mean and SEM) of specific leukocyte subsets in the liver (A) and spleen (B), as assessed by flow
cytometry after excluding dead cells.
doi:10.1371/journal.pone.0136106.g002
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mice than in IrRepl mice (p = 0.0028 and 0.0035 at 6 and 12 hours after ConA administration,
respectively) (Fig 3A). This was associated with reduced serum levels of the pro-inflammatory
cytokines IFNγ, IL6 and TNFα, which reached statistical significance at 6 hours after ConA
injection (p = 0.0037, 0.0013 and 0.0021, respectively; Fig 3B). Similar changes were observed
in the intra-hepatic expression of Il4 and Tnfa, whose transcript levels significantly decreased
in IrDef mice 12 hours after ConA injection (p = 0.0053 and p = 0.021, respectively; Fig 3C).
These data were consistent with the results of the liver histopathology analysis, which revealed
decreased hepatocyte necrosis and inflammatory infiltration in IrDef as compared to IrRepl
mice (p = 0.0082 and 0.0020, respectively) (Fig 3D).
Reduced iron availability impairs lymphocyte proliferation and activation
ConA administration triggers an inflammatory cascade that requires activation of T and NKT
lymphocytes and eventually results in liver tissue damage [15, 21]. Following ConA activation,
lymphocytes produce IFNγ, which is directly involved in the pathogenesis of ConA-induced
hepatitis [21–23]. Furthermore, NKT cells down-regulate NK1.1 and CD3 surface markers,
Table 1. Gene expression in liver, spleen andmesenteric lymph nodes (mesLN) of immune-related molecules from IrDef and IrRepl mice. FC is
exhibited as Log2 of IrDef/IrRepl values. Genes with significant differential expression are highlighted in bold.
Liver Spleen mesLN
Symbol Name FC p.value FC p.value FC p.value
Il2 Interleukin 2 0.75 0.090 -0.49 0.20 -0.26 0.28
Il4 Interleukin 4 0.32 0.14 -0.038 0.90 0.24 0.50
Il6 Interleukin 6 -0.20 0.39 -0.094 0.70 -0.48 0.15
Il10 Interleukin 10 -0.15 0.48 -0.11 0.74 0.060 0.83
Il15 Interleukin 15 0.098 0.68 -0.38 0.18 0.36 0.13
Ifng Interferon gamma 0.31 0.26 -0.72 0.044 0.40 0.54
Tnf Tumor necrosis factor -0.36 0.032 -0.29 0.38 0.024 0.94
Tgfb1 Transforming growth factor, beta 1 0.17 0.14 -0.26 0.14 -0.12 0.53
Foxp3 Forkhead box P3 -0.046 0.88 -0.32 0.34 0.052 0.85
Cd86 CD86 antigen 0.003 0.97 -0.41 0.083 -0.24 0.26
Cd274 CD274 antigen 0.10 0.38 -0.40 0.10 0.020 0.95
doi:10.1371/journal.pone.0136106.t001
Table 2. Serum level of cytokines measured by Luminex technology from IrDef and IrRepl mice. FC is
exhibited as Log2 of IrDef/IrRepl values.
Symbol Name FC p.value
IFNy Interferon gamma 0.85 0.59
IL-1α Interleukin 1alpha -0.73 0.57
IL-2 Interleukin 2 -3.35 0.20
IL-4 Interleukin 4 0.90 0.48
IL-6 Interleukin 6 -0.48 0.68
IL-10 Interleukin 10 -1.11 0.26
IL-15 Interleukin 15 1.47 0.10
IL-17 Interleukin 17 -1.69 0.15
CXCL10 chemokine (C-X-C motif) ligand 10 (IP-10) 0.008 0.96
CXCL9 chemokine (C-X-C motif) ligand 9 (MIG) 0.41 0.61
TNF α Tumor necrosis factor alpha -0.27 0.51
doi:10.1371/journal.pone.0136106.t002
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and the expression of these markers is inversely correlated to the degree of NKT activation
[24]. To explore if the effects of iron deficiency are mediated by defective lymphocyte activa-
tion, we isolated spleen and intra-hepatic lymphocytes at different time points following ConA
administration and assessed their phenotypic and functional properties. In IrDef mice, ConA
induced significantly less accumulation of liver-infiltrating CD3+ lymphocytes than in IrRepl
mice (p = 0.048 at 6 hours; Fig 4A). This was associated with a less striking decrease in the
expression of NK1.1 among CD3 cells (a marker of NKT cell activation) both at 3 and 6h fol-
lowing ConA injection (p = 0.0056 and 0.029, respectively; Fig 4A). In addition, as compared
to IrRepl, 3h after ConA administration intra-hepatic NKT and T lymphocytes from IrDef dis-
played lower intra-cellular IFNγ levels (p = 0.034 and 0.081, respectively; Fig 4B). Interestingly,
in contrast to the significant differences observed in the liver compartment, the frequence of
IFNγ-producing lymphocytes in the spleen was similar in IrDef and IrRepl mice (Fig 4C).
To confirm the effects of iron deficiency on T cells, we incubated splenocytes in vitro with
ConA (0.1mg/mL) in the presence of low doses of a specific hydroxypyridinone iron chelator
[16, 17] (HPO CP182; 5μM) or desferoxamine (DFO; 10μM). Iron chelation resulted in
impaired CD3+CD4+ T cell proliferation (p<0.001). Furthermore, iron chelators also
Fig 3. Iron deficiency results in attenuated immune-mediated hepatitis following ConA administration. (A) Serum levels of alanine aminotransferase
(ALT; IU/mL) before, 6 hours and 12 hours after administration of ConA in mice fed for 3 weeks with an iron deficient (IrDef) or iron replete (IrRepl) diet. (B)
Cytokine levels in serum samples collected before, 6 hours and 12 hours after the administration of ConA. (C) Transcript levels of Il4, Il6 and TNFα in liver
tissue samples collected before and 12 hours after the administration of ConA. (D) Representative liver histology (200x) at 12 hours after the administration of
ConA (upper panel) and histologic evaluation of necrosis and infiltration (lower panel).
doi:10.1371/journal.pone.0136106.g003
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hampered the activation of isolated CD4+ naïve T cells, which, following stimulation with
plate-bound anti-CD3/CD28, showed decreased CD25 expression and cell proliferation
(Fig 5).
The effects of iron deficiency in intra-hepatic inflammatory responses
are independent from changes in the gut microbiota
Given the influence of the gut microbiota on the liver environment [25] and the well-recog-
nized effects of iron levels on bacterial growth and intestinal microbial composition [26], we
next investigated if the reduced immune-mediated hepatitis observed in IrDef mice could be
mediated by changes in the number of gut bacteria. IrDef and IrRepl mice received a 3-week
course of a 4-antibiotic cocktail known to eliminate>90% of the fecal microbial populations,
and ConA was injected at the end of the 3-week period. The results were similar to those
Fig 4. ConA-induced T and NKT lymphocyte activation is reduced in iron deficiency. (A) Intra-hepatic
frequency of CD3+ expressing NK1.1 and CD3+NK1.1- at baseline, 3 hours and 6 hours after ConA injection.
(B) Intra-hepatic frequency of IFNγ production by NKT cells and T cells, defined as CD3+NK1.1+ and
CD3+NK1.1-, respectively, (left panel) and representative staining of IFNγ production by NKT cells (right
panel) (C) Frequency of splenic CD3+ NK1.1- T cells and the percentage of these ones producing IFNγ.
doi:10.1371/journal.pone.0136106.g004
Iron Deficiency Impairs Intra-Hepatic Lymphocyte Response
PLOS ONE | DOI:10.1371/journal.pone.0136106 August 19, 2015 9 / 16
observed in mice receiving no antibiotics, with ALT levels being significantly reduced in IrDef
as compared with IrRepl mice (Fig 6A).
Intra-hepatic inflammatory responses are influenced by iron but not by
baseline hepcidin level
Iron deficiency results in reduced hepcidin expression which in some models can exert direct
immune regulatory effects [19]. We sought to determine if the effects of the iron deficient diet
on immune-mediated hepatitis could be due to differences in hepcidin levels rather than to
changes in iron status. Mice fed with a standard diet were treated with a 3 day-course of the
HPO CP28 iron chelator [16, 17] capable of specifically chelating intra-cellular iron without
decreasing intra-hepatic hepcidin expression (p = 0.48) (Fig 6B). Similarly to what was
observed employing iron deficient diet, mice treated with the iron chelator displayed a signifi-
cantly reduced ConA-induced hepatitis (p = 0.041) (Fig 6C). In parallel, administration of
exogenous hepcidin to IrDef mice 2h prior to ConA injection did not restore the blunted
immune-mediated hepatitis induced by ConA (p = 0.84; Fig 6D). Altogether, these results sug-
gest that iron restriction inhibits lymphocyte activation and ConA-induced hepatitis indepen-
dently from its effects on hepcidin secretion.
Fig 5. Iron chelation impairs CD4+ T cell activation and proliferation in vitro. (A) Percentages of CD3+CD4+ cells from splenocytes undergoing in
at least one division are represented with representative fluorescent histogram in the lower part. Splenocytes were incubated 96 hours in presence of ConA
(0.1mg/mL) and in presence of low doses of iron chelator (HPO CP182, 5μM or DFO, 10μM). (B) Percentages of CD3+CD4+ cells from isolated naive CD4+
cells undergoing in at least one division and (C) CD25 MFI are represented are displayed with representative fluorescent histogram in the lower part. Isolated
CD4+ naïve T cells incubated 5 days in presence of anti-CD3/CD28 plate-bound antibody (2μg each).Unmeans unstimulated cells.
doi:10.1371/journal.pone.0136106.g005
Iron Deficiency Impairs Intra-Hepatic Lymphocyte Response
PLOS ONE | DOI:10.1371/journal.pone.0136106 August 19, 2015 10 / 16
Discussion
In the current study we investigated the impact of small changes in systemic iron status on
intra-hepatic lymphocyte-mediated immune responses. Our experiments were prompted by
the results of a recently reported multi-centre clinical trial of immunosuppression discontinua-
tion following liver transplantation [11, 27], in which liver recipients who developed rejection
exhibited lower iron storage markers (e.g. serum ferritin and serum and intra-hepatic hepcidin)
than recipients who successfully discontinued immunosuppression (operationally tolerant
recipients). These differences were statistically significant and very reproducible, but small in
magnitude and not clinically apparent. Given that spontaneous liver allograft tolerance is
known to require activation of recipient alloreactive T cells prior to lymphocyte deletion [12,
13, 28], we hypothesized that the iron/hepcidin axis could play an unappreciated role in the
regulation of intra-hepatic lymphocyte activation and function.
To test this hypothesis we selected a well-established model of immune-mediated hepatitis
that is tightly controlled by the interplay between cytokines, lymphocytes and Kupffer cells,
and in which intra-hepatic T/NKT cell activation is necessary for inflammatory liver damage
to occur [15, 21, 23]. We replicated the mild iron homeostasis changes observed in the cohort
of liver transplant recipients by feeding mice with an iron-deficient diet for just 3 weeks or by
administering low-dose iron-specific chelators. Short-term reduction in iron intake did not
have a significant impact on the hepatic steady-state immune homeostasis. On the other hand,
the magnitude of liver damage upon ConA stimulation was significantly reduced in iron defi-
cient mice, as assessed by decreased serum ALT levels, hepatic necrosis and intra-hepatic cellu-
lar infiltration. This was associated with a decrease in systemic levels of pro-inflammatory
cytokines such as IL6, TNFα and IFNγ, and with reduced intra-hepatic transcript levels of IL4
and Tnfα, all of them known to regulate ConA immune-mediated hepatitis.
A beneficial effect of dietary iron restriction or DFO iron chelation on liver inflammation
was previously reported in experimental animal models of thioacetamide-induced toxic
Fig 6. The inhibitory effects of iron deficiency in ConA-induced hepatitis are independent from changes in gut microbiome and hepcidin levels. (A)
ALT serum levels (IU/mL) before, and 12 hours after the administration of ConA to mice fed for 3 weeks with an iron deficient (IrDef) or iron replete (IrRepl)
diet, in the presence or absence of a 4-antibiotic (Atb) cocktail. (B) Relative expression of Hamp in liver tissue samples frommice receiving a 3 day-course of
HPO CP28 (20 nmoles, daily) compared to control mice receiving PBS (p = 0.48). (C) ALT serum levels 12 hours after ConA challenge in mice treated with
HPO CP28 or with PBS (p = 0.041). (D) ALT serum levels 12 hours after ConA challenge in mice pre-treated two hours before with a single intraperitoneal
injection of 100μg of mouse hepcidin or sterile PBS (p = 0.84). Bar plots display mean and SEM.
doi:10.1371/journal.pone.0136106.g006
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hepatitis [5] and Fas-induced fulminant hepatitis [6]. The anti-inflammatory effects of iron
restriction were attributed to a reduction in oxidative stress, and a decreased Kupffer and
hepatic stellate cell activation. While oxidative stress and macrophage activation are certainly
involved in amplifying liver damage following ConA administration, our findings that iron
deficiency results in decreased intra-hepatic T/NKT lymphocyte infiltration and reduced lym-
phocyte activation and effector function indicates that iron deficiency can also influence the
outcome of immune-mediated hepatitis by directly inhibiting intra-hepatic lymphocyte func-
tion. These results were confirmed in in vitro experiments in which isolated T cells were stimu-
lated with either ConA or anti-CD3/anti-CD28. In these experiments, iron chelation resulted
in impaired T cell activation and proliferation.
Our observations indicating that changes in iron status can regulate inflammatory organ
damage by influencing lymphocyte activation and proliferation are consistent with results
obtained in experimental autoimmune encephalomyelitis, a CD4+-driven model in which iron
deficiency prevents the development of immunopathology [7]. The mechanisms responsible
for T lymphocyte inhibition still remain to be fully deciphered. Intracellular iron deprivation
can impair the function of various enzymes involved in cell-cycle control, such as the ribonu-
leotide reductase [29], involved in DNA synthesis during phase S of cell cycle, cyclin A, and
Cdc2 [30]. Iron restriction can also inhibit the hydrolysis of phosphatidyl inositol-4,5-bipho-
sphate and the activity of kinase C protein, both of which are key in the cascade of intracellular
signalling events elicited by T cell activation [10, 31]. In addition, at least in the central nervous
system, DFO inhibits CXCL10 release following Toll-like receptor 3 (TLR3) engagement [32],
which can result in decreased tissue infiltration by CXCR3+ T cells.
Given that in some experimental models hepcidin has been reported to be capable of
directly inhibiting systemic inflammatory responses independently from iron levels [19, 33],
we explored the relative contributions of low iron versus low hepcidin levels in the regulation
of ConA-induced immune hepatitis. As expected, iron deprivation resulted in decreased hepa-
tocyte hepcidin expression, which persisted even following the induction of immune-mediated
liver damage (data not shown). We investigated the role of low iron levels by administering an
iron-specific chelator that does not influence hepatocyte hepcidin expression. Iron chelation
replicated the results observed by feeding the animals with an iron deficient diet. We next
tested the effect of injecting exogenous hepcidin prior to ConA challenge, which did not
modify the inhibitory effects of iron deprivation. We concluded that low iron levels are the
major determinant of the reduced liver inflammatory damage observed in iron deficient mice
following ConA administration. Considering the effector role played by macrophages in
ConA-induced hepatitis, our results appear to be in contrast with observations indicating that
iron-deprived macrophages exhibit increased release of pro-inflammatory mediators following
activation with LPS [19, 33]. While these observations still need to be clarified, as they have not
been confirmed by other studies [34], they suggest that iron deficiency elicits complex immu-
nological effects that are dependent on the specific cell being targeted and on the organ
involved in the inflammatory response. Hence, we speculate that the need for effective T cell
activation in order for ConA to induce immune mediated liver damage injection, in contrast to
what happens when systemic inflammation is provoked by LPS administration, is what deter-
mines the different outcomes observed in the 2 models in situations of iron deficiency.
Dietary iron manipulations can modify gut microbiota composition, which may influence
liver metabolism and immunogenicity [25]. To exclude this possibility we employed an antibi-
otic cocktail capable of eliminating>90% of the fecal microbial populations [14]. Iron defi-
ciency was still associated with significantly reduced immune mediated liver damage even in
the presence of markedly reduced intestinal bacterial populations. It is noteworthy, however,
that as compared with control animals receiving no antibiotic treatment, mice treated with
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antibiotics exhibited lower transaminase levels following ConA. This was particularly striking
in IrDef mice, in which hepatitis was almost completely abrogated. These observations are in
agreement with a previous report in which gentamycin decreased ConA-induced liver injury
by impairing intestinal dendritic cells function and intra-hepatic NKT cells activation [35].
Thus, in the ConA model, iron deficiency and antibiotic treatment are likely to deliver additive
effects by powerfully inhibiting T/NKT cell activation.
While serum Il6 level was decreased after ConA injection in IrDef, we observed an increase of
Il6 expression in the liver. Il6 is commonly described as a pro-inflammatory molecules but our
clear read-out of transaminases in the ConAmodel excludes an exacerbation of liver inflamma-
tion. Conversely, Il6 and the subsequent STAT3 phosphorylation have been described to be asso-
ciated with a reduction of liver injury [36, 37]. The increase Il6 expression is consistent with a
hepatoprotective effect in our setting, but whether IrDef directly participate to this increase of Il6
expression or this expression is hampered by higher liver damages in IrRepl remains to be deter-
mined. The inverse correlation of Il6 levels between serum and liver may reflect the different
immunological effects exerted by iron deficiency in the liver as compared with other compart-
ments, or may be the result of an opposite effect exerted on different cell types (e.g. hepatocytes
versus macrophages). Indeed, low hepcidin levels induced by IrDef could be responsible of
increased IL6 production by intra-hepatic macrophages as previously described [33].
In conclusion, we report here that iron deprivation impairs intra-hepatic lymphocyte activa-
tion and proliferation and results in a beneficial effect on immune mediated hepatitis. Given
the central role of the liver in the regulation of iron homeostasis, both as an iron reservoir and
as the main source of circulating hepcidin, these findings have implications for a variety of
inflammatory liver disorders. Further studies will be needed to ascertain whether all lympho-
cyte subsets are equally sensitive to iron deprivation, and to determine how iron influences
lymphocyte function in situations of chronic antigenic stimulation.
Supporting Information
S1 Fig. percentages of dead cells (7AAD+CD4+) relative to control in presence of various
concentrations of DFO and CP182 with splenocytes activated with CD3/CD28 antibodies
during 3 days (1A) and in experiments presented in Fig 5A and 5B and 5C with activated
total splenocytes or CD4+ naïve T cells, respectively. Representative Annexin V stainings in




The research was funded by the Medical Research Council (MRC) grant no. MR/L008890/1.
The research was supported by the MRC Centre for Transplantation (MRC grant no. MR/
J006742/1) and by the National Institute for Health Research (NIHR) Biomedical Research
Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The
views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health.
Author Contributions
Conceived and designed the experiments: ER RDMML ASF. Performed the experiments: ER
RDMMP EK RMMMBMML. Analyzed the data: ER RD JJ MBMML. Contributed reagents/
materials/analysis tools: HLC RCH. Wrote the paper: RD HLC RCHMML ASF.
Iron Deficiency Impairs Intra-Hepatic Lymphocyte Response
PLOS ONE | DOI:10.1371/journal.pone.0136106 August 19, 2015 13 / 16
References
1. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia
of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. The Journal of clini-
cal investigation. 2004; 113(9):1271–6. doi: 10.1172/JCI20945 PMID: 15124018; PubMed Central
PMCID: PMC398432.
2. Ganz T. Systemic iron homeostasis. Physiological reviews. 2013; 93(4):1721–41. doi: 10.1152/
physrev.00008.2013 PMID: 24137020.
3. Nairz M, Fritsche G, Crouch ML, Barton HC, Fang FC, Weiss G. Slc11a1 limits intracellular growth of
Salmonella enterica sv. Typhimurium by promoting macrophage immune effector functions and impair-
ing bacterial iron acquisition. Cellular microbiology. 2009; 11(9):1365–81. doi: 10.1111/j.1462-5822.
2009.01337.x PMID: 19500110; PubMed Central PMCID: PMC3467104.
4. Oexle H, Kaser A, Most J, Bellmann-Weiler R, Werner ER, Werner-Felmayer G, et al. Pathways for the
regulation of interferon-gamma-inducible genes by iron in humanmonocytic cells. Journal of leukocyte
biology. 2003; 74(2):287–94. PMID: 12885946.
5. Otogawa K, Ogawa T, Shiga R, Nakatani K, Ikeda K, Nakajima Y, et al. Attenuation of acute and
chronic liver injury in rats by iron-deficient diet. American journal of physiology Regulatory, integrative
and comparative physiology. 2008; 294(2):R311–20. doi: 10.1152/ajpregu.00735.2007 PMID:
18032466.
6. Sato T, Kobune M, Murase K, Kado Y, Okamoto T, Tanaka S, et al. Iron chelator deferasirox rescued
mice from Fas-induced fulminant hepatitis. Hepatology research: the official journal of the Japan Soci-
ety of Hepatology. 2011; 41(7):660–7. doi: 10.1111/j.1872-034X.2011.00821.x PMID: 21711425.
7. Grant SM, Wiesinger JA, Beard JL, Cantorna MT. Iron-deficient mice fail to develop autoimmune
encephalomyelitis. The Journal of nutrition. 2003; 133(8):2635–8. PMID: 12888650.
8. Ikeda Y, Ozono I, Tajima S, Imao M, Horinouchi Y, Izawa-Ishizawa Y, et al. Iron chelation by deferoxa-
mine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction. PloS one. 2014; 9(2):
e89355. doi: 10.1371/journal.pone.0089355 PMID: 24586712; PubMed Central PMCID: PMC3929716.
9. Minamiyama Y, Takemura S, Kodai S, Shinkawa H, Tsukioka T, Ichikawa H, et al. Iron restriction
improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. American journal of
physiology Endocrinology and metabolism. 2010; 298(6):E1140–9. doi: 10.1152/ajpendo.00620.2009
PMID: 20215574.
10. Kuvibidila S, Baliga BS, Murthy KK. Impaired protein kinase C activation as one of the possible mecha-
nisms of reduced lymphocyte proliferation in iron deficiency in mice. The American journal of clinical
nutrition. 1991; 54(5):944–50. PMID: 1951169.
11. Bohne F, Martínez-Llordella M, Lozano J-J, Miquel R, Benítez C, Londoño M-C, et al. Intra-graft expres-
sion of genes involved in iron homeostasis predicts the development of operational tolerance in human
liver transplantation. J Clin Invest. 2012; 122(1):368–82. doi: 10.1172/JCI59411 PMID: 22156196
12. Benseler V, McCaughan GW, Schlitt HJ, Bishop GA, Bowen DG, Bertolino P. The liver: a special case
in transplantation tolerance. Seminars in liver disease. 2007; 27(2):194–213. doi: 10.1055/s-2007-
979471 PMID: 17520518.
13. Li W, Kuhr CS, Zheng XX, Carper K, Thomson AW, Reyes JD, et al. New insights into mechanisms of
spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells.
American journal of transplantation: official journal of the American Society of Transplantation and the
American Society of Transplant Surgeons. 2008; 8(8):1639–51. doi: 10.1111/j.1600-6143.2008.02300.
x PMID: 18557727.
14. Corbitt N, Kimura S, Isse K, Specht S, Chedwick L, Rosborough BR, et al. Gut bacteria drive Kupffer
cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preser-
vation-reperfusion injury after orthotopic liver transplantation. The American journal of pathology. 2013;
182(1):180–91. doi: 10.1016/j.ajpath.2012.09.010 PMID: 23159949; PubMed Central PMCID:
PMC3532712.
15. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by con-
canavalin A. The Journal of clinical investigation. 1992; 90(1):196–203. doi: 10.1172/JCI115836 PMID:
1634608; PubMed Central PMCID: PMC443081.
16. Fakih S, Podinovskaia M, Kong X, Schaible UE, Collins HL, Hider RC. Monitoring intracellular labile
iron pools: A novel fluorescent iron(III) sensor as a potential non-invasive diagnosis tool. Journal of
pharmaceutical sciences. 2009; 98(6):2212–26. doi: 10.1002/jps.21583 PMID: 18823046.
17. Baek JH, Reiter CE, Manalo DJ, Buehler PW, Hider RC, Alayash AI. Induction of hypoxia inducible fac-
tor (HIF-1alpha) in rat kidneys by iron chelation with the hydroxypyridinone, CP94. Biochimica et bio-
physica acta. 2011; 1809(4–6):262–8. doi: 10.1016/j.bbagrm.2011.04.010 PMID: 21558026.
Iron Deficiency Impairs Intra-Hepatic Lymphocyte Response
PLOS ONE | DOI:10.1371/journal.pone.0136106 August 19, 2015 14 / 16
18. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, et al. Differential Ly-6C expres-
sion identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver
fibrosis. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109
(46):E3186–95. doi: 10.1073/pnas.1119964109 PMID: 23100531; PubMed Central PMCID:
PMC3503234.
19. Pagani A, Nai A, Corna G, Bosurgi L, Rovere-Querini P, Camaschella C, et al. Low hepcidin accounts
for the proinflammatory status associated with iron deficiency. Blood. 2011; 118(3):736–46. doi: 10.
1182/blood-2011-02-337212 PMID: 21628413.
20. Evstatiev R, Bukaty A, Jimenez K, Kulnigg-Dabsch S, Surman L, SchmidW, et al. Iron deficiency alters
megakaryopoiesis and platelet phenotype independent of thrombopoietin. American journal of hematol-
ogy. 2014; 89(5):524–9. doi: 10.1002/ajh.23682 PMID: 24464533; PubMed Central PMCID:
PMC4114532.
21. Wang HX, Liu M, Weng SY, Li JJ, Xie C, He HL, et al. Immune mechanisms of Concanavalin A model
of autoimmune hepatitis. World journal of gastroenterology: WJG. 2012; 18(2):119–25. doi: 10.3748/
wjg.v18.i2.119 PMID: 22253517; PubMed Central PMCID: PMC3257438.
22. Kusters S, Gantner F, Kunstle G, Tiegs G. Interferon gamma plays a critical role in T cell-dependent
liver injury in mice initiated by concanavalin A. Gastroenterology. 1996; 111(2):462–71. PMID:
8690213.
23. Sass G, Heinlein S, Agli A, Bang R, Schumann J, Tiegs G. Cytokine expression in three mouse models
of experimental hepatitis. Cytokine. 2002; 19(3):115–20. PMID: 12242077.
24. Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang CR, et al. The response
of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and
expansion. Proceedings of the National Academy of Sciences of the United States of America. 2003;
100(19):10913–8. doi: 10.1073/pnas.1833166100 PMID: 12960397; PubMed Central PMCID:
PMC196902.
25. Bjorkholm B, Bok CM, Lundin A, Rafter J, Hibberd ML, Pettersson S. Intestinal microbiota regulate
xenobiotic metabolism in the liver. PloS one. 2009; 4(9):e6958. doi: 10.1371/journal.pone.0006958
PMID: 19742318; PubMed Central PMCID: PMC2734986.
26. Tompkins GR, O'Dell NL, Bryson IT, Pennington CB. The effects of dietary ferric iron and iron depriva-
tion on the bacterial composition of the mouse intestine. Current microbiology. 2001; 43(1):38–42. doi:
10.1007/s002840010257 PMID: 11375662.
27. Benitez C, Londono MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ, et al. Prospective multicenter
clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatol-
ogy. 2013; 58(5):1824–35. doi: 10.1002/hep.26426 PMID: 23532679.
28. Crispe IN. Hepatic T cells and liver tolerance. Nature reviews Immunology. 2003; 3(1):51–62. doi: 10.
1038/nri981 PMID: 12511875.
29. Hoffbrand AV, Ganeshaguru K, Hooton JW, Tattersall MH. Effect of iron deficiency and desferrioxa-
mine on DNA synthesis in human cells. British journal of haematology. 1976; 33(4):517–26. PMID:
1009024.
30. Lucas JJ, Szepesi A, Domenico J, Takase K, Tordai A, Terada N, et al. Effects of iron-depletion on cell
cycle progression in normal human T lymphocytes: selective inhibition of the appearance of the cyclin
A-associated component of the p33cdk2 kinase. Blood. 1995; 86(6):2268–80. PMID: 7662974.
31. Kuvibidila SR, Baliga BS, Warrier RP, Suskind RM. Iron deficiency reduces the hydrolysis of cell mem-
brane phosphatidyl inositol-4,5-bisphosphate during splenic lymphocyte activation in C57BL/6 mice.
The Journal of nutrition. 1998; 128(7):1077–83. PMID: 9649588.
32. Imaizumi T, Sakashita N, Mushiga Y, Yoshida H, Hayakari R, Xing F, et al. Desferrioxamine, an iron
chelator, inhibits CXCL10 expression induced by polyinosinic-polycytidylic acid in U373MG human
astrocytoma cells. Neuroscience research. 2015. doi: 10.1016/j.neures.2015.01.001 PMID: 25591911.
33. De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, et al. Hepcidin mediates tran-
scriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin
Invest. 2010; 120(7):2395–405. doi: 10.1172/JCI42011 PMID: 20530874; PubMed Central PMCID:
PMC2898601.
34. Wang L, Harrington L, Trebicka E, Shi HN, Kagan JC, Hong CC, et al. Selective modulation of TLR4-
activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest. 2009; 119
(11):3322–8. doi: 10.1172/JCI39939 PMID: 19809161; PubMed Central PMCID: PMC2769199.
35. Chen J, Wei Y, He J, Cui G, Zhu Y, Lu C, et al. Natural killer T cells play a necessary role in modulating
of immune-mediated liver injury by gut microbiota. Scientific reports. 2014; 4:7259. doi: 10.1038/
srep07259 PMID: 25435303; PubMed Central PMCID: PMC4248284.
Iron Deficiency Impairs Intra-Hepatic Lymphocyte Response
PLOS ONE | DOI:10.1371/journal.pone.0136106 August 19, 2015 15 / 16
36. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, et al. T cell activation-associated
hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. The Journal of exper-
imental medicine. 1994; 179(5):1529–37. PMID: 8163936; PubMed Central PMCID: PMC2191474.
37. Klein C, Wustefeld T, Assmus U, Roskams T, Rose-John S, Muller M, et al. The IL-6-gp130-STAT3
pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. The Journal of clinical
investigation. 2005; 115(4):860–9. doi: 10.1172/JCI23640 PMID: 15761498; PubMed Central PMCID:
PMC1059450.
Iron Deficiency Impairs Intra-Hepatic Lymphocyte Response
PLOS ONE | DOI:10.1371/journal.pone.0136106 August 19, 2015 16 / 16

172 
Appendix C: Paper: Molecular Characterization of Acute 
Cellular Rejection Occurring During Intentional 
Immunosuppression Withdrawal in Liver Transplantation. 
Molecular Characterization of Acute Cellular Rejection
Occurring During Intentional Immunosuppression
Withdrawal in Liver Transplantation
E. Bonaccorsi-Riani1,†, A. Pennycuick1,†,
M.-C. Londo~no2, J.-J. Lozano3, C. Ben!ıtez2,
B. Sawitzki4, M. Mart!ınez-Picola2, F. Bohne5,
M. Mart!ınez-Llordella1, R. Miquel1, A. Rimola2
and A. S!anchez-Fueyo1,2,*
1Department of Liver Studies, Division of Transplantation
Immunology and Mucosal Biology, Medical Research
Council Centre for Transplantation, Faculty of Life
Sciences and Medicine, King’s College London University,
King’s College Hospital, Denmark Hill, London, UK
2Liver Unit, Hospital Clinic Barcelona, Institut d’
Investigacions Biomedicas August Pi i Sunyer (IDIBAPS),
Networked Biomedical Research Centre of Hepatic and
Digestive Diseases (CIBERehd), University of Barcelona,
Barcelona, Spain
3Bioinformatics Platform, CIBEREHD, Barcelona, Spain
4AG Transplantationstoleranz, Charite Universit€atsmedizin,
Institut f€ur Med. Immunologie, Berlin, Germany
5Institute of Virology, Technische Universit€at M€unchen/
Helmholtz Zentrum M€unchen, Munich, Germany
!Corresponding author: Alberto Sanchez-Fueyo,
sanchez_fueyo@kcl.ac.uk
†Contributed equally.
Acute cellular rejection occurs frequently during the
first few weeks following liver transplantation. During
this period, its molecular phenotype is confounded by
peri- and postoperative proinflammatory events. To
unambiguously define themolecular profile associated
with rejection, we collected sequential biological
specimens from 55 patients at least 3 years after liver
transplantation who developed rejection during trials
of intentional immunosuppression withdrawal. We
analyzed liver tissue and blood samples obtained
before initiation of drug withdrawal and at rejection,
alongside blood samples collected during the weaning
process. Gene expression profiling was conducted
using whole-genome microarrays and real-time poly-
merase chain reaction. Rejection resulted in distinct
blood and liver tissue transcriptional changes in
patients who were either positive or negative for
hepatitis C virus (HCV). Gene expression changeswere
mostly independent from pharmacological immuno-
suppression, and their magnitude correlated with
severity of histological damage. Differential expression
of a subset of genes overlapped across all conditions.
These were used to define a blood predictive model
that accurately identified rejection in HCV-negative,
but not HCV-positive, patients. Changes were detect-
able 1–2 mo before rejection was diagnosed. Our
results provide insight into the molecular processes
underlying acute cellular rejection in liver transplanta-
tion and help clarify the potential utility and limitations
of transcriptional biomarkers in this setting.
Abbreviations: ABMR, antibody-mediated rejection;
ACR, acute cellular rejection; AKI, acute kidney injury;
ALT, alanine aminotransferase; AST, aspartate amino-
transferase;AUC, areaunder the curve; CNI, calcineurin
inhibitor; CSA, cyclosporin A; DSA, donor-specific
antibody; FC, fold change; FDR, false discovery rate;
GGT, g-glutamyltransferase; GSEA, gene set enrich-
ment analysis; HBV, hepatitis B virus; HCV, hepatitis C
virus; IFN-g, interferon-g; IS, immunosuppression;
MSigDB, Molecular Signatures Database; MMF, myco-
phenolate mofetil; mTOR, mammalian target of rapa-
mycin; NA, not available; NES, normalized enrichment
score; PCR, polymerase chain reaction; TAC, tacroli-
mus; TCMR, T cell–mediated rejection; Tx, transplant
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Introduction
Over the past three decades, liver transplantation has
become an accepted and well-standardized treatment for
end-stage liver disease. Together with improvements in
surgical techniques, intensive care and infection control, the
development of efficient immunosuppressant drugs has
been instrumental in increasing patient and graft survival
rates (1). Acute cellular rejection (ACR) remains a frequent
event, particularly early after liver transplantation,with recent
series reporting incidenceof"30% (2–4). Provideddiagnosis
is made early, ACR can be easily controlled with additional
immunosuppressive medication and does not have negative
prognostic implications. If unchecked, it can induce irrevers-
ible graft damage and thus remains a key consideration in
the differential diagnosis of liver allograft dysfunction. This
results in the need to closely monitor transplant recipients
and to conduct confirmatory liver biopsies, which are
cumbersome and incur substantial costs.
In kidney transplantation, molecular profiling techniques
have been widely used to clarify the pathophysiology of
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ACR and to develop novel diagnostic tools. In contrast,
very few studies have attempted to comprehensively
characterize ACR in liver transplantation; therefore, the
molecular features of clinical liver allograft rejection remain
only partially understood.
Molecular profiling studies in liver transplantation are
complicated by the fact that ACR overwhelmingly occurs
during the first 2–3 weeks after transplantation, during
which time (1) allograft function is often abnormal as a
consequence of inflammatory liver damage induced by
reperfusion injury and surgical complications, and (2) a
substantial proportion of liver recipients develop spontane-
ously resolving subclinical rejection episodes that are not
detected unless protocol liver biopsies are conducted.
Unambiguously defining rejection-associated molecular
changes remains challenging in this scenario. Trials of
intentional immunosuppression withdrawal in selected
stable liver recipients provide a unique opportunity to
thoroughly characterize the immunobiology of rejection
because the medical intervention and the initiation of the
rejection response can be timed, potential confounders can
be adequately controlled, and sequential biological speci-
mens including liver biopsies are typically obtained. In the
current study, we analyzed sequential blood and liver tissue
specimens collected from adult liver transplant recipients
enrolled in two multicenter clinical trials of immunosup-
pression withdrawal. We were able to identify rejection-
specific gene expression markers in these cohorts.
Furthermore, we showed that gene expression changes
preceded the clinical diagnosis of ACR and could be used
as a predictive tool in this clinical scenario.
Patients and Methods
Patient population and study design
A total of 136 stable liver transplant recipients at least 3 years after liver
transplantation were enrolled in two prospective multicenter clinical
trials of immunosuppression withdrawal. The first trial (ClinicalTrials.gov
NCT00647283) (5) enrolled 102 patients, 12 of whom had hepatitis C virus
(HCV) infectionwith detectable HCVRNA. The second trial (ClinicalTrials.gov
NCT00668369) enrolled 34 patients, all whom were HCV RNA positive (6).
Identical drug withdrawal protocols were used in the two studies and have
been described previously (5,6) (Figure 1). Briefly, immunosuppressive drug
doses were gradually tapered by reducing approximately one-quarter to half
of the doses every 3 weeks until complete discontinuation over a 6- to 9-mo
period. Patients were then followed-up for at least 12 additional months.
Protocol liver biopsy samples were obtained in all patients at baseline, at
12 mo after successful drug withdrawal in patients who did not reject, or at
time of rejection. Blood samples were taken at enrollment, every 3 weeks
during the withdrawal period, at the rejection episode, and monthly during
the 12 mo after drug cessation or after resolution of the rejection episode.
Patients who did not develop rejection were classified as operationally
tolerant as long as immunosuppressive drug cessation was maintained for
at least 12 mo and no histological evidence of acute and/or chronic rejection
was observed. Rejection was diagnosed by the combination of allograft
dysfunction and characteristic liver biopsy findings according to Banff
criteria (7).
In the first trial, drug withdrawal was successfully achieved in 41 patients,
whereas 57 rejected. In the second trial, withdrawal was successful in
17 patients and rejection occurred in 15. Rejection episodes were
predominantly mild to moderate and resolved promptly following reinstitu-
tion of immunosuppression. No grafts were lost due to rejection. For the
current study, we analyzed sequential samples collected from 55 rejecting
recipients, 9 of whom were HCV RNA positive (Table 1). In addition, we
collected blood samples from a cohort of 86 stable immunosuppressed liver
recipients who were matched for age, sex and time from transplantation,
with no biochemical evidence of rejection and in whom no attempts at drug
withdrawal were performed. Nine early posttransplant rejection biopsies,
collected from HCV-negative patients within the first 4 weeks following
transplantation and outside the drug-withdrawal setting, were included as a
control cohort. Finally, we reanalyzed previously generated gene expression
data derived from baseline blood samples from a subset of 25 tolerant
recipients.
Figure 1: Flow chart showing immunosuppressionwithdraw-
al trial design. Data were included from two trials with identical
withdrawal protocols (ClinicalTrials.gov NCT00647283 and
NCT00668369). A subset of these patients was included in the
current study. HCV, hepatitis C virus.
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Biological specimens
Liver biopsies were taken before the initiation of the immunosuppressive
drug withdrawal protocol (baseline) and at the time of rejection. Histological
analysis was performed including quantitative measurements obtained for
lobular inflammation, central vein perivenulitis, central vein endothelitis,
portal inflammation, interface hepatitis, bile duct lesions, ductular reaction,
ductopenia, portal vein endothelitis, perisinusoidal fibrosis and portal
fibrosis. Blood samples were collected at enrollment, at each drug dose
modification (every 3 weeks), at the time rejection was diagnosed,
andmonthly during the year after rejection or complete drug discontinuation.
For the current study, sequential blood and liver tissue specimens were
made available from 77 and 33 patients, respectively. RNA was extracted
from tissue and blood samples, as described in the Supplementary
Methods.
Liver tissue and blood microarray gene expression experiments
Transcriptional profiling of liver tissue sampleswas conducted using Illumina
microarrays. Forty liver tissue RNA samples (preweaning and rejection time
points) from 20 patients (13 HCV-negative and 7HCV-positive patients) were
profiled, as described in the Supplementary Methods.
RNA extracted from blood samples was analyzed on a custom Agilent
complementary DNA microarray containing probes for 5069 preselected
immunology-related transcripts (8). Seventy-four blood samples (37 prewean-
ing blood samples and 37 rejecting blood samples) from 37 nontolerant
HCV-negative patients were analyzed. Data acquisition and normalization
methods are described in the SupplementalMethods. Analysis for differential
expression on a probe basis was done by limma, including correction for
multiple testing using the false discovery rate (FDR) method.
We defined statistically significant differences in gene expression as those
showing fold change (FC)>1.2 and FDR<0.05. To compare expression data
across different microarray platforms (i.e. blood vs liver tissue), a lower
threshold of significance was used (FC >1.2 and p-value <0.01).
Gene set enrichment analysis
To assess the functional pathways associatedwith ACR,we used a gene set
enrichment analysis (GSEA) application (9,10). This tool compares differen-
tially expressed genes with previously identified gene sets. Three different
gene set databases were used for our analyses: (1) the Hallmark gene sets
from the Molecular Signatures Database (MSigDB) at the Massachusetts
Institute of Technology Broad Institute (10), with 50 gene sets mapped to
known biological processes; (2) the HaemAtlas gene set database (11),
which contains gene sets preferentially expressed by specific peripheral
blood cell subsets (CD4, CD8, CD19, CD14, CD56, CD 66B, EB, MK); and (3)
pathogenesis-based transcript gene sets, which have been associated with
different subtypes of rejection in both experimental animal models and
human kidney and heart allografts (http://atagc.med.ualberta.ca/Research/
GeneLists/Pages/default.aspx) (12,13). The full list of gene sets used is
shown in Table 3 and Table S2. All analyses were performed using the
GSEAPreranked tool, based on t-statistic and a weighted scoring scheme
with 1000 permutations.
Correlation between gene expression and liver histopathology
To investigate which histological compartment contributed to the rejection-
associated transcriptional changes, we correlated histopathology data
with complete liver tissue microarray data. We used a set of 80 biopsy
samples from which full quantitative histological data could be uniquely
mapped to tissue microarray data. This included 21 samples taken at
the point of rejection, 57 biopsies obtained prior to weaning, and two follow-
up samples from tolerant patients 1 year after cessation of immunosup-
pression. Quantitativemeasurementswere available for each of 11 available
histological parameters. Each parameter was graded from 0 to 3 for
each sample. For each parameter, differentially expressed genes were
identified using the limma bioconductor package. A linear regression
model was constructed to correlate gene expression with severity of that
parameter.





Age at transplant (years) 48.23" 11.73
Age at weaning start (years) 55.53" 11.83










Time from transplant to weaning start (years) 6.83" 3.55
Time from weaning start to rejection (months) 7.82" 4.49





Cyclosporin A þ mycophenolate 5
CNI-based immunosuppression at weaning start (%) 85
Immunosuppressive drug trough levels
at weaning start (ng/ml)
Tacrolimus 5.2" 2.3
Cyclosporin A 57.4" 36
Liver function tests at weaning start
AST (U/l) 33" 22
ALT (U/l) 38" 35
GGT (U/l) 40" 70
Alkaline phosphatase (U/l) 172" 64






Banff score$ 4 (2–9)
Liver function tests at rejection time
AST (U/l) 150" 137
ALT (U/l) 207" 196
GGT (U/l) 188" 208
Alkaline phosphatase (U/l) 287" 173
Total bilirubin (mg/dl) 1.55" 4.51
Rejection treatment
Baseline IS 23
Baseline IS þ prednisone 20mg/day (4–6 weeks) 26
Baseline IS þ prednisone 40–60mg/day (4–6 weeks) 4
Corticosteroids boluses 2
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CNI,
calcineurin inhibitor; GGT, gglutamyltransferase; HBV, hepatitis B virus;
HCV, hepatitis C virus; IS, immunosuppression.
$Banff score is expressed as median (range).
Data are expressed as mean" standard deviation.
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Influence of type of immunosuppression on gene expression
patterns
We assessed the influence of immunosuppression (tacrolimus, TAC;
cyclosporine A, CSA; mycophenolate mofetil, MMF) on baseline gene
expression profiles by constructing linear regression models that explored
the impact of each type of immunosuppression on the blood (n¼ 72) and
liver tissue (n¼ 33) microarray data, using the limma bioconductor package.
Validation real-time polymerase chain reaction experiments in
peripheral blood samples
Quantitative real-time polymerase chain reaction (PCR) gene expression
experiments were performed using a Fluidigm Biomark HD system, fully
described in the SupplementaryMethods. The gene expression profiles of 45
target genes plus two housekeeping genes (Table S1) were quantified in 21
paired blood samples (collected at baseline and at the time of rejection) from
14 HCV-negative and 8 HCV-positive patients. An additional group of blood
samples collected from 86 stable immunosuppressed liver recipients with no
biochemical evidence of rejection was used for comparative purposes. To
define a gene expression signature predictive of rejection, we performed a
multivariate logistic regression analysis incorporating all Fluidigm gene
expression data in the set of paired samples from the group of HCV-negative
patients. The best gene model was used to compute the risk probability of
rejection in thebloodsamplescollected fromthesamepatientsbut atdifferent
intervals and in all available blood samples from the remaining patients.
In addition to the Fluidigm analyses, we conducted additional real-time PCR
experiments as part of the biomarker portfolio studies dictated by the
Reprogramming the Immune System for the Establishment of Tolerance
(RISET) European consortium. These experiments used an Applied
Biosystem real-time PCR platform and quantified the expression of CD3,
FOXP3,MAN1A1, PRF1, and TOAG-1 in blood samples collected before the
initiation of weaning.
Identification of predictive signatures of rejection
We used multivariate logistic regression to identify gene signatures
predictive of rejection among the 45 genes analyzed by Fluidigm real-time
PCR. A training set of 14 nontolerant patients from whom Fluidigm data
were available both at baseline and at the point of rejection (total samples
n¼ 28) was initially assessed. Given the small number of samples available,
the analysis was restricted to signatures containing up to two genes. The
regression algorithm used is defined in the varSelec method of the MMIX
bioconductor package.
Following variable selection, a generalized linear model was generated using
the glm method of the R statistical package (R Foundation for Statistical
Computing), using the 28 paired samples to classify a given sample into a
rejection or nonrejection (baseline) group. Internal cross-validation was
performed using the boot R package. This model was then applied to
additional samples to generate a probability of being rejection sample. When
applied to samples frompatients not exhibiting clinically apparent rejection,we
defined themodel as giving a ‘‘correct’’ result if the probability of rejectionwas
<50% and an ‘‘incorrect’’ result if predicted rejection with >50% probability.
Results
Acute cellular rejection is associated with a common
transcriptional signature regardless of the presence
of underlying liver inflammation
To identify the transcriptional patterns most highly associ-
ated with ACR, we conducted a paired microarray analysis
comparing baseline (preweaning) liver tissue samples with
those obtained at the time of rejection in patients with or
without HCV infection (7 and 13, respectively). In HCV-
negative recipients, rejection was associated with statisti-
cally significant changes in 34 transcripts. The impact of
rejection was more substantial in HCV-positive recipients,
in whom it significantly modified the expression of 408
genes. HCV-positive and -negative recipients shared a
common set of 19 genes (Figure 2, Table 2).
We explored functional pathways more highly associated
with ACR using GSEA. We compared our data with
Hallmark gene sets from MSigDB to identify high-level
functional pathways. Differentially expressed genes were
involved in a variety of pathways related to, among others,
inflammatory response, interferon signaling, IL-6/JAK/
STAT3 signaling and apoptosis (Table S2). We next
explored the overrepresentation of pathogenesis-based
transcript gene sets, which were previously validated in
kidney and heart human allografts (12,14–21). Liver
samples with ACR showed significant overlap with gene
sets associatedwith T cell–mediated rejection in kidney and
heart transplantation, with infiltrating macrophages and
effector T lymphocytes being the principal cell subsets
involved. ACR was also associated with enrichment in
transcripts related to B cells and donor-specific antibodies
(DSAs), although the signal was weaker than for T cell–
associated transcripts (Table 3).
To confirm the specificity of our results for ACR, we
compared our 13 HCV-negative patients with 9 early
posttransplant rejection biopsies all taken from HCV-
negative patients within the first 4 weeks after transplanta-
tion. Although the two cohorts of rejecting patients (i.e.
those enrolled in the weaning study and those developing
ACR shortly after transplantation) differed in the expression
of 213 genes, no differences were noted in the expression
of the 19 genes associated with rejection across all
conditions (Figure 2C). Furthermore, GSEA revealed
enrichment in similar functional pathways (Table S3).
Histological features of rejection correlate with
specific gene expression changes
Liver ACR is characterized by portal and, sometimes,
lobular inflammation, portal tract nonsuppurative cholan-
giolitis and portal and/or central vein subendothelial
inflammation. To identify the main histological drivers of
transcriptional patterns associatedwith ACR,we correlated
gene expression profiles with quantified histological data
(Table 4, Table S4). Table 4 shows the distribution of
histological damage in our cohort and the number of genes
for which expression was significantly correlated with
severity of damage (FC >1.2, FDR <0.05).
We observed a correlation between the magnitude of
histological damage in each histological compartment and
expression of a set of 423 genes mostly associated with
Bonaccorsi-Riani et al
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inflammation and rejection. The genes expressed were
relatively homogeneous across histological compart-
ments; however, the signal was much stronger in acute
inflammatory processes such as lobular inflammation,
portal inflammation and interface hepatitis (Figure 3,
Table S4).
We used GSEA to investigate the functional pathways
driving these histological processes (Table S5). Again, this
demonstrated homogeneity across histological compart-
ments, with inflammatory and rejection-associated path-
ways upregulated across all compartments (with the
exception of ductopenia, which was a very infrequent
finding and thus could not be adequately explored).
Within the group of rejection biopsies, the overall severity
of rejection as defined by the Banff Rejection Activity
Index (7) was not associated with significant differential
gene expression (based on 20 biopsies with complete
rejection activity index data) (data not shown).
Acute cellular rejection results in distinct
transcriptional changes in blood that only partially
overlap with those observed in the liver allograft
We used the same exploratory approach described above
to identify ACR-associated transcriptional patterns in whole
blood. This was conducted in paired baseline/rejection
samples from 37 HCV-negative patients, with a custom
Agilent microarray. Overall, 293 differentially expressed
genes were identified with FDR <0.05 and FC >1.2
(Figure 4). Functional analysis usingGSEAwith theMSigDB
Hallmark gene sets showed similar pathways to be
upregulated in blood and liver tissue, although the signal
was weaker in blood than in tissue (Table 3). Additional
analyses usingHaemAtlas gene sets (11) revealed that ACR
was significantly associated with transcripts preferentially
expressed by CD14-positive cells (monocytes). In contrast,
transcripts associated with CD8 (cytotoxic T cells) and
CD66B (granulocytes) cells were significantly downregu-
lated at the time of rejection. No other blood cell types
significantly contributed to the rejection-associated tran-
scriptional pattern. A small group of 22 genes, mostly
related to immune response and cell cycle control (e.g.
CXCL9, CXCL10, CNPM, CDC20, CCNB2, and CD74),
were significantly associated with ACR in both blood and
liver tissue samples (Figure 5).
The expression of ACR-associated markers at
baseline does not predict the outcome of
immunosuppression discontinuation
TodeterminewhetherACR-specificgenesweredifferentially
expressed between tolerant and nontolerant liver recipients
Figure 2: Transcriptional changes associatedwith rejection in HCV-negative and -positive patients. (A) Venn displaying the number
of upregulated (red) or downregulated (green) genes at FDR <5% and FC >1.2 following limma analysis comparing liver tissue samples
obtained from HCV-negative and -positive patients at baseline (before IS weaning) and at the time of rejection. (B) Heat map displaying the
common set of 19 significantly expressed genes (FC>1.2 and FDR<0.05) comparing baseline (preweaning) liver tissue sampleswith those
collected at time of rejection in HCV-negative and -positive patients. (C) Heat map showing the 19-gene set in HCV-negative patients
undergoing weaning and in HCV-negative patients developing rejection shortly after transplantation.HLA-DRA is excluded due to poor data
quality in the control group. ACR, acute cellular rejection; FC, fold change; FDR, false discovery rate; HCV, hepatitis C virus; IS,
immunosuppression; Tx, transplant.
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before immunosuppression weaning was initiated, we
reinterrogated a previously described Affymetrix micro-
array gene expression database generated with blood
samples collected at baseline (before the initiation of
weaning) from 43 nontolerant and 25 tolerant liver
recipients (22). At baseline, none of the ACR-associated
gene expression markers differed between patients who
eventually rejected and those who successfully discon-
tinued immunosuppression (data not shown). In addition
to the microarray data, we quantified the expression of
CD3, FOXP3, MAN1A1, PRF1, and TOAG-1, which were
part of the RISET consortium biomarker portfolio and had
been previously assessed in the setting of kidney
transplantation (8,23). Foxp3 expression, which was
upregulated in tolerant recipients, was the only marker
differentially expressed between the tolerant and non-
tolerant recipients at baseline (Figure 6).
Pharmacological immunosuppression has a minimal
impact on rejection-associated gene expression
changes in both blood and liver tissue
We explored the transcriptional impact of specific immu-
nosuppressive drugs to investigate the extent to which
pharmacological immunosuppression could act as a con-
founder in the analyses. The type of immunosuppressive
agent did not influence liver tissue gene expression.
Analyses of blood gene expression patterns revealed no
differences between patients on tacrolimus monotherapy
versus cyclosporin A monotherapy. In contrast, a set of
17 genes was differentially expressed between patients on
calcineurin inhibitor monotherapy and patients on mycopheno-
latemofetilmonotherapy (Table5), but onlyeightwere included
in the set of 293 genes associated with ACR (LOC652494,
ENST00000359488, LOC100132941, ENST00000377226,
C13ORF33, A_24_P110487, ENST00000322032, SPTA1).
Sequential gene expression profiling in blood
samples during the immunosuppression withdrawal
process predicts the development of rejection
To investigate whether changes in rejection-associated
transcriptional markers precede the clinical diagnosis of
ACR and could be used as a predictive tool, we quantified
the expression of a set of 45 target genes in sequential
blood samples collected from 14 HCV RNA–negative and
8 HCV RNA–positive recipients. A mean of six sequential
blood samples collected before the diagnosis of rejection
were available per patient. Univariate analysis of blood
samples collected at baseline and at time of rejection
revealed that eight and two genes were significantly
upregulated at the time of rejection in HCV-negative and
-positive patients, respectively (Table 6). Using stepwise
multivariate logistic regression, we identified CXCL10
plus FOXP3 as the best combination of markers discrimi-
nating between rejection and baseline blood samples in
Table 2: Liver tissue gene expression markers associated with acute cellular rejection











CXCL9 Chemokine (C-X-C motif) ligand 9 3.214 0.002 3.241 1.42 x 10!6
GPNMB Glycoprotein (transmembrane) nmb 1.779 0.006 1.832 0.001
HLA-DMA Major histocompatibility complex, class II, DM alpha 1.573 0.027 1.764 0.001
SLC1A3 Solute carrier family 1 (glial high affinity glutamate transporter),
member 3
1.572 0.027 1.854 0.001
HLA-DRA Major histocompatibility complex, class II, DR alpha 1.529 0.027 1.734 0.001
ITM2A Integral membrane protein 2A 1.554 0.027 1.615 0.003
HLA-F Major histocompatibility complex, class I, F 1.520 0.041 1.605 0.004
HLA-DQB1 Major histocompatibility complex, class II, DQ beta 1 1.615 0.008 1.607 0.005
ANXA2 Annexin A2 1.556 0.032 1.743 0.006
UBD Ubiquitin D 3.370 0.002 1.678 0.009
CD83 CD83 molecule 1.615 0.008 1.667 0.009
FABP5 Fatty acid binding protein 5 (psoriasis-associated) 2.105 0.002 1.625 0.011
CD2 CD2 molecule 1.480 0.034 1.503 0.013
PLA2G7 Phospholipase A2, group VII 1.631 0.013 1.454 0.022
RFX5 Regulatory factor X, 5 (influences HLA class II expression) 1.419 0.029 1.403 0.026
IL8 Interleukin 8 1.549 0.021 2.194 0.029
IL32 Interleukin 32 1.848 0.006 1.537 0.031
CXCL10 Chemokine (C-X-C motif) ligand 10 3.738 0.002 1.485 0.039
TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 1.651 0.027 1.363 0.047
Table 2 shows the 19 common differentially expressed genes in HCV-negative and -positive recipients when comparing liver samples at rejection
timewith liver samples collected before the start the ISwithdrawal. FC>1.2, FDR<5%, p< 0.001. FC, fold change; FDR, false discovery rate; HCV,
hepatitis C virus.
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Table 3: Pathogenesis-based transcript sets significantly enriched in liver allograft rejection–associated transcriptional patterns (GSEA)









GRIT1 Human orthologs of IFN-g dependent, rejection associated transcripts
defined in mice; expressed in TCMR, especially in association with
AMAT1
(17) 19 2.64 0.00# 2.42 0.00#
QCMAT Macrophage associated transcripts defined in purified cell lines,
associated with TCMR in kidney patients
(16) 45 2.54 0.00# 2.34 0.00#
QCAT Transcripts associated with cytotoxic T lymphocytes, defined in purified
cell lines; associated with TCMR in renal transplants, with expression
levels correlating with T cell infiltration
(15) 21 2.48 0.00# 2.44 0.00#
IRITD3 Injury and rejection induced transcripts upregulated day 3 after isograft
transplant (humanized results from mouse model)
(39) 173 2.30 0.00# 2.60 0.00#
IRITD5 As for IRITD3, measured on day 5. (39) 133 2.25 0.00# 2.68 0.00#
CIRIT Cardiac injury- and repair-induced transcripts, expressed following heart
isograft transplant; mouse data extrapolated to humans
(40) 174 2.20 0.00# 2.22 0.00#
IRRAT Injury-repair response associated transcripts, defined in early renal
transplants with no rejection, derived as a model for AKI
(39) 22 2.05 0.00# 1.67 0.00#
BAT B cell–associated transcripts, derived from purified B cells; upregulated in
both ABMR and TCMR
(19) 55 1.97 0.00# 2.15 0.00#
DSAST DSA-positive–specific transcripts derived from comparative analysis of
DSA with and without renal biopsies; observed in both ABMR and
TCMR with much higher levels in ABMR
(18) 15 1.64 0.01# 1.18 0.29
HTS Heart-selective transcripts derived from control mice without
inflammation present
(40) 385 1.54 0.03# 1.59 0.01#
TCB T cell–specific transcripts based on purified cell lines (21) 4 1.47 0.04# 1.66 0.00#
ENDAT Endothelial cell associated transcripts derived from purified cell lines;
increased in ABMR and TCMR with higher levels in ABMR
(20,41) 81 1.46 0.04# 2.23 0.00#
NKB Natural killer cell–specific transcripts derived from purified cell lines;
identified in early TCMR and late ABMR in renal patients
(21) 3 1.43 0.05 1.04 0.43
IGT Immunoglobulin associated transcripts, observed in both ABMR and
TCMR
(19) 4 1.36 0.08 1.57 0.01#
AMAT1 Alternative Macrophage Associated Transcript 1; human orthologs of
mouse data; high GRIT1 plus AMAT1 scores correlate with TCMR
(16) 6 1.31 0.12 1.73 0.00#
MCAT Mast cell associated transcripts, associated with scarring and poor
survival in renal transplants
(22) 3 !0.80 0.78 1.13 0.32
ABMR, antibody-mediated rejection; AKI, acute kidney injury; DSA, donor-specific antibody; FDR, false discovery rate; GSEA, gene set
enrichment analysis; IFN-g, interferon-g; NES, normalized enrichment score; TCMR, T cell–mediated rejection.
#Significance threshold based on FDR <0.05
1Size is the number of transcripts in the gene set.
2NES as calculated by GSEA software (http://www.broadinstitute.org/gsea/doc/GSEAUserGuideTEXT.htm#_Interpreting_GSEA_Results).
Table 4: Differential gene expression by histological compartment
No. of patients by severity level
Histological compartment 0 1 2 3 Gene count
Lobular inflammation 29 34 15 0 354
Portal inflammation 17 33 21 2 223
Interface hepatitis 44 23 10 0 284
Central vein perivenulitis 53 12 4 0 10
Endothelitis central vein 0 3 0 0 1
Endothelitis portal veins 54 16 3 1 4
Bile duct lesions 51 19 3 1 16
Ductular reaction 50 20 0 0 0
Ductopenia 76 3 0 0 4
Perisinusoildal fibrosis 52 8 5 0 0
Portal fibrosis 29 24 21 2 31
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HCV-negative patients (cross-validated area under the
curve [AUC] 0.82). When using this signature in all
sequentially collected blood samples, we observed that
the probability of ACR progressively increased with time,
with a peak that coincided with the time of the diagnosis of
biopsy-proven ACR and a rapid decline following reinstitu-
tion of robust immunosuppression (Figure 7A). CXCL10
plus FOXP3 expression correctly predicted the absence of
rejection in 81% of 86 liver recipients with stable graft
function under immunosuppression 3–10 years after
transplantation. In contrast, this model failed to correctly
classify 70% of 57 blood samples sequentially collected
from seven tolerant liver recipients who were successfully
weaned from immunosuppression. Given the well-known
influenceof calcineurin inhibitors onFOXP3expression (24),
we repeated the logistic regression analysis excluding
FOXP3. This resulted in CXCL10 alone being selected as
the most robust predictor. CXCL10 accurately classified
rejecting samples with a cross-validated AUC of 0.76 and
correctly predicted absence of rejection in 79% of stable
patients and 67% of samples from tolerant patients
(Figure 7C). The probability of rejection as predicted by
CXCL10 expression increased 1–2 mo prior to rejection
being clinically apparent and a liver biopsy considered
indicated. A detailed analysis of the kinetics of liver function
tests, however, revealed that the changes in CXCL10
expression mirrored mild but gradually increasing changes
in g-glutamyltransferase, aspartate aminotransferase and
alanine aminotransferase occurring over the same time
period (Figure 7D). In contrast to these results observed in
Figure 3: Differentially expressed genes across histological compartments. (A) Clustered heat map demonstrating all genes
significantly differentially expressed across histological compartments (fold change >1.2 and false discovery rate <0.05 in at least one
compartment). Analysis performed in limma comparing gene expression against quantified severity score for each histological parameter.
Red indicates upregulation, green indicates downregulation. (B) Venn diagramshowing the number of genes differentially expressed in each
histological compartment and demonstrating overlap between compartments.
Figure 4: Differentially expressed genes in whole blood. Heat
map of the top 50 genes differentially expressed in whole blood
based on t-statistic comparing paired baseline (preweaning) and
rejection samples. All patients were negative for hepatitis C virus.
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HCV-negative recipients, a gene expression model with
adequate diagnostic performance could not be generated
from the 45-gene PCR expression data set in the cohort of
seven recipients with active HCV infection (data not
shown).
Discussion
The identification of reproducible noninvasive biomarkers
of graft rejection remains an important area of research
in organ transplantation. In kidney transplantation, the
molecular profiles associated with allograft rejection
have been comprehensively defined, and results from
single- and multicenter studies have shown that specific
biomarkers, in particular, mRNAs, can be useful diagnostic
tools. In contrast, in liver transplantation, the field is
much less developed, and our understanding of the
predictive accuracy and specificity of molecular biomarkers
in different biological specimens is incomplete.
Similar to other organ transplantation settings, our micro-
array experiments revealed that there are transcriptional
differences between rejecting and nonrejecting liver
allografts. Many genes identified in our study are well
studied in the context of transplant rejection and corre-
spond to functional networks known to be associated with
rejection, such as nuclear factor-kB, STAT1/interferon-g,
tumor necrosis factor-a, chemokine receptor networks and
immune effector networks (25). In particular, the set of 19
genes that we identified in tissue samples in both HCV-
positive and -negative patients includes genes previously
associated with rejection in kidney (CXCL9, HLA-DMA,
IL32, CXCL10, HLA-F, CD2) (26,27), in lung (ITM2A, IL8,
IL32) (28), and in heart transplantation (CXCL9, HLA-F,
CXCL10) (29). Ameta-analysis by Spivey et al (25) identified
330 genes known to be differentially expressed in rejection
tissue samples across a variety of transplanted organs,
including liver, kidney, heart and lung. From our set of 19
genes, 12 were previously identified (CXCL9, HLA-DMA,
HLA-DRA, ITM2A, HLA-F, HLA-DQB1, UBD, CD2, IL8,
Figure 5: Significantly expressedgenes in liver tissues and in PBMCof HCV-negative patients. Heatmaps displaying the commonset
of 22 significantly expressed genes (fold change >1.2 and false discovery rate <0.05) when comparing baseline (preweaning) liver tissue
samples (A) with those collected at the time of rejection in HCV-negative patients and in PBMC samples (B) at the same time points for the
same patient groups. HCV, hepatitis C virus; PBMC, peripheral blood mononuclear cells.
Figure 6: Baseline acute cellular rejection–associated gene expression in nontolerant and tolerant patients. Graphics showing the
quantitative gene expression of five genes included in the Reprogramming the Immune System for the Establishment of Tolerance (RISET)
consortium biomarker portfolio performed at baseline (preweaning) in 43 nontolerant and 25 tolerant patients. No-Tol, nontolerant; Tol,
tolerant. !p<0.05.
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IL32, CXCL10, TAP1), whereas seven were unique to our
study (GPNMB, SLC1A3, ANXA2, CD83, FABP5, PLA2G7,
RFX5).
Specific to the liver, Sreekumar et al identified a gene
signature associated with ACR in HCV-positive patients
(30). This study highlighted the difficulties of differentiating
ACR from HCV histopathologically. Our HCV-positive
results implicate many of the same pathways (e.g. MHC,
ubiquitin), if not exactly the same genes. The large number
of differentially expressed genes in HCV-positive patients
relative to HCV-negative patients in our study supports
previous data showing a significant interaction between
HCV infection and alloimmune responses at a molecular
level (6). The identification of ACR-specific genes indepen-
dent of HCV infection, however, supports the conclusion
of Sreekumar et al that molecular profiling could be useful
to aid in this difficult histopathological diagnosis.
T cell–related transcripts were more highly differentially
expressed in the liver at the time of ACR. These findings
indicate that at the transcriptional level, liver allografts
respond to T cell–mediated rejection (TCMR) similarly to
what has been described for other organs, particularly
kidneys. A significant association, however, was also found
with genes known to be overexpressed in kidney allografts
exhibiting antibody-mediated rejection (ABMR; i.e. B cells
and natural killer cells). This is not entirely surprising, given
that the transcriptional differences between TCMR and
ABMR in kidney transplantation are more quantitative
than qualitative (i.e. pathways described as being specific
for ABMR are also observed, albeit with a weaker signal,
in the setting of TCMR). This observation will need to be
considered if transcriptional profiling is ever used to provide
pathogenic guidance in the analyses of liver allograft
biopsies exhibiting mixed or unclear histological pheno-
types. In contrast to the liver tissue transcriptome results, T
cell–related transcripts were decreased in blood at the
time of ACR. We hypothesize that this is due to the well-
known homing of T cells, particularly CD8þ T cells, to the
transplanted organ at the time of allograft rejection (31).













TAC 18 0 29 0 12 0
CSA 14 23 11
CNI monotherapy 32 0 52 171 23 NA
MMF monotherapy 6 12 0
CNI monotherapy 32 0 52 12 23 33
CNI þ MMF 6 8 6
mTOR inhibitor 2 134 0 NA 2 35
Other therapies 44 72 29
CNI, calcineurin inhibitor; CSA, cyclosporin A;MMF,mycophenolatemofetil;
mTOR, mammalian target of rapamycin; NA, not available; TAC, tacrolimus.
1FA2H,SPTA1,TFPI, ENST00000322032,C13ORF33, LOC653513;LOC727893;
LOC727927;LOC727942;LOC728802;PDE4DIP;XXYAC-YX155B6.2, CCNF,
POGK, SLFN12, LOC652494, ENST00000359488, LOC100132941,
ENST00000377226, IGJ, A_24_P110487, LOC644538, PTPRF.
2IFNA2.
3CENPM, EZH2, PARVG.
4TIMD4, GDF15, FOS, IL8, CXCR7, MELK, CETP, JUN, EZH2, CIDEC, STAB2,
FOLR2, ZGPAT.
5CD74, TOP2A, HLA-DMA.
Table 6: Significantly differentially expressed genes at baseline vs
rejection based on univariate analysis of Fluidigm data














































HCV, hepatitis C virus.
#Significant difference between baseline and rejection (p < 0.05).
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In comparing ACR signatures in tissue and blood, we
acknowledge that the use of different microarray platforms
presents challenges in drawing firm conclusions. A
relatively low significance threshold was required for
between-platform analyses to extract meaningful data.
We note, however, that functional analyses were similar
between tissue and blood, supporting our findings of
overlapping transcriptional profiles.
Our histological analysis demonstrates a clear correlation
between severity of inflammatory histological damage and
expression of genes associated with inflammatory and
rejection processes. This is a homogeneous finding across
the different histological compartments, but the signal is
particularly striking in lobular and portal inflammation and
in interface hepatitis. Similar results have been reported
in renal patients, in whom expression of inflammatory
response genes correlates with the Banff scoring system
for histological rejection (32). It should be acknowledged
that the number of patients exhibiting severe central vein
endothelitis or ductopenia was small (Table 4). This is
because patients were very closely followed, and rejection
Figure 7: Prediction of rejection by sequential gene expression in blood samples. (A, B) Time evolution of risk probabilities based on
gene signatures for CXCL10 plus FOXP3 and CXCL10 alone, respectively. Both models show a peak coinciding with acute cellular rejection
biopsy-proven diagnosis (time 0), with a rapid reduction following reinstitution or reinforcement of IS. (C) Evolution of risk probabilities in
operationally tolerant patients up to and after complete withdrawal of immunosuppression (time 0), showing that CXCL10 plus FOXP3, but
not CXCL10 alone, misclassifies as rejecting 70% of blood samples. (D) Sequential risk probabilities based on gene signature models
alongside conventional LFTs (logarithmic scale). Risk increases gradually from !1–2 mo prior to rejection, mirroring a rise in LFTs. IS,
immunosuppression; LFT, liver function test.
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was diagnosed as soon as allograft dysfunction occurred.
Consequently, our ability to detect transcriptional signa-
tures for the most severe forms of rejection was limited.
CXCL10 and FOXP3 whole-blood expression warrants
further investigation as a potential biomarker for rejection,
although its utility in the setting of immunosuppression
withdrawal is questionable, given the influence of CNI on
FOXP3 expression. In this setting, CXCL10 alone is a more
robust marker, although it is noteworthy that this model
misclassified as rejecting 33% of blood samples collected
from tolerant liver recipients exhibiting no clinical signs of
rejection. We hypothesize that some of these misclassifi-
cations may reflect subclinical inflammation caused by the
withdrawal process that was not sufficiently severe to lead
to a diagnosis of rejection.
The clinical applicability of transcriptional biomarkers of
rejection in bloodwill need to be established in larger clinical
trials in which gene expression data are combined with
sequential liver function test measurements. We hope to
improve on diagnosis based on liver function tests alone,
which are neither sensitive nor specific for rejection (33). A
note of caution is warranted, however, considering that
blood gene expression was not sensitive enough to detect
rejection inpatientswithchronicHCV infection. Furtherwork
is required to identify other potential confounding factors.
Our study provides insight into the processes underlying
ACR in liver transplant patients. We observed significant
overlap with T cell–mediated rejection processes that are
well characterized in renal patients and identified charac-
teristic tissue and blood signatures specific to the liver.
Clinically, we demonstrated the potential utility of tran-
scriptional markers in peripheral blood as a predictor for
rejection. Although further work is required, these markers
could lead to more accurate diagnosis and reduce the need
for invasive biopsies.
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Table S1: List of gene expression markers assessed using
Fluidigmquantitative polymerase chain reaction experiments.
Table S2: Functional pathways significantly overrepresented
in liver allograft rejection–associated transcriptional patterns
(Hallmark pathways, Molecular Signatures Database; gene
set enrichment analysis).
Table S3: Comparison of functional pathways associated
with rejection in patients enrolled in withdrawal trials
against early posttransplant rejection outside of the trial
setting.
Table S4: Full list of genes differentially expressed in
different histological compartments, showing t-statistic.
Table S5: Functional pathways associated with severity of
different histological parameters. Analysis performed using
gene set enrichment analysis software against Hallmark
gene sets from the Molecular Signatures Database and
pathogenesis-based transcript sets from the University of
Alberta. Normalized enrichment score and false discovery
rate (FDR) are shown for each parameter. Significantly
enriched pathways (FDR <0.05) are highlighted.
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ABCB1 ATP-binding cassette, sub-family B member 1 
APOL3 Apolipoprotein L, 3 (APOL3), transcript variant beta/a, 
CCL19 Chemokine (C-C motif) ligand 19 
CCN2B Cyclin B2 
CD52 CD52 molecule 
CD74 CD74 molecule, major histocompatibility complex, class II invariant chain 
CD8A CD8a molecule (CD8A), transcript variant 2, mRNA. 
CDC20 Cell division cycle 20 
CECR1 Cat eye syndrome chromosome region, candidate 1 
CENPM Centromere protein M 
CXCL10 Chemokine (C-X-C motif) ligand 10 
CXCL9 Homo sapiens chemokine (C-X-C motif) ligand 9 
DHRS9 Dehydrogenase/reductase (SDR family) member 9 
DOCK11 Dedicator of cytokinesis 11 
EMILIN2 Elastin microfibril interfacer 2 
EZH2 Enhancer of zeste homolog 2 
FOXP3 Forkhead box P3 
GBP1 Guanylate binding protein 1, interferon-inducible 
GBP2 Guanylate binding protein 2, interferon-inducible 
GPNMB Glycoprotein (transmembrane) nmb 
GZMB Granzyme B 
GZMK Granzyme K (granzyme 3; tryptase II) 
HLA-DMA Major histocompatibility complex, class II, DM alpha 
HLA-DMB Major histocompatibility complex, class II, DM beta 
HMMR Hyaluronan-mediated motility receptor 
IL15 Interleukin 15 
IL18BP Interleukin 18 binding protein 
IL32 Interleukin 32 
IRF1 Interferon regulatory factor 1 
LYZ Lysozyme 
ME2 Malic enzyme 2, NAD(+)-dependent, mitochondrial 
MMP9 Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) 
PARVG Gamma-parvin 
PLEKHG1 Pleckstrin homology domain containing, family G (with RhoGef domain) member 1 
PRF1 Perforin 1 (pore forming protein) 
RFX5 Regulatory factor X, 5 (influences HLA class II expression) 
STAT1 Signal transducer and activator of transcription 1 
TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 
TGFb1 Transforming growth factor, beta 1 
TK1 Thymidine kinase 1, soluble 
TLR8 Toll-like receptor 8 
TOP2A Topoisomerase (DNA) II alpha 170kDa 
TYMS Thymidylate synthetase 
UBD Ubiquitin D 






Supplementary Table 2. Functional pathaways significantly over-represented in liver 
allograft rejection-associated  transcriptional patterns (Hallmark pathways, MSigDB, 
GSEA analysis). 













ALLOGRAFT_REJECTION 2.93 0.00* 2.97 0.00* 1.84 0.02* 
INTERFERON_GAMMA_RESPONSE 3.00 0.00* 2.38 0.00* 2.11 0.00* 
E2F_TARGETS 2.51 0.00* 2.56 0.00* 1.79 0.02* 
INTERFERON_ALPHA_RESPONSE 2.77 0.00* 1.78 0.00* 2.14 0.00* 
G2M_CHECKPOINT 2.31 0.00* 2.55 0.00* 1.69 0.03* 
IL6_JAK_STAT3_SIGNALING 2.25 0.00* 2.22 0.00* 1.86 0.02* 
INFLAMMATORY_RESPONSE 2.49 0.00* 2.24 0.00* 1.56 0.07 
TNFA_SIGNALING_VIA_NFKB 2.66 0.00* 2.25 0.00* 1.13 0.39 
APOPTOSIS 2.28 0.00* 2.33 0.00* 1.37 0.17 
IL2_STAT5_SIGNALING 2.19 0.00* 2.25 0.00* 1.31 0.22 
COMPLEMENT 2.08 0.00* 2.09 0.00* 1.26 0.23 
EPITHELIAL_MESENCHYMAL_TRANSITIO
N 1.79 0.00* 2.60 0.00* 0.97 0.66 
P53_PATHWAY 1.91 0.00* 2.07 0.00* 1.29 0.20 
MYC_TARGETS_V1 1.36 0.07 1.62 0.01* 1.75 0.02* 
ESTROGEN_RESPONSE_LATE 1.75 0.00* 1.91 0.00* 1.05 0.48 
UV_RESPONSE_UP 1.66 0.00* 1.48 0.03* 1.52 0.08 
PI3K_AKT_MTOR_SIGNALING 1.60 0.01* 1.66 0.01* 1.30 0.21 
APICAL_JUNCTION 1.64 0.01* 1.86 0.00* 0.89 0.73 
MTORC1_SIGNALING 1.72 0.00* 1.65 0.01* 0.96 0.66 
KRAS_SIGNALING_UP 2.28 0.00* 2.48 0.00* -0.80 1.00 
ADIPOGENESIS 1.21 0.21 1.16 0.23 1.38 0.17 
PEROXISOME 1.30 0.11 1.27 0.13 1.08 0.46 
DNA_REPAIR 1.12 0.34 1.54 0.02* 0.73 0.91 
SPERMATOGENESIS 0.91 0.66 1.31 0.10 1.07 0.48 
NOTCH_SIGNALING 0.95 0.62 1.46 0.03* 0.81 0.84 
MITOTIC_SPINDLE 1.87 0.00* 2.00 0.00* -0.83 1.00 
TGF_BETA_SIGNALING 0.92 0.66 1.18 0.21 0.93 0.67 
MYC_TARGETS_V2 0.88 0.71 1.19 0.21 0.94 0.67 
ANGIOGENESIS 1.83 0.00* 2.23 0.00* -1.26 1.00 
HYPOXIA 1.56 0.01* 1.71 0.00* -0.73 1.00 
GLYCOLYSIS 1.60 0.01* 1.80 0.00* -0.86 1.00 
MYOGENESIS 1.69 0.00* 1.41 0.04* -0.60 0.98 
ESTROGEN_RESPONSE_EARLY 1.55 0.01* 1.80 0.00* -0.88 1.00 
HEDGEHOG_SIGNALING 1.50 0.02* 1.45 0.04* -0.73 1.00 
PROTEIN_SECRETION 1.39 0.06 1.64 0.01* -0.88 1.00 
UNFOLDED_PROTEIN_RESPONSE 1.42 0.04* 1.49 0.03* -0.78 1.00 
COAGULATION 1.45 0.03* 1.59 0.01* -0.98 1.00 
ANDROGEN_RESPONSE 1.10 0.36 1.50 0.03* -0.64 1.00 
UV_RESPONSE_DN 1.47 0.03* 1.60 0.01* -1.12 1.00 
REACTIVE_OXIGEN_SPECIES_PATHWAY 1.64 0.01* 0.99 0.50 -0.84 1.00 
HEME_METABOLISM 1.48 0.03* 1.19 0.21 -1.19 0.95 
WNT_BETA_CATENIN_SIGNALING 1.09 0.37 1.42 0.04* -1.05 1.00 
APICAL_SURFACE 0.97 0.59 1.61 0.01* -1.23 1.00 
PANCREAS_BETA_CELLS -1.13 0.43 0.83 0.77 1.36 0.17 
KRAS_SIGNALING_DN 1.10 0.35 0.90 0.66 -1.33 1.00 
CHOLESTEROL_HOMEOSTASIS 1.30 0.11 -1.61 0.04* 0.82 0.84 
XENOBIOTIC_METABOLISM 0.81 0.82 -1.55 0.03* 1.22 0.26 
OXIDATIVE_PHOSPHORYLATION -1.04 0.50 -1.25 0.10 1.50 0.08 
FATTY_ACID_METABOLISM -0.83 0.84 -1.41 0.04* 1.25 0.22 
BILE_ACID_METABOLISM -1.31 0.25 -1.50 0.03* -0.92 1.00 
1 Normalised Enrichment Score, as generated by GSEA software 
2 False Discovery Rate 
Gene set name NES FDR q-val NES FDR q-val
HALLMARK_INTERFERON_GAMMA_RESPONSE 2.84 0.00 2.97 0.00
HALLMARK_E2F_TARGETS 2.81 0.00 2.52 0.00
HALLMARK_G2M_CHECKPOINT 2.79 0.00 2.30 0.00
HALLMARK_INTERFERON_ALPHA_RESPONSE 2.59 0.00 2.79 0.00
HALLMARK_TNFA_SIGNALING_VIA_NFKB 2.52 0.00 2.65 0.00
HALLMARK_IL6_JAK_STAT3_SIGNALING 2.47 0.00 2.27 0.00
HALLMARK_INFLAMMATORY_RESPONSE 2.30 0.00 2.50 0.00
HALLMARK_ALLOGRAFT_REJECTION 2.29 0.00 2.89 0.00
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 2.21 0.00 1.43 0.05
HALLMARK_MTORC1_SIGNALING 2.18 0.00 1.71 0.00
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 2.17 0.00 1.81 0.00
HALLMARK_UV_RESPONSE_UP 2.17 0.00 1.66 0.01
HALLMARK_COMPLEMENT 2.14 0.00 2.07 0.00
HALLMARK_APOPTOSIS 2.12 0.00 2.28 0.00
HALLMARK_P53_PATHWAY 2.11 0.00 1.94 0.00
HALLMARK_BILE_ACID_METABOLISM -2.09 0.00 -1.31 0.63
Early-transplant rejection 
samples vs HCV-neg 
patients at baseline 
(unpaired analysis)
Rejection samples from 
HCV-neg withdrawal trial 
patients vs baseline 
samples from same 
patients (paired analysis)
Supplementary Table S3
We performed a comparative analysis of the 13 HCV negative patients with rejection enrolled in withdrawal 
trials against 9 biopsies from HCV negative patients with early post-transplant rejection (within 4 weeks of 
transplantation). 
Comparing pre-weaning samples from trial-enrolled patients to early post-transplant rejection samples 
showed 1193 differentially expressed genes, which included 14 of the 19 ACR-related genes described in this 
study (Figure 2C). Comparing rejection samples from trial-enrolled patients against early post-transplant 
rejection samples showed 213 genes differentially expressed, which showed no overlap with the 19 ACR-
related genes above. 
Functional analysis using GSEA did not identify any significant differences between early post-transplant 
rejection and rejection in the withdrawal-trial setting. Full GSEA data is shown below. 
Analysis performed using Gene Set Enrichment Analysis (GSEA) software against Hallmark gene sets from 
MSigDB and Pathogenesis Based Transcript (PBT) sets from the University of Alberta. Normalised Enrichment 
Score (NES) and False Discovery Rate (FDR) are shown for each parameter. NES is a quantified measure of 
strength of enrichment determined by the GSEA software and defined on the MIT Broad Institue website 
(http://www.broadinstitute.org/gsea/doc/GSEAUserGuideTEXT.htm#_Normalized_Enrichment_Score). 
Significantly enriched pathways (FDR < 0.05) are highlighted
HALLMARK_MITOTIC_SPINDLE 2.05 0.00 1.89 0.00
HALLMARK_MYC_TARGETS_V1 1.97 0.00 1.39 0.06
HALLMARK_IL2_STAT5_SIGNALING 1.94 0.00 2.20 0.00
HALLMARK_ANGIOGENESIS 1.94 0.00 1.79 0.00
HALLMARK_KRAS_SIGNALING_UP 1.84 0.00 2.28 0.00
HALLMARK_CHOLESTEROL_HOMEOSTASIS 1.81 0.00 1.30 0.12
HALLMARK_APICAL_JUNCTION 1.79 0.00 1.64 0.01
HALLMARK_HYPOXIA 1.75 0.00 1.55 0.02
HALLMARK_ESTROGEN_RESPONSE_LATE 1.75 0.00 1.75 0.00
HALLMARK_DNA_REPAIR 1.70 0.00 1.13 0.33
HALLMARK_PI3K_AKT_MTOR_SIGNALING 1.70 0.00 1.61 0.01
HALLMARK_GLYCOLYSIS 1.70 0.00 1.62 0.01
HALLMARK_MYC_TARGETS_V2 1.69 0.00 0.89 0.69
HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 1.68 0.00 1.66 0.01
HALLMARK_COAGULATION 1.55 0.01 1.48 0.03
HALLMARK_MYOGENESIS 1.50 0.02 1.68 0.01
HALLMARK_ESTROGEN_RESPONSE_EARLY 1.49 0.02 1.56 0.02
HALLMARK_OXIDATIVE_PHOSPHORYLATION -1.41 0.06 -1.04 0.79
HALLMARK_UV_RESPONSE_DN 1.35 0.08 1.46 0.04
HALLMARK_HEDGEHOG_SIGNALING 1.31 0.10 1.48 0.03
HALLMARK_HEME_METABOLISM 1.26 0.14 1.45 0.04
HALLMARK_FATTY_ACID_METABOLISM -1.26 0.15 -0.83 0.92
HALLMARK_ADIPOGENESIS 1.20 0.19 1.21 0.21
HALLMARK_ANDROGEN_RESPONSE 1.20 0.19 1.10 0.37
HALLMARK_PROTEIN_SECRETION 1.20 0.19 1.37 0.07
HALLMARK_PANCREAS_BETA_CELLS -1.17 0.20 -1.12 0.70
HALLMARK_XENOBIOTIC_METABOLISM 1.17 0.22 0.78 0.84
HALLMARK_SPERMATOGENESIS 1.16 0.23 0.93 0.64
HALLMARK_NOTCH_SIGNALING 1.11 0.30 0.94 0.61
HALLMARK_TGF_BETA_SIGNALING 1.09 0.32 0.95 0.62
HALLMARK_PEROXISOME 1.05 0.38 1.29 0.12
HALLMARK_WNT_BETA_CATENIN_SIGNALING -1.01 0.46 1.07 0.42
HALLMARK_APICAL_SURFACE -0.97 0.53 0.96 0.59
HALLMARK_KRAS_SIGNALING_DN 0.97 0.53 1.10 0.37
PBT_QCMAT 2.72 0.00 2.53 0.00
PBT_CIRIT 2.66 0.00 2.18 0.00
PBT_IRITD3 2.62 0.00 2.30 0.00
PBT_IRITD5 2.53 0.00 2.22 0.00
PBT_GRIT1 2.26 0.00 2.63 0.00
PBT_IRRAT 2.18 0.00 2.05 0.00
PBT_QCAT 2.06 0.00 2.52 0.00
PBT_DSAST -1.55 0.02 1.61 0.01
PBT_HTS 1.25 0.15 1.53 0.02
PBT_BAT 1.21 0.18 1.97 0.00

















































































































CXCL9 9.44 6.71 7.21 2.46 0.00 3.17 3.69 1.14 0.23 1.56 3.98
HLA-DMA 6.70 6.03 7.19 3.85 1.24 3.73 4.16 0.88 1.06 1.57 4.50
CD2 7.10 6.44 5.55 2.00 0.38 2.88 3.52 1.09 -0.28 1.26 3.74
CCL4L2 7.05 4.77 4.67 3.73 0.59 2.18 3.62 1.84 0.52 2.32 3.74
TAP1 7.03 5.73 5.12 3.50 1.13 2.31 2.81 0.66 -0.06 0.91 3.34
GBP5 7.00 5.13 5.32 2.42 0.14 2.59 2.53 0.54 0.49 0.94 2.91
GBP2 6.98 5.02 5.16 3.62 0.74 2.37 3.05 0.41 -0.36 1.80 3.32
TLR8 5.91 6.95 6.59 2.35 1.58 4.23 4.89 1.71 -0.77 1.64 4.56
CD8A 6.74 6.09 6.37 3.07 1.86 3.24 3.36 1.52 -0.42 1.53 3.56
SLAMF6 6.65 5.24 5.60 2.12 0.67 2.42 3.36 1.03 1.02 1.10 3.31
WARS 6.65 5.23 4.09 3.06 0.76 2.78 3.11 0.56 0.45 0.89 2.44
HLA-DRA 6.57 5.23 5.25 2.67 0.86 3.13 3.22 0.64 0.13 1.41 3.63
RFX5 6.57 6.28 5.40 2.92 -1.83 3.41 3.27 -0.88 0.65 1.10 3.92
CD83 6.57 5.85 4.82 2.03 -0.12 3.33 3.89 0.58 0.13 1.61 2.87
GBP1 6.54 5.19 4.24 2.91 0.82 2.89 2.84 0.94 1.02 1.29 2.83
ITGB2 6.53 5.36 5.36 2.92 1.55 3.16 3.59 1.52 -0.49 1.02 2.87
RARRES1 4.54 6.52 5.42 1.82 1.31 3.77 4.05 1.29 0.48 1.04 2.64
CD3D 6.04 6.00 6.50 3.62 1.35 1.93 3.32 1.70 0.21 1.40 4.19
FABP5 5.57 6.43 5.81 3.54 -1.74 3.68 3.55 1.01 0.05 1.24 3.00
CXCL10 6.39 6.17 4.99 2.86 0.77 2.13 2.49 0.85 0.42 1.41 3.75
FCGR1B 6.38 5.59 5.39 3.64 0.93 3.54 3.58 1.61 0.76 1.88 4.78
CCL19 5.34 4.97 6.34 2.96 0.39 2.75 2.63 -0.01 0.32 0.40 2.91
HLA-H 6.33 5.24 4.57 2.49 1.25 1.15 2.23 0.85 -0.32 0.73 3.01
TYMS 4.51 6.33 5.48 2.58 0.29 2.43 2.60 1.43 0.39 1.16 3.93
PLEK 6.33 4.94 4.33 3.13 1.34 2.50 2.41 0.12 -0.11 1.26 2.41
BTG2 4.30 6.33 5.07 1.99 0.35 2.02 3.15 1.65 0.51 0.71 2.96
CTLA4 4.47 5.63 6.30 4.11 0.71 3.17 4.43 1.50 -1.19 1.78 3.93
MCOLN2 6.28 5.26 5.45 2.04 -0.27 2.62 2.53 0.22 0.61 1.53 3.47
FYB 6.26 4.78 4.92 2.23 0.65 1.39 2.51 1.88 -0.33 0.69 2.89
CECR1 6.24 4.72 4.51 2.36 -1.16 2.41 2.78 0.82 0.39 0.88 2.73
LAPTM5 5.87 6.19 4.77 2.07 1.36 3.88 3.74 1.16 0.38 0.64 3.61
CD48 5.45 5.39 6.17 3.48 1.12 2.40 2.68 1.07 0.34 0.94 3.02
CD72 5.18 5.53 6.16 2.65 0.22 2.56 3.87 1.21 -0.33 0.69 3.63
APOL3 6.15 5.64 4.23 3.32 1.31 -1.75 1.88 -1.81 0.96 1.25 4.06
TBC1D10C 5.77 5.31 6.10 2.51 0.64 2.03 2.80 0.22 -0.05 1.60 3.24
PARVG 6.08 4.39 4.75 3.31 1.12 1.35 2.76 0.73 -0.70 0.53 2.48
ITK 6.07 4.84 5.22 2.44 0.05 1.56 2.75 -0.17 0.31 1.23 3.43
ICOS 4.96 5.61 6.07 1.96 -0.64 3.18 3.79 -0.81 1.47 1.11 3.08
HLA-F 6.06 4.73 4.44 4.06 2.05 0.44 2.35 1.27 0.43 0.68 3.53
CD74 5.81 6.03 6.05 2.10 0.44 2.92 4.67 1.84 0.95 1.75 4.37
GPNMB 6.05 5.99 5.45 2.51 -0.44 4.08 4.01 0.45 1.15 1.48 2.96
GBP4 6.04 4.80 4.61 1.45 -0.80 2.26 3.01 1.16 0.43 1.16 3.40
CD37 5.06 6.03 5.59 2.38 -0.21 2.81 4.18 1.83 0.30 0.48 2.91
ANXA2 6.02 5.47 5.30 2.42 0.81 3.90 2.93 0.24 1.17 0.50 3.88
Supplementary Table S4. Full list of genes differentially expressed in different histological compartments, 
showing t-statistic. Genes shown satisfy a significance threshold of FC > 1.2 and FDR < 0.05 in at least one 
histological compartment. Red indicates increased expression with increasing severity of a histological parameter; 
green indicates decreased expression.
BIRC3 6.02 4.74 3.73 1.52 -1.08 0.90 1.01 0.40 -0.75 1.34 2.64
GZMK 6.00 4.99 5.75 2.22 0.43 1.65 2.13 0.73 0.01 1.95 3.59
PRKCD 5.96 3.25 4.19 3.42 1.37 -1.56 1.31 0.70 -1.72 -1.91 2.42
HLA-DMB 5.36 5.28 5.95 3.15 1.04 2.29 2.73 1.32 0.41 1.59 3.83
MTHFD2 5.95 4.72 3.98 1.93 -0.74 2.56 2.37 1.47 1.13 -1.18 2.29
UBD 5.90 5.93 5.51 2.75 0.73 2.43 2.50 0.74 -0.23 0.87 4.04
CTSC 5.91 4.91 4.92 -2.45 -2.19 3.82 3.50 -2.60 0.43 0.60 2.57
LCP1 5.91 4.83 4.28 1.95 0.80 1.10 2.36 1.03 -0.50 0.89 2.27
MMP9 4.02 4.68 5.91 1.51 0.84 3.15 2.93 0.00 -0.18 0.55 2.31
HLA-DOB 5.89 4.85 5.20 2.68 0.93 2.37 2.85 0.21 0.30 0.47 3.60
ADA 5.13 5.89 5.02 2.92 1.88 2.06 3.05 2.09 0.05 0.88 3.42
RUNX3 5.88 4.51 5.40 2.28 0.60 1.88 2.85 0.53 -0.96 1.03 2.99
EOMES 5.87 5.08 5.41 2.91 0.15 1.49 3.44 0.97 0.34 1.45 3.59
HMMR 5.22 5.87 5.03 1.87 -0.43 4.95 4.23 -0.17 0.46 1.04 2.80
SRGN 5.86 4.43 4.90 4.16 2.03 2.57 3.58 2.38 0.72 1.83 3.60
IL32 5.85 5.75 4.85 3.65 1.80 1.79 2.79 1.51 1.81 2.06 4.99
OBFC2A 5.85 4.79 4.37 3.12 0.85 2.60 3.57 1.13 0.95 1.71 2.96
CD53 5.82 5.27 4.44 2.07 0.43 2.30 2.88 1.31 0.64 0.92 3.49
STAT1 5.82 5.59 4.52 3.35 0.90 1.56 2.52 0.66 0.39 1.13 3.23
RAC2 5.81 5.50 5.46 3.30 1.21 1.86 3.22 1.61 0.34 1.05 2.88
HLA-DQA1 5.79 4.86 4.86 1.10 0.86 2.58 2.87 1.17 0.40 0.42 2.43
PILRA 5.78 3.10 3.88 3.23 1.69 2.31 2.99 1.53 1.37 2.25 3.20
C16orf75 3.65 5.76 4.50 3.02 0.44 2.37 1.76 0.15 0.68 0.12 3.11
CD69 5.75 4.41 4.04 1.11 -0.27 1.86 1.38 0.37 0.87 1.29 2.56
STAMBPL1 5.74 4.53 4.61 1.66 -0.65 3.24 2.95 0.45 -0.05 0.76 2.89
PPP1R1A -5.73 -4.19 -3.74 -2.04 -0.23 -1.42 -1.94 -0.40 -0.83 -0.74 -3.25
MMP7 3.54 3.86 5.72 3.07 -0.32 1.70 2.99 0.57 0.17 1.65 4.50
FERMT3 5.72 4.94 5.23 3.53 1.57 2.71 3.08 2.05 1.37 0.96 3.62
TAP2 5.72 3.93 3.32 1.30 -0.54 1.28 1.42 -1.55 -1.21 1.12 1.74
IRF1 5.70 3.32 3.61 3.12 0.83 1.76 1.00 -0.21 0.14 1.73 2.37
LYVE1 -5.52 -5.53 -5.70 -3.57 -0.26 -1.39 -2.25 -0.56 -1.42 -0.84 -5.15
MCM6 4.11 5.69 3.85 1.58 -0.29 1.79 1.37 0.39 -0.36 0.72 2.84
CTSS 5.69 4.48 4.36 0.88 -0.17 2.52 2.11 1.15 0.21 1.19 2.94
ASNS 5.68 3.39 4.29 2.47 -1.10 0.84 1.87 1.27 0.38 0.85 1.91
CDC45L 4.59 5.68 5.20 2.72 0.18 2.67 2.11 0.72 -0.40 0.98 3.80
WASPIP 5.67 4.70 4.53 0.54 -0.32 1.97 2.37 1.07 -0.88 -0.01 1.35
HLA-DRB6 5.66 4.28 4.77 3.03 1.64 1.60 1.93 0.53 1.52 0.47 2.85
IL18BP 5.66 4.50 4.74 3.15 1.00 2.21 2.11 -0.69 1.13 -1.56 2.27
LPXN 4.39 4.84 5.66 1.59 -0.47 1.90 2.93 0.54 -0.53 1.21 3.37
DGKA 3.63 4.52 5.65 2.83 2.01 1.99 2.97 -1.59 1.07 1.23 1.83
ARHGAP9 5.64 4.82 5.37 2.80 1.53 1.99 3.04 1.77 -0.44 1.89 3.04
CD79A 4.39 4.51 5.64 2.47 -0.55 1.66 3.30 -0.35 -0.43 0.66 2.63
HLA-DOA 5.44 5.28 5.62 3.02 0.86 2.76 3.95 2.12 0.23 1.14 4.28
LTB 4.57 4.72 5.61 2.51 1.22 0.99 2.30 0.84 -1.31 1.43 3.03
MELK 5.50 5.60 5.24 2.44 0.47 3.71 3.49 0.93 -0.73 0.80 2.50
AIM2 5.59 4.10 3.45 2.47 1.22 1.74 2.24 1.19 1.58 1.21 2.11
IL7R 5.59 4.81 4.52 1.34 -1.64 2.00 2.14 -0.50 -0.84 1.06 2.23
C15orf48 5.59 4.25 4.08 2.03 -1.41 4.67 3.53 -1.15 1.63 1.05 3.79
SLFN11 5.59 4.94 4.19 0.66 -2.16 2.89 2.39 -0.51 1.32 1.72 2.60
UHRF1 4.77 5.59 4.95 2.65 0.98 2.95 2.51 1.65 -0.38 1.96 3.18
CCND2 5.58 4.58 4.77 1.95 0.96 1.21 2.49 -0.67 -0.92 0.42 2.05
EMILIN2 5.57 4.91 5.54 2.66 0.19 1.91 2.89 0.43 0.71 1.35 3.58
ARHGEF3 4.92 5.56 4.24 1.51 0.93 1.46 3.35 1.09 -0.10 -0.03 1.68
FCN1 4.67 3.88 5.56 3.11 0.83 2.61 3.86 1.43 0.88 2.11 3.69
SAMD9L 5.54 3.83 2.59 1.86 0.08 0.91 2.05 0.97 0.18 1.30 2.72
IFI30 5.04 5.53 5.13 5.05 2.60 3.38 3.37 1.72 0.87 0.29 3.86
HIST1H3F -0.99 -2.62 -3.33 -0.84 -0.11 -4.19 -5.52 -0.03 -0.64 -0.17 -0.72
SPOCK2 5.33 5.29 5.52 2.19 0.00 2.10 3.13 0.46 -0.40 0.77 3.28
PIM2 4.56 4.97 5.52 3.64 1.13 1.01 2.68 1.15 0.59 1.32 2.89
ACADSB -4.13 -4.60 -4.49 -3.99 -1.49 -2.54 -2.56 -1.12 -0.30 -0.74 -5.52
GPR98 -5.50 -3.81 -5.07 -2.57 0.55 -2.03 -2.51 1.04 -1.87 -0.53 -3.01
CDH23 -4.82 -5.48 -4.71 -3.37 1.10 -2.45 -2.62 -0.88 2.04 1.36 -4.80
ADAMDEC1 3.69 4.46 5.47 1.19 0.38 4.25 3.41 -0.09 -0.32 -0.16 2.07
STX11 5.46 3.37 3.18 1.36 0.68 1.35 1.34 0.49 -0.45 0.64 2.55
ANKRD29 4.68 3.87 5.45 1.52 -0.74 1.11 1.07 1.47 0.44 0.88 3.64
SAMD4A -5.45 -3.08 -3.28 -0.93 1.10 -0.48 -0.44 0.82 -1.14 -1.49 -3.17
HCG4 5.44 4.71 4.40 2.33 1.26 -1.75 2.94 1.62 -0.66 1.11 2.72
SERPINB8 5.41 4.31 4.17 2.04 0.39 3.65 2.37 0.79 1.40 1.40 4.44
SAMSN1 5.41 4.31 3.78 2.17 0.74 2.34 2.85 1.35 0.61 0.86 2.29
NIN 5.41 4.02 3.53 2.64 -1.42 2.20 2.34 0.89 -1.74 -1.60 1.96
GPR18 4.62 4.44 5.40 1.16 -1.00 3.35 3.80 0.94 0.48 3.44 3.14
ITM2A 4.67 5.25 5.40 1.53 -0.20 2.27 2.56 -0.68 -0.22 0.85 3.04
PKM2 5.39 4.45 4.76 2.23 -1.15 2.78 3.85 2.05 -0.88 1.71 2.45
CD38 5.38 4.65 4.09 3.69 0.76 2.98 2.93 1.16 0.51 2.12 3.47
TNFSF13B 5.38 5.37 4.80 2.97 0.98 2.46 3.68 1.95 0.90 1.28 3.66
APOBEC3G 4.61 5.37 4.60 2.62 1.22 1.87 2.11 0.56 1.24 2.10 3.34
EHD4 5.37 4.07 3.89 3.35 0.95 2.58 2.30 -0.29 2.19 0.65 3.01
AMICA1 4.33 5.36 4.46 1.56 0.61 1.60 2.54 1.63 -0.41 0.50 3.36
HLA-B 5.35 4.53 4.20 2.76 1.34 0.49 1.76 0.81 -0.29 0.72 3.17
CD96 5.03 4.64 5.34 2.75 1.09 2.72 3.19 0.64 1.11 1.83 2.96
CCDC109B 5.00 5.34 5.20 1.58 -0.28 2.50 3.21 0.61 0.31 1.35 3.21
TNRC6B -0.98 -0.92 -0.24 -0.10 1.06 -3.54 -4.21 0.88 -5.34 0.64 -0.16
SEMA4D 5.32 4.30 3.96 1.93 0.00 0.98 2.21 0.88 -0.60 1.07 2.67
GPR56 5.31 3.66 4.70 2.20 0.53 -1.17 1.24 -1.13 1.00 1.70 3.75
UBE2C 4.41 5.31 4.71 3.50 1.16 4.05 4.43 1.59 -0.73 1.26 2.97
DUOXA1 -2.46 -2.31 -2.06 -2.98 -1.80 -2.86 -1.92 -0.68 -5.30 -1.98 -2.72
ABCB1 5.29 4.57 4.97 0.58 -1.16 2.01 3.72 -0.20 1.08 0.77 2.80
PTTG1 4.57 5.15 5.29 3.62 1.79 4.13 4.40 1.56 -0.75 0.96 3.76
HPR -4.60 -3.77 -4.53 -3.75 0.13 -1.49 -2.04 0.49 -2.15 -1.18 -5.29
FCRLA 3.30 4.06 5.28 1.43 0.55 2.23 2.96 -0.20 0.12 0.23 1.88
FAIM3 5.10 5.15 5.27 1.45 0.13 2.00 2.93 0.53 -0.15 0.57 2.92
GK 5.27 3.98 3.62 1.24 -0.72 2.21 3.10 -1.01 1.32 0.19 2.74
IL1B 5.27 2.76 2.17 2.46 0.78 1.21 1.69 0.93 -0.11 1.38 2.37
ANKRD22 5.26 3.52 3.23 1.70 -1.86 2.70 2.05 1.64 -0.84 1.49 3.21
ABCB4 5.26 4.29 4.25 1.47 -1.11 4.23 3.63 -1.01 2.18 0.76 2.93
IER3 5.25 2.91 3.29 3.25 0.69 2.93 2.38 -0.71 1.68 -0.69 2.51
HCST 4.93 4.46 5.25 4.16 2.09 1.71 3.64 1.81 1.08 1.36 4.59
CD86 5.25 4.71 4.92 4.69 1.58 1.98 3.25 1.93 0.75 2.75 3.97
TNFRSF12A 5.24 3.56 3.53 2.02 0.25 2.17 2.58 0.40 1.44 2.72 3.56
SLA 4.80 5.24 4.22 4.48 1.75 1.59 2.07 1.40 0.69 1.85 3.39
MGC4677 4.70 4.04 5.24 4.32 1.47 -0.37 1.55 -1.10 0.63 -1.21 5.03
HAVCR2 5.23 3.88 4.43 3.33 0.96 1.45 2.28 1.15 -0.40 1.49 3.27
PLCB2 5.23 3.45 3.88 2.37 0.95 1.52 2.48 1.01 -0.02 1.28 1.76
CD52 4.75 5.07 5.23 2.79 1.50 3.44 4.88 1.95 0.14 1.73 3.88
GZMA 5.23 4.06 4.96 3.32 0.99 0.70 1.74 1.45 0.47 1.75 3.33
RASAL3 5.23 4.38 4.69 2.16 0.26 1.41 2.10 -0.97 -0.02 1.28 2.08
RGS10 4.39 4.21 5.22 3.79 1.69 3.49 3.48 1.06 2.06 1.91 3.49
CXCL11 5.22 3.84 3.10 1.19 -0.96 1.77 2.18 0.45 0.42 1.22 2.47
SORL1 -2.61 -2.88 -2.88 -5.21 -2.31 -1.81 -2.28 -0.78 -0.46 0.56 -2.50
IGSF6 5.20 5.01 4.93 3.32 1.52 3.68 3.62 1.46 0.48 0.81 3.28
UPP2 5.19 2.88 3.53 1.72 -1.10 0.79 1.66 0.60 3.14 1.53 3.62
FCER1G 5.18 4.31 4.52 3.70 1.75 2.72 3.65 2.57 0.48 0.83 2.85
TOP2A 4.88 5.18 5.12 2.57 1.06 3.95 3.38 0.06 0.09 0.76 2.57
BTN3A3 5.18 4.02 3.41 2.62 1.67 -0.06 1.01 0.56 -0.50 0.63 2.76
DOCK10 5.18 3.61 4.27 2.29 0.83 1.67 2.77 0.21 -0.93 1.51 1.86
FAM99A -5.18 -4.42 -4.81 -2.18 -0.52 -2.26 -2.83 0.26 -1.97 -1.92 -3.07
SLC16A3 3.83 3.70 5.18 4.77 1.46 1.21 2.60 1.45 0.35 1.97 3.95
TNFAIP8 5.17 4.57 4.73 1.60 0.80 2.00 1.76 0.37 -0.60 2.48 2.92
EVI2B 5.16 4.80 4.82 2.40 1.23 2.07 2.70 0.46 -0.34 0.75 2.30
DOCK11 5.16 4.42 4.82 0.93 -1.52 1.80 2.40 0.12 0.01 1.50 3.31
ITGAX 5.16 3.60 4.41 1.89 -1.37 2.20 1.63 0.46 1.11 1.95 3.03
PKLR -5.16 -3.78 -3.43 -2.05 1.01 -1.44 -2.18 -2.48 -1.65 -2.30 -2.82
E2F2 5.15 5.14 4.59 2.88 1.20 2.47 3.21 1.20 -0.62 0.70 2.79
LOC606724 5.15 5.12 4.95 2.13 -0.87 1.38 2.04 1.30 -2.80 -1.97 2.38
NUSAP1 4.97 5.12 5.14 2.41 1.16 4.15 3.23 1.04 -0.90 1.56 3.21
CXCR4 5.13 4.78 5.14 1.96 0.73 3.84 3.36 0.52 0.65 2.24 2.71
CCL3L3 5.13 3.77 3.16 3.15 0.63 2.00 2.99 1.42 0.56 1.55 3.33
CKS2 4.99 5.13 4.85 3.90 2.44 2.08 2.63 1.46 -1.42 0.88 3.68
GPER -5.13 -2.81 -2.93 -1.56 1.08 -3.19 -3.00 -1.26 -4.79 -0.30 -4.11
IFI16 5.12 4.02 4.06 1.08 -0.03 -0.19 0.78 0.28 -0.08 0.59 3.07
PSMB9 5.11 4.83 4.18 4.34 1.85 1.02 2.09 1.37 0.47 1.42 3.68
LXN 3.65 4.42 5.09 1.52 -0.61 2.29 2.58 0.01 -0.43 1.86 3.07
CD6 5.09 4.90 4.69 2.01 0.85 1.95 2.58 0.38 -0.75 0.78 3.19
PLA2G7 3.80 5.08 4.87 2.82 0.56 4.47 3.73 0.30 -0.10 -0.18 3.01
SLC1A3 4.33 4.19 5.08 3.25 -0.43 3.46 3.19 0.04 1.65 1.66 3.69
PTPRCAP 3.25 5.08 4.81 3.88 2.55 2.92 4.35 1.06 1.07 1.20 3.39
HLA-A 5.06 4.59 4.11 3.03 1.90 1.22 2.26 1.01 -0.61 0.65 2.59
CASP1 5.06 4.21 4.12 2.52 0.61 1.31 2.35 1.68 2.08 1.19 3.41
CCL8 5.05 2.69 1.94 3.71 0.78 1.00 1.30 2.03 1.03 1.43 2.51
CD44 5.04 4.31 4.12 1.60 0.90 2.31 4.48 1.64 0.45 0.54 2.84
FAT1 5.02 4.19 4.48 1.97 -0.47 1.85 1.88 -0.60 2.09 1.20 3.44
SCPEP1 4.76 4.59 5.01 3.30 1.30 2.20 1.77 0.56 -0.79 1.02 2.52
IGFALS -5.01 -3.22 -3.87 -2.34 -0.02 -2.20 -2.52 1.28 -2.11 -0.62 -3.33
CXCR6 4.56 4.08 5.01 1.62 0.24 3.01 2.97 0.51 0.44 2.00 2.83
CCNB2 4.27 4.73 5.01 2.53 0.39 4.39 4.88 0.58 -0.30 0.75 2.65
LOC652493 5.00 4.23 4.21 3.67 0.89 1.15 1.86 0.36 0.87 0.80 3.36
VIM 5.00 4.96 4.45 0.81 0.34 2.18 2.22 -0.59 0.69 0.97 2.75
GINS2 4.07 4.99 4.05 3.12 1.06 2.17 1.66 1.71 -0.32 0.95 3.37
CCL5 4.83 4.99 4.75 2.73 0.88 1.70 3.18 1.68 0.02 1.75 4.35
FGL2 4.98 3.88 3.71 1.97 0.60 2.87 2.93 1.37 0.42 1.69 2.86
GZMB 4.11 4.64 4.97 2.44 0.41 1.07 2.55 2.25 -0.13 1.07 2.31
MUC13 4.96 2.97 4.04 2.08 -0.32 1.20 2.30 0.81 0.20 1.30 3.26
PRAMEF10 2.74 2.60 1.68 1.08 -0.84 3.56 4.96 -0.81 3.32 -1.11 2.83
C13orf15 4.10 4.25 4.94 1.41 0.55 1.33 1.29 -0.68 1.80 1.48 3.03
ADRA1B -4.59 -4.94 -3.48 -1.58 0.46 -2.70 -1.53 0.46 -0.31 -0.41 -2.77
CCL3L1 4.05 4.16 4.68 3.74 1.02 4.93 3.75 0.99 1.79 0.70 3.06
DLEU1 -4.92 -3.44 -2.47 -0.69 0.79 -1.31 -1.36 0.68 -0.78 -0.47 -1.76
GSTA3 -4.92 -2.47 -2.61 -1.90 -0.38 -0.75 -2.34 -1.34 -1.39 -1.18 -2.46
ECGF1 4.91 3.92 3.86 3.14 1.48 1.91 2.27 1.23 0.43 1.04 3.28
AKR1B15 2.40 1.75 0.96 1.56 0.02 1.84 2.12 0.00 4.91 -0.52 1.58
KBTBD9 4.90 1.97 2.82 2.38 0.28 1.25 1.46 0.57 1.32 0.91 3.76
MAP4K1 4.48 4.57 4.89 2.41 -1.22 2.74 4.48 0.38 -0.39 1.54 2.52
GSN 3.60 3.92 4.52 1.99 0.51 -1.49 0.64 0.57 2.70 2.71 4.86
RPS6KA1 4.86 3.75 3.01 2.12 1.05 -0.65 1.29 0.85 0.20 -0.77 2.36
ZWINT 4.85 4.85 4.33 3.26 1.24 2.25 2.54 -1.13 -1.87 -3.05 2.61
RENBP 4.36 3.97 4.85 4.21 1.57 3.24 3.03 -0.11 0.45 1.03 2.83
RCAN1 4.85 3.19 2.70 0.70 -1.13 0.68 1.06 0.44 1.64 -1.61 2.77
NELL2 4.71 4.75 4.84 0.97 -1.22 1.75 2.12 -0.10 0.23 1.46 2.90
FCGR1A 4.67 4.84 3.89 2.36 0.14 2.52 2.48 0.67 0.09 1.84 3.70
TRIM22 4.83 4.71 3.85 1.84 0.85 0.97 1.79 1.40 0.35 0.52 2.34
UBE2L6 4.83 4.05 3.17 3.36 1.88 1.22 1.54 1.28 1.34 0.77 3.01
RGS1 4.61 3.95 4.82 3.05 0.38 3.82 3.17 0.48 0.23 0.96 3.12
CYP2C19 -3.87 -3.01 -3.27 -3.20 -2.91 -0.91 -1.71 -0.62 -2.11 -0.47 -4.82
SLC2A3 4.61 3.76 4.82 1.89 -0.17 1.72 2.40 0.30 0.17 0.62 1.59
MAD2L1 4.39 4.81 4.60 1.89 0.64 3.48 3.44 -1.43 -0.90 0.81 2.46
DRAM1 4.79 4.53 3.85 2.88 1.37 1.09 2.34 2.53 -0.29 0.79 4.44
LGALS3BP 4.79 3.28 3.41 1.85 0.67 0.68 0.70 0.19 1.43 1.19 2.64
HAAO -4.79 -3.37 -2.94 -2.10 -0.58 0.24 -0.80 -1.38 0.75 -1.04 -2.73
C12orf43 -3.18 -3.42 -2.67 -4.79 -1.56 -0.96 -1.26 1.38 -0.55 0.52 -2.46
SGK 4.78 3.57 3.06 2.61 0.84 1.30 1.99 0.77 1.16 1.74 3.16
ZGPAT -4.78 -3.40 -3.61 -1.90 1.02 -1.93 -2.18 -1.52 1.07 -0.79 -2.15
VAMP5 3.96 4.25 4.26 3.91 1.34 2.18 3.22 0.99 1.83 1.35 4.77
MS4A7 4.77 4.31 4.48 2.35 1.80 3.12 3.63 -0.23 0.33 0.85 3.11
FYN 4.77 4.04 4.25 0.76 -1.38 1.57 2.92 1.18 0.33 0.75 2.18
KIF20A 4.05 4.76 4.33 2.23 1.41 4.49 4.60 0.77 -0.54 0.37 2.26
STMN1 3.47 4.37 4.76 3.40 1.85 2.53 2.58 1.56 -1.35 -1.21 2.73
LILRB3 4.76 3.25 3.35 1.74 0.19 2.00 2.06 0.35 -0.40 1.24 2.50
CD27 4.75 4.17 4.72 3.10 0.34 3.25 2.67 -1.24 1.24 1.20 3.50
SLAMF8 4.75 3.86 4.73 3.85 0.73 2.75 3.37 0.65 1.16 1.08 3.73
MAP3K8 4.75 2.95 2.71 1.13 -0.12 1.33 1.65 0.76 -0.20 1.39 1.46
TSPAN17 4.36 3.79 4.22 4.74 2.13 1.63 1.43 0.21 0.96 1.30 3.97
OVGP1 -4.72 -3.43 -3.47 -2.38 0.01 -0.37 -1.29 0.99 -0.64 -0.90 -1.53
SUSD1 4.71 3.41 3.60 1.64 1.13 1.23 1.82 1.48 -0.59 0.43 2.25
TK1 3.05 4.71 3.98 3.19 1.98 1.94 2.36 0.62 -1.45 0.11 2.07
PTPRE 4.70 3.80 3.33 1.58 -0.67 1.83 2.94 -0.80 1.21 1.17 1.85
RNASE6 3.01 3.74 3.79 4.70 2.82 3.34 2.31 0.73 1.71 0.88 3.16
OIP5 3.25 4.67 4.09 2.20 1.01 2.95 3.00 1.00 -1.79 1.50 2.87
MCM2 3.45 4.67 3.52 1.25 -0.52 1.68 1.50 1.01 -0.84 0.20 2.69
LOC647450 4.67 3.99 3.98 3.44 0.58 1.00 1.55 0.12 0.94 0.77 3.09
C3orf14 3.61 4.67 4.64 4.27 1.69 1.86 2.81 0.48 0.92 1.19 3.59
CDCA5 4.37 4.66 4.56 2.89 0.63 3.20 3.11 0.38 -1.02 0.88 3.01
GPBAR1 3.60 2.01 2.25 4.66 2.64 2.58 2.82 1.06 1.44 1.20 2.29
FGR 4.65 4.39 3.98 3.57 1.02 3.34 3.49 2.45 1.20 2.17 3.81
TMPRSS3 4.64 3.35 4.20 2.48 -1.62 -3.55 -2.18 -1.17 2.77 -2.24 4.25
VMO1 3.16 3.47 3.04 4.64 2.91 0.37 3.17 0.97 0.43 0.50 2.82
DOCK8 4.64 3.31 3.99 0.78 -0.01 0.39 0.74 -0.18 -0.46 0.45 1.51
MTHFD2L -2.13 -2.60 -3.06 -3.13 -0.28 -4.64 -2.70 0.66 -0.02 0.63 -2.31
C18orf56 3.16 4.64 4.43 3.02 1.34 1.46 1.40 1.59 0.36 1.26 3.17
UCP2 4.40 4.62 4.16 2.94 1.43 1.37 2.82 2.45 -0.25 0.60 2.00
DNAJC12 -4.61 -4.08 -3.91 -1.93 1.28 -3.42 -2.96 1.16 -0.96 -0.49 -3.92
HLA-DRB3 3.67 3.82 4.60 1.29 0.77 2.01 1.85 -0.58 0.89 0.15 1.20
EPSTI1 4.60 3.41 2.79 2.22 1.18 0.02 0.85 0.40 -0.15 1.14 2.65
PSMB8 4.60 4.39 3.86 4.01 2.07 1.50 2.95 1.35 0.77 -1.13 3.61
NKG7 3.98 4.59 4.33 3.07 1.25 1.76 4.13 2.56 0.45 1.30 3.22
MBL1P1 -3.34 -4.22 -4.59 -1.91 -0.64 -1.90 -1.25 -1.07 0.63 -0.02 -3.41
ENPP2 4.58 2.75 3.00 1.28 -1.05 0.77 0.30 0.67 1.21 1.76 4.45
CD247 3.66 3.27 4.57 4.13 1.68 -0.13 2.18 0.86 -0.77 1.48 3.12
OSTbeta 4.38 4.07 3.00 2.37 -0.38 4.56 3.91 -0.28 3.66 0.66 3.34
CPVL 4.19 4.55 4.04 2.37 1.46 3.73 2.87 0.53 -1.00 -0.50 3.14
ARPC5 4.54 3.26 3.42 1.53 0.37 1.15 0.24 0.35 -0.55 -0.34 2.33
SARDH -4.53 -2.74 -2.98 -2.08 -0.89 -0.63 -0.54 -0.80 1.10 -1.32 -2.56
GPSM3 4.53 4.46 4.00 2.73 1.48 3.16 2.77 -0.26 0.98 0.59 2.17
HCP5 4.52 4.32 3.65 2.65 1.61 0.74 2.02 0.62 -0.90 0.77 2.22
COL3A1 4.52 3.66 3.36 0.96 -1.15 1.18 1.23 -0.21 0.82 3.39 2.22
IGLL1 4.51 3.76 4.32 2.70 0.69 1.12 1.06 -0.56 0.27 0.79 2.48
SH3PXD2A -2.69 -2.79 -3.28 -2.76 -1.70 -1.09 -0.30 -0.36 -1.50 -1.65 -4.50
CCL21 3.94 3.99 4.50 3.19 1.18 1.40 1.87 0.01 0.62 0.82 2.97
FPR3 4.48 4.40 3.39 2.78 1.18 1.22 1.50 1.34 0.69 2.20 3.41
LPAL2 -4.48 -3.37 -3.20 -2.49 0.21 -2.31 -1.89 0.52 -1.68 -0.75 -2.95
RAD51AP1 4.47 4.13 4.03 1.64 0.04 3.46 3.15 0.26 -0.30 0.41 3.62
GPR125 -2.96 -4.46 -4.45 -2.92 -1.63 -2.75 -2.60 1.58 -1.03 2.94 -3.31
KCNN2 -4.15 -2.54 -2.80 -2.31 -0.10 -0.27 -0.42 -0.22 -1.27 -1.84 -4.44
LOC642113 4.31 4.04 4.43 3.14 0.57 1.97 1.82 0.65 0.68 0.69 3.13
ALOX5AP 3.41 3.66 4.43 2.61 1.63 0.17 1.39 1.11 -0.60 0.96 3.14
DHRS9 4.41 3.70 4.18 2.66 0.86 3.79 4.10 -0.65 1.42 1.79 1.80
TIMP1 3.93 3.77 4.40 3.47 1.29 1.63 2.21 -0.41 1.14 0.93 3.93
PCOLCE2 -4.39 -3.89 -3.84 -3.39 -1.14 -1.21 -1.64 -0.71 -0.54 -0.66 -2.54
ZDHHC23 2.54 2.75 4.37 1.60 0.88 1.25 0.97 -1.30 0.04 0.06 0.85
KIAA0101 3.87 4.36 4.09 3.69 1.81 2.26 2.37 -1.68 -0.58 1.61 3.37
AURKA 4.08 3.70 4.34 2.36 1.09 2.83 3.32 0.47 0.03 0.52 3.29
GSTA5 -4.33 -2.11 -2.25 -2.08 0.17 -1.08 -2.83 0.10 -1.21 -0.66 -1.89
CACNA1H -4.33 -3.94 -3.39 -3.43 -1.40 -0.17 -1.19 1.21 -2.72 -0.66 -3.77
PIGR 4.29 4.32 3.76 2.63 1.43 1.25 1.13 1.21 -0.90 0.69 3.15
SELL 4.32 3.84 3.76 0.80 -0.46 1.47 2.79 0.64 -0.39 0.68 1.63
LOC652694 4.00 4.32 3.71 3.42 0.58 1.20 2.18 0.55 0.98 0.97 2.81
DNMT3L -4.31 -2.24 -2.29 -1.64 0.53 0.28 -0.82 0.70 -1.79 -1.25 -1.87
TRIM55 -2.58 -1.66 -3.24 -1.77 1.24 1.06 0.68 0.72 -1.16 -0.78 -4.30
ATP1B3 4.19 4.30 4.07 1.87 -0.64 1.58 2.42 1.47 -1.89 -2.70 2.19
PLGLB1 -3.62 -3.59 -4.30 -3.21 -0.31 -3.89 -2.78 1.06 -1.38 0.43 -1.66
RNF144B -3.12 -4.03 -4.07 -2.37 0.26 -3.16 -4.29 0.33 -2.84 -0.23 -2.35
LYZ 3.04 3.59 4.28 2.77 1.72 2.30 2.42 0.93 0.38 1.32 2.53
BCHE -3.34 -3.12 -4.28 -4.02 -1.24 -1.23 -3.25 0.04 -1.70 -0.72 -3.71
BLVRA 3.43 3.62 4.13 4.27 2.34 1.53 1.93 1.58 0.01 0.83 2.93
ANKRD35 -3.76 -2.86 -3.07 -2.13 0.13 1.10 0.36 1.07 -0.53 1.60 -4.27
MATN2 -4.27 -2.98 -2.89 -3.33 -0.74 -1.27 -2.51 0.42 -2.65 -0.18 -2.44
PRKCB1 4.13 3.23 4.25 2.62 1.14 1.00 1.93 1.97 -1.02 1.05 1.57
PLA2G4C 4.24 3.69 3.50 3.30 0.66 0.64 0.67 -0.44 0.97 1.17 2.63
PCOLCE -3.14 -2.89 -3.24 -2.24 0.28 -0.24 -1.42 0.25 -0.56 -0.43 -4.24
DIRAS3 -4.17 -4.24 -3.40 -3.47 -1.61 -0.91 -2.46 -0.23 0.14 0.40 -1.95
MOXD1 3.97 4.22 3.75 1.31 -0.62 2.78 3.12 -1.91 0.50 0.74 2.44
NCOR1 -4.22 -3.45 -2.79 -1.18 0.51 -0.47 -0.51 0.48 0.37 -1.32 -3.48
LGALS9 2.47 3.71 2.85 2.58 0.69 2.60 4.22 2.01 0.62 0.94 2.55
SLC15A3 4.19 3.39 2.56 2.26 1.33 1.22 1.20 -0.06 -0.28 0.89 1.71
SLC38A1 3.88 4.19 3.62 -0.81 -1.67 1.20 1.68 1.06 -0.67 -0.49 2.19
CDC20 3.16 3.97 4.01 2.94 0.92 3.65 4.16 1.10 -1.01 0.10 2.64
CXCL6 4.16 3.66 3.85 2.27 -0.43 1.61 2.04 -0.82 0.88 1.91 3.49
HSD17B14 -4.16 -3.71 -3.18 -1.97 -0.72 1.03 -0.26 -1.15 -0.56 -1.20 -3.25
LOC644322 -4.13 -1.87 -2.66 -1.09 0.23 -1.41 -1.02 -0.01 -0.39 -0.98 -2.05
IL8 4.13 4.03 3.86 2.65 -0.33 2.70 2.55 0.49 0.16 1.30 4.11
ASPM 3.45 4.13 3.62 1.33 0.05 3.12 2.92 -0.12 -1.16 -0.07 2.09
LOC401115 3.48 3.26 4.13 2.93 1.39 0.60 1.31 0.62 -0.14 0.67 3.80
KDELR3 4.12 3.58 4.13 1.89 -0.83 1.61 0.93 0.90 0.56 0.92 3.69
XLKD1 -4.13 -3.69 -3.70 -2.40 -0.11 -1.91 -2.79 -1.28 -0.21 -0.10 -3.95
PNMA6A -4.12 -2.88 -2.10 -1.83 -2.13 -1.12 -0.76 -0.40 -0.49 -0.92 -0.55
FAM129A 4.12 3.62 3.42 1.26 -0.28 0.98 1.40 0.79 -0.37 1.37 2.21
ISG20 4.12 3.69 3.00 2.96 1.15 0.49 1.14 0.33 0.72 0.96 3.14
MNS1 3.94 3.61 3.50 2.38 0.32 3.08 2.78 -1.57 3.41 1.51 4.11
NCAPG 4.02 3.96 4.11 1.85 -0.67 2.82 2.62 0.18 -0.70 0.96 2.54
FAM134B -3.57 -4.11 -3.65 -2.60 -1.81 1.61 -2.51 -0.55 1.94 0.78 -3.68
CD24 4.10 2.98 2.91 2.10 -0.80 0.86 1.71 0.57 0.96 0.94 3.18
CCL15 -4.10 -3.07 -3.48 1.82 2.09 1.70 2.05 1.60 -1.54 -2.73 -2.20
LOC644743 3.26 3.00 3.20 2.48 -0.07 4.09 2.44 0.24 2.31 0.29 2.91
GSTA2 -4.09 -2.50 -3.05 -2.85 -0.85 -0.20 -1.29 0.63 -1.40 -0.06 -3.05
LAMP2 4.07 3.59 3.42 1.22 -0.90 1.99 1.41 -1.13 1.20 0.87 2.24
KRT8 3.24 3.50 3.49 3.37 0.85 3.59 3.05 0.62 2.43 -0.07 4.07
ADCY1 -3.57 -3.01 -2.10 -2.56 -0.21 0.85 -1.25 -0.16 0.06 -0.78 -4.06
HPS5 4.06 2.23 1.97 0.42 -0.39 0.43 0.90 1.08 1.16 1.09 3.01
UGT2A3 4.05 2.70 2.67 1.03 -0.27 1.16 0.82 -0.49 -1.01 1.19 2.28
HLA-DPB1 4.05 3.05 3.41 1.00 -0.03 1.00 1.06 -1.24 0.25 1.47 2.31
CHST9 3.56 2.18 3.31 2.78 1.05 0.68 0.65 -0.25 0.87 0.82 4.04
NEDD4L 3.78 4.04 3.31 2.89 0.80 1.64 1.41 0.05 2.12 -0.35 3.24
FIS -3.79 -2.71 -4.03 -3.56 0.14 -0.53 -1.48 0.45 -1.31 -2.20 -3.98
HSD17B13 -4.02 -3.63 -3.74 -3.69 0.69 -2.72 -3.96 -0.84 -1.47 -1.10 -3.24
CCL20 3.78 3.00 3.03 2.56 0.99 1.05 1.69 0.26 0.19 0.99 4.01
PRC1 3.99 4.00 4.00 2.64 0.93 3.13 2.97 0.06 -1.15 0.32 2.33
CXCL13 2.68 3.05 3.98 0.35 -0.64 2.31 2.66 0.86 -0.96 0.76 1.36
LIPC -3.96 -3.98 -3.58 -2.34 0.38 -2.43 -2.61 0.15 -0.44 0.51 -2.08
C1orf54 3.79 2.39 3.97 3.70 1.19 0.90 2.19 1.87 -0.91 0.79 2.81
KBTBD11 -2.81 -3.41 -3.96 -2.06 -0.35 -2.05 -3.16 -1.81 -1.74 -0.99 -3.17
ACSL4 3.16 2.80 -2.86 -1.68 -0.51 1.46 1.10 1.18 -2.57 -3.96 -2.31
SLC43A1 3.96 2.35 2.88 2.18 1.10 0.13 0.30 0.39 1.12 0.33 2.82
GDF15 2.86 3.44 3.96 1.48 0.00 3.22 2.73 -0.18 2.27 0.68 2.20
SERPINE2 3.32 3.53 3.93 1.02 -0.76 1.05 1.17 -0.58 0.36 -0.03 3.03
H2AFZ 2.60 3.15 3.91 2.69 1.83 1.70 1.83 0.93 -0.83 0.19 2.01
LOC654201 -3.91 -3.33 -2.86 -2.51 -1.19 0.63 -0.19 -0.62 -0.54 -0.39 -3.14
LPA -3.90 -3.48 -3.01 -2.57 -0.85 -2.85 -1.73 0.61 -1.29 -0.73 -2.81
TMEM45B 3.90 1.91 1.74 1.15 -0.01 0.16 -0.36 -0.23 1.21 0.62 2.67
MAP2K1 -3.60 -3.56 -3.89 -1.97 0.05 -2.12 -2.53 -0.83 -2.23 0.18 -2.89
S100A4 3.79 3.54 3.88 2.72 2.45 1.30 1.89 1.96 -0.51 0.92 2.33
SLCO2A1 3.86 2.01 2.70 1.50 -0.23 0.15 0.63 -1.49 3.28 1.63 2.06
USH2A -3.84 -2.84 -3.79 -2.42 0.28 -2.34 -2.48 1.20 -0.86 1.07 -3.35
LUM 3.83 3.01 3.73 -1.29 -0.36 1.88 0.71 -1.70 0.74 1.59 1.72
BTN3A2 3.22 3.83 3.36 1.64 -0.71 1.63 2.25 -0.31 -0.44 1.16 2.24
ANXA1 3.82 2.98 2.88 0.51 0.34 0.93 0.41 -0.16 -0.36 1.78 1.07
RNASE1 3.31 3.53 3.80 3.65 1.82 1.51 1.90 0.50 1.95 0.68 2.26
KRT222 3.43 3.78 3.02 2.69 0.73 2.49 2.35 -0.50 0.39 -0.41 2.23
FLJ40504 2.67 2.73 3.78 2.54 1.78 3.43 1.78 -1.08 1.85 0.98 2.69
LOXL4 3.75 2.78 3.09 2.28 -0.45 2.62 2.22 -0.05 2.57 1.24 3.78
HLA-DRB4 3.59 3.57 3.77 0.81 -2.16 2.31 2.14 0.78 1.49 1.98 3.18
FXYD1 -3.75 -2.19 -1.52 -0.63 0.50 0.47 -0.54 -0.33 0.95 -1.24 -1.78
ZNFX1 3.74 3.28 2.16 2.69 1.33 0.81 1.12 0.74 0.58 0.37 2.35
RARRES3 3.71 3.28 3.04 3.21 2.25 -0.25 1.18 1.23 -0.73 0.99 2.32
DTNA 3.17 3.69 3.32 1.27 -1.05 1.47 1.54 -1.23 2.25 1.99 3.67
GCDH -3.69 -1.93 -1.94 -1.18 -0.60 -1.26 -0.58 -0.13 1.42 -0.52 -2.30
IL2RB 3.22 2.38 3.66 2.37 0.55 1.24 2.02 -1.30 -0.88 0.52 0.84
EMP1 3.54 1.90 1.12 0.82 -0.42 1.31 1.13 0.21 3.64 0.55 2.45
CAP2 3.64 3.37 2.95 1.43 -1.11 2.64 1.86 -0.81 1.43 1.08 2.45
OSTalpha 3.01 2.81 3.42 1.77 -1.14 1.96 3.00 0.20 2.00 0.42 3.64
HLA-G 3.37 3.57 3.64 1.66 1.04 0.82 1.21 -0.17 -0.53 0.11 1.95
OAS2 3.64 2.56 1.52 1.69 1.50 0.88 -0.62 0.31 -0.48 0.91 1.79
NEU4 -3.64 -3.25 -3.02 -1.80 0.75 -0.64 -2.47 0.38 -0.54 0.28 -2.91
TACSTD2 3.64 2.47 2.76 1.83 0.07 0.89 1.29 -0.78 -0.01 1.32 2.68
IFIH1 3.62 2.32 1.76 0.88 0.01 -0.07 -0.24 -0.55 0.05 0.41 1.08
LOC649923 3.08 3.61 3.24 2.07 -0.26 1.57 1.31 0.07 0.77 0.45 1.78
CES7 -3.60 -1.36 -2.14 -1.53 -0.25 -0.18 -0.62 1.71 -1.36 -0.74 -1.76
VIL1 -3.25 -3.59 -3.05 -2.30 -0.70 -0.21 -0.93 1.02 0.06 0.06 -1.89
CHAD -3.55 -3.04 -2.46 -2.43 -1.78 -1.19 -1.43 -0.05 0.20 -0.60 -1.73
GZMH 3.54 2.82 3.43 2.77 1.31 0.25 1.59 2.19 -0.54 1.53 3.05
SLITRK3 -3.07 -3.44 -3.42 -1.32 0.09 -1.34 -0.70 0.13 -0.85 -0.82 -3.52
CCND1 3.52 2.85 2.74 1.68 0.04 0.83 1.27 -1.29 1.07 1.48 3.09
PPT1 3.51 2.63 2.90 1.05 0.81 -0.03 0.38 0.82 -1.06 0.27 1.78
PTGDS 3.00 2.66 3.51 1.66 -0.59 0.93 1.68 -0.12 0.60 1.56 2.58
IFIT3 3.50 3.00 1.67 1.89 1.05 1.27 1.40 0.77 1.07 0.80 2.01
THOP1 -3.50 -1.84 -3.41 -1.62 -0.23 0.61 -0.92 0.98 -2.07 -2.25 -3.31
HOPX 2.64 2.99 3.50 1.34 0.87 2.64 2.59 1.15 0.21 1.92 1.59
LOC339766 -3.48 -2.27 -2.67 -2.18 0.09 -1.06 -1.52 0.62 -0.88 -0.23 -2.57
GNMT -3.48 -2.90 -3.07 -1.27 -0.59 -2.01 -1.58 -0.75 -0.06 0.12 -1.94
MDK 2.86 3.34 3.47 3.26 2.35 2.18 1.61 1.11 -1.66 -0.76 2.56
JUN 3.46 1.79 2.93 1.97 -0.16 1.84 1.54 -0.44 2.84 1.53 2.49
LY96 3.39 2.97 3.35 3.23 1.96 0.07 0.73 1.38 -0.03 0.54 2.14
ARHGAP10 -2.51 -2.45 -3.39 -1.86 0.67 -1.64 -1.01 -0.16 -0.61 -0.54 -2.29
CDKN1A 3.36 3.18 2.25 1.24 0.27 0.34 0.29 0.08 1.70 1.17 3.11
SAMD9 3.36 2.28 1.84 1.82 1.00 -0.56 -0.29 0.66 -0.49 0.66 1.43
ASB9 -3.36 -1.76 -2.17 -1.14 -0.76 -1.78 -1.11 0.53 -0.44 -1.89 -1.92
CCL2 3.35 2.86 2.33 2.24 0.26 1.41 0.96 -0.39 0.75 2.00 1.99
BBOX1 -3.15 -2.31 -2.38 -1.18 -0.05 -3.03 -3.34 0.11 -1.33 0.05 -2.00
CRIP1 3.16 3.25 3.34 2.64 1.41 1.06 1.81 -0.17 0.50 0.74 2.12
GPX2 0.82 3.31 2.40 3.02 2.49 0.76 1.61 0.27 -0.16 0.18 1.89
RND2 -3.21 -3.31 -2.41 -1.76 -1.06 -2.48 -2.15 -1.11 -0.26 -0.10 -3.00
DDX60 3.28 2.45 1.77 0.82 0.29 -0.21 0.61 0.28 -0.10 0.82 1.68
PACSIN3 -3.28 -3.02 -3.28 -1.04 -0.21 -1.10 -0.60 -0.06 -0.49 -1.09 -2.86
SP110 3.27 2.70 2.35 2.16 1.29 1.22 0.88 -1.94 1.77 0.96 1.38
EFHD1 -3.17 -2.56 -1.67 -1.77 -1.30 0.98 0.20 1.09 -0.67 -1.67 -3.26
LOC651751 3.25 2.96 2.88 2.28 -0.46 1.92 1.20 -0.17 1.08 1.72 2.06
IFI27 3.24 2.66 2.14 2.93 1.56 -1.43 -0.13 0.72 -0.40 1.15 3.01
LOC651894 -3.22 -1.74 -1.89 -0.88 0.75 -0.26 -0.77 0.59 -0.38 -1.73 -1.35
TMEM20 2.87 3.21 3.09 1.81 0.22 1.27 0.67 -0.23 0.30 0.06 2.64
FCAMR 3.19 2.85 2.01 2.10 1.22 0.21 -0.35 1.00 -1.66 1.54 2.52
IL1RAP -3.14 -2.17 -1.20 -1.54 -1.36 -2.90 -2.08 -1.11 -0.40 -0.35 -1.68
IFIT2 3.13 2.09 1.10 1.50 0.77 0.52 0.39 -0.93 1.19 0.84 1.57
IGJ 3.09 1.91 2.02 2.10 0.93 0.89 0.23 -0.32 0.19 1.51 1.27
ALDH1L1 -4.87 -4.21 -3.85 -1.14 0.60 -4.27
B3GNT9 -0.05 0.81 -3.13 -5.42 0.18 -1.64 -0.64 -0.25 -0.56
DOCK2 5.47 5.13 2.33 0.34 2.63 3.73 1.12 -0.22 1.45 2.86
HLA-DPA1 6.04 5.35 5.13 1.19 2.84 2.81 0.17 1.09 3.70
LIPA 4.69 3.97 3.26 0.83 0.30 2.02 2.14 -0.95 0.70 1.83
TYROBP 4.71 4.80 5.47 1.67 3.78 1.09 4.37
ZBTB33 5.35 4.38 4.35 2.30 0.54 1.54 4.41
ZNF511 -5.94 -5.19 -0.24 -2.14 -0.84 -0.75 -4.11
Gene Set NES FDR NES FDR NES FDR NES FDR NES FDR NES FDR NES FDR NES FDR NES FDR NES FDR NES FDR
PBT_QCMAT 2.65 0.00 2.61 0.00 2.63 0.00 0.90 0.89 1.84 0.00 1.94 0.00 2.32 0.00 2.47 0.00 2.44 0.00 2.45 0.00 2.59 0.00
PBT_QCAT 2.54 0.00 2.54 0.00 2.60 0.00 0.50 1.00 1.95 0.00 1.76 0.01 1.87 0.00 2.31 0.00 2.61 0.00 2.44 0.00 2.48 0.00
PBT_CIRIT 2.40 0.00 2.39 0.00 2.40 0.00 0.93 0.89 1.32 0.12 1.27 0.26 1.49 0.07 2.29 0.00 2.01 0.00 1.72 0.01 1.92 0.00
PBT_GRIT1 2.38 0.00 2.51 0.00 2.43 0.00 0.87 0.92 1.47 0.04 2.03 0.00 1.69 0.01 2.04 0.00 2.51 0.00 2.44 0.00 2.37 0.00
PBT_IRITD5 2.32 0.00 2.19 0.00 2.41 0.00 -0.98 1.00 1.81 0.00 0.98 0.69 1.09 0.50 1.89 0.00 1.88 0.00 1.30 0.14 1.88 0.00
PBT_IRITD3 2.20 0.00 2.11 0.00 2.15 0.00 1.68 0.07 1.86 0.00 1.24 0.28 1.34 0.19 2.04 0.00 1.96 0.00 1.88 0.00 2.22 0.00
PBT_BAT 2.09 0.00 2.31 0.00 2.26 0.00 0.64 1.00 0.85 0.77 1.13 0.45 0.93 0.69 2.06 0.00 2.13 0.00 1.59 0.02 1.66 0.01
PBT_ENDAT 1.95 0.00 1.79 0.00 1.90 0.00 1.27 0.41 1.60 0.01 0.79 0.97 1.05 0.56 1.11 0.34 1.15 0.32 1.35 0.10 1.52 0.02
PBT_TCB 1.72 0.00 1.74 0.00 1.77 0.00 -0.82 1.00 1.17 0.31 0.72 0.99 1.14 0.45 1.52 0.03 1.62 0.01 1.33 0.12 1.56 0.02
PBT_IRRAT 1.59 0.01 1.65 0.01 1.70 0.00 0.84 0.94 1.46 0.05 1.14 0.44 1.14 0.43 1.53 0.03 1.58 0.02 1.25 0.18 1.58 0.01
PBT_AMAT1 1.56 0.01 1.04 0.46 1.70 0.00 0.67 1.00 0.74 0.92 0.54 0.99 1.14 0.44 1.59 0.02 1.56 0.02 0.95 0.66 1.06 0.42
PBT_IGT 1.49 0.03 1.38 0.06 1.49 0.03 0.84 0.96 1.13 0.35 0.64 1.00 -1.09 1.00 1.18 0.26 1.11 0.37 1.48 0.04 1.34 0.09
PBT_HTS 1.40 0.05 1.40 0.05 1.33 0.09 1.17 0.50 1.24 0.20 -1.05 1.00 1.05 0.54 1.31 0.12 1.15 0.32 0.86 0.79 1.05 0.42
PBT_NKB 1.25 0.15 1.21 0.19 1.48 0.03 1.40 0.26 1.35 0.11 1.37 0.18 1.18 0.40 1.17 0.27 1.39 0.07 1.33 0.12 1.10 0.34
PBT_DSAST 1.18 0.23 1.38 0.06 1.52 0.02 1.09 0.61 1.63 0.01 1.31 0.22 0.91 0.71 1.38 0.07 1.40 0.07 1.17 0.28 0.52 1.00
PBT_MCAT -1.10 0.50 -0.55 0.99 -0.52 0.99 1.23 0.42 -1.10 0.52 1.16 0.44 0.96 0.66 0.71 0.93 -0.53 1.00 -1.17 0.43 -1.16 0.34
HALLMARK_INTERFERON_GAMMA_RESPONSE 2.97 0.00 2.93 0.00 2.68 0.00 1.28 0.43 1.91 0.00 2.20 0.00 1.84 0.00 2.10 0.00 2.22 0.00 2.80 0.00 2.69 0.00
HALLMARK_ALLOGRAFT_REJECTION 2.92 0.00 2.92 0.00 2.94 0.00 0.54 1.00 2.06 0.00 1.80 0.01 1.91 0.00 2.45 0.00 2.75 0.00 2.70 0.00 2.63 0.00
HALLMARK_INTERFERON_ALPHA_RESPONSE 2.76 0.00 2.81 0.00 2.53 0.00 0.90 0.88 1.75 0.01 2.21 0.00 1.85 0.00 1.62 0.01 1.78 0.00 2.63 0.00 2.40 0.00
HALLMARK_TNFA_SIGNALING_VIA_NFKB 2.63 0.00 2.39 0.00 2.38 0.00 1.58 0.08 2.12 0.00 1.09 0.52 1.15 0.45 2.03 0.00 2.32 0.00 2.31 0.00 2.40 0.00
HALLMARK_E2F_TARGETS 2.57 0.00 2.65 0.00 2.64 0.00 0.78 1.00 1.90 0.00 1.40 0.16 1.79 0.01 2.62 0.00 2.48 0.00 2.37 0.00 2.37 0.00
HALLMARK_G2M_CHECKPOINT 2.56 0.00 2.56 0.00 2.64 0.00 -1.08 1.00 1.96 0.00 1.33 0.21 1.75 0.01 2.46 0.00 2.40 0.00 2.07 0.00 2.16 0.00
HALLMARK_INFLAMMATORY_RESPONSE 2.56 0.00 2.47 0.00 2.36 0.00 -0.69 0.95 2.04 0.00 1.40 0.17 1.56 0.04 1.92 0.00 2.11 0.00 2.03 0.00 2.21 0.00
HALLMARK_IL6_JAK_STAT3_SIGNALING 2.48 0.00 2.40 0.00 2.45 0.00 0.52 1.00 1.61 0.01 1.61 0.04 0.98 0.65 1.76 0.00 1.95 0.00 2.17 0.00 2.19 0.00
HALLMARK_KRAS_SIGNALING_UP 2.45 0.00 2.41 0.00 2.41 0.00 1.16 0.48 1.72 0.01 1.15 0.44 1.40 0.14 2.09 0.00 1.92 0.00 1.97 0.00 2.33 0.00
HALLMARK_APOPTOSIS 2.36 0.00 2.41 0.00 2.35 0.00 1.28 0.45 1.71 0.01 1.36 0.19 1.80 0.00 2.08 0.00 2.13 0.00 1.94 0.00 2.18 0.00
HALLMARK_COMPLEMENT 2.33 0.00 2.24 0.00 2.32 0.00 1.15 0.49 1.52 0.03 0.85 0.93 1.37 0.16 1.94 0.00 2.04 0.00 1.75 0.00 2.11 0.00
HALLMARK_MITOTIC_SPINDLE 2.23 0.00 2.13 0.00 2.21 0.00 1.35 0.32 1.68 0.01 -1.01 1.00 0.90 0.72 2.26 0.00 2.02 0.00 1.25 0.18 1.83 0.00
HALLMARK_IL2_STAT5_SIGNALING 2.20 0.00 2.24 0.00 2.18 0.00 0.93 0.87 1.37 0.09 1.21 0.34 1.36 0.17 2.03 0.00 2.16 0.00 1.73 0.01 1.88 0.00
HALLMARK_MTORC1_SIGNALING 2.12 0.00 2.21 0.00 2.18 0.00 1.03 0.69 1.44 0.05 1.31 0.22 1.80 0.01 1.61 0.02 1.63 0.01 1.95 0.00 1.80 0.00
HALLMARK_P53_PATHWAY 2.12 0.00 2.22 0.00 2.15 0.00 1.48 0.17 1.70 0.01 1.82 0.01 1.37 0.16 1.68 0.01 1.80 0.00 2.17 0.00 1.97 0.00
HALLMARK_ANGIOGENESIS 2.05 0.00 1.93 0.00 2.07 0.00 1.61 0.10 1.70 0.01 0.58 1.00 0.89 0.72 1.85 0.00 2.01 0.00 1.60 0.02 2.08 0.00





























































Supplementary Table S5. Functional pathways associated with severity of different histological parameters. Analysis performed using Gene Set Enrichment Analysis (GSEA) software against 
Hallmark gene sets from MSigDB and Pathogenesis Based Transcript (PBT) sets from the University of Alberta. Normalised Enrichment Score (NES) and False Discovery Rate (FDR) are shown for 
each parameter. NES is a quantified measure of strength of enrichment determined by the GSEA software and defined on the MIT Broad Institue website 















































HALLMARK_HYPOXIA 1.93 0.00 1.70 0.00 1.85 0.00 1.25 0.40 1.69 0.01 0.84 0.93 -1.06 0.96 1.41 0.06 1.34 0.11 1.62 0.01 1.62 0.01
HALLMARK_ESTROGEN_RESPONSE_LATE 1.89 0.00 1.84 0.00 1.77 0.00 -1.01 1.00 0.98 0.62 0.98 0.70 1.12 0.44 1.63 0.01 1.76 0.00 1.63 0.01 1.44 0.04
HALLMARK_MYC_TARGETS_V1 1.85 0.00 1.83 0.00 1.85 0.00 1.21 0.44 0.90 0.73 1.09 0.51 1.31 0.21 1.48 0.04 1.16 0.31 1.88 0.00 1.73 0.00
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 1.78 0.00 1.76 0.00 1.75 0.00 0.82 0.95 1.16 0.31 1.24 0.29 1.30 0.21 1.17 0.27 1.07 0.45 1.58 0.02 1.60 0.01
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIO1.77 0.00 1.66 0.01 1.78 0.00 1.03 0.71 1.72 0.01 -1.31 1.00 1.05 0.55 1.36 0.08 1.38 0.08 0.98 0.60 1.57 0.02
HALLMARK_PI3K_AKT_MTOR_SIGNALING 1.76 0.00 1.77 0.00 1.98 0.00 1.21 0.43 1.64 0.01 1.03 0.59 1.08 0.53 1.47 0.04 1.50 0.03 1.60 0.02 1.54 0.02
HALLMARK_ANDROGEN_RESPONSE 1.75 0.00 1.53 0.02 1.52 0.02 -0.94 1.00 0.86 0.77 1.14 0.44 0.83 0.81 1.34 0.10 0.89 0.75 0.92 0.70 1.24 0.18
HALLMARK_COAGULATION 1.73 0.00 1.62 0.01 1.76 0.00 1.55 0.10 1.10 0.38 -0.86 0.92 -1.21 0.88 1.54 0.03 1.25 0.19 1.16 0.28 1.47 0.03
HALLMARK_ESTROGEN_RESPONSE_EARLY 1.68 0.00 1.46 0.03 1.54 0.02 1.10 0.61 1.08 0.42 0.77 0.97 0.99 0.65 1.42 0.06 1.48 0.04 1.26 0.18 1.31 0.11
HALLMARK_UV_RESPONSE_DN 1.62 0.01 1.39 0.06 1.37 0.07 1.17 0.49 1.52 0.03 0.88 0.91 -1.11 1.00 1.48 0.04 1.04 0.50 1.04 0.49 1.22 0.20
HALLMARK_DNA_REPAIR 1.60 0.01 1.85 0.00 1.51 0.02 0.83 0.94 1.14 0.34 1.70 0.02 1.88 0.00 1.62 0.01 1.49 0.04 1.81 0.00 1.71 0.00
HALLMARK_PROTEIN_SECRETION 1.60 0.01 1.88 0.00 1.74 0.00 1.00 0.75 1.17 0.31 0.98 0.68 1.20 0.39 1.53 0.03 1.47 0.04 1.22 0.21 1.57 0.02
HALLMARK_GLYCOLYSIS 1.58 0.01 1.51 0.02 1.74 0.00 1.27 0.42 1.25 0.20 1.04 0.62 0.99 0.64 1.59 0.02 1.51 0.03 1.44 0.06 1.56 0.02
HALLMARK_APICAL_SURFACE 1.57 0.01 1.23 0.17 1.62 0.01 -0.87 1.00 1.16 0.31 0.99 0.70 -1.03 0.86 1.18 0.26 1.23 0.22 1.17 0.27 1.20 0.21
HALLMARK_WNT_BETA_CATENIN_SIGNALING 1.48 0.03 1.30 0.11 1.45 0.04 0.75 1.00 0.93 0.67 -0.99 0.93 0.64 0.98 1.09 0.37 1.22 0.23 1.36 0.10 1.45 0.04
HALLMARK_ADIPOGENESIS 1.41 0.05 1.31 0.10 1.17 0.25 1.19 0.46 1.24 0.21 -0.96 0.94 -0.88 1.00 1.42 0.06 1.15 0.31 0.79 0.89 1.19 0.22
HALLMARK_HEME_METABOLISM 1.37 0.07 1.56 0.01 1.58 0.01 0.93 0.85 0.94 0.67 1.32 0.23 0.94 0.70 1.36 0.08 1.18 0.29 1.47 0.04 1.28 0.14
HALLMARK_PEROXISOME 1.37 0.07 1.61 0.01 1.60 0.01 1.42 0.24 -1.35 0.80 1.26 0.27 1.24 0.32 1.53 0.03 1.50 0.03 1.23 0.19 1.46 0.04
HALLMARK_TGF_BETA_SIGNALING 1.32 0.10 0.70 0.95 0.79 0.87 0.73 1.00 0.89 0.73 1.51 0.09 1.18 0.41 0.78 0.87 -0.60 1.00 0.91 0.71 1.18 0.23
HALLMARK_APICAL_JUNCTION 1.30 0.11 1.47 0.03 1.63 0.01 1.25 0.42 1.20 0.27 0.83 0.91 0.80 0.86 1.69 0.01 1.52 0.03 1.36 0.10 1.41 0.05
HALLMARK_HEDGEHOG_SIGNALING 1.28 0.13 1.30 0.11 1.38 0.06 1.38 0.27 1.25 0.20 -0.68 0.96 1.31 0.22 1.07 0.41 1.34 0.11 0.76 0.91 1.47 0.03
HALLMARK_SPERMATOGENESIS 1.28 0.13 1.48 0.03 1.38 0.06 -1.23 0.88 0.92 0.69 0.98 0.67 0.93 0.69 1.23 0.20 1.26 0.18 0.92 0.70 1.40 0.06
HALLMARK_CHOLESTEROL_HOMEOSTASIS 1.25 0.16 1.35 0.08 1.28 0.13 -1.51 0.25 1.68 0.01 0.87 0.92 1.78 0.00 0.96 0.59 1.03 0.49 1.57 0.02 1.56 0.02
HALLMARK_OXIDATIVE_PHOSPHORYLATION 1.24 0.15 1.55 0.02 1.40 0.05 1.08 0.60 -0.97 0.73 -0.85 0.87 -0.81 0.89 1.27 0.16 1.05 0.48 1.09 0.39 1.21 0.21
HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY1.21 0.19 1.27 0.14 1.31 0.10 1.59 0.09 1.42 0.07 0.84 0.91 -1.00 0.88 0.94 0.62 1.03 0.50 1.13 0.32 1.38 0.07
HALLMARK_MYC_TARGETS_V2 1.14 0.29 1.28 0.12 1.18 0.25 0.70 1.00 1.74 0.01 1.40 0.19 1.15 0.44 1.10 0.36 1.00 0.53 1.67 0.01 1.03 0.46
HALLMARK_KRAS_SIGNALING_DN 1.10 0.35 1.08 0.39 0.92 0.68 -0.84 1.00 0.97 0.61 -0.95 0.88 1.00 0.63 1.02 0.49 1.18 0.29 -1.04 0.49 0.80 0.85
HALLMARK_FATTY_ACID_METABOLISM 0.98 0.56 0.93 0.67 1.01 0.52 -0.97 1.00 0.63 0.98 1.05 0.61 0.90 0.71 1.04 0.46 0.74 0.93 0.77 0.90 0.81 0.84
HALLMARK_NOTCH_SIGNALING 0.91 0.68 0.77 0.90 0.94 0.65 -0.74 1.00 1.13 0.35 0.86 0.93 -1.21 1.00 -0.83 1.00 -0.81 1.00 0.95 0.65 1.37 0.07
HALLMARK_MYOGENESIS 0.75 0.93 1.21 0.20 0.72 0.93 0.89 0.90 1.34 0.11 -1.08 1.00 1.05 0.57 1.14 0.30 0.69 0.96 -1.12 0.37 -1.30 0.36
HALLMARK_BILE_ACID_METABOLISM 0.69 0.97 0.68 0.95 0.89 0.73 1.09 0.62 -1.08 0.51 0.73 1.00 -0.90 1.00 1.19 0.26 0.77 0.90 -0.90 0.67 -1.12 0.35
HALLMARK_PANCREAS_BETA_CELLS 0.40 1.00 -0.76 1.00 1.06 0.42 -0.71 1.00 -1.21 0.67 -0.88 0.94 1.03 0.58 1.49 0.04 0.83 0.85 0.61 0.99 -0.61 0.98




Biological specimen collection 
For liver biopsies, a 2- to 3-mm portion of the biopsy cylinder was immediately 
preserved in RNAlater reagent (Ambion) following percutaneous liver biopsy, 
kept at 4ºC for 24hours, and then cryopreserved in liquid nitrogen after 
removal of the RNAlater reagent. Blood samples were immediately stabilised 
in Paxgene tubes and cryopreserved at -80ºC. 
 
Total RNA extraction from liver tissue and whole blood samples 
Cryopreserved liver tissue samples were homogenized in TRIzol reagent 
(Invitrogen) using a pestle and nuclease-free 1.5-ml reaction tubes (Ambion). 
Total RNA was then extracted following the manufacturers guidelines, and 
quality was assessed with the Agilent2100 Bioanalyzer (Agilent 
Technologies). To extract RNA from the cryopreserved whole blood samples, 
the PAXgene Blood RNA kit (PreAnalytikX) was used following the 
manufacturers guidelines. 
 
Liver tissue data acquisition and normalisation 
Samples were processed into cRNA and hybridized onto IlluminaHT-12 
Expression BeadChips containing 48,771 probes corresponding to 25,000 
annotated genes and analysed using a BeadArray Reader (Illumina). 
Microarray expression data was computed using BeadStudio data analysis 
software (Illumina) and subsequently processed employing quantiles 
normalisation using the Lumi bioconductor package.  Next we conducted a 
conservative probe-filtering step excluding those probes with a coefficient of 
variation <4%, which resulted in a list of 20,965 evaluable from the from the 
original set of 48,771 probes. 
 
Blood sample data acquisition and normalisation  
Samples were hybridized on the custom Agilent cDNA microarrays according 
to the manufacturer’s instructions. Array images were acquired with Agilent’s 
microarray scanner G2505C and signal data were collected with dedicated 
Agilent Feature Extraction software (v9.5.1). Probes with gIsPosAndSignif 
value of zero in at least 10 samples were disregarded and labeled as "null". 
Background adjustment and normalization were done using normexp and 
quantile normalization. Median values were calculated for multiple probes with 
the same Agilent Probe ID. 
 
Gene expression data processing from Fluidigm Biomark HD samples 
DNA was removed from total RNA preparations using Turbo DNA-free DNAse 
treatment (Ambion), and RNA was then reverse transcribed into cDNA using 
the HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems). A 
pre-amplification step was performed as per Fluidigm Biomark HD protocol. 
To quantify transcript levels target gene Ct values were normalized to the 
housekeeping genes HPRT1 and GAPDH to generate ΔCt values. The results 
were then computed as relative expression between cDNA of the target 
samples and a calibrated sample according to the ΔΔCt method. 
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